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ABSTRACT 
HAMID, ABEER, A., Masters: June: 2020, Clinical Pharmacy and Practice 
Title: Evaluation of the Pharmacovigilance System in Qatar: A Mixed Method Study 
on Structure, Process and Outcome 
Supervisor of Thesis: Mohamed Izham Mohamed Ibrahim. 
Introduction: It is evident that pharmacovigilance (PV) centers are the 
entities required to ensure medication safety and protect public health from drug-
related morbidity and mortality. In many developing countries PV systems are 
mostly immature or non-existent. In Qatar, a centralized PV center does not exist. 
Therefore, this research aimed to conduct a comprehensive system assessment by 
evaluating the current state of PV in Qatar in order to establish a baseline 
understanding of PV situation and to identify weaknesses and improvement 
opportunities for PV.  
Methodology: This mixed-method case study (i.e., concurrent) provided 
multiple case evaluation for: a) in-depth subnational PV systems case evaluation, 
b) comparative case analysis, and c) evaluation of the overall national PV system. 
Quantitative approach included a cross-sectional descriptive study utilizing the 
World Health Organization (WHO) PV indicators (i.e., structure, process, and 
outcome). It included the Ministry of Public Health (MOPH); public sector; private 
sector; academic institutions; pharmaceutical industry. Descriptive statistics were 
used to describe systems' performance based on a scoring scheme. Qualitative 
approaches included semi-structured interviews, document review and field 
observation. Deductive content analysis was used to analyze qualitative data. 
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Additionally, the WHO minimum requirements for a functional PV system were 
employed in the evaluation. 
Findings: The WHO five minimum requirements for an operational PV 
system are not available in Qatar. The overall national PV system achieved a good 
total system performance status. Most subnational PV systems obtained good total 
system performance. The MOPH system revealed weak performance status. 
However, MOPH plans to establish a medication safety program and patient safety 
reporting system. The highest scores were for structural indicators with most 
subnational PV systems demonstrating excellent performance. MOPH structural 
shortfalls included the lack of PV specific legislation, national reporting system, 
and a dedicated budget for PV. Process indicators revealed good performance status 
for the public and private sectors. However, existing PV processes are mostly at an 
early stage of advancement. Outcome indicators showed the weakest performance 
across the subnational PV systems. 
Conclusion: Subnational PV systems strengthening is required to address 
the identified challenges to effective PV and performance disparities between 
systems. The overall performance of the country needs to be improved following a 
system-based approach. It is recommended to: 1) improve PV prioritization in the 
regulatory, practice and academic agendas; 2) establish effective PV structures, 
especially PV specific legislation and PV center; 3) target efforts to improve and 
coordinate PV between national stakeholders; 4) build the national PV system 
capacity to meet the minimum requirements of WHO. Finally, future research can 
focus on aspects related to the governance of the PV system and the feasibility of 
establishing the proposed PV center organizational structure. 
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CHAPTER I: INTRODUCTION 
 
This chapter will introduce the pharmacovigilance field with an emphasis on 
pharmacovigilance systems and the assessment of such systems. This chapter will 
demonstrate the concepts behind the planned assessment of the pharmacovigilance 
system in a Middle Eastern country (i.e., Qatar). It will identify the guiding evaluative 
framework (i.e., the World Health Organization pharmacovigilance indicators) and the 
employed research approach (i.e., mixed-methods research). In addition, it will present 
the problem statement, research rationale, aim and objectives, and study contribution. 
1. Background  
1.1. Pharmacovigilance  
According to the World Health Organization (WHO), pharmacovigilance (PV) 
is defined as “the science and activities relating to the detection, assessment, 
understanding, and prevention of adverse effects or any other drug-related problems” 
(1). The WHO is a specialized agency established in 1948 for global cooperation in and 
improvement of public health conditions. The agency falls under the United Nations, 
and one of its main mandates is to promote the achievement and/or realization of “the 
highest possible level of health” for the world population at the international level (2).  
A series of milestone events shaped the development of drug safety and PV as 
a distinct scientific discipline (1, 3-6). However, conforming to the WHO interpretation, 
the official beginning for PV as a science and practice can be traced back to 1961. In 
1961, the thalidomide tragedy resulted in thousands of incidences of phocomelia, a 
congenital malformation that occurred in the infants of pregnant females who were 
exposed to the drug (1, 7). As a prompt response to the thalidomide tragedy, the World 
Health Assembly proposed the concept of a global joint project designed for the early 
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identification of possible occurrences similar to the thalidomide tragedy (7, 8). Later, 
in 1968, the program was named the WHO Programme for International Drug 
Monitoring (PIDM). The program was established to serve as a holistic system for the 
collection of adverse drug reaction (ADR) reports at the international level (9). 
 The tragedy highlighted the importance of the safety claims produced by 
pharmaceutical companies being followed up by systematic approaches to validate the 
information provided in drug safety profiles in the preauthorization stage. Additionally, 
it highlighted the need for systematic approaches to the collection, assessment, and 
communication of information on ADRs and other unidentified safety issues during the 
mass exposure of various populations to medicines that have been tested and found to 
be safe, efficacious, and of good quality in specifically designed preclinical and clinical 
studies (1, 4, 5, 7). 
At present, the scope of PV covers aspects relevant to ADRs, medication errors, 
drug-drug interactions, lack of effectiveness of drug products, substandard medications, 
misuse of medicines, and counterfeit medicines (10). Additionally, contemporary PV 
is concerned with vigilance regarding various products such as modern medicines, 
vaccines, traditional medicines, biosimilars, and medical devices (7, 11). 
1.2. Pharmacovigilance Systems at the Global Level 
In the course of the growth of the PV field, PV systems have been established 
to perform the necessary PV and drug surveillance activities (10). These systems are 
the cornerstone for the legal monitoring of authorized medicinal product safety and the 
oversight responsibility for drug risk-benefit analysis in a country. PV systems are the 
entities required to safeguard public health and medication safety in a country (12-15). 
Essentially, they are the basis of the structures, processes and outcomes required to 
allow effective and prompt detection, collation, and evaluation of adverse events 
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resulting from the use of medicinal products. Accordingly, they aid in decision making 
about safety issues, risk communication, and risk management applied in all sectors of 
a health care system (10, 11). According to the directive of the European Economic 
Community, a PV system is defined as “a system [that is] used to collect information 
useful in the surveillance of medicinal products, with particular reference to adverse 
reactions in human beings, and to evaluate such information scientifically” (16). 
At the international level, the PIDM represents a focal point for member 
countries to work together in the reporting and analysis of international data on ADRs 
and signal identification from the collated individual case safety report (ICSR) 
databases of member countries. The PIDM network consists of the following main 
actors: a) the WHO headquarters in Geneva, which is concerned with policy issues; b) 
the Uppsala Monitoring Centre (UMC) in Sweden, which oversees the operational and 
scientific aspects; and c) member country national PV centers, which are responsible 
for reporting national data to the international database (i.e., VigiBase) (1, 11). 
The number of countries with a specific PV program increased from 10 in 1970 
to 136 in 2019, which is promising for the concept of therapeutic product safety 
surveillance. In the Arab world, 10 countries are full members, and 7 countries are 
associate members. Associate members do not contribute data to VigiBase (17). With 
the increased number of national PV centers contributing to the global arena of PV, 
there is a need to evaluate the functionality and performance of those systems to ensure 
that their contributions to global PV data and practices are positive and effective (11, 
18, 19).  
In various countries, the PV system or the activities performed by the system 
can suffer from deficiencies that affect medication safety, public health, the efficient 
use of available national resources, and compliance with internationally recognized 
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standards of public health and safety (20, 21). A questionnaire-based analysis of 55 
developing countries indicated that PV system gaps and challenges were related to the 
slow and ineffective development of PV. Shortfalls were encountered in the 
establishment of organized PV systems, regulatory frameworks, and governance, as 
well as in the necessary coordination with international PV actors (e.g., the UMC and 
WHO) (21). Similarly, an expert review on PV systems in developing countries 
pinpointed the need to develop more effective regulatory frameworks and legislation 
specific to the country context. It also highlighted the importance of coordination with 
global PV professional bodies. In doing so, PV systems will be effectively supported, 
and their advancement and sustainability will be made feasible (20). 
1.3. Pharmacovigilance Systems in the Arab Countries 
Recently, PV has been recognized as an important component of the healthcare 
system among Arab countries. This increased interest has resulted in the development 
of PV with respect to regulations, concepts, and activities (22, 23). For instance, in 
2015, the Arab guideline for PV was developed by the Higher Technical Committee for 
Medicine under The Arab League (24).  
In Arab countries with well-structured PV systems (e.g., Morocco, Jordan, and 
Egypt), many achievements in PV have been highlighted (23). For instance, Morocco 
was acknowledged by the first Eastern Mediterranean Region/Arab Countries Meeting 
of Pharmacovigilance to be a good model for other Arab countries that are striving to 
build their PV capacity and improve their PV activities. Additionally, Morocco is 
contributing to the international PV system, as it is one of the collaborating centers of 
the WHO (23).  
Despite the continuous development of PV in the Arab world, the PV system 
scenario is heterogeneous with respect to the existing structures, processes and achieved 
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outcomes (25). Such discrepancies in system capacity and maturity have resulted in 
challenges for many Arab countries, including challenges for committed countries in 
implementing a successful PV program, establishing a dedicated national PV center, or 
managing and maintaining a sustainable PV program (25-27). 
A study by Qato using official PV key performance indicators (KPIs) to assess 
PV systems indicated that only 75% of the countries reported the availability of a 
dedicated workplace for PV, and only one-third of the countries reported the allocation 
of a specific budget for PV activities. Hence, the low performance of some PV systems 
in the Arab region is not surprising given the limitations (25). Additionally, in some 
countries, PV activities suffer from the fragmentation and duplication of stakeholders’ 
efforts, which can be highly detrimental for countries with unstable political systems or 
financial issues (26).  
The literature pertinent to PV in the Arab region has highlighted the importance 
and need to understand the PV scenario of each country, as Arab region countries are 
heterogeneous not only with respect to their PV system maturity and performance but 
also in their developmental, economic, social, political, and cultural characteristics. 
Therefore, understanding each country's situation will highlight many of the factors that 
can affect PV system and will help to explain some of the deficiencies affecting the 
development or implementation of a national PV system (25-28). 
2. Research Focus  
2.1. Pharmacovigilance System Assessment  
The literature has discussed the assessment of PV systems and the development 
of PV systems in different geographical contexts (10, 11, 29-31).  The PV system 
assessment requires the use of validated PV KPIs for an objective system assessment 
based on structural, process, and outcome criteria. Evidence collected from studies 
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utilizing PV KPIs developed by international professional bodies such as the WHO and 
the Strengthening Pharmaceutical Systems (SPS) Program allows the development of 
strategic and operational recommendations and can help in the identification of 
limitations in the systems based on structure, process, and outcome criteria (10, 11, 32).   
When evaluating PV systems and where relevant, national PV stakeholders’ 
contributions, as well as objective PV KPIs, should be considered as early as possible 
to ensure that the PV system evaluation is executed in a systematic and comprehensive 
manner. The quality of a context-based system evaluation is made more purposeful 
through national PV stakeholder views and perceptions and is strongly dependent on 
the nature of the PV challenges present in the country. This information can be used to 
evaluate the appropriateness of national PV processes and identify solutions to PV 
challenges (10, 11, 18, 32). 
2.2. Pharmacovigilance System in Qatar 
The state of Qatar is located in the Arabian Peninsula on the Persian Gulf in the 
region of the Middle East and North Africa (MENA). Qatar has one of the largest 
economies in the world, with an estimated population of 2.7 million and a gross 
domestic product (GDP) of 191 billion USD in 2018, which makes it a high-income 
country (33). Qatar has experienced tremendous advances in the field of healthcare. In 
2014, it had an annual healthcare GDP budget of $3071 per capita, one of the highest 
among the countries in the Arab region (34). Expatriates constitute 80% of the 
population and are the major workforce in the country (35). 
In the context of Qatar, in 2012, a study by Wilbur indicated the need to 
establish a national PV center to serve the needs of the population (36). Furthermore, a 
number of deficiencies were reported in the Qatari Healthcare System, including the 
absence of an integrated regulatory framework to manage health institutions and 
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professionals, the lack of a national drug policy, the underprovision of education and 
training pertinent to medication safety, issues in reporting ADRs and medication safety 
issues, and a less-than-optimal rate of ADR reporting compared to that in other 
countries (27, 36, 37). 
According to Al Hail et al., the Qatar public sector, namely Hamad Medical 
Corporation (HMC), has its own ADR reporting form, and PV is considered well 
structured (38). However, public sector PV activities focus mainly on ADR reporting, 
which is considered one of the older methods for PV data collection (11, 30). 
Furthermore, pharmacists at private healthcare institutions have reported problems with 
the availability of reporting forms (36). Similarly, a survey among community 
pharmacists in Qatar indicated that the unavailability of reporting forms is a factor that 
can undermine ADR reporting practices in Qatar (37).  
Moreover, concerns have been raised over the underreporting of ADRs among 
pharmacists in the public sector. Assessment of the knowledge, attitudes, and practices 
of ADR reporting revealed that the majority had positive attitudes toward ADR 
reporting. However, 60% of pharmacists reported that they had reported no ADRs 
during a one-year period. Additionally, a lack of knowledge of ADRs among 
pharmacists was linked to the underreporting problem (38). 
Consequently, there is a need to understand the current status of PV in Qatar 
since there is no specific PV center to coordinate PV at the national level.   
3. Problem Statement  
International organizations aimed at the continuous improvement and 
development of PV, including the WHO and SPS, have concluded that a PV system 
assessment is an essential step toward establishing a successful and sustainable PV 
system (10, 11, 32). 
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According to the WHO, the status of PV in countries around the world is an area 
of major concern because governments often do not support PV systems. Many factors 
can lead governments to neglect PV or consider it a nonpriority. For instance, in 
developing countries or countries with weak PV systems, the resources required to 
improve, establish, and sustain PV are often limited or mobilized to serve other areas, 
such as the treatment of prevalent ailments. Furthermore, the human resources needed 
to provide PV services can be deficient in terms of the number of personnel and/or 
expertise level. Second, many countries rely on developed nations' safety data, and 
government and healthcare professionals often incorrectly assume that drugs that have 
been on the market for many years are entirely safe. Third, the concept of collecting PV 
data such as ADRs, medication errors, and quality issues can be perceived as a fault in 
the system by various stakeholders, including government officials, healthcare 
professionals, patients, and society in general (1, 39). 
PV as a concept is considered to be at an early stage of development in Qatar, 
even though the basic PV practice of ADR reporting is included in the public sector 
system (36, 38). This sector has indicated the underreporting of ADRs as a challenge 
for PV (38). This underreporting can be detrimental to the success of PV in Qatar (27, 
36, 37). In addition, Al Hail et al. reported a lack of interest, lack of accountability, fear 
of reporting consequences, false belief in the absolute safety of marketed drugs, and 
judgment bias as contributing factors to underreporting (38). 
As mentioned above, Qatar has no dedicated national program or center for PV. 
Therefore, the country is an associate member of the PIDM. Associate member 
countries do not contribute to the global ICSR repository (25-27). Therefore, 
information on the safety profile of medicines used in the population remains unclear 
(e.g., genetic factors effect on drug therapy). This information is important for 
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international PV practices and could be used to alter the safety profiles or 
manufacturing practices of certain medications used in the population (1).  
Currently, there is no national reporting system to manage ADR reports or any 
other drug-related issues. The unavailability of an official unified reporting system and 
reports presents a major challenge for the PV system in Qatar (27, 36, 37). For instance, 
the fate of submitted reports and their subsequent evaluation for healthcare 
professionals practicing in Qatar is unclear (36, 37). These challenges and the need to 
ensure medication safety and patient safety can be addressed by: 1) understanding the 
existing challenges and success factors for PV in Qatar, 2) strengthening the current 
subnational and national PV systems, and 3) establishing a well-structured national PV 
center or program and ensuring its sustainability (10).  
Barriers encountered in the Qatar healthcare system and the factors influencing 
PV concepts and practices in the country are worth investigating, as they will be the 
first step toward developing feasible recommendations to improve PV in Qatar and to 
develop future plans to implement a national PV program or center for the management 
of medication safety, quality, and effectiveness in the country (10). Moreover, none of 
the PV system assessment studies conducted in the Arab world including the state of 
Qatar evaluated the PV system following a full system-based approach of structure, 
process, and outcomes components with the complete utilization of validated 
internationally recognized tools (i.e., PV KPIs). 
The current PV status at various levels of the Qatar healthcare system is an area 
worth investigating in order to improve the national PV situation. The areas of 
importance include: 1) the status of the national PV system with respect to structures, 
processes, and achieved outcomes; 2) the current good PV practices followed in the 
country; 3) the challenges facing the PV system and affecting its development; and 4) 
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national stakeholders' views on PV system improvement and the idea of a centralized 
PV system. Therefore, it is essential to understand the current situation in Qatar and 
how it can be improved to comply with the internationally recognized requirements for 
a functional PV system defined by the WHO and other international PV organizations, 
e.g., the SPS program (10, 11, 32, 40).  
4. Study Rational  
Medication safety issues can impose an additional burden on the healthcare 
system (41). In the literature, ADRs are a well-documented cause of mortality and 
morbidity in addition to the cost in terms of losing trust in the health care system. 
Additionally, ADRs can lead to additional costs related to hospital admissions, the 
prolongation of hospital stays, and the need for additional therapeutic interventions (42-
44).  In a meta-analysis study, ADRs were associated with more than 100 thousand 
deaths in the United States (U.S.) making ADRs the fourth to sixth leading cause of 
mortality in 1994 (42). A recent systematic review evaluated the economic impact of 
preventable ADRs in Western countries. The review found that the cost implications of 
preventable ADRs were between €2,851 and €9,015 in the inpatient setting and between 
€174 and €8,515 in the outpatient setting (44). In addition, a major study in the United 
Kingdom (UK) found that ADRs were associated with a longer hospitalization period, 
with an annual cost of up to € 706 million (45). Similarly, a major report by the U.S. 
Institute of Medicine reported the deaths of approximately 98 thousand individuals 
annually due to medication errors and found that treating injury resulting from 
medication error can have an annual cost of up to 29 billion U.S. dollars (41). 
Consequently, medication safety issues and ADRs are significant elements in 
healthcare system expenditures, and cost-saving benefits are associated with their early 
detection and prevention. Therefore, PV is an integral part of any healthcare system 
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that aims to reduce the burden of drug product-related morbidity and mortality (1, 10, 
41).  
The continuous growth and scope expansion of PV have been accompanied by 
challenges that impose burdens on PV systems at the strategic and operational levels 
(46). The SPS program has indicated that challenges affect PV system abilities to 
perform effectively and efficiently (10). Irrespective of the organizational structure and 
the developmental stage of a PV system, it faces a set of challenges. Additionally, 
regional differences require PV systems to identify a suitable approach to address 
contextual challenges, as a uniform approach may not be appropriate for all PV systems. 
Since the PV system is a subset of the healthcare system in a country, it is affected by 
some factors that affect the capacity of the PV system to achieve the desired outcomes 
(10, 11, 18, 32, 46, 47). 
To this end, the quality and evaluation of PV systems are important areas that 
have been recently discussed in the literature (10, 11, 18, 30, 32, 47). It has been stated 
that predefined measures (i.e., PV KPIs) are necessary to understand the effectiveness, 
performance, and adequacy of systems to achieve their objectives. Furthermore, the 
evaluation of systems can directly inform the concerned parties about the potential areas 
that require improvements or corrective actions, as the sources of the PV system 
underperformance will then be understood and can be addressed accordingly. This is 
essential in countries where PV systems are continuously challenged, and their 
effectiveness in safeguarding medication safety is not deemed satisfactory. Therefore, 
carrying out evaluation studies on PV systems is necessary to ensure patient safety in a 
country. Determining the strategic, structural, and operational grounds of such a unique 
system requires systematic and comprehensive system analysis (10, 11, 18, 30, 32, 47).  
Consequently, there is a need to evaluate the current PV situation in Qatar since 
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a specific PV system does not exist and the PV situation has not been comprehensively 
assessed using validated PV KPIs before. In the literature, only a few validated PV KPIs 
(e.g., the WHO PV indicators) exist for a comprehensive PV and medicine safety 
system assessment. Such PV KPIs permit a comprehensive evaluation with respect to 
structure, processes, and outcomes to detect the existing opportunities and deficiencies 
in order to develop, enhance or even monitor PV and medicine safety systems (11, 18, 
32). To the best of our knowledge, the present study will be the first in Qatar to use the 
WHO PV indicators for the purpose of a critical evaluation of the PV system. Finally, 
it is important to emphasize that there is no centralized PV center and a focal point in 
Qatar. Therefore, this research will use the knowledge of the available experts operating 
in the Qatar healthcare system in the specific area of PV. 
4.1. Research Aim and Objectives 
4.1.1. The Overall Aim 
This research aimed to conduct a comprehensive system assessment by 
evaluating the current state of the existing PV and medicine safety systems in Qatar 
with reference to the WHO PV indicators. Therefore, this study aimed to assess the 
state of PV at the subnational levels of Qatar's healthcare system. The study was 
extended to distinct levels of the Qatar healthcare system to obtain a better 
understanding of various stakeholders' views and subnational PV systems status, 
including PV system performance, challenges, strengths, and opportunities. In doing 
so, it determined the feasibility of identifying and generating recommendations to 
enhance the PV situation of Qatar. 
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4.1.2. Objectives 
The PV system analysis aimed to fulfill the following objectives:  
I. Evaluate the baseline PV situation using the WHO PV indicators. These 
recently developed PV KPIs allowed the measurement and assessment of the 
current PV system structures, processes, and outcomes achieved in the context 
of medicine and patient safety in Qatar. 
II. Compare the current PV situation in Qatar to the minimum recognized 
international standards for a functional PV system determined by the WHO. 
III. Identify the potential strengths, opportunities, and limitations that can affect the 
development of the PV system as well as the establishment and sustainability 
of a specific PV center. 
IV. Advocate feasible recommendations aimed at different stakeholders for the 
improvement of the PV situation as well as the creation and continuity of a well-
functioning PV system specific to Qatar's needs.  
5. Research Methodology  
The literature on research methodologies suggests that to obtain a 
comprehensive understanding of research problems and to overcome the limitations 
inherent to either the qualitative or quantitative approach alone, researchers can employ 
a mixed-methods research (MMR) approach (48, 49). The area of PV system 
assessment is no exception. PV systems assessment can be a comprehensive process of 
inquiry in which the qualitative and quantitative approaches can facilitate the 
assessment process and provide a means to negotiate the expected national goals and 
outcomes (50-52). In this light, MMR can be time and resource consuming, but there is 
growing evidence that MMR, if well designed, can be worth the investment because it 
enables researchers to gain a complete understanding by conducting both the qualitative 
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and quantitative methods. Because each method alone would provide only a partial 
view of a PV system (11, 49).  
This study aimed to conduct a comprehensive PV and medication safety system 
assessment employing an MMR case study design. According to Creswell and Clark, it 
is “a type of mixed methods study in which the quantitative and qualitative data 
collection, results, and integration are used to provide in depth evidence for a case(s) or 
develop cases for comparative analysis”. Within this complex design, the convergent 
core design was applied. It is a type of MMR design in which qualitative and 
quantitative data are collected concurrently, analyzed in parallel, and combined to 
provide a full understanding of the research problem (49). In this study, quantitative 
data were used to compare the performance of the national and subnational PV systems 
(i.e., the studied cases) to the WHO PV indicators, the latest assessment tool for PV 
systems. These PV KPIs represent the functionality and sophistication of the PV system 
and can aid in the development of strategic and operational recommendations to 
improve the PV system as well as to determine the measures required to achieve a fully 
operational system. Previous studies as well as the PV KPIs developed by the SPS 
program were used to complement the WHO PV indicators, including a few 
recommended PV KPIs thresholds used to obtain information not covered by the WHO 
PV indicators and the adaptation of a scoring system since the WHO PV indicators do 
not have one. The qualitative data obtained in the semistructured interviews on the 
subject of PV with national PV stakeholders from various sectors were used to provide 
a context-based system evaluation that was strongly dependent on the stakeholders' 
views and perceptions of the limitations, strengths, and opportunities present in the 
country. In addition, document review and field observation were employed to obtain 
qualitative information. The reason for collecting both qualitative and quantitative data 
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was to obtain a more comprehensive understanding of and deeper insight into the PV 
system in Qatar as well as to overcome the limitations inherent in using either the 
qualitative or quantitative approach alone (49, 53).  
6. Study Contribution 
As an introduction to this important topic in Qatar, this research included 
collecting, analyzing and compiling information on the aforementioned subject on the 
basis of the gathered available and accessible data. With the coordination of my advisor 
(Professor Mohamed Izham Mohamed Ibrahim, Ph.D.), this thesis is arranged to meet 
the requirements of the Master of Science (MSc) degree of Qatar University. The 
research describes various methods in the evaluation of PV systems. A detailed 
discussion of the findings of the study and its conclusions focuses on PV system 
requirements and their improvement. The available data are utilized at various levels of 
the healthcare system, mainly the healthcare regulatory bodies, public sector, private 
sector, pharmaceutical industry sector, academic institutions, and governmental health-
related organizations. 
Different stakeholders, including administrators in the Qatari healthcare system, 
can benefit from this system analysis. For instance, administrators at the Ministry of 
Public Health (MOPH), HMC, Primary Health Care Corporation (PHCC) and other 
sites can utilize the results and propose recommendations to implement and/or develop 
policies, regulations, activities, and programs aimed at improving public health and 
ensuring medication safety. In addition, the findings highlight some key aspects of the 
Qatar National Health Strategy, including the preparedness of the healthcare system 
and the development of a comprehensive healthcare system that takes into consideration 
the needs of the whole population (54). The following issues could be targeted: 
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I. Governmental bodies and healthcare institutions can improve the medication 
use process and ensure patient safety through the development, provision, and 
monitoring of specific policies, processes, and norms related to PV. 
II. Providing an a priori assessment is the foundation of the establishment of a 
national PV center that can play an active role in the PV field at the national and 
international levels. 
III. A sense of ownership and accountability among stakeholders in the decision-
making process regarding PV and the coordinated practices of PV should be 
encouraged. 
IV. Awareness of the need for a platform that encourages collaboration among 
academic, regulatory, and healthcare institutions through research and other 
activities that are valuable in addressing the current gaps and important aspects 
related to medication safety, efficient use of resources, decision-making 
processes, and system capacity building should be increased. 
V. Legal structures and guidelines for PV practices based on the evidence available 
in the WHO PV indicator manual and the current literature should be proposed. 
VI. The importance of launching a national medicine policy in Qatar to enforce the 
aspects of good PV practices should be highlighted since there is currently no 
such policy. 
VII. Improvements of the national data management systems or sharing networks for 
postmarketing surveillance activities, medication safety, medication errors, 
therapeutic guidelines, and system quality that are currently available and used 
in Qatar should be recommended to create valuable datasets for future 
utilization (e.g., research and development purposes). 
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VIII. The current gaps in PV practices should be communicated to the relevant 
authorities to be addressed for further improvements in the healthcare system to 
comply with international standards. 
7. Thesis Outline  
I. Chapter II, Literature review: This chapter will cover the literature pertinent to 
the history and criteria of PV system assessment and the concept of using 
different methodologies and PV KPIs. Additionally, it will identify the study 
guiding evaluative framework (i.e., the WHO PV indicators) and the planned 
research methodology. 
II. Chapter III, Methodology: This chapter will elaborate on the measures required 
to address the specific research problem at different levels, starting from 
reflecting on the employed research paradigm, followed by a description of the 
methodological approach, research design, and the specific qualitative and 
quantitative procedures for data collection, analysis, and interpretation.  
III. Chapter IV, Results: This chapter will concentrate on establishing the 
documented results required to address the specific research objectives 
including integrated results of the WHO PV indicators and qualitative research 
approaches. These results will be reported by subnational stakeholder level as 
well as at the overall Qatar system level. 
IV. Chapter V, Discussion and Conclusion: This chapter will include the 
interpretation of the study findings and their significance in the context of the 
research aim and specific objectives. Moreover, it will discuss the study 
findings to compare the national PV situation with other studies, standards and 
best practices from the literature. Additionally, it will present the limitations 
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associated with the design and conduct of this study. Finally, it will provide the 
recommendations and conclusions.  
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CHAPTER II: LITERATURE REVIEW 
 
This chapter will provide an overview of the literature concerning the 
pharmacovigilance (PV) discipline as a whole as well as the research foci on PV 
systems and the assessment of such systems. First, the concept of PV and PV systems 
around the globe will be delineated. Then, the literature using various methods and tools 
for PV system assessment will be discussed. This will be followed by a gap analysis of 
the PV situation in the Arab countries, with an emphasis on the PV situation in Qatar. 
To this end, the selected research methodology and the developed conceptual 
framework will be used as a guiding framework to realize the research aim. 
1. Pharmacovigilance  
International standards require that any drug to be released in the market must 
follow a specific system that ensures the efficacy and safety of the drug in preclinical 
testing and clinical trial testing. However, the thalidomide tragedy, in 1961, was the 
trigger for the publication of “International Drug Monitoring: The Role of National 
Centres.” This document fostered international awareness of the need for a specific 
system to identify drug safety issues at the postmarketing stage as well as awareness of 
the potential adverse effects of drugs considered to be safe in the premarketing stage. 
This document provided the input of subject matter experts around the globe and was 
guided by the WHO (4, 5, 8). After the realization of the need for continuous monitoring 
of released products, the idea of a system for postmarketing surveillance and/or PV was 
officially introduced and became a global standard system. (1, 13, 54). In 1968, the 
holistic system for the collection of ADR reports at the international level was officially 
named the WHO PIDM (9).  
The term “pharmacovigilance” was officially introduced in the 1970s by a group 
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of French researchers to identify the scientific field of concern about drug safety (55). 
PV can be referred to as drug safety, postmarketing surveillance, drug surveillance, or 
drug monitoring (56). The key terminology utilized in PV is defined differently by 
various authors and organizations. The main definitions used within this research are 
based on the WHO and UMC frameworks as well as the European Medicines Agency 
(EMA) when stated (15, 57, 58). 
PV is concerned with the systematic processes of the collection, collation, and 
analysis of reports of suspected ADRs as well as signal identification of suspected 
ADRs. It is also concerned with communicating safety information to PV stakeholders 
and the general public (11, 12, 15). Further, per the European Union (EU) PV system, 
PV can involve the decision-making process with respect to medication safety issues, a 
proactive risk management process, and an audit of PV processes as well as the 
associated outcomes (13). 
At the global level, the UMC is one of the collaborating centers within the WHO 
PIDM and is responsible for the development of the PV discipline and the technologies 
employed for drug safety. The UMC has also played a vital role in the development of 
the operational activities of PV, such as the management and maintenance of VigiBase, 
a repository database for collecting international ICSRs. There are four other WHO 
collaborating centers in the global PV network. The other centers are located in 
Norway, Morocco, the Netherlands, and India (59, 60) 
In addition to the establishment of the global PV network and the PIDM 
specifically, the safety issues that have emerged throughout the history of 
pharmaceutical products have fostered the adoption of various countermeasures and 
targeted efforts by international organizations and national regulatory bodies around 
the globe. These efforts have taken the form of programs, projects, and targeted 
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initiatives, such as the creation of standards for postmarketing drug surveillance to 
ensure effective PV (1, 56). For instance, a very early initiative in response to the 
thalidomide tragedy was the creation of reporting schemes for suspected safety issues 
in the UK. The yellow cards scheme, which was developed in 1964 to capture 
information regarding ADRs, to date remains in place to serve UK healthcare 
professionals and the public (61). More recently, the Strengthening Collaboration for 
Operating Pharmacovigilance in Europe (SCOPE) Joint Action was initiated in 
European nations in November 2013. SCOPE is aimed at strengthening the European 
PV network, improving the operational PV capabilities, and expanding collaborative 
work by national European medicines regulators. The project has resulted in the 
development of guidance and has provided training on the fundamental aspects of PV, 
and it has resulted in the development of some publicly available tools and templates 
to support PV practices (62). Such PV initiatives are continuously evolving as the 
medical community’s awareness and interest in PV as a discipline have increased 
through the continuous growth of this discipline and its potential contributions to the 
medical community (5). 
One of the strengths of PV as a discipline is the heterogeneity of the parties 
concerned and interested in the whole therapeutic product life cycle (5, 18, 63, 64). For 
more than 70 years, the PV discipline has shown promising growth with respect to 
global efforts to streamline and standardize PV through the development of specific 
parameters, methods, tools, terminologies, and infrastructural concepts to enable PV 
and to facilitate information sharing among various parties involved in it (5, 18, 63, 64). 
The importance of communication between PV parties has been further endorsed by 
the publication of the Erice Declaration, which has placed additional emphasis on the 
need for effective communications on medication safety among the various parties (65).  
  
22 
 
A constellation of various parties, namely, the UMC, national regulatory 
agencies, national PV centers, other reputable agencies such as the Food and Drug 
Administration (U.S. FDA), and the EMA has created a holistic and formal system for 
the global management of pharmaceutical product safety issues. In addition, it has been 
highlighted that in addition to the initial efforts by the WHO and the abovementioned 
key players, further efforts from national PV systems are essential to enhance PV global 
cooperation (1, 18, 59, 66). The active engagement of individual countries in global 
cooperation is a fundamental aspect of contemporary PV to identify and mitigate drug 
safety issues and to continuously shape and develop the global PV system. In fact, 
global data and knowledge sharing can play a major role in investigating and mitigating 
drug safety issues and in empowering healthcare professionals and the general public  
(18).  
National PV centers (i.e., PV systems) have been established in many countries 
to ensure that a systematic process is followed to guarantee drug safety in the country. 
Postmarketing surveillance and/or PV requires that systems and structures be in place 
to undertake the required functions. To establish an effective PV center, specific criteria 
should be followed. This process is almost harmonized, as many global parties (e.g., 
the WHO and SPS program) have shaped the criteria for countries to create a purposeful 
plan for building an effective PV center. An organized PV center requires the effective 
build-up of the formal capacities that are required for effective, efficient, and 
sustainable functionality and development. This depends mainly on the functions of the 
legal framework and PV policies, which will define the system and roles. Building these 
capacities also entails the proper management and monitoring of medications and other 
health-related products. These functions will become feasible with the proper 
utilization of workforce and infrastructure. The latter will be aided by the effective 
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utilization of services and equipment. All the aforementioned components, if managed 
well and benefiting from proper coordination, will ensure effective capacity building  
(10, 11, 13, 40, 67-69).   
Traditionally, national PV systems have been based mainly on passive PV 
approaches. Spontaneous reporting of ADRs, case series reports, and summary reports 
are examples of passive surveillance activities in which the eligible reporters are only 
encouraged to report medical product safety issues, and no specified active measures 
are undertaken to detect and act on ADRs or other safety issues. Passive surveillance is 
dependent mainly on the submission of spontaneous reports from various PV 
stakeholders such as the pharmaceutical industry, marketing authorization holders 
(MAHs), healthcare professionals, and, less commonly, patients. Those reports are 
mainly voluntarily reported; however, some countries mandate this form of reporting. 
However, more recently, active PV has gained ground in the developed countries, and 
active approaches are now utilized, e.g., through epidemiological and PV studies such 
as cohort event monitoring, intensive monitoring, and targeted reporting (10, 11, 30, 
68, 70). For a PV system to be considered a comprehensive entity for PV-related 
activities, it must cover both passive and active approaches. An all-encompassing 
system will aid in the processes of identifying medication safety issues, establishing 
mechanisms for the communication of safety information to the target audience, 
nurturing collaboration and coordination at the national and global levels, and fully 
integrating PV-related activities at all levels of the healthcare system  (11, 68, 70).   
Few countries have the resources required to initiate active surveillance as the 
prevailing approach for PV (10, 18, 29, 31). Countries with limited resources or rich 
countries with weak PV systems (i.e., developing countries) (71) rely on the more 
common passive method or appropriate data from other developed systems in which 
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both aforementioned types of PV activities are implemented as a way of communicating 
knowledge on the subject. Developed countries with well-established PV systems rely 
on both active and passive surveillance, as it is believed that the two forms provide 
complementary yet divergent approaches in terms of sensitivity and robustness, with 
an overarching aim of collecting a more comprehensive risk-benefit profile of available 
medicines (10, 18, 29, 31).  
2. Pharmacovigilance Systems in the Developing Countries  
In the past two decades, there has been considerable growth in the awareness of 
improving safety mechanisms among developing countries to ensure patient safety. 
This involves attention to improving PV practices and establishing national PV 
programs. Many developing countries have succeeded in becoming full members or 
associate members of the PIDM (20, 71, 72). Additionally, as shown in the UMC recent 
data, there has been encouraging substantial growth in developing countries reporting 
input to VigiBase, as reporting increased from 6.7% to 12.5% between 2011 and 2017 
(72). Nevertheless, developing countries often fail to successfully implement PV in the 
national healthcare system (20, 21, 72, 73). As described by Al Elshafie et al., 
developing countries are lagging in their awareness of PV systems and PV policies  
(73). This has been clearly reflected in the low numbers of ADR reports from 
developing countries received by the UMC in comparison to those received from 
developed nations (72).  To illustrate, an analysis of VigiBase reports found that low-
income countries, even those that had mass administration of medication and prevalent 
disease, had lower reporting rates than developed countries (74). Ampadu et al. reported 
that while the number of African countries entering the WHO PIDM grew, the reporting 
rate growth remained lower than 1% (75).  
De Abajo indicated that to date, spontaneous reporting is the main and possibly 
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the sole tool used to collect PV data in many developing countries. The author related 
this dependence to the simple and economical nature of spontaneous reporting (76). 
However, Giezen et al. noted that the use of such concepts in a PV system makes the 
system outdated (77).  Notably, Rodrigues and Khan reported that the shift from the 
prevalent method of spontaneous reporting to active approaches can put pressure on a 
PV system  (78). This shift can be especially challenging for less developed PV systems 
or systems based on outdated PV methods  (77, 78).  
Another challenge in spontaneous reporting among developing countries is the 
quality of the submitted reports (79). For instance, a study by Bandekar et al. aimed at 
evaluating ADR reporting forms, including quality, in various countries found that 
developing countries performed poorly with regard to the standard quality baseline of 
reporting forms; for example, Pakistan scored 6 of 18 possible points, and Sub-Saharan 
African countries scored 12. According to Rachlis et al., the unsatisfactory quality of 
reports as well as the lack of essential data that prevents further investigation is a 
challenge for PV systems  (80). Likewise, Pan indicated that the availability of high-
quality information is essential for PV systems (46). In developing countries, PV 
processes such as causality assessment and signal investigation can be unfeasible 
without solid data (21, 46, 79). In addition, Bandekar et al. concluded that there is a 
need for global guidelines on reporting forms to ensure that individual countries' 
contributions to the WHO global database are appropriate (79).  
As mentioned in the section on global PV systems, PV systems are established 
based on a hierarchical structure that starts at the global level, with the WHO PIDM 
and the UMC, and extends to national PV centers and subnational PV centers (e.g., 
regional centers) in individual countries (19, 81). In developing countries, the 
unavailability of dedicated PV centers, as well as the lack of subnational centers, was 
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confirmed by Olsson et al. and Isah et al. The authors related the shortage of PV centers 
to the dearth of monetary and nonmonetary assistance, namely, government support, 
human resources, infrastructure, capacity building initiatives, and PV methodologies 
(21, 82). A major study by the SPS program of 46 African countries reported that 26% 
of the countries had no dedicated PV center, and of the sample, almost 90% had a 
nonfunctional systems (31). Similarly, a study covering five Asian countries reported 
that no more than 50% of the assessed health facilities had a functional system (29).  
Regarding PV legislation in their analysis of 55 countries, Olsson et al. reported 
that developing countries' PV systems are burdened by a lack of PV legislation or 
challenged by ineffective PV legislation. Olsson et al. noted that there is a need for 
better legislation for proper coordination of PV systems (21).  Similarly, PV studies in 
developing countries have suggested that 59% of African countries lack national 
policies on the subject of PV or medication safety (31) and that fewer than 60% of 
Asian countries' health facilities have guidelines or standard operating procedures 
(SOPs) that address PV (29). 
Additionally, the authors attributed the successful operation of PV systems to 
the acquisition of and proper allocation of resources. Resources include monetary and 
nonmonetary (e.g., technological infrastructure, human resources, public participation) 
assistance (20, 46, 82, 83). For instance, it has been reported that the effective 
management of existing resources for the operation of a system is one of the most 
crucial factors in the success of a PV system (83, 84). Isah et al. asserted that PV 
systems operate within a limited budget and that this scenario is more prominent in 
developing countries, as many countries suffer from political or social challenges, 
forcing them to target their limited resources and efforts toward prominent challenges 
such as war and poverty. This investment often does not include PV implementation, 
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and PV is not a priority within the healthcare system (82). Similarly, a survey conducted 
in 2016 by Suwankesawong et al. indicated that Association of Southeast Asian Nation 
(ASEAN) countries reported the lack of resources as one of the main challenges 
affecting the development of PV systems (85). Olsson et al. reported that a common 
challenge for developing countries is the lack of technical capacity (20, 21). 
Shortcomings in the skills, knowledge, and experience required for PV are interfering 
with the efficient operation of PV systems as well as the developmental capacity of PV 
systems (10, 20, 21, 46).  
 As mentioned above, public participation (e.g., of patients and consumers) is 
one of the important resource elements for successful PV operation, as these 
participants are considered key stakeholders in contemporary PV (1, 46, 78). In 
developing countries, public participation and involvement are minimal (21, 46, 86), 
Additionally, it has been reported that in developing nations, there is a lack of trust in 
the healthcare system (87). This issue is especially challenging, as there is a reported 
lack of trust among the general public, even in developed nations, regarding drug safety 
systems and the pharmaceutical industry (88). Therefore, building effective 
relationships with consumers is necessary within the context of developing nations.  
According to Palaian, the failure of PV implementation in developing countries 
occurs in various stages, as described below (72): 
I. National level: PV systems can lack the commitment of regulatory authorities 
or the health ministry e.g., omissions in PV policy provisions. 
II. Institutional level: PV programs remain uninstitutionalized, and PV programs 
often fail to receive support from the leadership or management of an institute.  
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III. Individual level: PV system implementation and subsequent success often 
depend on the efforts of few enthusiastic and dedicated individuals. This 
reliance on a few individuals, often without the necessary monetary and 
nonmonetary assistance, can lead to failure to realize PV goals. 
To conclude, Pan remarked that international efforts need to be targeted toward the 
subject of strengthening PV systems in countries where PV systems are overburdened 
or simply do not exist. In addition, it is important to evaluate the outcomes of growing 
PV systems (46).   
3. Pharmacovigilance Systems Evaluation 
Over the years, PV as a science has developed to include sophisticated structures 
and processes, and its scope has expanded due to the efforts of international 
organizations and the global PV network. At the heart of those efforts is the 
establishment of PV systems as entities required to ensure medication safety and protect 
public health. Despite the surging advancement of PV, the need to develop objective 
metrics for PV system assessment, evaluation, and monitoring was realized not long 
ago. However, because monitoring the safety, quality, and effectiveness of medications 
has been a focus of PV around the globe, the development of PV systems has been 
accompanied by the development of tools to assess those systems. In the field of PV, 
there have been few initiatives by international organizations and professional groups 
to develop objective measures (i.e., PV KPIs) to assess the performance and adequacy 
of PV systems. Those PV KPIs have been established as validated tools to evaluate the 
performance of PV systems on the way to identifying areas that need proper investment 
to improve PV systems in terms of performance and capacity (18, 32, 47). 
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3.1. Pharmacovigilance Indicators History and Development: A Permeable to 
International Efforts  
In 2006, the Fraunhofer survey, the European Community System of 
Pharmacovigilance Assessment, was one of the early initiatives to comprehensively 
assess PV systems and propose some useful metrics to serve as PV KPIs in the 
European context. The survey report provided details on the suggested success factors 
as well as the PV KPIs required for a robust PV system. The system assessment 
included the EMA, EU member states’ medicines agencies, MAHs, and other 
stakeholders. The assessment focused on aspects related to the legal framework, 
technical and human resources, stakeholder coordination and/or cooperation, PV data 
collection, safety studies, quality management, PV data management (e.g., systems and 
databases), signal detection, PV data assessment, decision-making processes, and the 
communication and implementation of actions. It found that any legal framework helps 
harmonize the work and makes regular action more effective, but at the same time, 
managing such a framework can be complicated because of the differences between the 
various authorities involved that make it difficult to oversee the existing guidelines. It 
also alluded to the frequently difficult communication between agencies of varying 
quality and with different standards. Moreover, a portion of the work was duplicated 
among different agencies. In addition, the lack of safety studies and related data was a 
substantial hurdle at the time, and most databases were insufficient to manage the 
necessary data. Additionally, the decision-making process was delayed beyond an 
acceptable time, and experts from abroad were suggested to be beneficial if they were 
available and managed correctly. The Fraunhofer survey concluded that for a successful 
and more robust system, there was a need to review the different sources of PV data 
used, review and streamline the decision-making process, systematically examine 
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communications and the implemented actions, ensure the accountability of MAHs in 
complying with the legal obligations, identify and correct system weaknesses, and 
perform continuous audits to ensure the realization of PV targets (e.g., impact values) 
(89). Subsequent to the Fraunhofer survey, other international efforts have resulted in 
the development of comprehensive PV KPIs for PV systems (18).  
First, in 2009, was the effort by the European Society for Quality in Health Care, 
Office for Quality Indicators. A set of indicators was developed with the aim of serving 
as a tool to monitor patient safety quality problems (90). Those indicators, although not 
specific to PV, covered aspects relevant to PV, including medication errors and culture. 
Because the indicators are not specific to PV, they are not utilized as an assessment tool 
in this research.  
Second, in 2009, “The Management Sciences for Health (MSH) – U.S. Agency 
for International Development (USAID) Indicator-based Pharmacovigilance 
Assessment Tool” (IPAT) was developed to assess PV systems on the basis of a system-
based approach to structure, processes, and outcomes. The SPS program published a 
manual for this PV indicator tool, which was designed for implementation in 
developing countries. There are two main PV KPIs: core categories (n=26) and 
supplementary categories (n=17), and each indicator category is intended to cover a 
group of essential component of PV, specifically, a) “Policy, law, and regulation”; b) 
“System, structure, and stakeholder coordination”; c) “Signal generation and data 
management”; d) “Risk assessment and evaluation”; and e) “Risk management and 
communication”. The IPAT has a scoring scheme based on the ability of the PV system 
to meet the threshold of functionality for each indicator. If an indicator is available or 
reaches the standard threshold of functionality, the indicator score is entered as “2” for 
core and “1” for supplementary; if the standard threshold is not attained, a score of “0” 
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will be recorded. This tool has high validity and wide applicability in the context of 
developing countries, where systems are at an early stage of development. The IPAT 
implementation will be discussed further in this chapter since the tool will be used to 
complement the main assessment PV KPIs: the WHO PV indicators. This involves 
including a few recommended thresholds of IPAT, inquiring about information that is 
not covered by the WHO PV indicators, and adapting the IPAT scoring system (32).  
Third, Kshirsagar et al. published a paper in 2010 with the aim of providing a 
set of desirable features for objective PV KPIs specially tailored to PV system 
assessment. Those PV KPIs were used to compare PV system performance in the U.S. 
and in Africa to demonstrate the potential applicability and usefulness of the selected 
indicators in PV systems at varying stages of development. The authors concluded that 
irrespective of the PV system stage of advancement, continuous monitoring and 
evaluation are required to ensure that the system achieves the target outcomes of PV 
(47).  
Fourth and finally, in 2015, the WHO developed PV KPIs as a tool to evaluate 
a PV system’s capacity, performance, and ability to fulfill its objectives. The indicators 
measure the aforementioned aspects based on structure, process, and outcome criteria. 
This tool will be utilized in the evaluation of the PV system in Qatar given its high 
validity, reliability, and applicability and because it is the most recent PV KPIs 
developed. The WHO PV indicators will be reviewed in more detail in this chapter (11).  
In addition, the literature has reported the existence of checklists used for 
regulatory assessment. However, the metrics used do not provide a comprehensive 
assessment. Some PV inspections rely on the use of metrics to evaluate the systems. 
However, these metrics have often been developed for use in MAH systems, and many 
other PV stakeholders are often excluded. Moreover, countries can establish their own 
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performance metrics. For instance, in France, the French healthcare system established 
PV KPIs for the routine evaluation of its PV system as well as for national health 
facilities (18, 91). Similarly, countries such as Belgium, Canada, and Portugal follow 
the same practice of evaluating their systems based on country-specific criteria that may 
depend on published or unpublished metrics (30). Nevertheless, this chapter will not 
discuss the application of those measures since the most predominantly used, 
comprehensive, and validated PV KPIs are the IPAT and the WHO PV indicators, both 
of which offer the opportunity to evaluate different systems, including regulatory 
bodies and other subnational PV systems, within the context of developing countries 
and/or developing PV systems (18).  
4. World Health Organization Pharmacovigilance Indicators  
The main research tool, the WHO PV KPIs, is considered the latest PV systems 
assessment tool, it was developed after years of continuous development by the WHO, 
the professionl organization responsible for the PIDM, which covers almost 90% of the 
global population (11, 59).  
The WHO PV indicators manual is a validated and standardized tool that is 
available on the WHO website (11).  The idea of the WHO PV indicators was first 
discussed in 2007 during a meeting of Pharmacovigilance Sans Frontiers that involved 
PV experts from African countries and was supported by the WHO and the UMC, the 
main PV partners at the global level. Accordingly, a consensual approach was followed 
to develop a set of objective measures to assess PV systems (11, 92). Afterward, the 
initial set of PV KPIs was utilized in a systematic assessment of PV systems, with a 
focus on the elements of structure, processes, and outcomes. In addition to the 
consensual approach, the process of identifying PV KPIs was reliant on other 
established WHO indicator methodologies (11), the “Australian Therapeutic Indicator 
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Schema” (18), and key findings from a major questionnaire-based study on PV systems 
covering 55 countries (21). This was followed by further selection and categorization 
of the PV KPIs (93). To validate the final PV KPIs set, many PV experts were involved, 
and in 2015, the WHO PV indicators were made publicly available on the WHO website 
(11). 
According to the WHO manual, the PV KPIs are “specific objective measures 
that allow the evaluation of the baseline, situation and progress in a system and the 
assessment of services and interventions”. It “measures the input, processes, outputs, 
outcomes, and impact of development projects, programs or policies related to health 
systems and services….on how well a PV programme is achieving its objectives” (11) 
The WHO PV indicators are designed to be reproducible and have been successfully 
adapted in various countries. The selected WHO PV indicators, when used as an 
assessment tool, can provide simple measures for the compliance of PV systems with 
the expected PV WHO framework. The PV KPIs are specific and can be used to detect 
and interpret recognizable gaps in a PV system or simply to explore and outline the 
current structures, the process of PV systems, and the PV system’s impact on the 
healthcare system (11, 18). 
  PV KPIs are classified based on a system-based approach to: a) Structural 
indicators: indicators selected to recognize and evaluate the PV structures required for 
a visible and standard-compliant PV system; b) Process: indicators selected to assess 
the breadth and depth of PV functionalities, e.g., activities relevant to the collection, 
collation, analysis, and evaluation of PV data, including ADRs; c) Impact or outcome 
indicators: indicators selected to measure the consequences as outcomes for the 
development and effect of PV activities to ensure patients' safety as a key objective; d) 
Public health program (PHP) indicators: indicators selected to assess the PV system 
  
34 
 
situation at the program level; and e) Background information: indicators selected to 
outline the demographics, the pharmaceutical sector, and much other relevant 
information on the country or site being assessed (11).  
4.1. World Health Organization Pharmacovigilance Indicators 
Implementation  
Table 1 below highlight the international studies that have utilized WHO PV 
indicators for a PV system assessment. Some studies have been conducted in the Arab 
world; therefore, they will be discussed under the Arab world section.  
Some of the below mentioned studies' limitations will be addressed by 
developing a scoring system, utilizing all of the WHO PV indicator categories, 
including various stakeholders across the healthcare system to ensure better 
representation of the national PV scenario, and utilizing the qualitative research 
approach to ensure a comprehensive collection of context-specific data. This will be 
described in detail in the current study section of this chapter.
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Table 1. Characteristics of the included literature on the subject World Health Organization (WHO) pharmacovigilance (PV) indicators 
implementation 
Author 
and 
date  
Background 
and/or objective 
Methods  Findings Review  
Opadeyi 
et al. 
(2018)  
A study on PV 
status in six 
tertiary hospitals 
with the aim of 
improving the PV 
situation in the 
south-south zone 
of Nigeria (94). 
• The WHO PV core 
indicators were 
adapted, phrased, 
and employed in the 
assessment. 
• The sample was 
randomly selected. 
• The sample reported the presence of a 
PV department. However, only three 
systems could be considered 
appropriately functional.  
• The main challenges identified in the 
hospital setting were the unavailability 
of ADR reporting forms in some 
hospitals, underreporting problems 
(e.g., only one institution reported 
submitting reports to the national PV 
center), and poor documentation 
systems and PV data practices.  
• The authors described the need to 
strengthen PV systems with a special 
emphasis on the need to institutionalize 
PV as a first step toward improving PV 
in hospital settings. 
• The limitations of the study included the 
small number of included hospitals and the 
fact that the study did not include other 
levels of the healthcare system, e.g., 
regulatory bodies, the pharmaceutical 
industry, and academic institutions. 
• Limitations inherent to the WHO PV 
indicators when used in survey design. For 
instance, it was reported that the actual 
details and system functions were not 
reflected by the dichotomous response 
provided by the structural indicators. 
Additionally, challenges of the successful 
implementation of outcome indicators were 
reported.  
• The authors reported the need to develop a 
scoring scheme to enable system 
weaknesses to be demonstrated in numerical 
terms, since the WHO PV indicators do not 
yet have a scoring system. 
Shin et 
al. 
(2019) 
A study in 15 
Asia-Pacific 
region countries 
to evaluate the 
• The authors used a 
modified WHO PV 
indicator 
questionnaire to 
• Based on the recorded data, disparity 
exist between systems. For instance, for 
process indicators, the source of the 
ADR reports differed between 
• The limitations of the study can be 
attributed to the survey design using emails, 
as it can be affected by response bias or 
arbitrary interpretation.  
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Author 
and 
date  
Background 
and/or objective 
Methods  Findings Review  
structure, 
process, and 
outcome 
components of 
the PV system 
and to understand 
PV regulatory 
differences 
between 
countries (95). 
assess the systems 
using an email 
survey with 
questions and 
subquestions. 
• The authors 
developed a simple 
scoring system that 
recorded responses 
as “no/not 
applicable” or “yes” 
(i.e., categorical 
variable). 
countries. In addition, for outcome 
indicators, the U.S. was reported to be a 
very active country in terms of active 
PV efforts. 
• In conclusion, the authors 
recommended global harmonization, 
which can include guidelines 
harmonization, as an essential step 
toward PV improvement. 
• The WHO PV indicators were not used 
comprehensively (i.e., the full set of 
indicators was not used). Therefore, the 
ability to benchmark the PV systems against 
the standardized WHO requirements is 
inadequate.  
• The study is limited because it represents 
only the regulatory body system 
performance and adequacy, whereas the 
level of PV implementation across the 
different levels of the healthcare systems 
remains unclear, and no opportunities will 
be available to compare subnational PV 
situations, e.g., private sector performance. 
• Nevertheless, the authors achieved expert 
agreement on the development of the study 
questionnaire. 
• This study contributed by increasing our 
understanding of the differences in 
regulatory PV and the effect on the PV 
system functionality observed between the 
surveyed countries.  
• Moreover, harmonization as a final 
recommendation is highly valuable, given 
that it will be executed strategically to 
benefit different systems by improving PV 
at the national and global levels.  
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Author 
and 
date  
Background 
and/or objective 
Methods  Findings Review  
Ejekam 
et al. 
(2017) 
A study 
conducted in 
Nigeria to 
evaluate the PV 
system in three 
selected national 
PHPs (96). 
• A cross-sectional 
descriptive study 
employed the WHO 
PV indicators 
namely, PHP 
indicators. 
• The study used 
interviews with 
national PV key 
informants to collect 
the required 
information on the 
national programs' 
PV system 
structures, 
processes, and 
outcomes. 
• The main structures required for PV 
activities were available; however, the 
system lacked optimal implementation 
of PV. For instance, underreporting 
ADRs and poor documentation of PV 
data were affecting the PHP systems.  
• In addition to the aforementioned 
limitations, financial resources and 
human resources were deemed common 
issues in the authors’ thematic analysis. 
• It was not feasible to examine the study in 
detail to obtain information on the values 
and detailed results, as only the abstract of 
this study was available. 
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5. Minimum Requirements of the World Health Organization  
For countries seeking to improve their PV systems, the WHO minimum 
requirements for PV were defined as the first standard by the WHO (2010)  for countries 
to use as the measuring criteria for their systems (i.e., PV center, ADR or PV advisory 
committee, spontaneous reporting system. national database, ADR reporting form, and 
communication strategy). These requirements are the lowest acceptable quality level 
that ensures that a PV system exists and can function properly (40). Those requirements 
will be used in this research as an assessment guide to identify the minimum capacity 
of a functional PV compared to the WHO PV indicators that assess the complete all of 
the PV system components. Table 2 below highlights the international studies that have 
utilized WHO minimum requirements for a PV system assessment. 
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Table 2. Characteristics of the included literature on the subject World Health Organization (WHO) minimum requirements implementation  
Author 
and 
date  
Background 
and/or objective 
Methods  Findings Review  
Maigett
er et al. 
(2015) 
The authors 
studied the PV 
system in 
Uganda, South 
Africa, and India 
and compared 
them to the 
minimum 
requirements for 
PV systems by 
the WHO (97). 
• Data collection for this 
research involved 
conducting multiple 
interviews as well as a 
literature review (i.e., 
gap analysis).  
• After analyzing the 
data, the authors 
compared their findings 
with the WHO 
requirements. 
• Maigetter et al. concluded that the 
countries examined need more funding 
so that the PV activities could be 
coordinated and sustained according to 
the WHO requirements.  
• The authors emphasized the need for a 
systematic approach so that PV 
practices and facilities could be 
regularly monitored and evaluated. 
• The authors noted a limitation in the 
WHO guidance, as one full-time staff 
member was deemed inadequate for 
running a PV center. This review also 
contained the remark that one full-time 
staff member would not be able to handle 
emergency cases that require immediate 
action. 
Suwank
esawong 
et al. 
(2016) 
The authors 
studied the PV 
landscape in the 
ASEAN 
countries and 
identified the 
challenges that 
these systems 
face (85). 
• The authors utilized the 
WHO minimum 
requirements to assess 
each country. 
• In addition to the 
assessment of the 
minimum requirements, 
the authors determined 
a few PV KPIs related 
to the PV process, 
namely, the number of 
ICSRs, signal detection 
and management, and 
• The authors indicated that Malaysia, 
Singapore, Thailand, and Indonesia 
met and/or exceeded the minimum 
requirements, while the remaining 
countries did not.  
• The authors concluded that an advisory 
committee should provide technical 
assistance to strengthen the PV 
systems. 
• Additionally, an effective 
communication strategy between the 
different entities was considered 
essential in strengthening PV systems. 
• This study developed the following 
scoring scheme for the minimum 
requirements: “no” (0), “yes” (1), and 
“unclear answer” (0.5). This scoring 
system enabled the quantification of data 
to compare countries, and the addition of 
a score (0.5) for ambiguous response 
implies that the authors attempted to 
deliver a fair evaluation across the 
sample. 
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Author 
and 
date  
Background 
and/or objective 
Methods  Findings Review  
sending reports to the 
global database.  
McEwe
n et al. 
(2016) 
In a current 
opinion published 
in the Drug 
Safety journal, 
McEwen et al. 
presented the 
case of Pacific 
Island countries 
and their ability 
to meet the five 
minimum 
requirements 
(98). 
• Not provided. • The authors indicated that most of 
these countries did not have the 
capacity or resources to meet the 
requirements and that PV is ineffective 
in a setting of such limited resources.  
• Therefore, the authors proposed that 
for small countries with very limited 
capacity, external support is needed 
and that targeting the quality of 
medications should be a priority before 
attempting to build the capacity to 
impose the five WHO requirements on 
an operational system. 
• The review emphasized the authors' 
remark on the need for external support to 
understand a country's situation when it 
fails to meet the lowest required 
standards of operation. Understanding the 
challenges and prioritization based on the 
national context would be even more 
crucial in such cases compared to striving 
to establish a standard that may not solve 
context-specific situations. 
• A limitation is that the assessment 
methodology was not described since this 
was not a research article. 
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6. Indicator-based Pharmacovigilance Assessment Tool Implementation  
To date, the IPAT has been successfully utilized in more than 50 countries. The 
international efforts to apply the IPAT will be presented in Table 3. The PV effort in 
the below-mentioned countries has been reported as the consequence of empirical 
research and a review of the relevant literature. This is a signpost of the necessity of 
evaluating the PV system in each unique context to identify the best fit for the purpose 
of a solution aimed at the advancement of PV and PV systems at the national and 
international levels.  
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Table 3. Characteristics of the included literature on the subject Indicator-based Pharmacovigilance Assessment Tool (IPAT) implementation 
Author and 
date  
Background and/or 
objective 
Methods  Findings Review  
The SPS 
program (2011) 
Forty-six countries 
located in Sub-
Saharan Africa were 
evaluated by the 
SPS program to fill 
the gap in the PV 
scenario, including 
identifying context-
based challenges, 
success factors, and 
recommendations 
(31). 
• The methodology included a 
survey of the literature, mail 
surveys, and in-depth 
situational analyses of 9 
selected countries. 
• The countries' PV system 
performance and capacities 
were evaluated using the 
IPAT. 
• The impact of challenges on PV system 
capacity was very clear, as 87% of the 
countries failed to have a functional PV 
system.  
• The main challenges reported were the 
absence of medication safety policies 
(59%) and the absence of a policy for 
adverse event monitoring (70%). In 
addition, the document mentioned the 
lack of an organized PV center (26%) 
and a dedicated advisory committee on 
medication safety (61%). 
• The methodology and 
findings were included 
in a document posted on 
the WHO website.  
• For this research, the 
previously published 
studies’ methodological 
best practices will be 
utilized, and findings 
from the major works 
(e.g., challenges and 
recommendations) will 
be included in the 
supplementary 
assessment questions 
related to the WHO PV 
indicators. This will 
facilitate the collection 
of supplementary data 
when the stakeholders 
do not satisfy the WHO 
PV indicator standards. 
The Systems 
for Improved 
Access to 
Pharmaceutical
s and Services 
(SIAPS) 
Program (2013) 
SIAPS Program 
conducted an 
analysis of the PV 
systems of 5 Asian 
countries 
(Bangladesh, the 
Philippines, 
Thailand, Nepal, and 
Cambodia) (29). 
• The methods used were a 
review of the literature 
pertinent to the PV systems 
and regulatory frameworks 
in the selected countries 
followed by an in-depth 
single-country assessment 
using the IPAT.  
• Then, based on the results of 
the in-depth assessment, a 
comparative analysis of the 
countries was performed. 
• The findings provided information on the 
variations in the PV systems as well as 
the challenges faced by each system.  
• The study indicated that the statutory 
provisions available to define PV and 
medication safety vary between 
countries. For instance, even though both 
the Philippines and Cambodia have legal 
mandates for pharmaceutical industry 
reporting, only the Philippines has a 
legally binding mandate for the industry 
to conduct postmarketing surveillance of 
its products.  
• The identified areas of system weakness 
were similar to those in Africa, as less 
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Author and 
date  
Background and/or 
objective 
Methods  Findings Review  
than half of the health facilities surveyed 
reported the existence of a functional PV 
center or unit. In addition, only 50% had 
established a drug and therapeutics 
committee to provide support as well as 
advice on medication safety and PV.  
• The study concluded with a call for 
international efforts to strengthen PV 
systems and safeguard patients' safety in 
Asian countries 
Nwokike and 
Joshi (2009)  
A diagnostic system 
analysis of the 
existing PV system 
in Rwanda as part of 
the SPS program 
work in developing 
nations (99). 
• The authors used structured 
interviews following the 
IPAT assessment questions.  
• Additionally, they reviewed 
the national documents and 
interviewed key informants.  
• The study gave information on the 
national system capacity, including the 
relevant national departments and 16 
health facilities. 
• Based on the recorded data, including the 
“SWOT analysis,” the national PV 
scenario could be improved by 
strengthening the legal provisions and 
approving required PV and medication 
safety-specific legislation, establishing a 
center for PV and drug information 
under a regulatory body, establishing a 
national PV committee, and 
strengthening the pharmacy and 
therapeutics committees at the health 
facility level. 
• The study described the 
usefulness of the IPAT 
as a diagnostic tool that 
can be used for the 
routine monitoring of 
systems. 
• This research will also 
employ the SWOT 
analysis framework.  
Lebega et al. 
(2012)  
Lebega et al. 
conducted a 
comprehensive 
assessment to 
• The authors collected 
evidence based on 
interviews with national 
• At that time, the findings were 
considered the highest results achieved 
for PV system performance, with an 
• Limitation and 
possibility of error 
because the study relied 
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Author and 
date  
Background and/or 
objective 
Methods  Findings Review  
benchmark the 
performance of 
Ukraine’s healthcare 
system by including 
different levels of 
national PV systems, 
such as academia 
and the healthcare 
industry (100). 
stakeholders as well as a 
literature survey pertinent to 
PV and medication safety in 
Ukraine. 
overall result exceeding the performance 
of 40 countries. 
• The authors provided information on 
weaknesses affecting the system related 
to medical device surveillance, national 
PV implementation, and active PV or 
surveillance activities.  
• Therefore, it was recommended that the 
aforementioned weaknesses be resolved 
through a robust legislative base, 
targeted solutions, and national 
coordination and cooperation. 
on the data collector 
interpretation when 
transforming qualitative 
findings into quantitative 
forms.  Additionally, the 
study did not verify the 
provided responses. 
• Lower-level health 
facilities were not 
included affecting the 
study generalizability. 
Kabore et al. 
(2013) 
The authors 
evaluated the PV 
system in Burkina 
Faso to identify 
possible areas of 
improvement and 
used the IPAT as the 
means of data 
collection (101). 
• The IPAT was the mean for 
data collection. 
• The interviewed Key 
informants were selected by 
convenience sampling.  
• Based on their results, PV-specific 
guidelines were lacking, and the 
coordination of stakeholders was 
insufficient.  
• Kabore et al. also provided suggestions 
to help implement and design pertinent 
activities to improve PV in the country.  
• The sample was limited 
in number, and the study 
did not include some 
healthcare sectors e.g. 
private sector. 
• The study included a 
high number of 
respondents from a 
pharmacy background 
(i.e., 75%). 
Allabi and 
Nwokike 
(2014) 
A situational 
analysis of the Benin 
PV system 
conducted in 2009. 
The system analysis 
was deemed 
necessary after the 
• The IPAT tool was 
employed in the system 
assessment. 
• The quantitative approach 
included semistructured 
interviews with national 
stakeholders, including 
• The authors recommended that PV be 
improved in the country by establishing a 
national PV center, forming a PV 
committee, building human resource 
capacities (e.g., providing training, 
utilizing university students), and 
• The study took both 
quantitative and 
qualitative approaches, 
each of which delivered 
a unique understanding 
of the PV situation. 
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Author and 
date  
Background and/or 
objective 
Methods  Findings Review  
increased 
accessibility of 
antimalarial 
medications due to 
changes in the 
malaria control 
policy (50). 
practicing healthcare 
professionals, drug 
representatives, and 
representatives of the 
pharmaceutical industry, to 
assess their knowledge, 
attitude and practices related 
to ADRs.  
• The qualitative approach 
included conducting a focus 
group discussion with 
national regulatory officials 
of Benin to obtain their 
views on the measures 
required to improve PV in 
the country 
ensuring strong links among national 
stakeholders. 
• The recognized strength 
of the study is its use of 
various methods, each of 
which targeted a 
component of the 
system, e.g., the 
reporters (e.g., 
healthcare professionals) 
and the data analyzers 
(e.g., the regulatory 
body), as well as the 
system itself (using the 
validated indicator tool).  
• Additionally, the study 
allowed the authors to 
conduct a SWOT 
analysis to inform the 
development of the 
recommendations. 
Abiri and 
Johnson (2019)  
The authors aimed 
to provide 
information on the 
PV functionality 
status of the national 
stakeholders since 
the country (i.e., 
Sierra Leone) had 
officially become a 
member of the 
PIDM (52). 
• A descriptive cross-sectional 
study conducted in 2016 
using the IPAT on the PV 
systems of various national 
stakeholders (i.e., the 
regulatory body, PHPs, and 
medical facilities) in Sierra 
Leone. 
• The study included 14 
respondents from various 
sites, namely, the national 
• When a threshold of 60% was set to 
categorize system performance, the 
recorded data showed that the regulatory 
body was able to reach and exceed the 
target threshold, but the other 
stakeholders’ systems did not satisfy the 
criteria, and the PV systems clearly 
required further strengthening. 
• However, some 
limitations were related 
to the reliance on the 
convenience sampling 
method and the small 
number of study sites.  
• Additionally, the study 
had the commonly 
encountered issue of 
reliance on the key 
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Author and 
date  
Background and/or 
objective 
Methods  Findings Review  
regulatory body, 3 teaching 
hospitals and 3 regional 
referral health facilities, and 
6 PHPs. 
informants’ information 
and assertions.  
• In addition, the 
identified gap was that 
the threshold of overall 
functionality (i.e., 60%) 
was subjectively set with 
no evidence from IPAT 
and no consideration of 
statistical targets, e.g., 
performance based on a 
quartile range. 
Nwokike and 
Eghan (2010)  
Nwokike and Eghan, 
representing the SPS 
program, conducted 
a comprehensive 
situational analysis 
at the request of the 
regulatory body in 
Ghana (51). 
• Using multiple methods 
including semistructured 
interviews with national key 
informants and document 
review. 
• The main shortfalls were the lack of 
statutory provisions on PV, the lack of a 
mechanism to coordinate among 
stakeholders, and the lack of a dedicated 
budget for PV.  
• Additionally, the process and outcome 
domains required to attain a well-
functioning system were deficient.  
• Accordingly, the authors recommended 
revising the existing legal provisions, 
developing PV guidelines, establishing a 
postmarketing directorate under the 
regulatory body, improving cooperation 
and coordination among national 
stakeholders, and implementing or 
enhancing PV activities, e.g., 
spontaneous reporting. 
• The authors discussed 
the PV situation across 
the different levels of the 
Ghana health system and 
how it could be 
improved to ensure the 
safety of health 
products. However, the 
limited number of the 
included representative 
sample can affect the 
generalizability. 
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• In addition, at the health facilities level, 
they recommended measures to improve 
the contribution of drug and therapeutics 
committees to PV-related activities.  
• Finally, the authors recommended 
prioritizing areas worth targeting through 
medication safety research to improve 
PV. 
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7. Other Research Methodologies to Assess Pharmacovigilance Systems  
In addition to the use of PV KPIs and guidance documents to assess PV system 
capacity, other forms of research can deliver insight into PV systems or an aspect of 
those systems. These can include but are not limited to PV review articles, qualitative 
studies, and policy assessments. 
Narrative reviews or expert opinions on the PV situation can be performed for 
a single country or across several countries (20, 26, 102-105). These assessments are 
performed by conducting a literature survey that often includes published scholarly 
articles, governmental documents, and governmental websites to determine the current 
standing of PV systems. Although they can be affected by the limitations of selection 
bias, the quality of the content included, and the methodology used to extract the 
relevant literature, reviews have been used to describe PV in many countries. For 
instance, Olson et al. described the PV landscape in developing countries through an 
expert review that is commonly cited because it discusses the challenges affecting 
developing countries' capacity to improve PV (20). Additionally, Gupta et al. compared 
PV regulations among four countries to identify areas that required improvement and 
provided recommendations, e.g., the need for harmonization  (106). In addition, reviews 
can include a discussion of a country's PV system. For instance, Zhang et al. described 
the PV scenario in China in a leading article published in Drug Safety (81). This 
approach will not be utilized alone, as it does not rely on evidence-based tools or 
methodology for PV system assessment.  
Qualitative research often focuses on aspects selected for study through an 
exhaustive qualitative methodology, such as country case studies and in-depth 
interviews with key informants (107). Such initiatives require time, are limited in their 
generalizability, and/or can be influenced by the researcher role; however, they can 
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deliver a wealth of details on the components required for a functional PV system (108). 
For instance, Ampadu et al. conducted qualitative semistructured interviews to 
investigate how different categories of resources and relations with concerned PV 
parties can affect unsuccessful and successful PV activities in 18 African countries 
(109). Similarly, Moscou et al. used qualitative semistructured interviews and 
document reviews to compare active surveillance approaches and the use of 
postmarketing evidence in the decision-making process between North American and 
European regulatory agencies (110). Qualitative research will not be utilized alone, as 
the PV KPIs provide a more objective, comprehensive, and validated assessment 
methodology that covers all the PV system components: structure, process, and 
outcome.  
Anantachoti and Kaewpanukrungsi used various approaches to collect 
qualitative and quantitative data as a means of evaluating the Thai national PV center 
performance. The authors used interviews, field observations, and document reviews to 
collate data on a set of selected questions and PV KPIs. Content analysis was used for 
the analysis of the qualitative data, and descriptive statistics was used for the 
quantitative data. The recorded data were reviewed by PV experts as a mean of data 
triangulation, clarification, and validation. The use of several approaches offered an in-
depth understanding of the current PV system performance. However, a limitation to 
consider was that the assessment did not utilize an internationally validated PV KPIs 
such as the IPAT or WHO PV indicators (111).  
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8.  A Gap Analysis of Pharmacovigilance System Assessment in the Arab World 
and Qatar  
8.1. Overview of Pharmacovigilance Challenges in the Arab World 
After the introduction of the Arab PV guidelines, many Arab countries 
significantly improved their PV systems to comply with the guidelines. However, to 
date, some Arab countries still face challenges in establishing the basic foundation of 
PV activities; therefore, it may require years to successfully implement, sustain, and 
further develop the full scope of PV. The challenges facing the Arab region and less 
developed PV systems in the region may negatively impact drug safety and patient 
safety. Additionally, in many settings, PV activities suffer from fragmentation and the 
duplication of stakeholder efforts, which can be highly detrimental to countries with 
unstable political systems or financial issues (25-28). For instance, despite the efforts 
of the Yemen PV center, the Yemen PV system still suffers from the consequences of 
political instability, including an immature PV system that is currently operating under 
a shortage of basic structures and funds (26). Further, many nations are in the 
burgeoning stage of PV, as reflected in achieving less than the desired PV outcomes 
(25). Findings in the region indicate that there is a need to develop PV through 
collaborative efforts (i.e., national, regional, and international efforts), mobilization of 
resources, targeting efforts to address governance, policy and pragmatic challenges, and 
educational efforts targeting various stakeholders (25-28).  
8.2. Pharmacovigilance System Assessment in the Arab World  
Table 4 below highlights the research foci that have been conducted on the 
subject PV system assessment in the Arab world. 
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Table 4. Characteristics of the included literature on the subject pharmacovigilance (PV) system assessment in the Arab world 
Author 
and 
date  
Background 
and/or objective 
Methods  Findings Review  
Wilbur, 
K.  
(2013) 
Wilbur used 
survey methods 
to assess the PV 
situation in 
thirteen Middle 
Eastern countries 
(27). 
• The survey questions 
were adapted from the 
2008 “UMC 
Assessment of 
Country 
Pharmacovigilance 
Situation 
Questionnaire”. 
• Wilbur estimated that up to 50 million of 
the Arabic-speaking population (e.g., 
Qatar) lacked a national PV center.  
• Additionally, even among 11 of the 
responding countries, challenges related 
to financial and human resources were 
affecting the PV systems. 
• Wilbur recommended exploring regional 
collaboration mechanisms and 
information technology to improve PV. 
• The limitations of the research were 
associated with the email survey 
method, which is entirely dependent on 
the provided responses, as responses can 
be limited in their reliability. For 
instance, in cases with no evidence of 
the existence of the selected parameters 
or cases, the situation in nonresponding 
countries remained ambiguous. 
Additionally, surveys sent to officials 
may be delegated to less relevant PV 
key informants, which can affect the 
quality and accuracy of the received 
information.  
• However, the survey offered insight into 
PV and was the first to assess the PV 
situation in the Middle East. 
The 
Uppsala 
report 
(2015) 
The report 
included an 
assessment of the 
WHO PV 
indicators 
structural 
components of 
the Oman PV 
system by 
Almaskari (112). 
• The author conducted 
a survey to gather 
information on the 
structural complement 
of the regulatory body 
system of Oman. 
• This was followed by 
a comparison of 
Oman's performance 
• The assessment and subsequent 
comparison allowed the exploration of 
system weaknesses. 
• It was found that Oman’s system 
performance on core structural indicators 
was 35% compared with 70% in the 
Netherlands and 75% in Ireland. 
• The author concluded that in addition to 
the recommended implementation of the 
• A limitation to note is the sole reliance 
on the structural components of the 
WHO PV indicators; further studies in 
Oman should include all of the system 
components to identify the structures 
available to attain a satisfactory level of 
operational capacity.  
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date  
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and/or objective 
Methods  Findings Review  
as a developing nation 
to that of the 
regulatory bodies and 
systems of other 
developed nations, 
namely, Ireland and 
the Netherlands. 
measures required to improve the Oman 
PV system, continuous monitoring of the 
system using validated tools as well as 
benchmark comparisons would be 
necessary to ensure the attainment of a 
functional and contemporary system in 
the country.. 
• Additionally, the survey method can be 
influenced by response bias and/or 
arbitrary interpretation. 
• However, based on the recorded data, 
the study was the first to utilize the 
WHO structural PV indicators and 
compare the situation with that of other 
benchmark countries. 
Qato, D. 
(2018) 
In 2015, Qato 
used survey 
methods to 
describe the state 
of PV systems in 
20 Arabic and 
Eastern 
Mediterranean 
countries (25). 
 
• Cross-sectional survey 
methods. 
• In this study, the IPAT 
and WHO PV 
indicators were used 
to assess the 
performance of each 
country, represented 
by its regulatory 
authority or the 
national PV center. 
• The author selected a 
few PV KPIs from 
each tool to assess the 
countries (i.e., 10 
structure, 10 
processes, and 7 
outcomes).  
• A simple scoring 
scheme was developed 
• Based on the recorded data, the countries 
with higher overall system performance 
status were Egypt, Morocco, and Jordan, 
while those with the lowest performance 
were Libya and Lebanon.  
• Additionally, of the 20 countries that 
completed the internet survey, 4, e.g., 
Qatar, reported the lack of a dedicated PV 
program or center.  
• Qato found varying differences in the 
performance of the PV systems in the 
studied countries and recommended 
prioritizing PV within the countries' 
healthcare systems. This can be achieved 
by increasing the budgetary allocation for 
PV implementation, addressing policy 
gaps, implementing educational 
interventions and fostering regional 
coordination to realize common goals and 
achieving a good PV standing that meets 
international standards 
• A limitation to consider is the use of a 
few PV KPIs from each tool, as none of 
the tools were implemented 
comprehensively. 
• Additionally, the use of email surveys 
can generate results that are possibly 
influenced by response bias and/or 
arbitrary interpretation.   
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date  
Background 
and/or objective 
Methods  Findings Review  
in which positive 
responses received a 
score of “1” or “2” 
based on the indicator 
selected, while 
nonresponses received 
a score of “0”. 
Elsidig 
et al. 
(2018) 
Elsidig et al. 
assessed the PV 
system in Sudan 
using the 
structural and 
process PV KPIs 
of the WHO PV 
indicators (113). 
• The study used the 
interview method to 
assess the three 
available PV centers 
in Sudan (i.e., 1 
national and 2 
subnational). 
• In addition, the study 
included school 
healthcare curriculums 
across Sudan. 
• Elsidig et al. found that the national PV 
center is well structured, with available 
accommodation and national legislation 
as well as national ADR reports for the 
general public and healthcare 
professionals.  
• In healthcare schools, PV is incorporated 
into programs for graduate and 
undergraduate students of pharmacy 
schools, but dentistry schools do not 
provide theoretical education on PV.  
• However, challenges were reported in 
relation to the resources required for 
operational centers, including irregular 
budgetary allocations as well as 
inadequate human resources (i.e., only 2 
pharmacists). Regarding the process of 
reporting, Elisidig et al. reported that the 
report management process is not clearly 
defined.  
• The authors concluded that the observed 
poor status of PV is attributable to 
• Finally, the authors did not address the 
outcome PV KPIs domain, which could 
shed light on the impact on the PV 
activities that are currently available in 
Sudan (e.g., the effect on clinical and 
financial outcomes).  
• It was not feasible to examine the study 
in detail to obtain information on the 
values and detailed results, as only the 
abstract of this study was available. 
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unstable funding for PV and the 
inadequate inclusion of PV in academic 
curricula 
Hamid, 
A. and 
Moham
ed 
Ibrahim 
(2017) 
A systematic 
scoping review 
was conducted by 
Hamid, A., and 
Mohamed 
Ibrahim (i.e., a 
research team) to 
explore the state 
of governance 
and PV in the 
MENA region 
(28). 
• The scoping review 
used a 
pharmacogovernance 
(PG) framework that 
consisted of domains 
with specific 
definitions to evaluate 
and explore the 
available challenges, 
strengths, and 
opportunities for PV 
and effective PG in the 
region. 
• Based on the information provided, the 
review indicated challenges that affected 
effective PV and PG, including 
limitations in the policies, laws and 
regulations; insufficient resource 
allocation and availability; deficiencies in 
transparency and accountability between 
various stakeholders; and limited 
participation and inclusion of the general 
public. 
• The authors stated, “The key to a robust 
PV system is the development and 
enforcement of comprehensive 
regulations that engage all stakeholders 
effectively to ensure a culture of patient 
safety that is built on the principles of 
transparency, accountability, and equity.” 
• Although the review provided an 
explicit methodology, it remained 
limited in the data provided, which were 
restricted by the inclusion criteria (e.g., 
only studies published in Arabic and 
English). 
• Additionally, the review provided an 
understanding at the regional level, not 
at the specific country level. This was 
addressed in the review, as it identified 
the need for research based on empirical 
data to understand the observed 
variances between the PV systems in the 
region, and it recommended utilizing 
qualitative and/or mixed-methods 
research to study the PV and 
pharmacogovernance situation in the 
national context. 
Al 
Shamma
ri et al. 
(2019)  
Al Shammari et 
al. provided a 
narrative review 
of the research 
foci for the PV 
situation in 22 
Arab countries 
(26). 
• The authors used the 
available literature to 
discuss the PV system 
in each country, 
including challenges 
and strengths. 
• In the Qatar context, it is worth noting 
that Al Shammari et al. reported that the 
Gulf Cooperation Council (GCC) 
countries, namely, Qatar, Kuwait, United 
Arab Emirates, Oman, Bahrain, and 
Saudi Arabia, have the privilege of GCC 
membership, which offers them better 
opportunities, including the acquisition of 
• All those factors, if utilized strategically, 
can create many success factors to 
establish a well-structured system or to 
maintain the sustainability and 
efficiency of already existing PV 
systems.  
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the capacity and support needed to 
establish a PV system.  
• In GCC countries, such programs have 
the privilege of receiving governmental 
support and are considered wealthy 
countries.  
• Regarding the quality of using review 
papers to provide insight into PV 
systems, this review is limited, as no 
methodology for conducting the review 
was provided.  
• Additionally, narrative reviews cannot 
provide the real-world data that are 
required to characterize and measure PV 
system capacity and functionality. 
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8.3. The State of Pharmacovigilance in Qatar  
Only PV research efforts and literature related specifically to Qatar will be 
discussed, as it is the study’s scope of interest. Empirical research on the PV situation 
in Qatar was described in 3 articles by Wilbur and the aforementioned cross-sectional 
survey by Qato (25, 27, 36, 37). The latter was limited in its ability to provide an in-
depth, context-dependent evaluation because it did not comprehensively use the 
international PV assessment tools (i.e., utilize all PV KPIs for a full system evaluation) 
(25). Regarding Wilbur's studies, first, Qatar was included in the assessment of the PV 
situation in 13 Arabic-speaking countries (26). Second, Wilbur used survey methods in 
2012 to assess PV practices among pharmacists in hospital settings (36), and survey 
methods in 2013 to assess the knowledge, attitudes, and practices of ADR reporting in 
the community pharmacy sector in Qatar (37). Through survey methods, Wilbur 
identified challenges to effective PV related to the lack of a national PV program and 
the lack of a unified reporting system, including the availability of a national ADR 
form. However, these studies are limited in their ability to provide details on the factors 
that influence PV from a system perspective, including the exact pattern of interaction 
between national systems and stakeholders, the national capacity to establish a central 
PV entity, and other details on the exact functionality of the Qatar system. Further, the 
studies focused on pharmacists as a professional group, so details on the challenges and 
perspectives of other healthcare professionals remain ambiguous. Hence, per the IPAT 
and WHO PV indicators, the rate of reporting can be measured for each healthcare 
professionals group since PV is a responsibility shared by any individual concerned 
about medication and patient safety. Similarly, a commentary by Al Hail et al. was 
published in 2018 to describe the current PV practices, which were mainly passive 
surveillance and ADR reporting, in the public sector of Qatar. The authors identified 
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challenges related to underreporting and lack of awareness of PV (38). Therefore, the 
system performance on other PV activities, e.g., signal identification and active 
surveillance, require further investigation. Additionally, Al Hail et al. commented on 
an internal survey to assess knowledge, attitudes, and practices that focused on 
pharmacists as a professional group; thus, details on this subject matter (i.e., the 
reporting of various HCPs) can also be investigated through the use of PV KPIs (e.g., 
the WHO PV indicator coded P2).  
Finally, and most importantly, none of the studies conducted in the Arab world 
and/or Qatar evaluated the PV system following a full system-based approach of 
structure, processes, and outcomes that completely utilized the validated, 
internationally recognized PV KPIs. Additionally, the Qatar PV studies were conducted 
in 2012, 2013, and 2015, and the national situation is likely to have changed since this 
period. Therefore, there is a need for research that considers qualitative and quantitative 
information on PV system structures, processes, and outcomes. In addition, there is a 
need to examine the usefulness of using PV KPIs in a comprehensive manner in a 
single-country context (i.e., the situation of Qatar).  
9.  The Current Study  
According to our knowledge, this is the first mixed-methods study in the Arab 
world or the MENA region to cover the full WHO PV indicators manual, including all 
three indicator domains, structure, processes, and outcomes, as well as the main 
indicator core and complementary PV KPIs. In addition, it is the first study to assess 
the PV and medication safety system in Qatar following a comprehensive system-based 
approach using various internationally recognized tools and research procedures, 
including the WHO PV indicators, the minimum WHO requirements for a functional 
PV system, and the input of various national PV stakeholders.  
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The current study will consider the following issues from the literature. First, a 
scoring system was developed for the WHO PV indicators, considering the statistical 
targets to be the threshold of functionality and/or performance capacity (i.e., 
performance based on a quartile range). Second, the WHO minimum requirements 
(2010) were used to provide a simple and minimal guide to assess and improve PV. 
Third, the IPAT PV KPIs were utilized to inquire about PV recommendations and the 
use of recommended IPAT thresholds for the PV KPIs, e.g., the reporting rate for a 
functional system. Fourth, multiple stakeholders were involved in the PV system 
assessment for better comprehensive coverage and a representative evaluation e.g., 
representatives of the pharmaceutical industry and academic institutions. Fifth, 
emerging methods of research and analysis (i.e., MMR) were used. Sixth, an analysis 
of PV system strengths, weaknesses, and opportunities was conducted. Seventh, an 
organizational structure for a proposed national PV center was developed. The 
aforementioned points offer an opportunity to develop solutions and recommendations 
to improve the PV situation in Qatar.  
9.1. Conceptual Framework  
9.1.1. The Objective of the Study Conceptual Framework 
Figure 1 was developed to guide the research process for a robust evaluation of 
the existing PV and medicine safety system in Qatar, including answering the 
supplementary assessment questions and generating recommendations.  
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Figure 1. The pharmacovigilance system assessment conceptual model
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9.1.2. Method for Developing the Conceptual Model  
First, the literature review shaped the development of the model and placed the 
model within the context of the meaning and importance of a PV and medicine safety 
system and its impact on patient and pharmaceutical product safety. This includes 1) 
PV as a discipline; 2) Factors (i.e., internal and external) influencing PV; 3) the PV 
system and its importance; 4) PV KPIs and the selection of WHO PV indicators; 5) 
Studies evaluating PV systems in other countries; and 6) The impact of PV and PV 
systems on the safety of pharmaceutical products, patients, and the public. 
Second, well-established frameworks were identified, including the distinct 
concepts of assessment approach, structure, process, outcomes, purpose, and the 
macrocontext. To develop the model, the conceptual models from the existing 
literature, namely, the Handler et al. framework (2008) (114) and the SPS program PV 
framework (10), were used to build a comprehensive model.  
9.1.3. The Framework Content 
Below is the current study conceptual framework content:  
I. Context: Qatar healthcare sector PV and medicine safety system.  
II. Macrocontext: Represents the environment directly or indirectly influencing the 
institutionalization and functionality of the PV system. It encompasses several 
factors. First are internal influences such as 1) Political, social, and economic 
influences; 2) The extent of the demand and need of the Qatar population; and 
3) Social values and preferences with respect to the medicine safety system. 
Second are external forces, which affect the system functionality (e.g., the 
nature of PV actors’ relationships).  
III. Structure, processes, and outcomes: Per the WHO PV indicators (i.e., core and 
complementary). 
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IV. System assessment approach: First, the core assessment approach, uses the 
validated instrument, the WHO PV indicators. Second, the complementary 
assessment approach, uses the qualitative method.  
V. Purpose or objective of the study: To conduct a comprehensive PV system 
analysis of Qatar.  
VI. Vision: In the future, a comprehensive PV and medicine safety system will be 
established to 1) Ensure efficiency and effectiveness; 2) Improve the quality of 
life of patients; and 3) Reduce morbidity and mortality. 
9.2. Research Question 
“What are the most important measures to improve the pharmacovigilance 
system in Qatar based on the WHO PV framework?” This question will be answered in 
the discussion chapter (section 4) in the form of recommendations following the 
structure, process, and outcome PV KPIs. Those recommendations will be aimed at 
different national PV stakeholders in Qatar. 
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CHAPTER III: METHODOLOGY 
 
In Qatar, a centralized and comprehensive pharmacovigilance (PV) system does 
not exist, and the slow advancement of PV in Qatar has been reported in different 
studies concerning the regulatory and practice aspects of PV. Therefore, empirical data 
are required to obtain an in-depth understanding of the PV situation in Qatar. This study 
aimed to conduct a comprehensive PV and medication safety system assessment, 
including exploring the opportunities available for effective PV as well as the important 
measures required for the improvement of PV and the development of a centralized PV 
system. This chapter will elaborate on the measures required to address the specific 
research problem at different levels, first reflecting on the employed research paradigm 
and then describing the methodological approach, research design, and specific 
quantitative and qualitative procedures for data collection, analysis, and interpretation.  
1. Topic Selection  
As an emerging economy seeking to enhance practices in the country's 
healthcare infrastructure, the state of Qatar is currently experiencing surging 
advancement in the field of medication safety. This study is intended to describe the 
status of the knowledge, reporting, experiences, systems, and framework structures of 
PV in Qatar. The primary investigator's interest is in PV, and the literature search 
indicated that a gap was observed throughout earlier studies conducted by Wilbur, who 
found that there is no national PV center and that such a center is needed in Qatar (27, 
36, 37). Therefore, this study aimed to assess the baseline situation to understand the 
gaps that could affect the establishment of such an entity. Accordingly, a search for 
evidence-based literature was conducted to address the research problem and assess the 
PV situation in Qatar. It was found that the WHO has published an PV KPI s assessment 
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tool that is designed for a comprehensive evaluation of the PV system structure, 
processes, and outcome. However, because a PV system does not exist, and the 
indicator tool would be difficult to implement, it was decided to utilize the knowledge 
of available experts as well as their views on PV. Therefore, in-depth MMR was 
conducted to address this problem. Refer to (Chapter II) for details.  
2. Research Paradigm 
First, the researchers need to select a research paradigm for their study. There 
are several paradigm worldviews (i.e., research paradigm) available for researchers to 
position their current study within a set of assumptions and beliefs that directly informs 
subsequent levels of the research process, including the methodological approach 
adopted and the specific methods and techniques used to collect, analyze, and interpret 
data (108, 115, 116). Morgan (117) along with Tashakkori and Teddlie (48) conveyed 
that the pragmatism worldview can be used as a philosophical basis to support MMR. 
The pragmatism worldview is widely accepted as the philosophical foundation for 
MMR, in which the researcher focuses on the research problem and then attempts to 
acquire knowledge on the problem utilizing pluralistic approaches. In pragmatism, 
researchers value the subjective and objective meaning involved in solving the research 
problem. Therefore, in pragmatism, researchers can utilize both qualitative and 
quantitative approaches in a single study, and they may abandon the dichotomy of 
worldviews, research approaches, and concepts of reality in order to prioritize the 
research question or problem as the most important concept and the guide to their 
philosophies and methods. As a result, the use of the pragmatism paradigm and MMR 
approach is suitable for the current study, as both qualitative and quantitative 
approaches will be used to address the specific research problem (48, 53). 
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3. Research Proposal 
A thesis proposal was prepared under the supervision of the main supervisor. It 
detailed the goals and process of the research, and it was presented to the student 
supervisory committee. The research proposal was approved with no additional 
changes suggested to the structure and methodology.  
4. Background Research: Desk Work 
Previously published research was utilized to develop the methodology while 
avoiding systematic gaps and weaknesses, and the study considered benchmarks to be 
the best research practice, e.g., complying with evidence-based PV KPIs and including 
a representative sample. Additionally, previous work was included in the design of the 
data collection instruments, specifically the semistructured interview guide that aided 
in inquiring about gaps (e.g., weak regulatory frameworks, governance of systems, and 
patient reporting) reported previously in the literature or best practices (e.g., causality 
assessment and signal management processes) that have been implemented in other 
countries of the world. Additionally, previous studies helped in addressing the 
feasibility of some recommendations addressed in the literature (e.g., establishing a PV 
center in an academic university). Finally, previous work enabled the researchers to 
outline the PV systems of some benchmark countries, such as Morocco or the European 
countries, on which Qatar could model a national PV center. Refer to (Chapter II) for 
details. 
5. Pharmacovigilance Key Performance Indicators  
Monitoring the safety of medications has been a focus of PV in many countries 
around the world. PV development has been accompanied by the development of PV 
systems and tools to assess those systems. In the field of PV, there have been few 
initiatives to develop objective measures (i.e., PV KPIs) to assess the performance and 
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adequacy of PV systems. The two most commonly used PV KPIs are the WHO PV 
indicators and IPAT. These PV KPIs will serve as the researchers’ validated tools to 
evaluate the performance of PV systems in the process of identifying areas that need 
proper investment to improve PV systems in terms of performance and adequacy. 
However, the IPAT tool was used only to identify supplementary information, e.g., the 
threshold of reporting rates, the threshold of individuals receiving training, examples 
of risk mitigation activities, and the regulatory framework of the PV system. The main 
indicator tool that was formally used to evaluate the PV system is the WHO PV 
indicators. Refer to (Chapter II) for details 
6. Ethical Considerations 
Ethical approval was obtained from the Institutional Review Board (IRB) at 
Qatar University (QU) (Research Ethics Approval No. is QU-IRB 826-E/17), Primary 
Healthcare Corporation (PHCC) ethics committee (Research Section, Clinical Affairs 
Department, Approval Number PHCC/IEC/1710/036), and the Medical Research 
Centre (MRC) at Hamad Medical Corporation (HMC) (Protocol No. MRC-01-17-069). 
In addition, a support letter was granted by QU. Consent forms were appropriately 
developed to ensure compliance with legal and ethical research regulations that cover 
information collection through interviewing key informants and, where applicable, 
review of official documents at each data level. A consent form was developed in both 
Arabic and English and submitted to all the relevant ethical committees. The PHCC 
research participant information sheet on the study was included with the consent 
forms. All the aforementioned ethics-related documents are presented in Appendix A, 
(from M1 to M3). 
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7. Introduction Letters and Forms to National Pharmacovigilance Stakeholders 
After ethical approval was obtained, official invitation letters and emails were 
sent to the stakeholders and/or target population to obtain their consent to participate in 
this research and to obtain the relevant information and data prior to starting the data 
analysis of this research. The generic introduction letter is presented in Appendix A, 
(M4). Along with the invitation letters, the approved study instruments, the approved 
proposal, and ethical permission forms were distributed to the target population and 
stakeholders. This was necessary to provide the participants with enough time to 
understand and prepare for the interviews and to save copies for their records. The 
distribution of these materials was through email, and printed copies were provided 
when conducting the face-to-face interviews and/or beforehand on request. The 
stakeholders’ responses to the invitation came at different times and will be mentioned 
in the study timeline section. 
8.Methodological Approach 
On the basis of the MMR design, the baseline PV situation was evaluated by 
adapting a mixed-methods case study design (convergent core design). The MMR case 
study design was employed to provide a comprehensive multiple case evaluation for: 
a) in-depth case evaluation of subnational PV systems, b) comparative case analysis 
across subnational PV systems, c) and evaluation for the overall national PV system. In 
the convergent core design, the two types of data were collected at the same time with 
equal weighting for the priority of collection. Mixing took place in the stage of data 
collection, data analysis, and interpretation of the findings. The approach allowed the 
researchers to build a strong foundation of data to assess the PV and medicine safety 
system and to integrate and interpret the two types of data for a comprehensive 
discussion of the research problem as indicated below in Figure 2. Furthermore, it is 
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used to benefit from the strengths and reduce the limitations inherent to the quantitative 
and qualitative methods. (49, 118).  
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Figure 2. Concurrent mixed-methods case study flow diagram 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Design and conduct of the quantitative phase 
   Utilizing the World Health Organization (WHO) 
Pharmacovigilance (PV) indicators checklist 
(survey method: core indicators n= 27, 
complementary (comp.) indicators n=36, and 
public health programs indicators n= 9) in face-to-
face semistructured interviews with key informants 
at different levels of the healthcare system (number 
of stakeholder category =6).  
   The structure (core n=10, comp n=11), process 
(core n=9, comp n=13), and outcome (core n=8, 
comp=12) indicators will be used to evaluate the 
status of PV of each level. 
   Convenience nonrandom sampling methods. 
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Design and conduct of the qualitative phase 
   Utilizing the qualitative semistructured 
interviews method, document review, and field 
observation to cover additional points from the 
WHO PV indicators manual and from evidence 
collected from reviewing existing literature on PV 
system assessment in developing countries.  
   Experts explanations on the PV system in Qatar 
was collected during the same semistructured 
interviews of the quantitative phase with the same 
sample of key informants (n= 30) at different levels 
of the healthcare system (number of stakeholder 
category =6). Data will be used to evaluate the 
status of PV of each level. 
   Convenience nonrandom sampling and snowball 
sampling methods (based on higher-authority 
decision at each level). 
Merged findings 
   Findings from both phases (i.e., qualitative and quantitative) will be used to 
obtain an in-depth understanding (by triangulation, conformation, and 
convergence) of the PV situation in Qatar and to conduct comprehensive 
pharmacovigilance and medication safety system assessment for: (a) in-depth 
case evaluation of subnational PV systems, (b) comparative case analysis across 
subnational PV systems, (c) and evaluation for the overall national PV system. 
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Interpretation of research findings to 
achieve 
Comprehensive system assessment 
Summary of key findings 
Discussion  
Conclusion 
Implications  
Future research directions  
Analyzing quantitative and qualitative data 
   Descriptive statistics and pictorial presentations will be used to describe the 
current status of the Qatari PV system with respect to structure, process, and 
outcomes system performance. 
   Using content analysis to identify existing potential opportunities, limitations, 
and recommendations that can mark the development of PV in Qatar.  
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A case study allows researchers to inquire about and observe the characteristics 
of a case (e.g., program, event, activity, process). This design is popular in evaluation 
studies because it allows researchers to conduct an in-depth analysis of a case that is 
circumscribed by time (i.e., one year), and many methods can be used to collect all the 
relevant data for that case (118) and/or to generate cases for comparative analysis (49). 
This design is frequently used in MMR (119). For this mixed-methods study, the case 
design is a multiple case study design (e.g., MOPH as a case of the PV system situation 
and HMC as a separate case) with a naturalistic structure (i.e., as a flexible design in 
the sequence it follows, as a flexible design in the size of the sample, and as a design to 
study cause and effect that is not experimental in nature) (119).  
The case study design aimed for a deeper understanding of the compliance 
provisions in each stakeholder's PV system, including the deficiencies in the 
implemented structures, processes, and procedures as measured by the WHO PV 
indicators. The design was utilized to assess the performance, status, and capacity of 
such elements of PV systems as the techniques and practices of PV and whether they 
showed a degree of compliance with international standards. Additionally, it enabled 
the researchers to understand the level of awareness regarding PV provisions (118) and 
to cover the thesis objectives. Furthermore, a case study design was used in a systematic 
qualitative assessment of the PV system. This qualitative approach respects individual 
meaning in providing an understanding of the complexity of a situation or research 
problem (119). Individual meaning and situational system analysis are important, as PV 
systems are influenced by the political, financial, technological, and financial status of 
the country. For example, developing countries' PV systems are an area of research 
interest due to continuous changes in the societal, behavioral, and political aspects of 
PV systems (10, 20, 21).  
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Following the convergent design enabled the research to employ quantitative 
and qualitative data to address the national context, as requested in the WHO 
framework (11), since both forms of data would be converged, triangulated, and 
corroborated to obtain results on a single topic. This study used qualitative and 
quantitative methods on the same sample of key informants in a single-phase study (i.e., 
at the same time). The rationale for the convergent design is to acquire complementary 
data that are different in nature to address the same topic with a deeper level of meaning 
and understanding. The immense amount of detail merged with the statistical results 
helped in constructing, validating, and synthesizing both quantitative and qualitative 
outcomes to develop a complete understanding at multiple levels within the national 
and subnational PV systems. The final outcome can be used to direct future 
interventions and research in relation to the national PV system (49). 
9. Quantitative Phase 
9.1. Instrumentation: World Health Organization Pharmacovigilance 
Indicators 
The WHO PV indicators manual is a validated and standardized tool that is 
available on the WHO website. The WHO indicators were selected for the purpose of 
the Qatar PV system evaluation because the PV KPIs were designed to be reproducible 
and have been successfully adopted in various countries. The selected PV KPIs were 
used as an assessment tool to provide simple measures for the compliance of PV 
systems with the expected PV WHO framework. The WHO indicators were used as the 
basis for the semistructured interviews and all other system assessment concepts. Each 
indicator was used to assess an objective that the national and subnational PV systems 
must meet. The results would serve as a baseline benchmark to enable future 
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comparisons and possibly to evaluate trends. The results were generated as counts or 
numerical values that quantitatively described specific aspects of PV stakeholders’ 
system compliance with WHO standards (11). 
The WHO PV indicator manual encompasses a ready-to-use checklist, 
presented in Appendix A, (M5), that was developed for use as a data collection tool. 
This data collection tool was adapted and utilized to collect all relevant data that address 
each specific indicator. It is important to emphasize that there is no centralized PV 
system in Qatar. Nonetheless, the study used the knowledge of the available experts in 
the area of PV in Qatar. The PV indicator checklist was shared with the key research 
informants and was adapted (i.e., changed ) only by substituting the name of the 
organization or data collection site surveyed for the term PV center. For example, the 
words “pharmacovigilance center” were changed to “Medication Safety and Quality 
Center in HMC”. Furthermore, the survey asked about each indicator in relation to the 
relevant study sites only; for example, the MOPH relevant indicator set was slightly 
different from the service delivery organization set. The WHO PV indicator manual has 
a specific section for identifying all the relevant stakeholder systems or data collection 
sites for each indicator. Table M6 in Appendix A provides the relevant and nonrelevant 
PV KPIs at each study site. 
9.2. Survey Design  
In this research, the survey design as a quantitative design was based on the 
WHO PV indicators questionnaire. The survey design followed a standard format to 
provide a numerical description of the trends, perceptions, and attitudes of a population 
through selecting and studying a representative sample to produce an outcome that can 
be generalized or aid in drawing inferences for the population (118).  
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Many benefits can be achieved from a standard survey design. Information can 
be obtained from different stakeholders representing a specific population. Surveys can 
obtain the data used to describe the sample composition. Additionally, surveys can be 
useful for assessing variables that need to be comprehensively described with respect 
to number and type. Surveys can be easy to develop and administer. Nevertheless, the 
results of surveys are in the form of compliance-level estimates rather than exact 
measurements (118, 120). In this research, a sample of national stakeholder PV systems 
were surveyed (i.e., a cross-sectional survey) to obtain baseline data on PV system 
performance that could provide an estimate for national PV system compliance. 
Another drawback of the survey method is that it is not possible to obtain bulky and 
large-scale information on a phenomenon. The nature of surveys that depend on a study 
sample response can create a bias, for instance, lack of response of key participants or 
uncertain accuracy of information provided, that affects the ability to generalize the 
results. Response bias can also have a degree of intentional misreporting; for example, 
in some cases, the respondents’ attempts to hide inappropriate or misimplemented 
practices imposed difficulty in assessing the compliance of the PV system with the 
WHO PV indicators (118, 120). The data collection was conducted during face-to-face 
interviews with one or more key informants at each data collection site. Although face-
to-face interviews are time-consuming and can be expensive compared to internet or 
phone surveys, they help ensure data availability for each indicator. MMR including 
Face-to-face interviews methods offer the opportunity to validate the findings through 
direct interaction with the key informants since documents can be sought, and the 
process can be observed where applicable (118). Moreover, additional data collection 
forms were used and were intended to be completed during the face-to-fac meeting. 
Details will be described in the qualitative phase instrumentation section (i.e., 10.6.).   
  
73 
 
9.3. Study Setting 
Qatar is located in the Arabian Peninsula on the Persian Gulf (or Arabian gulf) 
in the MENA region (121). The system analysis covers mostly representative study 
sites at the national level that are responsible for PV and medicine safety in the Qatar 
healthcare system. For this study, each sector represents a data collection level and each 
site is a unique case study. The following sites were assessed: 
I. Regulatory body: Ministry of Public Health or the Supreme Council of Health.  
II. Public sector: 1) Hamad Medical Corporation and 2) Primary Health Care 
Corporation. 
III. Private sector: 1) Health facilities or organizations; and 2) Community 
pharmacies. 
IV. Pharmaceutical industry. 
V. Higher academic education institutions. 
VI. Public health program: Mental Health Strategy case. 
Data collection involved various departments or units at each study site, 
covering the main stakeholders where the PV-relevant department was the focus of the 
conducted survey (e.g., Pharmacy Department, Drug and Therapeutics Committee, 
Quality Department, etc.).  
9.4. Population and Sample  
The target population is PV and medication safety systems (6 levels of the 
healthcare system; a total of 18 case studies) and potential stakeholders involved in 
ensuring medication safety and improving public health through participation in 
different activities, processes, and/or programs at their institutions. Table 5 explains the 
criteria of selection of national PV systems and representative stakeholders from each 
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level.  
 
 
Table 5. Criteria for selecting target study sites 
Data collection level  Justification for inclusion  
MOPH PV system  MOPH is the regulatory body for Qatar's national healthcare system 
and is responsible for legislation and policy setting, regulation and 
management, priority setting, providing advice and planning, and 
providing healthcare services. Consequently, MOPH is considered 
the current national-level PV system and was one of the primary 
sources of data for this study.  
HMC PV system  HMC offers healthcare services in the public sector and is 
considered the primary provider of healthcare services in Qatar. 
HMC hospitals treat individuals with common or specific needs, 
including cancer or cardiovascular disease patients, and it delivers 
care for different patient groups, such as women and children. Thus, 
HMC is considered a primary source of national PV data, including 
ADR reporting.  
PHCC PV system  Since the establishment of the PHCC in 2012, the primary healthcare 
centers have been the providers of primary healthcare services in 
Qatar. Given the accessibility of the 25 centers located in all regions 
of Qatar, specifically the northern, western, and central regions, the 
corporation plays an important role in ensuring medication safety for 
the Qatar population and is considered a rich data source on PV and 
medication safety.  
Private sector: 
healthcare institutions   
The healthcare system in Qatar is extended to include the private 
sector, where healthcare services are provided mainly as paid 
services. The study targeted the PV system of different private health 
institutions (i.e., private hospitals, private healthcare organizations, 
and semigovernmental hospitals). Each is considered a unique case 
and a potential source of PV data. 
Private sector: 
community pharmacies   
The community pharmacy is the first contact point for many 
patients. Given their accessibility, their current capacity and 
performance in contributing to PV at the national level is worth 
investigation. The assessment of the PV system at the community 
pharmacy level included chain pharmacy groups and independent 
pharmacies. Each is considered a unique case and a potential source 
of PV data. 
Pharmaceutical industry The pharmaceutical industry represents recent improvements in the 
Qatari pharmaceutical sector. The national pharmaceutical industry 
in Qatar is in the business of manufacturing generic medications. 
Thus, the performance and status of PV at the national 
pharmaceutical industry level is of great importance to this study. 
The reason is that the literature on WHO PV indicators has reported 
that the collection of details on the industry is required if users aim 
to assess the complete system.  
Mental health strategy  The WHO Public Health Program indicators require the assessment 
of governmental programs designed to protect public health; 
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Data collection level  Justification for inclusion  
therefore, the researchers approached governmental organizations 
that are concerned with the public health of various patient groups or 
medication classifications.  
Academic Institutions Academic institutions are one of the core structural indicators (i.e., 
CST8) required for a comprehensive evaluation of systems. 
Incorporating PV into the curriculum across different healthcare 
programs is essential for this study.  
 
 
The present study employed nonprobability sampling techniques, specifically 
the purposive and snowball sampling techniques (122). First, the study selected a group 
of respondents with predetermined characteristics. The first contact point or the initial 
authority at each site were as follows: 
I. MOPH: Pharmacy and Drug Control Department. 
II. Academic institutions: dean or associate dean.  
III. Pharmaceutical industry: CEO or general manager. 
IV. PHCC: ethics committee. 
V. HMC: executive pharmacy director at the corporate level. 
VI. Private sector: human resources department, medical director or research or 
pharmacy department, based on the study site. 
VII. Public healthcare programs: program coordinators and the MOPH (one key 
informant). 
Then, the snowball sampling method was applied. In this technique, the first 
contact point referred the researcher to other members who could serve as potential key 
informants to provide the necessary contributions to the study. At times, the initial 
contact point was the eligible key informant who participated as a sample to provide 
information. Many advantages were achieved by following this sampling technique. 
This sampling method allows researchers to access and recruit samples from a 
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population (i.e., higher-level authority and administrative teams) that is not easily 
accessible under normal circumstances. Furthermore, the sample size can be increased 
to allow the researcher to gather more in-depth and comprehensive data required for the 
study and thus to achieve the desired outcomes (i.e., comprehensive coverage of the 
WHO PV indicators). The participants recruited included experts in the field who 
directed the researcher to other experts until all relevant data or the best possible 
information was obtained (122, 123). Based on the WHO PV indicators, manual data 
were obtained from different sources, including stakeholders, databases, records, 
documents, and surveys specific to each study site. The candidate study sites were 
accessed, and information was obtained from representative members and experts at 
each institution. The study included 30 candidate representatives who were members 
of a department or unit that had relevant information and documents for the system 
analysis. The process of data collection was coordinated with the key informants 
working at each study site or institution (11). The ultimate key informant selection and 
the number of key informants representing each site were determined by the 
institutional authority or initial informant approached through the purposive and 
snowball sampling methods to avoid any constraints (e.g., legal, logistical, or ethical) 
or other key informant availability issues. Eligible members from various departments 
or units were approached to obtain their consent to participate in the study. 
No specific sample size was determined a priori, as this study employed the 
MMR principals to allow a comprehensive analysis of the availability and current status 
of PV systems in Qatar. Therefore, extensive data collection was required, and 
convenience sampling was used to ensure the attainment of a representative number of 
study sites and key stakeholders working at each site (i.e., 30 key informants or 
candidate representatives) (118). It is worth noting that based on Creswell’s work, a 
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sample size of 5 to 25 individuals is acceptable in qualitative research (124). Finally, 
stakeholders who were approached but did not agree to participate, along with their 
justifications, are presented in Appendix A, (M7). 
9.5. Data Collection Process 
The WHO PV indicator set was not pilot-tested, as it is a well-established tool, 
and the WHO methodology has been used previously in several countries. For a critical 
evaluation of the PV system, all the relevant information was collected through 
semistructured interviews. The identified key informant from each study site who 
provided informed consent was interviewed using the semistructured interview method 
(duration from 30 minutes to 3 hours). Moreover, when necessary, multiple interviews 
were undertaken with the same key informants; these arrangements were organized 
through the study participants. The interviews included questions about the PV KPIs 
specified in the WHO PV manual such as the activities held at each site and the actual 
implementation of any PV-related activities. Regarding the qualitative counterpart that 
will be mentioned in detail under the relevant section, additional feedback was sought, 
including any opinions or recommendations relevant to PV and medicine safety that 
were not highlighted in the ready-to-use WHO PV indicator checklist.  
Since this study is a single-phase MMR that involves the same stakeholders in 
both a case study design and a survey method design, further elaboration on the exact 
steps followed will be included in the qualitative part of the methodology section to 
comply with the detailed discourse nature of case studies (125). 
9.6. Timeline  
Research was conducted in Doha city and the surrounding areas. Data collection 
initiation at each stakeholder level was based on the granting of ethical approval. The 
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study started in early November 2017 after ethical approval was received from QU. The 
PV system analysis timeframe was extended due to delays and/or lack of response from 
some stakeholders despite conducting several site visits, requesting a response by 
phone, and sending e-mail requests to the committed stakeholders’ representatives. 
Meeting dates and frequencies were determined by the stakeholders. Finally, the PV 
system analysis ended in July 2019 even though some stakeholders still had not 
provided the requested information. Table M8 in Appendix A describes the stakeholder 
level, ethical approval receipt, date of the first visit for obtaining consent to participate, 
and meeting dates and frequencies.  
10. Qualitative Phase 
10.1. Study Setting  
For the setting, refer to section 9.3. in the Quantitative Phase. 
10.2. Population and Sample 
For the population and sample, refer to section 9.4. in the Quantitative Phase. 
10.3. Timeline 
For the timeline, as it is a single-phase study, refer to section 9.6 in the 
Quantitative Phase. 
10.4. Instrumentation 
The qualitative part of this study involved the use of instruments that were used 
as tools to measure the phenomena of interest and to guide the data collection process 
(118). The instruments included the WHO indicator checklist; semistructured interview 
protocols, one general and one based on the study site; and the instrument created by 
the researcher. The first tool was the WHO indicator ready-to-use checklist, as 
described previously, which is presented in Appendix A, (M5). Then, the 
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semistructured interview protocol, which included quires in the form of additional 
points, including follow-up points on the limitations and details for each indicator, was 
extracted from the WHO PV indicator manual, including closed-ended and open-ended 
questions, and is presented in Appendix A, (M9) (11). The researcher created an 
additional semistructured interview protocol to collect additional information following 
a system-based approach; it is presented in Appendix A, (M10). This helped in 
collecting information relevant to the strengths, weaknesses, opportunities, and 
recommendations for improvements to the PV system. This content was covered after 
covering the WHO PV indicators and the additional qualitative assessment for each 
indicator; if a subject had been mentioned previously during the discussion, it was not 
included (1, 10, 29). This instrument was developed for the service delivery level, the 
pharmaceutical industry level, and the academic institution level. Finally, the 
researcher-created instrument that collected information on the study participants and 
served as an observational protocol to collect all relevant information observed or 
mentioned during the semistructured interview is presented in Appendix A, (M11) 
(118). This survey collected information on the stakeholders and the data collection 
site. The survey was specifically designed to collect information relevant to the 
interview, the study site, and the research participant, including the date of the field 
visit, data collection level, name of the institution, name of the key informant, 
designation of the key informant, contact information, documents used and year of 
issue, topic discussed, and additional notes. This survey was used only to facilitate 
follow-up with the stakeholder and the system he/she represented, and its confidential 
content will not be published to ensure the anonymity of the research participants and 
the study site regulations. These data collection tools were all used during the same 
semistructured interviews.  
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10.5. Data C ollection Process 
The data collection process was mentioned briefly in the Quantitative Phase 
section. This section will elaborate further on the qualitative nature of this study. Data 
were collected through the following procedures: 
10.5.1. Semistructured Interviews 
Semistructured interviews were the main method of data collection, as 
mentioned in the quantitative phase. According to Kvale, as a data collection procedure, 
the semistructured interview is intended to elicit the in-depth meanings that the 
interviewees ascribe to a specific topic (126). Face-to-face semistructured interviews 
were the most suitable type for this study, allowing the collection of in-depth 
information and facilitating discussion using both closed-ended and open-ended 
questions (127). Thus, the study was able to collect the required information on all the 
objectives, from the first objective of evaluating the PV system performance to 
determining whether the national PV system complied with the standards of a 
functional PV system established by the WHO (11, 40), to the collection of 
stakeholders' views and opinions on the current strengths, limitations, and opportunities 
of the baseline PV situation and recommendations for how it can be improved. 
10.5.2. Document Reviews 
Electronic or paper-based documents, manuals, reports, and publications were 
reviewed at each study site. Documents identified through the field visit were sought 
from the key informants or directors at each study site. For example, the ADR reporting 
forms, the ADR policies in some organizations, the KPIs of organizations, and the terms 
of reference of the department concerned with PV were shared. Such documents were 
not published or shared as agreed upon and with respect to the legal requirements at 
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each site. The documents helped ensure the validity of responses as well as confirm 
data availability (118).  
10.5.3. Field Observation 
Some of the data collected were a result of close observation of some processes, 
for example, the use of electronic reporting systems, the databases created and how 
information is inputted, the approach to access the organization policy. Field 
observations allowed validating the participants' responses and obtaining an in-depth 
understanding of the actual environment PV (118). 
10.6. Data Recording Procedure 
10.6.1. Semistructured Interview Structure  
The semistructured interviews started by collecting all the relevant information 
about the key informants and the data collection site. Then, the WHO indicators and 
the supplementary questions for the PV KPIs were discussed in parallel, which allowed 
the researcher to gather the quantitative and qualitative data concurrently Appendix A, 
(M9). Then, the researcher-created instrument, which contained open-ended questions 
following a system-based approach to seek an in-depth understanding of the current 
strengths, weaknesses, opportunities, and recommendations of the interviewees, was 
presented. The key informants were asked to comment at the level of their system, the 
interface of their PV system with other subnational systems, and the national level 
represented by the regulatory authority (i.e., MOPH) system. This allowed the 
researcher to generate data concerning the status and implementation of PV in the 
healthcare system that were relevant to the individual institutional context as well as 
the country context. The interviews were conducted in Arabic or English, depending on 
the preference of the key informant. These interviews were conducted until the data 
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collection reached the saturation point.    
10.6.2. Validation of Interview Guide 
All data collection forms and the interview guide were reviewed by the research 
supervisor, who has expertise in the field of PV social and administrative pharmacy, 
and research methodology. Furthermore, although there was no pilot testing, the created 
data collection instrument that followed a system-based approach was utilized by the 
primary supervisor in an interview, and no changes to the structure or content were 
requested. Finally, the data collection tools and all the documents relevant to the study 
were reviewed by the ethics committees at QU-IRB, PHCC, and the MRC at HMC and, 
when applicable, by the private hospitals' research sections. 
10.6.3. Transcribing 
The semistructured interviews were audio-recorded using two recording tools 
and then transcribed. Translation was performed for the interviews conducted in both 
Arabic and English. The translation quality was not evaluated for two reasons. First, 
per the ethical requirements of the study, only the primary investigator and the primary 
supervisor were allowed to access the audio records and interview scripts. Second, the 
primary supervisor is not an Arabic speaker. The translated interview transcriptions 
were shared with the key informants (i.e., in the HMC case study), and no changes were 
made and/or requested. 
10.7. Role of the Researcher 
According to Creswell and Plano, MMR involves the researcher role on the 
quantitative (i.e., as the investigator who follows systematic procedures aimed at 
reducing bias and threats to the validity of the research) and qualitative (i.e., as the 
inquirer who can shape the findings and their interpretation through prior experience or 
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personal background) approaches. Accordingly, the role of the researcher was included 
in both approaches throughout all stages of the study from planning to data collection, 
data analysis, and interpretation (49, 118). The researcher has no conflict of interest or 
affiliation with the stakeholders’ systems or the key informants, which gives the study 
an advantage. Additionally, the systematic steps, e.g., relying on the higher authority at 
each level to select the participants, that were followed for each case study helped in 
limiting the potential bias that the researcher might bring to the data provided. However, 
the researcher role in inquiring about recommendations, challenges or strengths could 
influence the study results, as they were affected by the previously published literature 
and interactions with previous stakeholder systems, especially when the participants 
raised comments that the researcher pursued to investigate their occurrence in other 
settings.  
11. Variables: Outcome Measures   
For the quantitative phase, the study aimed to address objective number one: 
"Evaluate the baseline PV situation using the WHO PV indicators”. Based on the WHO 
PV indicator checklist presented in Appendix A, (M5), the quantitative phase addressed 
the following set of PV KPIs: 
I. Twenty-seven core PV KPIs (i.e., 10 structure, 9 process, and 8 impact/outcome 
indicators). 
II. Thirty-six complementary PV KPIs (i.e., 11 structure, 13 process, and 12 
impact/outcome indicators). 
III. Nine PV KPIs for PHPs. 
IV. Eleven indicators for the background information were not provided by any of 
the stakeholders. This omission was acceptable because the anonymity of the 
study sites was maintained. 
  
84 
 
The following operational definitions were used for the study variables that 
were assessed in the quantitative and qualitative  phases (11): 
I. Core indicators: Objective measures that are important, highly relevant, and 
useful to characterize PV. The ability of the PV system to perform well in the 
core indicators is a requirement for a PV system to be considered functional or 
performing at a satisfactory level. 
II. Complementary indicators: Objective measures that are considered additional, 
useful and relevant to characterize the PV situation in the assessed setting in 
further detail. The ability of the PV system to perform well in the 
complementary indicators is a requirement for a PV system to be considered a 
sophisticated system. However, complementary indicators need not be used in 
all cases. 
III. Structural indicators: A selected set of indicators to assess the availability of 
key structures, infrastructures, mechanisms, and systems for PV in a specific 
setting, the availability of which can provide visibility for PV. 
IV. Process indicators: A selected set of indicators to directly or indirectly assess 
the operational aspects of the PV system, including dynamic and interactive 
mechanisms and the activities performed by the system. The ability of the 
system to perform well can result in outcomes that can be used for further 
interventions and corrective actions. 
V. Outcome indicators: A selected set of indicators to assess the final outcomes as 
long-term or short-term effects or results of PV activities. The measured results 
and trends can be used for healthcare planning and the development of 
interventions, as the ability of the system to meet the final objectives of a fully 
operational PV system will be benchmarked. 
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VI. Public health program indicators: Nine selected indicators that cover the 
spectrum of structural (i.e., setup of the system), process (i.e., system 
operation), and outcome (e.g., early detection of harm) indicators that are 
relevant to the PHP setting. 
In addition, to address objective number two, the current national PV system 
(represented by the MOPH system) was assessed for its compliance with the five 
minimum recognized international requirements determined by the WHO for a 
functional national PV system (i.e., a PV center, ADR or PV advisory committee, 
spontaneous reporting system. national database, ADR reporting form, and 
communication strategy) (40).  
12. Data Analysis  
Mixed-methods research design requires rigorous analysis, as both qualitative 
and quantitative data are analyzed to provide a comprehensive understanding of the 
research problem (118). 
12.1. Quantitative Phase 
For the quantitative phase, all data required for the completion of the WHO PV 
indicator assessment checklist were analyzed by descriptive statistics using the 
Microsoft Excel Program. First, a database was created in the form of an Excel 
spreadsheet for each data collection level (e.g., PHCC), and a single spreadsheet was 
created for all stakeholders. The content of each database was based on a component of 
the WHO PV indicators manual. Furthermore, data or responses to each indicator, both 
qualitative and quantitative, were entered in the databases; that is, if an indicator was 
available or had reached the standard threshold of functionality, the indicator score was 
entered based on the indicator category, whereas if the standard threshold was not 
attained, a score of 0 was recorded. Based on the study scoring scheme, the parameters 
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that were not provided shall be granted less than a complete score or a zero score for 
fair consideration of the other competent stakeholders in this research. The exact 
scoring system was as follows:  
I. Core PV KPIs (*) score: (2) Yes, fully satisfactory; (1) Yes, partially 
satisfactory (2); (0) No, not satisfactory, missing data, no values, not applicable, 
or not clear; and (-) Not relevant for the stakeholder in this evaluation of PV 
system performance with WHO PV indicators. 
II. Complementary PV KPIs (*) score: (1) Yes; (0.5) Score for indicators with two 
parts or more, e.g., A and B (if A, the answer is No Score (0.5), and vice versa 
for B); and (-) Not relevant for the stakeholder in this evaluation of PV system 
performance with WHO PV indicators. 
The scoring system was adapted based on the IPAT tool with a modification to 
include the “Yes, partially satisfactory” score. The IPAT scoring system uses only 
satisfactory and not satisfactory. No formal reliability testing was performed; however, 
the scoring system was developed based on discussion and agreement with the primary 
supervisor. Additionally, the scores obtained for each stakeholder system were 
discussed in meetings with the primary supervisor and the supervisory committee, 
including the detailed purpose of each indicator, the stakeholder ability to satisfy the 
criteria of each indicator and issues with missing values, inadequate information, and 
no proof of evidence of the required PV KPIs. Furthermore, the scoring system received 
the approval of all ethics committees with no additional changes suggested. 
Descriptive statistics, including percentages and means, were considered 
appropriate to describe the observed trends. No further statistical tests or analyses were 
carried out, and only the percentages and means were used to represent or indicate the 
status of the PV system and its performance in Qatar. Table 6 represents an example of 
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how values were calculated and presented. The target performance range is described 
as percentages based on quartiles (Q1: 25%, Q2: 50%, and Q3: 75%) (128):  
I. Excellent performance 75-100% 
II. Good performance 50-74.9% 
III. Average performance 25-49.9% 
IV. Poor performance 0-24.9% 
 
 
Table 6. Examples of pharmacovigilance (PV)  system performance and capacity 
results measured by the WHO PV indicators 
CORE STRUCTURAL INDICATORS 
Code Assessment questions (main) Response Score  
Assessment 
(qualitative) 
CST1 
“Is there a pharmacovigilance 
centre, department or unit with 
a standard accommodation?” 
Yes, no 
specific PV 
department 
(1)  
Applicable but 
not a specific 
department for 
PV. 
Total core 
structural 
indicators 
score 
Out of x [x*2=(x)] is 
[(100%)] relevant 
indicators the 
obtained score is 
[(x) = 0.0%]  
 (x)  
 
 
In addition, graphical representations, namely, bar charts, radar charts, and 
creative charts, were used to demonstrate and compare the results for each indicator 
category and each system and for the comparative analysis of systems.  
This type of statistical analysis and graphical representations helped to address 
objective one of this thesis by presenting the evaluation findings for each subnational 
PV system, the overall system performance in Qatar and the comparative analysis of 
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the systems.  
The number of key informants representing each data collection site will be 
described in text format at the beginning of the results chapter. Additionally, the 
departments or units that they represent will be noted. However, no names or 
designations will be made available, as this study aims to preserve the confidentiality 
of the respondents, per the ethical requirements of each study site. 
12.2. Qualitative Phase 
Content analysis is a systematic and objective research method used for the 
description and quantification of a phenomenon. It is used to enhance the 
understandability of data, as a large volume of text is distilled into words, categories or 
concepts, and phrases. This aids researchers in presenting new insights and making 
valid inferences relevant to their context (129-131). In this research, the term category 
will be used to present data since it is a term commonly used in the literature (132).  
As a research method, content analysis can be challenged, as it is a simple 
technique that is not based on thorough statistical analysis. Additionally, the method 
has been criticized because even researchers with limited analytical abilities can attain 
simple results (132, 133). Nevertheless, the method has been used successfully in the 
literature for the analysis of the PV system (50, 110), as it offers the benefits of being 
a content-sensitive and flexible method with respect to research design (129, 134). 
Additionally, the case study design will aid in developing an understanding of the PV 
situation in Qatar because this method enables researchers to develop their 
understanding and identify critical issues (130, 132), as it is concerned with context, 
consequence, meanings, and intentions (135). 
There are two approaches to conducting a content analysis on data, namely, the 
inductive and deductive approaches. For this study, deductive content analysis was 
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used. Deductive content analysis is “used when the structure of analysis is 
operationalized on the basis of previous knowledge” (132). This applies to this study 
because it aimed to evaluate PV systems and the related concepts that have well-
established definitions in the relevant literature. The evaluation will rely on the use of 
the WHO PV indicators, which were developed on the basis of the PV system 
components of structure, processes, and outcomes. Additionally, the PV field is 
characterized by specific standardized definitions, terminology, concepts, and 
practices; therefore, it is most suitable to follow the deductive content analysis in this 
study by complying with the current practice. Accordingly, the study utilized the 
previous knowledge on PV systems and PV systems assessment methodology to 
conduct deductive content analysis following a system-based approach. Additionally, 
the study accounted for additional observed codes and categories that were applicable 
and relevant. Therefore, following the deductive content analysis method, a matrix of 
analysis was developed with predetermined codes and categories that represent the PV 
system model defined by the WHO framework (131). Subsequently, the data presented 
in the interview scripts were assessed and coded according to their correspondence to 
the developed unstructured or unconstrained categorization matrix (132, 136) (Table 
7).  
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Table 7. Unconstrained categorization matrix 
Main Category * Category ** Codes** 
Challenges  
 
Strengths  
 
Opportunities 
 
Recommendations  
Structure 
indicators  
Based on the core indicators:  
• Pharmacovigilance center/department  
• Policy, legislation or guidelines 
• Healthcare system regulatory authority (i.e., 
MOPH) 
• Financial provisions  
• Human resources  
• Adverse drug reaction reporting form  
• Report management process for reporting 
collection analysis and databases  
• Pharmacovigilance education  
• Pharmacovigilance information communication  
• Pharmacovigilance advisory committee 
Based on the complementary indicators:  
• Computerization of pharmacovigilance e.g., a 
computerized case report management system 
• Sources for data and information  
• Communication facilities  
• Essential medicine list  
• Laboratory for pharmacovigilance 
• Standard treatment guidelines  
• Pharmacovigilance training, e.g., courses and 
tools 
Process 
indicators  
Based on the core indicators: 
• Reporting rate  
• Feedback and responsiveness, e.g., feedback on 
ADR reporting  
• Causality assessment  
• Quality of reports  
• Sending reports to the regulatory body 
• Pharmaceutical companies’ functionality  
• Active surveillance activities 
Based on the complementary indicators: 
• Patient awareness of adverse drug reactions and 
pharmacovigilance  
• Healthcare provider awareness of adverse drug 
reactions and pharmacovigilance  
• Risk management strategies and process 
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Main Category * Category ** Codes** 
• Periodic safety update reports 
Outcome 
indicators  
Based on the core indicators: 
• Signals, e.g., identification and evaluation of 
signals  
• Regulatory actions  
• Clinical outcomes, e.g., medicine-related 
hospital admissions, medicine-related deaths, 
extension of hospital stays 
• Financial outcomes, e.g., cost in monetary units  
Based on the complementary indicators: 
• Preventable adverse drug reactions  
• Congenital malformations 
• Counterfeit and substandard medications 
Additional: 
system-based 
approach*** 
• Systems structure and networking 
o Organizational structure 
o Duplication, overlap or omission 
o Stakeholders coordination 
• Leadership and management 
o PV as a Priority  
o Expertise  
o Decision making 
• Culture  
o Accreditation and performance 
management 
o Ethics  
o Just or blame-free culture 
*Based on the study objectives. 
**Based on the WHO indicators for pharmacovigilance. 
*** Additional categories that emerged during the content analysis process (some were 
mentioned only once but were accounted for in the results section due to their importance). 
 
 
The deductive content analysis of the qualitative data in the form of 
recommendations and other text-based concepts obtained during the interviews and/or 
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the examination of the documents allowed a better and more detailed understanding of 
and reflection on the WHO PV indicator checklist. Such a combination allowed a 
comprehensive assessment of the PV and medicine safety system. The following 
sequence was followed for a valid assessment of the qualitative information: a) Data 
reduction: selection of all relevant information to be summarized, employing the 
unconstrained categorization matrix; b) Data display: representation of the findings 
using an organized comprehensive approach employing the predetermined coding 
process that included categories as appropriate (Table 7); and c) Conclusion drawing: 
drawing a solid conclusion based on summarizing the findings to address the specific 
concepts of situational PV system analysis. No sophisticated software was used for 
coding; instead, the analysis relied on hand-coding printed scripts. Table M12 in 
Appendix A presents a few examples of the coding process. The examples provided are 
from different stakeholders and different levels of the healthcare system, namely, the 
national level and the private and public sectors as well as academia. The results of this 
analysis will be presented in the results chapter as a general text-based qualitative 
assessment as well as in the tables showing the qualitative assessment of each indicator 
category to complement the results of the quantitative analysis. The results section will 
not include direct quotations, per the request of the key informants.  
13. Validity  
The steps mentioned below were followed to enhance the validity of the 
research findings. These measures are based on the work of Creswell (118):  
I. Triangulation of data sources: The study used many methods and sources to 
gather qualitative and quantitative data, including semistructured interviews, 
document review, and field observations. 
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II. Peer debriefing: The findings from each data collection site and for the whole 
study were discussed in detail with the primary supervisor as well as the 
supervisory committee. 
III. Participant checks (i.e., member check): The key informants were offered the 
opportunity to validate the findings at their level, so they were involved in the 
process based on their preference. Some, e.g., HMC, requested that the full 
interview script be provided; others, e.g., private health organizations, 
requested tabulated results; and others requested a final report and discussion 
to validate the findings. For example, the MOPH requested a one-hour 
meeting and an 8-page report discussing the findings. This meeting involved 
the primary supervisor and covered the MOPH case as well as the country PV 
situation. Other stakeholders made no requests, so no measures were taken to 
provide them with such information. 
IV. Potential biases: The study clarified potential biases for the study in the role 
of the researcher as well as the section limitations, e.g., response bias. These 
are presented in the discussion chapter.   
V. The use of rich description to present the findings: In the results section, the 
study will present the case studies with details; specifically, the MOPH 
findings are presented following a rich text format. This allowed many details 
on the qualitative components, such as the codes, to be shared. This process 
will provide readers with a more realistic picture.  
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VI. Presenting discrepant information: in the results section, some discrepancies 
reported across PV subnational systems and by different stakeholders will be 
shared.  
VII. Data collection: A long period was allowed for the data collection stage, 
especially for cases in which stakeholders requested many meetings. 
14. Reliability  
The following steps were followed to improve the reliability of the findings 
(118, 125): 1) details including date and time, sample or key informant information, 
and the study site where the interviews took place were included in the records of the 
interviews; 2) evidence on the procedure (e.g., the interview questions, content analysis 
with examples of some parts of the transcript, and results tables), was provided; 3) the 
accuracy of the transcripts was ensured; and 4) the unconstrained categorization coding 
matrix, scoring system, and data collection instruments were agreed upon with the 
primary supervisor. 
15. A Summary for the Mixed Methods Study 
This mixed-methods study is summarized as follows:  
I. The study started by identifying the national and subnational PV systems as 
well as the higher authority at each site who was the most suitable informant 
for facilitating the conduct of this research. The priority list was based on the 
stakeholder’s level of importance in the country’s PV system implementation. 
II. The research team applied for ethical approval and obtained it to comply with 
the QU and stakeholder system specified research processes and guidelines. 
III. The researcher approached each stakeholder in the priority list to obtain the 
approval of higher-level administration or management and started the study 
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by conducting a single interview or a series of semistructured interviews 
regarding the PV system with the department or unit to enable the collection of 
all the required data. 
IV. During the initial phase, the researcher shared, via email invitation, the full 
research proposal, data collection tools, main WHO PV indicators manual, 
ethics-related documents, and support letters. Additionally, the researcher 
visited and conducted initial meetings with the relevant key informants to 
explore the purpose of the given research, the process it would follow, and the 
nature and goals of the data collection and determined the roles the key 
informants could play in gathering the required data. 
V. The researcher started visiting the selected stakeholders after a prescheduled 
interview time frame was agreed upon with the key informant and a meeting 
agenda was established. The researcher started the qualitative (open-ended) and 
quantitative (close-ended) aspects of the data collection concurrently to 
determine the status in terms of the compliance, implementation, and situation 
of the PV system in relation to the WHO framework. 
VI. The process of data collection was performed through semistructured 
interviews in which information was gathered during face-to-face discussions. 
Further, information not available or accessible during the interviews was 
followed up through e-mail communication.  
VII. Some data and information were not addressed by the interviewed 
representatives due to the ethical regulations and internal policies of the 
concerned stakeholder system; in these cases, the evaluation and scoring were 
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identified within the assessment tables (e.g., data are available, but no values 
are reported for the given PV KPIs). In addition, it is worth noting that some 
information was not addressed by some stakeholders despite several phone call 
reminders as well as e-mail reminders; therefore, the scores for the specific 
missing data were assessed by the scoring system as partial performance or zero 
depending on the case and whether the indicator had been satisfactorily 
addressed during the meeting. 
VIII. The quantitative and qualitative data for the listed WHO PV indicators as well 
as the supplementary information received from each key informant were 
assessed concurrently as applicable or relevant. The gathered data were 
analyzed for the final results and scores that are presented in the tables, 
graphical presentations, and text. 
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CHAPTER IV: RESULTS 
 
This chapter presents the findings from the qualitative and quantitative data 
collected about PV and medication safety system assessment and improvements. This 
mixed-methods study will present a comprehensive PV and medication safety system 
assessment to provide a full understanding of the Qatar PV system at various levels of 
the healthcare system. In this study, the performance of the PV system was measured 
in terms of compliance with the WHO PV indicators (structure, process, and outcome 
indicators). The results of the PV KPIs represent the functionality and sophistication of 
the PV system and can aid in developing strategic and operational recommendations to 
improve the PV system as well as determining the measures required to achieve a fully 
operational system. The qualitative data will be used to provide a context-based system 
evaluation that is strongly dependent on stakeholders’ views and perceptions of the 
limitations, strengths, and opportunities present in the country. Additionally, qualitative 
data will be used to supplement the WHO PV indicator assessment. The reason for 
utilizing a MMR approach is to obtain a more comprehensive understanding and deeper 
insight into the PV system in Qatar and to overcome the limitations inherent to using 
the qualitative or quantitative approach alone. The results will be presented in the 
following sequence in order to respond to the research objectives: 
I. Evaluate the baseline PV situation using the WHO PV indicators.  
II. Compare Qatar's current national PV system to the minimum requirements of 
the WHO for a functional national PV system. 
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III. Identify the potential opportunities, strengths, and limitations to address the 
level of development of the PV system as well as the establishment and 
sustainability of a specific PV center. 
1. Evaluation of the Baseline Pharmacovigilance Situation Using the WHO 
Pharmacovigilance Indicators 
The results of the comprehensive evaluation of the PV system in Qatar are 
presented in this section as a selected case analysis as well as a comparative analysis 
among PV systems, including those at the national level (MOPH, regulatory body 
system), in the public sector (including HMC and PHCC), in private healthcare 
facilities and service delivery organizations (including private healthcare institutions 
and community pharmacies), in the local pharmaceutical industry, in PHPs (i.e., MHS), 
and in academic institutions. Each stakeholder performance level will be closely 
assessed in relation to the WHO PV structure, process, and outcome PV KPIs. For the 
indicator scores and calculation values, refer to Table R1a and Excel spreadsheet R1b 
in Appendix B. 
The sample of key informants included physicians, nurses, pharmacists, and 
other healthcare-related backgrounds. The total number of participants was 30 
individuals at different data collection levels: 
I. MOPH: five people. 
II. HMC: four people. 
III. PHCC: seven people.  
IV. Private sector institution 1: one person.  
V. Private sector institution 2: one person.  
VI. Private sector institution 3: one person.  
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VII. Private sector institution 4: two people.  
VIII. Private sector healthcare group: three people. 
IX. Private sector chain pharmacy group: one person.  
X. Private sector independent pharmacy: one person. 
XI. MHS: one person.  
XII. Pharmaceutical industry: one person. 
XIII. Qatar University College of Pharmacy: two people. 
XIV. Qatar University College of Medicine: one person. 
XV. Qatar University College of Health Sciences: one person (not a face-to-face 
interview but only email response, which was acceptable because there is only 
one indicator, CST8, for universities). 
XVI. College of the North Atlantic: one person. 
XVII. Weill Cornell College of Medicine: one person. 
XVIII. University of Calgary: one person. 
1.1. Ministry of Public Health (MOPH)/National Level 
The study assessed the PV system at the MOPH level, which was represented 
by 5 members from the Department of Pharmacy and Drug Control and the Department 
of Quality and Patient Safety (HQPS).   
1.1.1. Total Performance of the MOPH Pharmacovigilance System 
According to the assessment findings, the total score for the three PV structure, 
process, and outcome domains was 19.5 (23.8%; actual performance status) out of an 
allowed cumulative score of 82 (100%; desired performance status). The compliance 
of the MOPH PV system with the WHO PV indicators was highest for the structural 
indicator score of 12.5 (40.3%) and lowest for the outcome indicator score of 2 (9.1%). 
Figure 3 and Figure 4 represent the performance of the MOPH PV system based on the 
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measured compliance with the WHO PV indicators. As a result of the low performance 
on many of the indicators, the MOPH case will be presented following a qualitative text 
format. The full details on the MOPH system performance for each indicator can be 
found in the Appendices in table format, namely, Table R2 in Appendix B on the core 
indicators and Table R3 in Appendix B on the complementary indicators. 
 
 
 
Figure 3. National pharmacovigilance system performance at the MOPH level 
(presented as percentages) 
 
Figure 4. National pharmacovigilance system performance at the MOPH level 
(presented as scores) 
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1.1.2. Structural Indicators Performance 
The performance of the MOPH PV system as measured by the core structural 
indicators was 7 out of an allowed score of 20 (35%). The MOPH PV setup has not 
demonstrated the availability of the core PV structures, such as an independent PV 
center (i.e., CST1), a national policy or guidelines for PV (i.e., CST2), and a national 
ADR reporting form (i.e., CST6), required for a functional PV system in the WHO PV 
indicator manual; refer to Table R2 in Appendix B. The MOPH performed higher in 
the complementary structural indicators, achieving a score of 5.5 out of an allowed 
score of 11 (50%). The MOPH reported having data sources on drug safety information 
for daily PV activities, and data from stringent regulatory authorities in the U.S., 
Europe, and Australia are used to ensure that PV requirements are followed in the 
country. 
The regulatory framework for the Pharmacy and Drug Control Department 
includes guidelines for medicinal product registration, MAHs, manufacturing premises, 
and pharmaceutical premises. According to the MOPH, there is no specific statutory 
provision for PV and no specific national PV policy or guidelines (i.e., CST2). 
However, Qatar is a member of the GCC countries, which have well-established 
guidelines for drug registration, including PV.  
Moreover, the pharmaceutical law of Qatar covers aspects of medication safety, 
but the specific term PV is not employed. The current law does not cover the full scope 
of passive and active PV activities. Since the current law is relatively old, it is well 
enforced and well implemented by the Department of Pharmacy and Drug Control. 
Furthermore, the current law does not provide details on PV information sharing or 
transparency issues. Regarding the effectiveness of the current law for medication 
safety and patient safety, it was reported that it is not entirely effective, as it is not 
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comprehensive to cover the scope of PV (i.e., regulatory and practice PV). Additionally, 
Qatar does not have a national medicine policy to ensure medication safety.  
 The MOPH reported that there is a lack of efficiency because to date, there has 
been no improvement in national PV actions. Therefore, according to the MOPH, unless 
there is an appropriate law and bylaw that forces various national stakeholders to take 
action regarding PV, they will not perform those functions as required.  
Furthermore, MOPH has submitted a draft for an updated pharmacy law, or 
"Pharmacy Act". The draft includes many aspects that were not covered in the previous 
law, such as regulations for medical devices, manufacturing facilities, herbal products, 
and food supplements. The new law will include PV and medication safety as part of 
drug registration and pharmaceutical practices in the country. 
The reported functionality of the national PV system for the external 
pharmaceutical industry and service delivery healthcare institutions diverged and did 
not align with the expected performance required at the national level. According to the 
MOPH, the PV system is considered functional in relation to the pharmaceutical 
industry and international stakeholders. However, the current PV system from the 
national stakeholders' side can be considered nonfunctional. For instance, regarding the 
roles and responsibilities of stakeholders concerning medicine safety, it is required by 
law that MAHs and the local agent should declare any quality or safety issue to the 
MOPH, as represented by the Pharmacy and Drug Control Department, and such issues 
must be reported within a specific timeline. However, for healthcare professionals, 
there is no legally binding requirement for reporters in the law; instead, they are merely 
advised to report medication safety issues.   
At the national level, the ethical standards for healthcare professionals that are 
required to improve PV were considered appropriate from the perspective of the 
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MOPH. The MOPH reported that ethics has a high profile in the country, but there is 
still a need to combine it with a specific law or specific guidelines. If there is no law 
that forces or guides healthcare professionals to perform PV actions, then the situation 
will not be appropriate.  
Within the MOPH, there is no specific PV department (i.e., CST1). Rather, PV 
activities are incorporated into daily activities. Additionally, there is no allocated 
budget for PV, as there is no independent or segregated body responsible for PV, thus 
the current budget for covering medication safety activities does not directly reflect PV 
functions. It was reported that the budget is sufficient for the current operation of the 
system. However, to establish a national PV center, a dedicated budget must be properly 
allocated. 
The MOPH reported the absence of a national database for PV data management 
(i.e., CST7), and a limited number of relevant case reports have been received (i.e., 
fewer than 10 reports were received from Qatar Petroleum in 2017). The national 
reports received by the MOPH in recent years were relatively poor in quality and did 
not allow for a proper causality assessment. No new ADR cases were received, and 
most of the received reports were well established or mentioned in the leaflet. 
Currently, there is no public reporting form (i.e., CST6) for medication safety 
issues. However, the MOPH has a health website, and members of the public can 
register their complaints, inquiries, and requests with the Governmental Health 
Communication Center (GHCC) by filling out a form. The GHCC falls under the Public 
Relations Department and is directly under the minister, indicating that public 
complaints are taken seriously. 
 The MOPH key informants commented on the possibility that in the future, a 
specific form for ADR reporting may be created for use by the general public. They 
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stated that this will not be an easy initiative because Qatar has a diverse population; 
thus, many languages may be required to develop the national form, and cultural 
adaptation may be difficult. Consequently, the public contribution to reporting could 
continue to be very limited. 
The MOPH informants reported that they support public reporting in general 
and that in the patient safety reporting system that they are considering implementing, 
at some stage, the MOPH will look into giving the public access so that patients can 
directly report data, such as an incident, complaint or alert. 
 Regarding the possibility of having a specific ADR form that is available to the 
general public, the MOPH informants reported that public reporting should be 
performed in a simple and open manner to suit the level of the public, as it must 
accommodate all levels of the community and not discourage people from reporting. 
They reported that the MOPH wants to make the reporting system patient-centered and 
that ADR forms can restrict the public desire to provide information.  
The HQPS informants reported that currently, they do not have a process in 
place to ensure that they follow up on PV and medication safety (i.e., CST7). They 
reported that currently, the MOPH is still in the planning stage regarding medication 
safety. There is an intended plan to develop a medication safety program. The program 
is not specific to PV, but its basic elements depend on the “WHO Global Patient Safety 
Challenge on Medication Safety”, which aims to “reduce severe, avoidable medication-
related harm by 50% in the next five years”. Although the MOPH is at an early stage, 
it has made a commitment by signing the WHO pledge; currently, it is in the process of 
developing an action plan and engaging with national stakeholders.  
The HQPS informants reported that there is another future project under the title 
of the National Patient Safety Reporting System (i.e., CST7). This reporting system 
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includes reporting on ADRs and medication errors in general. This project is separate, 
but it acts as a medication safety program. Part of the agenda for this program is to be 
able to interface with existing systems in hospitals or other healthcare facilities and 
automatically transfer data to the national system. The HQPS future plan is to have a 
general reporting system, and part of this reporting system will include ADRs—
specifically, an ADR reporting form. However, the HQPS is not aware of the items that 
will be covered under this ADR report. The plan includes a proper classification system, 
but the HQPS is not fully aware of the content of this system. Furthermore, it was 
reported that developing a reporting form will be based partly on stakeholder 
engagement, so a team will be engaging with the various sectors to develop the ADR 
form based on evidence-based published literature. 
Previously, any issue received from the external pharmaceutical industry was 
communicated through the licensing department. Currently, the MOPH communicates 
this information to the Qatar Council for Health Care Professionals (QCHP), where it 
is publicized in a circular (i.e., CST9) with instructions and guidelines for clinicians on 
how to submit reports or how to act in cases of that specific medication. 
At present, there is no specific and/or organized PV or medicine safety advisory 
committee (i.e., CST10). Therefore, it was noted that in the future, having a functional 
committee will serve the needs of the country. For instance, to guard patient safety and 
the interests of MAHs, such a committee would enable the country to avoid potential 
conflicts of interest. It has been recommended that the best system models, such as that 
of Morocco, be used as appropriate benchmarks for improvement. If such a committee 
is established, it could be affiliated with the MOPH or an academic university. 
Additionally, it has been recommended that the advisory committee be made up of 
diverse experts, including 1) Academicians who have good access to reputable sources 
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of information and who can take a strong leadership role; 2) Regulators from the 
MOPH, who can provide input by following benchmarks and examining different 
regulatory agencies; and 3) Healthcare practitioners such as physicians who can also 
support the advisory committee. 
The tools that the MOPH uses to communicate with national stakeholders and 
within the ministry about PV and medication safety are mainly its website and emails 
(i.e., CST9 and ST3). Furthermore, the MOPH uses the mobile application Qatar 
National Formulary to list all ADR precautions and other safety concerns. However, a 
challenge was reported when the drug information services that were previously 
available as part of the structure of the Directorate of Pharmacy were deorganized and 
ceased functioning. The MOPH considers drug information services and PV services 
to be important aspects that must be in place in the near future. 
Additionally, the MOPH key informants made a note of a favorable initiative 
for PV education in creating or establishing an ADR newsletter (i.e., CST9). A 
newsletter would serve as a good way to communicate with confidence with physicians 
to increase their awareness of the PV system and specific ADRs reported in the country. 
Therefore, the newsletter could ultimately lead to developing desirable behaviors and 
would offer a good communication tool, as reporters would have the privilege of being 
acknowledged for their reporting of ADRs. For instance, their efforts could be 
described within the organization and perhaps at the national level. 
Currently, the MOPH is not very active in providing training at the national 
level (i.e., ST9 and ST10), apart from vaccine training, which is well implemented. 
However, it was reported that the MOPH has enough capacity to provide training to 
address the limited awareness of other stakeholders.  
One of the major weaknesses reported in the current PV system is 
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communication, which has a very low profile. Additionally, the pace of policymaker 
steps and actions was considered slow. In addition, the patients and the general public 
make minimal contributions to the PV system. Therefore, it was noted that to improve 
communication, there is a need for awareness and legislation to force stakeholders, 
mainly healthcare professionals, to take part in PV functions.  
1.1.3. Process Indicators Performance 
The assessment indicated that of a total possible process indicator score (i.e., 
core and complementary indicators) of 29, the MOPH achieved a score of 5 (17.2%). 
The MOPH reported a positive response only for core process indicator number eight 
(i.e., CP8), which includes the number of pharmaceutical companies registered with 
fully functional PV systems. For other process indicators, the MOPH does not have the 
main PV structures in place; therefore, the national PV system has limited capacity to 
meet the performance requirements of the process indicators. 
According to the MOPH key informants, the underreporting issue in Qatar is 
expected to continue owing to the lack of an appropriate documentation system and 
national ADR reporting form. However, they reported that underreporting was a 
challenge even when the previous national reporting form was available. The MOPH 
created the previous form and made it available online as part of the Qatar National 
Formulary, but because of certain legislative issues related to patient data security, the 
MOPH did not continue to use the form. In addition, with respect to establishing a 
national database to receive direct reports from different stakeholders, the MOPH 
reported that there is a large project called the eHealth Strategy. This is expected to 
offer an opportunity to implement such a data management system for ADR reporting 
and PV. The eHealth Strategy is expected to connect the public and healthcare 
stakeholders and providers, starting with health insurance payers, public hospitals, and 
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policymakers. In addition, training courses will be provided through eHealth. 
Coordination with stakeholders at the international level, for example, the WHO 
PIDM, is deemed a strength for the country. The MOPH has a good relationship with 
the UMC, and it has already been successful as an associate member. The MOPH has 
received the privilege of accessing the international system that is designed to receive 
reports. The MOPH considers this privilege a sign of strong collaboration and 
coordination since the UMC is a well-reputed organization that is pushing the country 
to become a full member. Consequently, it has been recommended that the country act 
to develop a national PV system, establish a PV center, hire the required staff, and start 
submitting reports to the UMC. On the other hand, national coordination among all 
stakeholders is a major challenge for PV because there is no proper coordination. The 
MOPH informants, namely, those from the Pharmacy and Drug Control Department, 
reported that they are informed at a very late stage about the medication safety and PV 
initiatives of other departments within the MOPH, such as the HQPS, or other 
stakeholders, such as the HMC. National stakeholders develop initiatives, but there is 
no proper coordination. Additionally, the MOPH informants reported that there is no 
national platform to enable PV activities. Furthermore, individual projects or activities 
are not linked or known to the national system of the MOPH. For example, any clinical 
trial or research projects will not be known until they are published in journals or 
otherwise included in the literature.  
The MOPH informants reported that national stakeholders’ accountability is 
deficient because the current healthcare system cannot be further improved without a 
national PV system. Additionally, they reported that there is an issue with transparency 
in data sharing among stakeholders despite Qatar being a small country. For instance, 
the eHealth Strategy project has been delayed for many years because of restrictions 
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and resistance, even from governmental hospitals and institutions, to sharing data.  
On the subject of reporting by community pharmacies, the MOPH reported that 
if reporters have good knowledge and are ambitious, they can report and communicate 
to the MOPH even in the absence of a national reporting form. The MOPH reported 
that equity is sustained, and people can take the lead and behave accordingly. This was 
noted because the community pharmacies ought to be able to respond to the challenges 
that can affect their reporting, including their restricted resources, work style, interests, 
and scope, which is mainly commercial.  
When addressing the capacity for evidence-based causality assessment, signal 
investigation and other forms of PV data analysis, it was recommended that awareness 
and training be mandatory, as such processes require expertise in all elements of 
healthcare. Although 90% of the HCPs in Qatar are expatriates, and some of them come 
from countries where PV is well established and known, there is still a need for training 
and awareness because most of them did not have PV and ADR reporting as their main 
job functions. Therefore, it was recommended that awareness be improved among 
HCPs, and in the stakeholder system PV could be included in the performance 
appraisals of staff at the organizational level. 
For active surveillance activities (i.e., CP9), the MOPH did not report any 
examples of studies that have been conducted, such as cohort event monitoring or phase 
4 clinical trials at the national level. Additionally, the MOPH does not have the capacity 
to conduct such studies. Collaboration on such studies between the MOPH and other 
sectors was deemed a potential idea. In the future, the MOPH will be ready to 
collaborate with other sectors and to allow some staff members to support these 
collaborations. However, because active surveillance activities are very expensive and 
require considerable technical knowledge, and most pharmaceutical companies can 
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perform them successfully, it was reported that it is best to rely on third parties and 
pharmaceutical companies. In addition, the MOPH utilizes the outcome of international 
active surveillance studies, specifically, data received from clinical trial studies. The 
MOPH considers clinical trials to be the most rigorous sources with valuable results; 
therefore, it will take action based on the data reported in these studies if there is a new 
medication or if there is a change in a specific product. In addition, unless the 
pharmaceutical companies submit clinical trial data, MOPH does not consider taking 
action.  
The MOPH is not aware of any current national initiatives on clinical trials. In 
Qatar, clinical trials are a function of the medical research centers (e.g., within HMC or 
Weil Cornell University), where the trials receive approval. Most of the centers perform 
either phase 3 or phase 4 trials, especially postmarket surveillance studies. However, 
the MOPH informants reported that a major challenge for the country is that a specific 
policy or law that covers the PV training for and conduct of clinical trials is not 
available, which could present a great risk. Additionally, the HQPS reported that the 
private sector is allowed to conduct clinical studies (including on human subjects), 
according to the Research Division of MOPH, which is responsible for the ethical 
involvement of humans in research and for establishing research policies in Qatar. 
Therefore, healthcare institutions can apply to conduct such studies, but they must 
follow a certain process and fulfill all the requirements of the MOPH. 
The MOPH requires risk management plans for all drug products in the 
registration process. Additionally, for risk management practices at the national level, 
the MOPH follows specific guidelines, and the informants reported that those 
guidelines should provide an appropriate risk management plan. The local 
pharmaceutical companies also provide the MOPH with information as part of 
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benchmarking and technology transfer. 
  Concerning the evaluation of the benefit-risk ratio, the Pharmacy and Drug 
Control Department reported that at the current level, it does not have the capacity to 
conduct such activities because decisions on the risk-benefit ratio reflect the use of 
medication in practice, which is not an easy task, requires expertise and may require a 
specific committee. 
1.1.4. Outcome/Impact Indicators Performance 
The lowest-performing domain for the MOPH was outcome indicators. For core 
outcome indicators, the MOPH obtained a score of 1 out of a possible total score of 16 
(6.3%). For complementary outcome indicators, the MOPH reported one positive 
response for O4, indicating that less than 1% of medications in Qatar are 
counterfeit/substandard, as there are stringent regulations, and Qatar procures 
medications only from reputable sources and mainly procures branded medications 
(Table R3: Appendix B).  
For signal evaluation (i.e., CO1), the MOPH informants commented that there 
is a lack of awareness about the signal evaluation process, including the use of the 
relevant tools and methods. Therefore, currently, no signals are generated at the national 
level. Additionally, the MOPH reported that the signal evaluation process requires great 
effort from most stakeholders, which can include improving the reporting rates and 
quality of documentation at the PV practice level. 
For decision-making and regulatory actions (i.e., CO2), the MOPH relies on 
benchmarks from other countries with stringent regulatory agencies because the 
national reports that it receives sometimes do not align with global data; thus, the 
MOPH cannot immediately take regulatory action based on those reports. The 
Registration Section Committee is responsible for taking regulatory actions to 
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withdraw, suspend or simply continue the use of a medication.  
With respect to MOPH responsiveness, the informants reported that the 
responsiveness to drug safety issues is good; in such cases, there will be very fast action 
and a decision to address the issue. However, because a PV system is not in place, the 
MOPH informants reported that such actions are not documented, well monitored or 
evaluated for the short-term and long-term impacts, as they would be in an appropriate 
PV system that monitors, documents, evaluates, and communicates PV actions. 
Additionally, they reported that an inappropriate review process takes place between 
receiving a report and initiating feedback or taking an action. Therefore, it was 
recommended that in the future, the review process, including specific timelines, be 
included in the country regulations. For example, the MOPH reviews Qatar Petroleum 
reports immediately, but there is no such policy or system for sending feedback; MOPH 
only appreciates the efforts of the reporters and encourages them to continue submitting 
reports. 
For the identification of medication safety issues from external sources, MOPH 
regularly uses MedWatch, the UMC website, the EMA, updates from the Therapeutic 
Goods Administration (TGA) of Australia, the WHO newsletter, and other ADR 
newsletters. Additionally, the MOPH relies on GCC countries' information, as Qatar is 
strongly socially connected to the GCC, and the MOPH receives some of those 
countries’ feedback and communications. However, the MOPH informants reported 
that there is no systematic approach or standardized process in place to process safety 
alerts from outside sources, although such processing is among the routine functions of 
the MOPH system. 
 In an example of actions that were taken based on outside sources, different 
sources mentioned that there was an increased utilization of Victoza; the MOPH 
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enacted a strict regulation that the medication could not be dispensed without an 
appropriate prescription. In another example, the MOPH found that loperamide was 
being improperly used, so it took a current regulatory action to restrict the use of 
loperamide. The MOPH reported that key informants at the MOPH revise and review 
by seeking benchmark countries before initiating regulatory actions at the national 
level. For instance, in one case, a drug was withdrawn from the market by the EMA 
and other countries in the region, such as the GCC countries. However, the MOPH 
concluded that Qatar would not take similar action after reviewing the situation and 
consulting with experts. Later in that particular case, the EMA notified the company, 
and the product continued to be used safely.  
The MOPH informants reported that a maximum of 1 to 2 days is the usual time 
lag between receiving a report of an external safety issue and taking regulatory action 
or communicating it at the national level. In addition, if there are any delays in taking 
action, the reason is that the MOPH does not have a clear picture. However, the MOPH 
reported a problem with how such information is received, as the route of 
communication among MOPH departments is very time-consuming, and the process 
can be slow. 
Regarding national data, the HQPS reported that service delivery organizations 
do not report hospital admission data (i.e., CO3). Additionally, the HQPS reported that 
deaths due to medication errors are not reported by service delivery organizations and 
that such data could be found as part of the morbidity and mortality data (i.e., CO5). In 
addition, the HQPS reported that capturing these data will be part of the future reporting 
system plan.  
Additionally, according to health economists in MOPH, regarding the financial 
aspects of the system relevant to core outcome indicators 6, 7, and 8, as well as 
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complementary outcome indicators 7 and 8, this information is currently not available 
in the MOPH, but it is very important and worthy of collection. This is especially true 
of indicator number 7, which is considered feasible, but good planning for the 
methodology is needed.  
1.2. Public Sector Level 
1.2.1. Public Sector Part 1: Hamad Medical Corporation (HMC) 
The study assessed the PV system at HMC, which was represented by 4 key 
informants from the Medication Safety and Quality Center (MSQC) and HMC 
Pharmacy Department.   
1.2.1.1. Total Performance of the HMC Pharmacovigilance System 
According to the assessment findings, the total score for the three PV structural, 
process, and outcome indicator domains was 45.5 out of a possible cumulative score of 
70 (65%). The compliance of the HMC PV system with the WHO PV indicator manual 
was highest for the structural indicators, with a score of 20.5 (82%), and lowest for the 
outcome indicators, with a score of 9 (39.1%). Figure 5 and Figure 6 represent the 
performance of the HMC PV system based on the measured compliance of the system 
with the WHO PV indicators. As a result of the good performance on many of the 
indicators, the MOPH case will be presented in table format with full details on the 
HMC PV system performance for each indicator. 
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Figure 5. HMC pharmacovigilance system performance (presented as percentages) 
 
Figure 6. HMC pharmacovigilance system performance (presented as scores) 
 
 
1.2.1.2. Structural Indicators Performance 
The tables illustrate the performance of the HMC system in 8 relevant core 
indicators (Table 8) and 9 relevant complementary indicators (Table R4: Appendix B), 
and a qualitative assessment accompanies each indicator. The performance of the HMC 
PV system measured by the core structural indicators achieved a score of 13 out of a 
possible score of 16 (81.3%). Similarly, the HMC system performed well in 
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complementary structural indicators, with a score of 7.5 out of a possible score of 9 
(83.3%). Notably, the overall scores, as well as the core and complementary structural 
indicator scores, indicate an excellent system performance (i.e., target quartile range 
Q3: 75% to 100%). 
HMC established the Medication Safety and Quality Center (MSQC), The 
MSQC is the unit responsible for PV (i.e., CST1), and it is overseen by the HMC 
pharmacy executive director. The MSQC plays an important role in the HMC PV 
system and has direct contact with the Pharmacy Department, the primary department 
responsible for pharmaceutical products in HMC. 
 The evaluation indicated that HMC has all the basic core PV structures required 
for a functional PV system under the WHO PV indicators, except for CST4, as no 
specific budget is allocated for PV (Table 8). The assessment showed that HMC has 
existing policies that cover the entire scope of PV (i.e., CST2), including the active and 
passive aspects of PV, but these policies covers mainly voluntary reporting and passive 
activities. Furthermore, each indicator has a policy document; for example, ADRs as 
an indicator have a specific policy document. HMC reported the existence of reporting 
forms used by healthcare providers and one form for patients. However, no reports were 
received from patients between 2018 and 2019. 
It was reported that while establishing the MSQC, human resource provision 
was a challenge (i.e., CST5). The need for expert staff was added to the strategy as “the 
inclusion of medication safety officer”. The MSQC has adapted well to this challenge 
by working with part-time members from 12 HMC hospitals; currently, it considers its 
efforts a success. 
Currently, the executive director of pharmacy is working to develop a center for 
PV. HMC reported that there is a need to contact the MOPH before this step because 
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this PV center will represent Qatar at the international level. In addition, if there will be 
a national PV center under HMC, then HMC should receive the approval of the 
regulatory body in the initial stage. 
1.2.1.3. Process Indicators Performance 
The assessment found that of a total allowed process indicator score of 22, the 
HMC PV system achieved 16 (72.7%). The HMC key informants reported a positive 
response (i.e., a score of 2 or 1) for all relevant core process indicators (Table 8). 
With respect to core PV process requirements, HMC has an internal system for 
the collation and analysis of PV data. The MSQC receives reports from the 12 hospitals 
under HMC. The MSQC medication safety officers are responsible for performing 
trend analysis, signal investigation, and other data analysis. Concerning the strength 
and growth of the HMC database, the informants conveyed that the reporting rate is 
increasing gradually each year by an average of 10 to 15%. 
 After the establishment of the MSQC, the Pharmacy Department reported that 
the total number of ADR reports at the HMC corporate level was 1599 by the end of 
December 2017 and more than 700 between 2018 and 2019. Although there has been 
an increase in the rate of reporting, underreporting remains a challenge for the HMC 
PV system, as the trends include reporting mainly by the pharmacists. 
 Table 8 highlights the information relevant to PV communication. It was 
reported that if important or significant information was identified after multiple 
reviews of the received reports, the MSQC would release it to the pharmacy executive 
director, who would present it to the Corporate Pharmacy and Therapeutic Committee 
(CP&TC), the Drug Supply Unit or the national regulatory body. 
 Although HMC has limited capacity to meet the performance requirements of 
active surveillance activities (i.e., CP9), there are plans for active PV, and this subject 
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has been taken into consideration by the relevant key informants (Table 8).  
For the complementary process indicators, the assessment found that HMC 
achieved a score of 4 out of a total possible score of 6 (66.7%) (Table R4: Appendix 
B). It was reported that the MSQC does not have data on the average number of reports 
per total number of healthcare providers; however, the majority of reports are from 
pharmacists, representing almost 80% of the total reports.  
1.2.1.4. Outcome/Impact Indicators Performance 
The lowest-performing domain for the HMC PV system was the outcome 
indicators. For the core outcome indicators, HMC obtained a score of 5 out of a possible 
total score of 12 (41.7%) (Table 8).  
There are plans for economic studies, but the MSQC has not yet conducted such 
studies. According to the Pharmacy Department, there is one ongoing study about 
clinical interventions of pharmacists and their impact on the cost and length of stay; 
however, the study is still in process, and the results have not yet been calculated. 
 HMC reported that data on the average cost of medicine-related hospitalization 
exist and can be found through the HMC administration. The administration is 
conducting studies and has information on the patient cost according to the specialty of 
the department, but this process does not occur under the Pharmacy Department or the 
MSQC (i.e., a value was not provided).  
Out of 11 relevant complementary outcome indicators, the obtained score was 
4 (36.4%). According to the MSQC, the percentage of preventable ADRs in 2018 was 
5% for all HMC hospitals. In addition, the number of patients affected by a medication 
error over the previous three years was 0.16 per thousand admissions (Table R4: 
Appendix B). 
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Table 8. Hamad Medical Corporation (HMC) pharmacovigilance (PV) system performance and capacity results measured by the WHO core PV 
indicators 
Code Response Score * Assessment (Qualitative) 
CORE STRUCTURAL INDICATORS 
CST1  Yes.  (2)  • Applicable but no specific PV department.  
• HMC has the Medication Safety & Quality Center (MSQC), which is the unit responsible for PV. 
• The MSQC has indicators relevant to PV, such as ADRs and medication errors. 
• The executive director of pharmacy is working to develop a center for PV; it was reported that for a 
national PV center to be under HMC, it should receive approval at the initial stage. 
CST2 Yes.  (2) 
 
• HMC has policies that cover the whole scope of PV, including active and passive aspects, but it 
covers mainly voluntary reporting and passive activities. 
• Each indicator has a policy; for example, there is a policy for ADRs and a policy for medication 
errors. 
• The body responsible for ensuring that the policy is enforced and implemented is the Pharmacy 
Department, and the process is performed by the executive director of the Pharmacy Department. 
CST3 Not relevant. (-) • Not relevant.  
CST4 No specific 
budget for 
PV. 
(0) 
 
 
• Although there is no specific budget allocated for PV the MSQC has a sufficient budget for its 
activities.  
• The executive director of pharmacy supports educational intervention (e.g., courses and workshops) 
and other aspects requested by the MSQC. 
CST5 Yes.  (1) 
 
 
• The MSQC encompasses a committee with the executive director of the Pharmacy Department as the 
chair. The committee is also made up of the director who is head of the center and is a medication 
safety officer and a member from each HMC hospital.  
• It was reported that all members work part time for the MSQC and full time at HMC. It was 
recommended that the center have full-time staff, as is the case in advanced PV systems. 
• It was reported that while establishing the MSQC, human resources were a challenge, and the need 
for expert staff was added to the strategy as “the inclusion of medication safety officers”. 
CST6 Yes.  (2) 
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Code Response Score * Assessment (Qualitative) 
 • HMC reported the existence of reporting forms used by healthcare providers and one form for 
patients.  
• Regarding healthcare professional reporting forms, HMC has a specific form for ADRs and a form 
for medication errors. In addition, the HCP reporting form has a free text area where the reporter can 
report cases of therapeutic ineffectiveness; suspected misuse of, abuse of or dependence on 
medications; and other medication-related problems.  
• HMC reported that suspected counterfeit or substandard medicine is extremely rare because HMC 
and the MOPH have control over medications and do not allow falsified medications to enter the 
Qatar pharmaceutical sector. 
• No reports were received from patients in 2018 and 2019. The patient reporting form is available in 
the pharmacy and the patient units, as patients who are willing to report must approach a healthcare 
provider and tell him/her about their willingness to report. The pharmacist will then help the patient 
complete the report. 
CST7 Yes.  (2) 
 
 
• The executive director of the pharmacy keeps two databases, one at the facility level and the other at 
the corporate level. The databases are in the form of Excel spreadsheets that are used for the 
management of reported data. 
• The report management process in the MSQC involves the evidence-based causality assessment 
conducted by medication safety officers, which includes the use of evidence-based tools such as 
the Naranjo scales. The scope of the data analysis involves the assessment of causality, severity, and 
preventability. 
• When the Pharmacy Department, specifically the MSQC unit, encounters a significant issue, it issues 
a newsletter or alert and tries to present data, usually as a proposition in the annual report or at a 
conference.  
CST8 Not relevant. (-) • Not relevant. 
CST9 Yes.  (2) • The Pharmacy Department publishes a monthly newsletter or an alert to provide information and 
notify the HCPs about medication safety issues and the required form of action. 
• The existing HMC policies provide guidance on communication and the pathway of information, 
such as the flow of information and timelines. In addition, the current activities of the Pharmacy 
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Code Response Score * Assessment (Qualitative) 
Department involve informing HCPs about any warnings from international organizations through 
the newsletters. 
• A specific policy document developed as a disaster plan provides guidance on communication during 
crises or emergencies. 
CST10 Yes.  (2) • The Corporate Pharmacy and Therapeutics Committee (CP&TC) is the expert committee in HMC. It 
is accessible and provides advice on medication safety and PV-related issues in a timely manner. 
• The members of the CP&TC (20 total) are physicians with a higher level of expertise (medical 
directors) from different specialties, and not all of them are experts in PV. Therefore, the burden will 
be on the Pharmacy Department to provide them with all the information required to make the 
necessary decisions. 
• In the HMC policies, the minimum number of CP&TC meetings is four per year. However, the 
committee meets routinely to address medication safety issues; currently, it meets on an almost 
monthly basis. 
Total Score  (13) Out of 8 [8*2= (16)] is [(100%)] relevant indicators, the obtained score was [(13) = 81.3%] 
CORE PROCESS INDICATORS 
CP1 1599 reports. (2) • After the establishment of the MSQC, the Pharmacy Department reported that the total number of 
ADR reports at the HMC corporate level was 1599 between January 2016 and December 2017.  
• Although the Pharmacy Department reported an increase in the rate of reporting, underreporting 
remains a challenge for the MSQC. The reporting increment was from pharmacists only. 
• The MSQC reported that there is a need to address the quality of documented reports, as some 
reporters provided inadequate information; this issue was discussed with the CP&TC. 
CP1a: not 
relevant. 
(-) • Not relevant. 
CP2 2300 reports 
for the 
previous 3 
years. 
(2) 
 
 
• 2300 reports over the previous three years. 
• The strength and size of the database are increasing, as the reporting rate is increasing gradually by 
an average of 10 to 15%, but the trend includes mainly reporting by pharmacists. The nursing staff is 
underreporting, so the MSQC has suggested a possibility of including reporting in nurses’ 
performance evaluations.  
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Code Response Score * Assessment (Qualitative) 
CP3 100%. (2) • All reports must be analyzed and acknowledged in the same month.   
CP4 100%. (2) 
 
 
• The Pharmacy Department requests that the MSQC conduct an assessment for each report. 
• The analysis is performed by the medication safety officer. All the information is sent to and 
recorded by the MSQC. Then, second round of review is conducted with hospital coordinators as 
well as drug information specialists to confirm the data, investigate cases further, and consolidate the 
reports from all HMC hospitals. 
CP5 No 
percentage 
provided. 
(1) 
 
 
• Only sever or new reports will be sent to the MOPH. 
• HMC indicated that in the past, data have been sent to the MOPH, but the MOPH did not respond or 
give feedback to HMC. 
• HMC has started sending reports to the WHO, especially for important cases. 
• 70% are complete and of good quality, and 30% have missing information.  
• HMC promotes the concept of a blame-free culture and provides training to its healthcare 
professionals. 
CP6 No 
percentage 
provided.  
(1) 
 
• The clinical pharmacist must report this issue using a different reporting form; trends are recorded in 
a separate database. 
• HMC has very few reports on therapeutic ineffectiveness because the clinical pharmacists play an 
active role in drug therapy management. 
• HMC does not have a detailed report that distinguishes between therapeutic and pharmaceutical 
factors. 
CP7 No 
percentage 
provided. 
(1) 
 
• Most cases are reported cases of near misses; trends are recorded in a separate database. 
CP8 Not relevant. (-) • Not relevant.  
CP9 No active 
surveillance 
studies. 
However, 
(1) • In the future, HMC plans to conduct active surveillance studies. HMC is currently in the initial phase 
and has not determined the type of study, but it has plans for active PV. 
• HMC targets specific drugs, e.g., the ondansetron study. 
• HMC has studies relevant to medication utilization and medication errors. 
  
123 
 
Code Response Score * Assessment (Qualitative) 
HMC has 
initiatives. 
Total Score  (12) Out of 8 [8*2= (16)] is [(100%)] relevant indicators, the obtained score was [(12) = 75%] 
Code Response Score * Assessment (Qualitative) 
CORE OUTCOME/IMPACT INDICATOR 
CO1 Yes.  (2) • The MSQC raises such cases at the corporate level to confirm the information. HMC indicated that 
the current staff does not have a great experience with signal detection, as the staff has not 
encountered many cases, and the established system is relatively new. 
• HMC has published studies on two cases in which a patient had a side effect, but the side effect was 
not documented. First, for labetalol, an antihypertensive agent, HMC encountered cases in which 
patients who took the medication suffered from contractions. HMC contacted the WHO and 
published the research. The second case concerned esomeprazole. 
CO2 Not relevant. (-) • Not relevant. 
• HMC sometimes translates drug leaflets, e.g., from French. 
• HMC uses information from the FDA or EMA. 
CO3 No cases 
reported. 
(1) • HMC is in the process of writing a proposal to evaluate admission due to adverse drug events, but it 
will be for one facility and not across HMC. 
• These data will be documented in the file, but HMC does not have a number of reports of such cases. 
• Underreporting and the possibility of cases remaining undiagnosed could be challenges. In addition, 
it is not easy to link the outcome to the drugs. 
• Most HMC reports are voluntary. However, HMC is working on developing clinical surveillance 
with the Cerner system to capture some triggers for specific drugs. 
• Clinical pharmacy professionals are not available in the emergency department, so HMC does not 
have these data. If clinical pharmacy professionals were active in the emergency department, they 
may be able to collect these data. However, due to the shortages in the clinics, such data cannot be 
obtained. 
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Code Response Score * Assessment (Qualitative) 
CO4 No cases 
reported. 
(1) • HMC does not have these data. 
CO5 Not relevant.  (-) • Not relevant. 
CO6 No, HMC 
does not have 
this data.  
(0) • HMC does not have these data. 
CO7 No, HMC 
does not have 
these data. 
(0) • HMC does not have these data. HMC has international data only. HMC members are writing a 
proposal for this subject to capture data retrospectively. 
CO8 Data were 
not provided. 
(1) • HMC has these data. The administration is conducting studies and knows the patient costs according 
to the specialty of the responsible department, but this information is not under the Pharmacy 
Department or the MSQC. 
Total Score  (5) Out of 6 [6*2= (12)] is [(100%)] relevant indicators, the obtained score was [(5) = 41.7%] 
(*) Score: (2) Yes, fully satisfactory; (1) Yes, partially satisfactory (2); and (0) No includes not satisfactory, missing data, no values, and not applicable. 
(*) Score (-): Not relevant for the evaluation of system performance with WHO indicators. 
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1.2.2. Public Sector Part 2: Primary Healthcare Corporation (PHCC) 
The study assessed the PV system of PHCC, which was represented by 7 
members from the Medication Management Section, Risk Management Section, 
Clinical Information Systems Team, and Health Information Management Team.  
1.2.2.1. Total Performance of the PHCC Pharmacovigilance System 
According to the assessment findings, the total score for the three PV structure, 
process, and outcome domains was 38.5 out of a total possible cumulative score of 54 
(71.3%). The compliance of the PHCC PV system with the WHO PV indicator manual 
was highest for structural indicators, with a score of 20.5 (82%), and lowest for the 
outcome indicators, with a score of 4 (57.1%). Figure 7 and Figure 8 represent the 
performance of the PHCC PV system based on the measured compliance of the system 
with the core and complementary WHO PV indicators. As a result of the good 
performance on many of the indicators, the PHCC case will be presented following a 
table format with full details on the PV system performance for each indicator. The 
tables illustrate the performance of the PV system in the relevant core indicators (Table 
9) and relevant complementary indicators (Table R5: Appendix B) as well as the 
qualitative assessment accompanying each indicator. 
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Figure 7. PHCC pharmacovigilance system performance (presented as percentages) 
 
Figure 8. PHCC pharmacovigilance system performance (presented as scores) 
 
 
1.2.2.2. Structural Indicators Performance 
The tables illustrate the performance of the PHCC system in 8 relevant core 
indicators (Table 9) and 9 relevant complementary indicators (Table R5: Appendix B). 
The performance of the PHCC PV system as measured by the core structural indicators 
was 13 out of a possible score of 16 (81.3%). Similarly, the PHCC PV system 
performed well in the complementary structural indicator assessment, as it achieved a 
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score of 7.5 out of a possible score of 9 (83.3%). Notably, the achieved total structural 
scores, as well as the core and complementary structural indicator scores, indicate 
excellent system performance in this category (i.e., target Q3: 75% to 100%). 
This finding highlights the fact that PHCC has key PV system structures. 
Although not specific for PV, the Medication Management Section is concerned with 
medication safety activities, including ADR reporting (i.e., CST1). PHCC has no 
specific PV policy or guideline but rather has a range of policies that focus on 
medication safety (i.e., CST2) and are implemented and regularly updated, e.g., the 
policy on ADR reporting. The CST7 assessment found that PHCC has two automated 
systems for routine PV activities. The electronic Datix and Cerner systems will store 
all the reports received. Furthermore, the Datix systems will enable PV information 
communication and feedback across the 25 centers. The Health Information 
Management Team records all the data from the reports and the interventions that are 
available for all patients in all PHCC centers. This enables a search for all PV activities 
that happened as well as all the ADR reporting that occurred in the main centers to 
generate a full report. 
The Pharmacy and Therapeutics Committee is a multidisciplinary committee 
with 10 members, including physicians, nurses, and pharmacists. The committee is 
responsible for providing advice on medication safety and PV at the corporate level 
(i.e., CST10). Furthermore, PV data are essential to PHCC guideline development (i.e., 
ST8). The guidelines committee, which includes more than 14 consultants, will use PV 
data obtained at the national level and/or from international sources of information to 
develop the clinical guidelines used in primary care. 
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1.2.2.3. Process Indicators Performance 
The assessment indicated that out of a total allowed process indicator score of 
22, the PHCC PV system achieved 14 (63.6%). PHCC reported a positive response for 
all relevant core process indicators except for CP9, which requires a number of active 
PV activities. It was reported that the Risk Management Team is performing passive 
surveillance activities through incident reporting only. For the complementary process 
indicators, the assessment found that PHCC achieved a score of 4 out of a total possible 
score of 6 (66.7%) (Table R5: Appendix B).  
With respect to core PV process requirements, PHCC has an internal system for 
the collation and analysis of PV data. The Datix system counted 50 reported ADR cases 
(i.e., CP1) for 2017. Many healthcare professionals are willing to report, as reporting is 
part of their monthly key performance indicators. Additionally, PHCC conducts 
continuous professional development programs to educate healthcare professionals on 
reporting, but to date, some of the received reports have had a degree of irrelevancy or 
deficiency (i.e., CP5). Some healthcare professionals lack knowledge of ADRs, and 
some fail to differentiate between ADRs and side effects. An event can be reported as 
an ADR, but when subjected to review, it will not be classified as an ADR. Some 
healthcare professionals report ADRs, but they do not provide the full information 
required for further analysis. PHCC does not conduct causality assessment (i.e., CP4). 
The Risk Management Team of PHCC performs systematic system analysis, but none 
has been performed for ADR cases. The Risk Management Team has experts with 
knowledge of statistical methods. The systematic system analysis will be based on the 
severity and recurrence of the received reports. 
According to PHCC, the national PV system of Qatar is not performing as 
expected; thus, the MOPH currently receives ADR reports only on vaccines. 
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Additionally, there is no well-defined system for reporting at the national level. 
Therefore, it was reported that there is a need to improve and activate PV as a 
centralized system at the national level. 
1.2.2.4. Outcome/Impact Indicators Performance  
The lowest-performing domain for the PHCC PV system was that for outcome 
indicators, especially for core indicators (Figures 7 and 8). For core outcome indicators, 
PHCC obtained a score of 0 out of a possible total score of 2 (Table 9). Out of 5 relevant 
complementary outcome indicators, the obtained score was 4 (80%). PHCC reported 
that the assessment of the percentage of preventable ADRs (i.e., O1) is not available 
(Table R5: Appendix B). 
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Table 9. Primary Healthcare Corporation (PHCC) pharmacovigilance (PV) system performance and capacity results measured by WHO 
core PV indicators 
Code Response Score * Assessment (Qualitative) 
CORE STRUCTURAL INDICATORS 
CST1  Yes, but no 
specific PV 
department. 
(1)  • Applicable, but no specific department for PV. PHCC has a Medication Management Section 
that is concerned with medication safety activities, including ADR reporting. 
CST2 Yes.  (2) 
 
• Range of policies that focus on medication safety e.g., ADR reporting. The policies are 
regularly updated. 
• The regulatory framework covers operations, clinical affairs, and quality. 
CST3 Not relevant. (-) • Not relevant. 
CST4 No specific 
budget for 
PV. 
(0) 
 
• No separate dedicated budget for PV. The budget for PV is included in the operation of the 
Medication Management Section. The current budget is sufficient.  
CST5 Yes. (2) 
 
 
• Sufficient; many staff members have master’s degrees, PharmD degrees, diplomas, and 
certification by the American board of pharmacotherapy. 
• PHCC will require more expertise in PV as they are opening new centers. 
CST6 Yes. 
 
 
 
(2) • Cerner and Datix system reporting forms. The form provides a field for medication errors and 
reporting suspected misuse, abuse, or dependence on medicine.  
• The form does not have a specific field for suspected counterfeit or substandard medicine or 
therapeutic ineffectiveness. The pharmaceutical products in Qatar are of good quality and 
effective. However, if a medication is damaged, has reached the expiration date, or needs to be 
recalled, it can be reported. 
• No form available for public reporting. Members of the public can report their concerns as 
complaints. 
CST7 Yes. (2) 
 
• The electronic Datix and Cerner systems will store all the reports received.  
• A comprehensive assessment of reported cases is conducted by the Pharmacy Department. 
Followed by a systematic system evaluation through the Quality Department, followed by 
Quality Department feedback and communication of actions. 
• The Health Information Management Team records all the data from the reports and the 
interventions that are available for all patients in all PHCC centers. This enables a search for all 
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Code Response Score * Assessment (Qualitative) 
PV activities that happened as well as all ADR reporting that occurred in the main centers to 
generate a full report. 
CST8 Not relevant. (-) • Not relevant. 
CST9 Yes. (2) • The reporting Datix software system is used for PV information communication. The Datix 
system is available to all PHCC centers.  
• There is no newsletter for PV specifically, but there is for the Medication Management Section 
as a whole. 
• For information communication to the general public, PHCC has many patient leaflets and 
brochures but not specifically on ADR. PHCC has brochures on antibiotics and missuse of 
medication in general. 
CST10 Yes. (2) • The Pharmacy and Therapeutic Committee is a multidisciplinary committee with 10 members, 
including physicians, nurses, and pharmacists. The committee meets on a regular basis, once per 
month. 
Total 
Score 
 (13) Out of 8 [8*2= (16)] is [(100%)] relevant indicators, the obtained score was [(13) = 81.3%] 
CORE PROCESS INDICATORS 
CP1 Yes. (2) • In the Datix system, there were 50 reported ADR cases for 2017. 
• ADR reports are reported in the Cerner and Datix systems. Usually, the ADRs reported in 
Cerner will be a subset of the Datix system. However, not all ADR reported in the Datix system 
will be documented in the Cerner system. Ideally, they should be, but this is not always the case. 
• Healthcare professionals are willing to report, as reporting is part of their monthly key 
performance indicators. In addition, PHCC conducts continuous professional development 
programs. Thus, the healthcare professionals report, but their reports can have a degree of 
irrelevancy.  
• Some healthcare professionals report ADRs but do not provide the full information required for 
further analysis. 
• Some healthcare professionals lack knowledge of ADRs, and some fail to differentiate between 
ADRs and side effects. Therefore, an event can be reported as an ADR, but when subjected to 
review, it will not be classified as an ADR. 
• The Risk Management Section has several projects on quality improvement and reporting of 
ADRs is one of the projects. 
CP1a:  
Not relevant.  
(-) 
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Code Response Score * Assessment (Qualitative) 
CP2 The value 
was not 
provided. 
(1) 
 
• Data were not provided. However, the data can be extracted.  
• The Risk Management Team is responsible for studying all incidents reported, including the 
trends and relevant calculations. PHCC relies on risk management analysis. 
CP3 100%. (2) 
 
 
• The Datix system allows PHCC staff to communicate and provide feedback on the same system. 
• Based on the type of incident, feedback will be provided through the Datix system, and the 
system will send an alert. For moderate to high-risk incidents, it is mandatory to provide 
feedback and a course of action to follow, and an email will be sent to all involved stakeholders 
selected from the Datix system (within 24-48 hrs.). For minor risk incidents, PHCC usually uses 
verbal phone communication and different interventions.  
• ADR reports receive feedback, but other low-risk incidents are investigated, and 
recommendations are provided. 
CP4 No; PHCC 
does not do 
causality 
assessment.  
(1) 
 
• PHCC does not perform causality assessment. The Risk Management Team of PHCC performs 
systematic system analysis, and none was done for ADR cases. 
• The Risk Management Team has experts with knowledge of statistical methods. Systematic 
system analysis is based on the severity and recurrence of events. 
CP5 No value 
provided.  
(1) 
 
 
• No value was provided for medication-related reports, but for vaccine ADR reports, it is 100%. 
• It was reported that the national PV system of Qatar is not performing as expected; thus, the 
MOPH receives ADR reports only on vaccines. In addition, there is no well-defined system for 
reporting at the national level. The Qatar National Formulary electronic application had a 
section for ADR reporting, but the license has expired and was not renewed, thus since February 
2017, there has been no form for reporting cases. Therefore, there is a need to improve and 
activate PV as a centralized system at the national level. 
CP5a: Not 
relevant. 
(-) 
CP6 PHCC has 
the data, but 
they are not 
calculated. 
(1) 
 
 
• PHCC does have this category in the Datix system, but it is not calculated. Additionally, factors 
contributing to therapeutic ineffectiveness are documented in the Datix system. Cases are 
detected by pharmacists, and they enter reports into the system. 
• Data are reported regarding dosage but not medication, hence PHCC does not consider the 
medication involved, as it has been reported that medications in the Qatar pharmaceutical 
market are of good quality and are effective. Therefore, the cases reported are related mainly to 
therapeutic causes and subclinical dosages. 
CP7 Yes. (2) 
 
• Percentages were not provided. Values were provided for incidents (n= 1191) and near misses 
(n=802). 
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Code Response Score * Assessment (Qualitative) 
 • It was reported that the culture of reporting and positive disclosure can be further improved in 
PHCC. 
CP8 Not relevant. (-) • Not relevant. 
CP9 None.  (0) 
 
 
• The PHCC Risk Management Team conducts passive surveillance activities through incident 
reporting only. In addition, the pharmacy supply management monitors for damaged 
medications. 
Total 
Score 
 (10) Out of 8 [8*2= (16)] is [(100%)] relevant indicators, the obtained score was [(10) = 62.5%]  
Code Response Score * Assessment (Qualitative) 
CORE OUTCOME/IMPACT INDICATOR 
CO1 None.  (0) • PHCC relies on external sources of data (e.g., an FDA notice on Avandia) and the MOPH only. 
CO2 Not relevant. (-) • Not relevant. 
• PHCC has internal initiatives. For example, PHCC reacted to the announcement of the WHO on 
antimicrobial resistance. A policy was developed, and recommendations were added to the 
PHCC drug formulary. In addition, PHCC restricted the prescriptions to certain healthcare 
professionals. This procedure will go through the National Stewardship Program.  
CO3 Not relevant.  (-) • Not relevant to primary care. Cases of drug-related problems such as allergies are referred to the 
HMC. 
CO4 Not relevant.  (-) • Not relevant.  
CO5 Not relevant. (-) • Not relevant. 
CO6 Not relevant. (-) • Not relevant. 
CO7 Not relevant. (-) • Not relevant. 
CO8 Not relevant. (-) • Not relevant. 
Total 
Score 
 (0) Out of 1 [1*2= (2)] is [(100%)] relevant indicators, the obtained score was [(0) = 0%] 
(*) Score: (2) Yes, fully satisfactory; (1) Yes, partially satisfactory (2); and (0) No includes not satisfactory, missing data, no values, and not 
applicable. 
(*) Score (-): Not relevant for the evaluation of system performance with WHO indicators. 
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1.3. Private Sector Level 
1.3.1. Private Sector: Healthcare Institutions   
The study assessed the PV system at 5 private health institutions (i.e., 3 private 
hospitals, one private healthcare organization, and one semigovernmental hospital). 
The sample of participants included 1 to 3 members from each health institution. This 
thesis will use the term Hospital to describe the health institutions, e.g., Hospital A. 
1.3.1.1. Total Performance of the Private Sector Health Institution 
Pharmacovigilance Systems 
The total possible score for the three PV structural, process, and outcome 
domains was 68 (100%). The mean total performance score for the 5 hospitals was 39.7, 
with a range from 33.5 for Hospital D to 44 for Hospital C (Table 10). To comply with 
the thesis page limit, the complete results for the 5 healthcare institutions will be 
presented in the appendix in table format with full details on the healthcare institutions' 
PV system performance for each indicator (Table R6 to Table R15: Appendix B). 
Although the health organizations have some deficiencies in their performance, all have 
functioning PV systems, and 4 hospitals achieved the target of good PV system 
performance (Table 10).  
 
 
Table 10. Total pharmacovigilance system performance of private sector healthcare 
institutions 
Hospital Code Total Performance Score (percentage) Target Performance 
Range* 
Hospital A 42 (61.8%) Good  
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Hospital Code Total Performance Score (percentage) Target Performance 
Range* 
Hospital B 39.5 (58.1%) Good  
Hospital C 44 (64.7%) Good  
Hospital D 33.5 (49.3%) Average  
Hospital E 39.5 (58.1%) Good  
*Target performance range (based on quartiles Q1: 25%, Q2: 50%, Q3: 75%): 
Excellent performance 75-100%, good performance 50-74.9%, average 
performance 25-49.9%, and poor performance 0-24.9%). 
 
 
Figure 9 and Figure 10 represent the actual performance of PV for the healthcare 
institutions in the main core and complementary indicators compared to the desired 
performance score measured by the WHO PV indicators, namely, structure, process, 
and outcome indicators. As illustrated, there are noticeable differences between 
healthcare institutions' performance. Overall, the performance on structural indicators 
was comparable in that all health institutions have achieved many of the core structures 
required for a functional PV system at the organizational level. For example, Hospital 
A achieved the highest score, 13 out of a possible total core structural indicator score 
of 16. On the other hand, the lowest performance of the PV system was in outcome 
indicators. Out of a possible score of 12, the mean score of core outcome indicators for 
the 5 hospitals was 2.4, with a range from 0 for Hospital A to 5 for Hospital B. The 
  
136 
 
health institutions’ score for core process indicators was between 13 for Hospital A and 
9 for Hospital D. For the aforementioned values, refer to Table R16 in Appendix B. 
 
 
 
Figure 9. Private healthcare institutions pharmacovigilance system performance 
(presented as percentages) 
 
Figure 10. Private health institutions pharmacovigilance system performance 
(presented as scores) 
 
  
137 
 
1.3.1.2. Structural Indicators Performance 
The assessment found that although there is no specific PV policy or guidelines 
(i.e., CST2), all the healthcare facilities have policies and guidelines that cover many 
elements relevant to PV, e.g., medication errors and ADRs. The key informants 
reported that a national PV guideline or policy document will be essential to ensure that 
all private sector institutions follow the standards and expectations set by the MOPH. 
Additionally, all 5 healthcare institutions had internal structures to enable PV at the 
organizational level. This includes the availability of a network or single department 
(i.e., CST1) responsible for PV activities, including the collation and analysis of and 
feedback on PV data (i.e., CST7). The departments responsible for PV among the 
research sample were usually the Quality Department, Pharmacy and Therapeutics 
Committee, and Pharmacy Department. 
 The results highlighted that PV structures and processes are usually 
coordinated at the organizational level. None of the healthcare institutions had a 
dedicated budget for PV or medication safety activities (i.e., CST4). In addition, all the 
healthcare facilities reported the existence of a report management process (i.e., CST7) 
that includes the availability of electronic or paper-based reporting forms (i.e., CST6) 
and a database for PV-related functions. Only one hospital (i.e., Hospital B) reported 
the availability of a reporting form designed for patient reporting. 
 For PV information communication, all the healthcare facilities had a structure 
in place for communication and feedback on PV and medication safety, which in some 
cases included website portals and newsletters (i.e., CST9). For sharing information 
with the public, although no PV training sessions were conducted, the healthcare 
facilities reported many initiatives for public outreach through TV media, radio talks, 
and social media, and one hospital reported visiting schools to raise awareness of 
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antibiotics and antimicrobial resistance among students. Healthcare facilities reported 
the need for a national contact point to address PV and to offer drug information 
services.  
Many healthcare institutions have initiatives to improve the efficiency of their 
PV and medication safety systems, including the utilization of PV and medicine safety 
data from internal and external sources to inform the development of their clinical 
guidelines (i.e., ST8), clinical practices, formulary updates (i.e., ST7), and educational 
interventions (i.e., ST9). 
1.3.1.3. Process Indicators Performance 
All the health institutions have procedures in place to ensure the completeness 
of submitted reports (i.e., CP5). For instance, Hospital B reported that the clinical 
pharmacist directly communicates with healthcare providers and patients to ensure that 
all the relevant information required for evidence-based causality assessment (i.e., CST 
4) is satisfactorily provided. Furthermore, among the sample, patients’ files were the 
most common source for ensuring the completion of reports.  
 Many of the health institution key informants reported that they rely on external 
reputable sources, such as other regulatory bodies' websites, to obtain valid information 
on PV and include it in routine clinical practice. For example, at the organizational 
level, Hospital C members check the FDA website and other official websites to follow 
up on aspects that can be addressed at the hospital level, including any warnings or 
instructions not provided by the MOPH. For example, no measures were taken or 
instructions reported for fluoroquinolones from the MOPH, but these issues were 
mentioned on the FDA website, and the information was published in the hospital 
monthly newsletter to inform clinicians.  
Two hospitals, namely, Hospital A and Hospital C, reported preparations to 
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purchase an electronic report management system to improve their current report 
management process. All the healthcare institutions reported initiatives at the 
organizational level to improve reporting rates. For instance, Hospital E reported that 
to improve the reporting rates and culture, the hospital leadership is involved. The 
hospital does leadership rounds, as leadership involvement will assure healthcare 
providers that there will be no penalties. Additionally, Hospital E conducted a patient 
safety culture survey for the staff, and based on the results, the line managers were 
instructed to assure staff that they would not be penalized; the hospital often reviews 
incentive potency. Similarly, Hospital B indicated that its reporting rate improved after 
some initiatives, including a) the clinical pharmacist was assigned to be involved in 
educational campaigns for the healthcare practitioners; b) reporting forms were 
distributed in the hospital to be accessible to the healthcare practitioners; c) the clinical 
pharmacists collaborate and are in close communication with healthcare practitioners 
and can assist them in reporting; d) healthcare providers were encouraged to report; and 
e) the hospital acknowledges every report and sends a thank-you letter to each reporter. 
Currently, not all healthcare institutions submit ADR reports to the MOPH, as 
ADR data are not requested by the MOPH (i.e., CP5a). However, information that has 
an impact will be communicated to the Pharmacy and Drug Control Department of the 
MOPH. All the healthcare institutions send their medication error data to the MOPH as 
key performance indicator requirements of the health service performance agreement 
between the MOPH and hospitals. The compiled and approved reports are sent to the 
HQPS on a monthly or quarterly basis.  
The key informants from the private sector reported that awareness of active PV 
is not uniform or consistent among healthcare professionals (i.e., CP9), and there is a 
lack of understanding of active PV studies. The factors that enable private hospitals to 
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participate in such studies include, first, such studies being mandated by the MOPH. 
Since active PV is not in alignment with the scope and nature of the work of the private 
sector, it is very difficult for private organizations to engage in these activities because 
they do not generate revenue. Second, a policy at the national level to cover active PV 
would be helpful. Third, incentives should be provided for organizations to conduct 
active surveillance, including MOPH support by providing expertise in PV and 
statistical analysis. 
1.3.1.4. Outcome/Impact Indicators Performance 
All the healthcare institutions have a process in place to assess reports received 
about medication-related issues, but due to the limited number of ADR reports, 
activities such as signal identification and evaluation (i.e., CO1) are not feasible. 
However, it was reported that an expert in PV, if available, can not only provide 
technical guidance but also contribute to PV policy development at the organizational 
level.  
For the outcome indicators related to financial outcomes (e.g., CO3, CO4, CO7) 
and clinical outcomes (e.g., CO6, CO8), it was reported that it is difficult to quantify 
such data, as the private sector does not have the required resources in terms of human, 
financial, and technical resources to collect and analyze data. Additionally, the private 
sector key informants reported that such PV KPIs do not align with the scope of the 
services provided, which are considered low risk. In addition, they reported that private 
sector institutions are focused more on treatment than prevention, which is better 
performed at the national level (i.e., MOPH). However, some institutions 
acknowledged that in terms of cost, such PV KPIs are beneficial for realizing profit 
margins, discovering areas that require attention and further investment, or 
understanding a health institution's position compared to that of others. 
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1.3.2. Private Sector: Community Pharmacies 
The assessment of the PV system at the community pharmacies level included 
one chain pharmacy group and one independent (single branch, 24-hour service) 
pharmacy. The sample of participants included 1 key informant from each pharmacy. 
This thesis will use the code Pharmacy to describe community pharmacies, e.g., 
Pharmacy A. The assessment findings will be presented in table format with full details 
on the PV system performance for each indicator.  
The tables illustrate the performance of the PV system in the relevant core 
indicators (Table 11 and Table 12) and relevant complementary indicators (Tables R17 
and Table R18: Appendix B) as well as the qualitative assessment accompanying each 
indicator. According to the system assessment relevant indicators, the total possible 
cumulative score for the three PV structure, process, and outcome domains was 42 
(100%). In addition, it is important to note that the core outcome indicators are not 
relevant to the community pharmacies level. The compliance of the community 
pharmacies PV system with the WHO PV indicator manual was highest for structural 
indicators, with a score of 14 (60.9%) for Pharmacy A and a score of 4.5 (19.6%) for 
Pharmacy B. Regarding the core structural indicators performance, Pharmacy A 
achieved a score of 9 out of 16 (56.3%), while Pharmacy B achieved a score of 1 out 
of 16 (6.3%). In addition, the lowest-performing indicator category for Pharmacy A 
was the outcome indicators, with a score of 4 (57.1%). In contrast, the lowest-
performing indicator category for Pharmacy B was the process indicators, with a score 
of 1 (8.3%).  
Figure 11 and Figure 12 represent the performance of the community 
pharmacies PV system based on the measured compliance of the system with the WHO 
PV indicators for core and complementary indicators. The observed inequality in 
  
142 
 
systems performance is expected since Pharmacy A is a chain pharmacy, while 
Pharmacy B is a single branch or independent pharmacy. 
 
 
 
Figure 11. Community pharmacies pharmacovigilance system performance (presented 
as percentages) 
 
Figure 12. Community pharmacies pharmacovigilance system performance (presented 
as scores) 
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Table 11. Community pharmacy “A” pharmacovigilance (PV) system performance and capacity results measured by WHO core PV indicators 
Code Response Score * Assessment (Qualitative) 
CORE STRUCTURAL INDICATORS 
CST1  No.   (1)  • There is no specific PV department for the chain pharmacy group, but the Academic Committee is 
responsible for medication safety and PV-related activities e.g., report management, training, and 
education. 
• There are clear instructions to follow for all affiliated chain pharmacists to report to the responsible person 
on the Academic Committee in case of any unwanted or adverse side effects reported by patients directly 
to pharmacists. 
CST2 No.  (0) 
 
• There is no statutory provision within the pharmacy group or even at the national level. 
• There are no clear national instructions on PV for community pharmacies.  
• The PV functionality of the pharmacy group is not at the highest level of professional conduct, but there is 
a crude way of performing activities. However, currently, many community pharmacists have not been 
trained in PV and do not understand the concept of PV. Therefore, the community pharmacy sector is still 
on basic grounds regarding PV. 
CST3 Not relevant. (-) • Not relevant. 
CST4 No. (0) 
 
 
• There is no exact budget allocated for PV, but the pharmacy group has a budget allocation for academic 
projects, for example, for developing academies within the organization. This includes a possible future 
PV related study. 
• It was reported that if the group focuses on PV, the budget provisions could be approved by the 
organization provided it returns some benefits in the form of better performance by the pharmacists and 
pharmacies. 
CST5 Yes.   (2) 
 
 
• The human resources are sufficient. 
• PV is not included in the job description of the pharmacist, but it is part of the commitment by the 
pharmacists as healthcare professionals.  
• The pharmacy group has master’s degree holders and PharmD degree holders. In addition, the pharmacy 
group provides the pharmacists with training programs or offers the opportunity to attend special seminars 
conducted by the MOPH.  
• The employees have specific requirements for continuous professional development (CPD), and the group 
continuously monitors whether the employees are attending the CPD programs. 
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Code Response Score * Assessment (Qualitative) 
CST6 No.  (0) 
 
 
 
 
 
• The group plans to develop an internal reporting form. 
• The pharmacists will declare and capture information on a group of incidents but not on individual cases, 
such as incidents happening within a short time span with a particular drug as well as severe cases. 
• Incidents captured or encountered are rare. In Qatar, there is underreporting from patients, as it is possible 
that patients are not able to identify ADRs or that patients are not being educated about adverse effects to 
medications. 
• Qatar's legal framework allows the pharmaceutical sector to be free of counterfeit medications. In 
addition, pharmacists are bound by law to report such cases to the MOPH. In chain pharmacies, it is 
almost impossible for a counterfeit medication to be purchased because they have a centralized system for 
purchasing medications. 
• A patient reporting system is available on the MOPH webpage, but public awareness of it is questionable. 
• There is no internal reporting form for the public; the pharmacy group receives cases only as complaints. 
• For public reporting in the future, the group is committed to helping patients, but for this change to be 
made, a change should be realized in the organizational and social levels. 
CST7 Yes.  (2) 
 
 
• The current functionality of the system that the pharmacy group uses is not at the highest professional 
level; there is a raw method of collecting information. Reporting is mostly for the group's internal 
purposes.  
• The pharmacy group may contact the company to ask for an explanation and, based on the explanation, 
will decide whether the drug will be taken off the shelf or continue to be used. Sometimes the group has a 
discussion with a physician, even if the case was a known ADR. 
• There is no database system, but the group collates data using an Excel spreadsheet. In addition, if there is 
regular reporting, they will immediately notify the company. 
• Underreporting by patients can sometimes occur because the patient feels that the reporting will be used 
against the physician. Thus, patients often deliberately do not report cases. This makes the process of 
information collection difficult, as the patients do not provide the required details. In addition, it is a 
challenge that when recording in the database, there is much missing information, such as patient age and 
medication history.  
CST8 Not relevant. (-) • Not relevant. 
CST9 Yes.  (2) • The pharmacy group has a newsletter published approximately once per week with the most relevant 
information for the practice. This newsletter is circulated to all the pharmacists. This initiative gives the 
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Code Response Score * Assessment (Qualitative) 
pharmacists more confidence in practicing and is used as a refresher for past information. It has a positive 
influence on the pharmacists and on their practice. 
• The pharmacy group has network and communication systems. Communication can be through emails, 
web page, and WhatsApp.  
• The pharmacy group webpage has a section for members of the public to send complaints or any kind of 
reporting they desire. Information relevant to PV and medication safety is not published on the website 
since it is a public domain. 
CST10 Yes.  (2) • The Academic Committee consists of seven individuals, all pharmacists, with a level of education ranging 
from a PharmaD degree to a bachelor’s degree. 
Total 
Score 
 (9) Out of 8 [8*2= (16)] is [(100%)] relevant indicators, the obtained score was [(9) = 56.3%] 
CORE PROCESS INDICATORS 
CP1 No. (0) 
 
• In 2017, one case was reported: a side effect, celecoxib and edema. 
• Many pharmacists are willing to report, but there is a need for training for a more professional way of 
understanding PV-related activities as well as the proper way to report ADRs. 
• Regarding the reporting culture, it was reported that it can be difficult to report in the community 
pharmacy, as pharmacists play many roles, and PV happens to be a lower-priority part of their role that 
sometimes can be missed and in some cases PV data can be underreported. 
• It was reported that reporting has a positive impact on the professional behavior and performance of the 
staff. The pharmacists feel that they have done something as a part of the pharmacy profession. This could 
have a positive influence on pharmacist counseling systems, such as asking additional questions. 
• It was reported that there is a general tendency in the medical field to believe that the responsibility of 
ADR education and ADR reporting rests on pharmacists only. This should not be the case; it should be a 
step-by-step process and should start with physicians. 
CP1a: 
Not relevant. 
(-) 
CP2 No value 
provided.  
(1) 
 
 
• In 2017, 14 reports were received, but they were not specific to ADRs. The database was created six years 
ago. 
• It was reported that the number of reports has increased, but regarding the severe cases, the numbers are 
almost stagnant. A few severe conditions or emergency cases were encountered.  
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Code Response Score * Assessment (Qualitative) 
• The pharmacy group has a monthly meeting of all the pharmacists. Training sessions are conducted in 
which the pharmacists are reminded of their professional duties. Some of those discussions are about how 
PV can be incorporated into the pharmacy group in the future. 
CP3 100%. (2) 
 
 
• Verbal feedback for each report. 
• Feedback depends on case-by-case prioritization based on the severity of the reported case.  
• Feedback is issued mostly within 48 hrs. 
CP4 Not relevant. (-) 
 
 
• A basic assessment is performed by the pharmacist. 
• Most of the reports do not have full information, e.g., cases when the medication was purchased from a 
different place, such as the PHCC or from HMC hospitals. 
• Questions on medication-related issues might come to the community pharmacy if it is the closest source.  
• The probable information received from very few patients after the pharmacist refers them to the hospital 
or the emergency department is that this case occurred because of the medication or because the doctor 
changed the medication. 
CP5 No.   (0) 
 
 
• No reports were submitted to the MOPH. 
• If a medication-related issue is repeatedly encountered within the pharmacy group, the group will report 
and try to prevent this medication from being sold in its pharmacies. This will be reported to the 
manufacturer. However, the group does not report directly to the MOPH since there is no PV center, and 
the MOPH does not have a system that requires reporting of cases directly. 
CP5a: 
Not relevant. 
(-) 
CP6 Not relevant. (-) 
 
• It was reported that there are cases of therapeutic ineffectiveness, but there is a thin line between an 
incorrect diagnosis and therapeutic ineffectiveness, and most community pharmacists do not have access 
to the basic necessities, such as the required assessment tools, to determine a final judgement. 
• Cases of therapeutic ineffectiveness and contributing factors are not documented. 
CP7 Not relevant. (-) • Not relevant. 
CP8 Not relevant. (-) • Not relevant. 
CP9 Not relevant. (-) • Not relevant. 
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Code Response Score * Assessment (Qualitative) 
• Research activity in collaboration with Qatar University includes a review of prescriptions only. 
Total 
Score 
 (3) Out of 4 [4*2= (8)] is [(100%)] relevant indicators, the obtained score was [(3) = 37.5%] 
CORE OUTCOME/IMPACT INDICATOR 
CO1 Not relevant.  
 
(-) • They receive incidents from external sources (i.e., an incident happened outside the organization practice), 
and the pharmacy group shares information with all the pharmacists.  
• The primary reporting occurs at the pharmacies, but for external incidents, the group sends a general alert 
through its system to notify the practicing pharmacists to be aware of the possibility of encountering this 
event. 
CO2 Not relevant. 
 
(-) • Withdrawal policies and other regulatory actions are taken by the MOPH. The pharmacy group's role is to 
inform the staff and follow the directions of the MOPH. The MOPH has a system, and possibly once or 
twice per month, it provides circulars or safety warnings. 
• It was reported that medicines registered in Qatar are approved by the GCC, where it takes two to three 
years to obtain approval for a medication. In addition, medicines registered in Qatar have FDA approval. 
Therefore, medications in Qatar are of high quality and effectiveness.  
• Internal alerts to pharmacists about the cautious use of a particular drug happened 8-9 times in 2017. 
CO3 Not relevant. (-) • Not relevant. 
CO4 Not relevant. (-) • Not relevant. 
CO5 Not relevant. (-) • Not relevant. 
CO6 Not relevant. (-) • Not relevant. 
CO7 Not relevant. (-) • Not relevant. 
CO8 Not relevant. (-) • Not relevant. 
Total 
Score 
 (-) Core outcome indicators are not relevant. 
(*) Score: (2) Yes. fully satisfactory; (1) Yes. partially satisfactory (2); and (0) No includes not satisfactory, missing data, no values, and not applicable. 
(*) Score (-): Not relevant for the evaluation of system performance with WHO indicators. 
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Table 12. Community pharmacy “B” pharmacovigilance (PV) system performance and capacity results measured by WHO core PV indicators 
Code Response Score * Assessment (Qualitative) 
CORE STRUCTURAL INDICATORS 
CST1  No. (0)  • Single-branch pharmacy with 24-hour operation. 
• It was reported that ADR reporting is beneficial. as the MOPH can collect data about adverse effects and 
other issues related to the medications. 
CST2 No.  (0) 
 
• The pharmacy has an internal policy for medication damage and expiration-date issues. 
• The pharmacy follows the MOPH guidance about the medication, e.g., registration for antibiotics, 
corticosteroids, and antidepressants. 
• There are no national guidelines for PV, but the MOPH issues circulars that the pharmacy receives from 
time to time. 
• The MOPH circulars are considered clear and almost specific regarding medication safety, but sometimes, 
there is a misunderstanding of some points; for example, the circulars sometimes cover a variety of 
medications that fall into one group.  
• The circulars do not cover all aspects that are required for the pharmacist to practice PV and medication 
safety related activities. 
• The circulars do not reach the pharmacy regularly Sometimes the pharmacy hears about a circular from 
other parties. The MOPH sends the circulars by mail, and they sometimes do not reach the pharmacy on 
time, e.g., a circular will sometimes take two to three months to arrive. 
• The MOPH performs regular inspections a maximum of three times per year. 
CST3 Not relevant.  (-) • Not relevant.  
CST4 No. (0) 
 
 
• The pharmacy does not have a specific budget. 
• The pharmacy stated that the challenge is not with the budget itself. The challenge is in awareness of PV, 
as only if the pharmacist is aware of PV and cares about his patients will he/she counsel them about the 
adverse effects and advise them to avoid them. 
CST5 Yes. 
Sufficient.   
(1) 
 
 
• No specific person is responsible for PV or medication safety activities. The total number of staff is 5 
pharmacists.  
• The current pharmacy staff members have a minimum of eight years of experience. In addition, the 
pharmacists have good communication and good information, but some of the staff consider information 
sharing a personal effort that is not related to the organization.  
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Code Response Score * Assessment (Qualitative) 
• The pharmacy hopes there will be PV training at the national level. In addition, it hopes that reporting will 
be voluntary and not mandatory because the pharmacists sometimes cannot obtain the required 
information from the customer. It was reported that patients often do not have time and do not want to 
have more communication with the pharmacist.  
CST6 No. 
 
 
(0) 
 
 
 
 
 
• There are no specific reporting forms or documents to collect such data except for items that will be 
removed from the shelves. 
• It was reported that the unavailability of national reporting forms can impose many challenges in the 
practice. For example, for atropine spray, although side effects that cause the patient to be addicted are not 
a serious issue, the pharmacy currently finds them very severe. The pharmacy does not have any reporting 
method or tool to provide the MOPH with this information. The pharmacy reported that it has never had 
this communication with the MOPH, and the pharmacy hopes to have a system of this nature in the future. 
• Reporting forms for the public are not available. The pharmacy reported that although public reporting is 
beneficial, it would not be easy to have such a form completed, as people are busy and do not have time to 
fill out forms. In addition, the majority of Qatar's population are foreigners so the pharmacist may not 
have adequate experience in languages to communicate with all patients. 
CST7 No.  (0) 
 
• There is no process in place, and the pharmacy does not have reports; however, the pharmacists can 
communicate between them if there is an issue. 
CST8 Not relevant. (-) • Not relevant. 
CST9 No.   (0) • The pharmacists communicate through email and a WhatsApp group. 
• It was reported that it will be important to have a national website that provides PV related information. In 
addition, communication by email between the pharmacy and a responsible key person who can 
addressing requests for information would be helpful. 
• It was reported that at the pharmacy level, it is not easy to have a newsletter or a small board to 
disseminate PV information because medication safety is an extensive aspect and thus this will be not 
feasible. 
• The pharmacists have internet access, but the staff uses mobile devices more than the computer due to 
connection problems. However, in general, the pharmacy can afford access to websites, e.g., Medscape, 
for information. 
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Code Response Score * Assessment (Qualitative) 
CST10 No.  (0) • None, because the pharmacy is not a chain pharmacy.  
• It was reported that the pharmacy cannot say that it is important to have an expert person or group in PV, 
although this could be applicable in a chain of pharmacies. 
Total 
Score 
 (1) Out of 8 [8*2= (16)] is [(100%)] relevant indicators, the obtained score was [(1) = 6.3%] 
CORE PROCESS INDICATORS 
CP1 No. (0) 
 
• The pharmacy does not have these data.  
• The pharmacists are of the opinion that when a case is encountered, they will report it. Three out of five 
will be aware of PV related definitions. If there is a chance for those who are interested in PV to have a 
national website to report and communicate with a responsible person, this would help the pharmacists 
improve their knowledge by obtaining complete information about the adverse effects of some drugs. 
Additionally, reporting can be added to the required credit hours for continuous professional development 
as an incentive. 
• It was reported that financial incentives are not important for increasing reporting. 
CP1a: 
Not relevant. 
(-) 
CP2 None. (0) • There is no database. 
CP3 None. (0) • None.  
CP4 Not relevant. (-) • Not relevant. 
CP5 No reports 
sent to the 
MOPH. 
(0) • The MOPH does not have a key person for the pharmacy to communicate with and request information to 
support the pharmacists.  
• The pharmacy has an employee in the office who is responsible for following up on the circulars, and 
he/she will send them to the pharmacists. To improve the process of communication, a website, email, or 
specific person within the MOPH who is responsible for this would be helpful. 
CP5 Not relevant. (-) • Not relevant. 
CP6 Not relevant. (-) • Not relevant. 
CP7 Not relevant. (-) • Not relevant. 
CP8 Not relevant. (-) • Not relevant. 
CP9 Not relevant. (-) • Not relevant. 
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Code Response Score * Assessment (Qualitative) 
Total 
Score 
 (0) Out of 4 [4*2= (8)] is [(100%)] relevant indicators, the obtained score was [(0) = 0%] 
(*) Score: (2) Yes, fully satisfactory; (1) Yes, partially satisfactory (2); and (0) No includes not satisfactory, missing data, no values, and not applicable. 
(*) Score (-): Not relevant for the evaluation of system performance with WHO indicators. 
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1.4. The Pharmaceutical Industry Level 
The assessment of the PV system at the pharmaceutical industry level included 
one pharmaceutical company. 
According to the assessment findings, the total score for the three PV structure, 
process, and outcome domains was 34 out of a possible cumulative score of 50 (68%). 
The compliance of the pharmaceutical company PV system with the WHO PV 
indicators was highest for the structural indicators, with a score of 21 (91.3%), and 
lowest for the process indicators, with a score of 9.5 (45.2%). Figure 13 and Figure 14 
represent the performance of the pharmaceutical company PV system based on the 
measured compliance with the WHO PV indicators. The pharmaceutical company case 
will be presented in table format with full details on the PV system performance for 
each indicator category. The tables illustrate the performance of the PV system in 
relevant core indicators (Table 13) and relevant complementary indicators (Table R19: 
Appendix B) as well as the qualitative assessment accompanying each indicator. 
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Figure 13. Pharmaceutical industry pharmacovigilance system performance 
(presented as percentages) 
 
Figure 14. Pharmaceutical industry pharmacovigilance system performance 
(presented as scores) 
 
 
The assessment found that the company adheres to the GCC legislation and 
guidelines (i.e., CST2). Additionally, the MOPH requirements are followed and 
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included in the governance framework of the company. The company reported that it 
changes its procedures and structures to ensure that it adheres to the requirements set 
by the regulatory body, the MOPH. For instance, the MOPH requested a modification 
in the ADR form, and the company modified it accordingly. The assessment found that 
standard operating procedures that include PV-related functions exist. Additionally, 
based on the MOPH requirements, the company is required to communicate with 
stakeholders using soft copies or hard copies when requested. In addition, it is mandated 
that it report any reported ADRs or other issues related to the company products to the 
MOPH. 
The company manufactures generic drugs, and such products have preexisting 
data. Therefore, it reported that there are no major or critical issues with its products, 
but some critical products (e.g., paracetamol, antibiotics, lidocaine) require evaluation 
of product safety and efficacy and how to manage the product in post-marketing 
experiences. Additionally, the company is producing intravenous (IV) products such as 
normal saline and dextrose, and such IV products do not require risk management plans. 
The Regulatory Affairs and Pharmacovigilance Department is the department 
responsible for PV and post-marketing surveillance activities (i.e., CST1). It was 
mentioned that the PV system stage of the development complies with the GCC 
guidelines and the MOPH requirements; hence, the company considers its PV system 
functional. 
The assessment found that the current human resources (i.e., CST5) are 
sufficient to cover PV activities. Furthermore, job descriptions include PV, and the 
current staff receives training related to PV. There is a defined procedure for training 
based on the GCC guidelines. The company representative reported that the department 
has four members and a manager, and all members work to ensure the fulfillment of 
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their responsibilities. Additionally, the company representative reported that an annual 
budget for PV (i.e., CST4) exists and is considered sufficient. The exact budget 
allocation is based on request, and the management decides accordingly. 
For routine PV communication (i.e., CST9) the company has a 24/7 working 
number to receive any complaint or to address any information request. Additionally, 
its web portal can be used to report any problem or to communicate information. In 
addition, email communication is employed in routine and emergency cases. 
A quality management system exists for any problem apart from what is 
mentioned in the leaflet; in these cases, the company will process the complaint. For 
the assessment process of a report (i.e., CST7), a form will be filled out and sent to the 
Quality Assurance Team for evaluation. After the team reaches a conclusion, the form 
will be transmitted to the general manager for approval. Although no critical safety 
reports have been received, the company reported that there is a proper system for such 
incidents. The company representative reported the existence of an Excel spreadsheet 
database. According to the quality assurance standard operating procedures, the 
company must issue feedback on received reports or complaints within 15 days. 
The company had not received any ADR reports or critical cases related to its 
products (i.e., CP1). Therefore, the company was not involved in signal identification 
and evaluation (i.e., CO1) at the national level. The company obtains PV information, 
including regulatory actions (i.e., CP2) from the national regulatory authority, GCC 
countries, and other regulatory bodies. 
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Table 13. Pharmaceutical industry pharmacovigilance (PV) system performance and capacity results measured by WHO core PV indicators 
Code Response Score * Assessment (Qualitative) 
CORE STRUCTURAL INDICATORS 
CST1  Yes. (2)  • The Regulatory Affairs and Pharmacovigilance Department. 
• It was mentioned that the PV system functionality complies with GCC guidelines and the MOPH 
requirements; hence, the company considers the system functional. 
• The company manufactures generic products, and such products have preexisting data from the 
pharmacopeia. The company produces IV solutions such as normal saline and dextrose. The company also 
produces some critical care products (e.g., paracetamol, antibiotics, lidocaine) that require evaluations of 
product safety and efficacy and how to manage the product in post-marketing experience. 
CST2 Yes.  (2) 
 
• The Gulf Cooperation Council (GCC) legislation and guidelines are followed. The company follows the 
GCC guidelines and requirements in evaluating the safety of the products. The MOPH requirements and 
guidelines are also followed. 
CST3 Not relevant. (-) • Not relevant. 
CST4 Yes.  (2) • It was reported that an annual budget for PV exists and is sufficient. The exact budget allocation is based 
on request, and the management processes the request and provides resources.  
CST5 Yes.  (2) 
 
 
• The current human resources are sufficient to cover PV activities.  
• The Regulatory Affairs and Pharmacovigilance Department consists of four members and one manager. 
All the members are full-time staff.  
• The job descriptions include PV, and details are submitted before product registration, as per the GCC 
guidelines. The staff receives training related to PV, and there is a defined procedure for training. 
CST6 Yes.  (2) • ADR reporting forms and standard operating procedures (SOPs) are available. 
• The ADR form can be used to report cases of medication errors, counterfeit and substandard medications, 
therapeutic ineffectiveness, abuse and misuse. The report format includes a checklist and a full-text area. 
The ADR report format complies with the GCC guidelines. 
• The report forms are available as a soft copy, and the company has a separate server that is fully 
integrated into the system. 
• Reporting by the public can be on the same form; there is no specific form for the public.  
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Code Response Score * Assessment (Qualitative) 
CST7 Yes; a process 
and database 
exist. 
(2) • A quality management system exists. If any problem apart from what is mentioned in the leaflet (ADRs) 
or summary of product characteristics is reported, the company processes the report or any complaint. 
However, to date, it has not received any critical complaints on its products. 
• For report assessment, a form will be filled out and sent to the Quality Assurance Team for evaluation. 
After the team reaches a conclusion, it is transmitted for approval to the general manager. 
CST8 Not relevant. (-) • Not relevant. 
CST9 Yes.  
 
(2) • It was reported that a strategy for communication exists. 
• Within the company, there is an FTP server that allows information sharing across departments.  
• For routine PV communication, the company has a 24/7 working marketing number to receive any 
complaint. The reporting forms can also be filled out to communicate any complaints. The company web 
portal can be used to report any problem and for information communication.  
• For emergency communication with external parties, all the concerned departments will contribute, 
depending on the situation or the case. 
• The company has a summary of product characteristics and product leaflets in English and Arabic that can 
be used to review all relevant information on their products. 
CST10 Yes.  (2) • Internally, the Regulatory Affairs and PV Department is responsible for providing information.  
• The company has a large workforce; different departments all work as a team, and each section head is 
involved (24 total). Diverse professional backgrounds exist, such as pharmacists, biopharmaceutical 
technology experts, chemists, microbiologists, nurses, and physicians. General meetings are held every 2 
weeks and depending on the situation. 
• The Pharmacy and Drug Control Department (MOPH) is responsible for providing advice on PV at the 
national level. 
Total 
Score 
 (16) Out of 8 [8*2= (16)] is [(100%)] relevant indicators, the obtained score was [(16) =100%] 
CORE PROCESS INDICATORS 
CP1 No cases. (1) • The company did not receive any ADR cases.  
• The company always updates its database and utilizes and follows information from the national 
regulatory authority or GCC regulatory authorities. 
CP1a:  
Not relevant. 
(-) 
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Code Response Score * Assessment (Qualitative) 
CP2 One case. (1) 
 
• Only one case of ciprofloxacin rash occurred; this case was mentioned in a leaflet and reported a number 
of years before. 
CP3 No cases. (1) 
 
 
• The company reported that this indicator is nonapplicable, as no cases were received.   
• The company has a proper system for analysis and feedback. The company indicated the presence of a 
strategy, and the incidents or complaints are documented using Excel spreadsheets. The documentation 
must include details on the complaint number, the details of the complaint, the action plan, and how to 
prevent the occurrence in the future. The company must make a full investigation and take action. Per the 
SOPs for quality assurance (QA), the timeline to issue feedback is 15 days. 
CP4 No cases. (1) • The company reported that no cases were received, so no assessment was done.   
• The SOPs have details on the procedure. This entails proper documentation to ensure compliance with 
standards.  
CP5 No cases. 
 
(0) 
 
 
• The company reported that no cases were received, so it did not send reports to the MOPH. 
• The MOPH requires the company to report postmarket issues of its products. 
• The products are registered with the MOPH, so the products comply with the MOPH requirements for 
safety and quality. In the future, if a case occurs, the company will check the drug leaflet and summary of 
product characteristics. If the data are already documented, the case will not be considered from the 
company; for any other situation, the company will process the case, and the product issue will be 
subjected to proper investigation.   
CP5a: 
Not relevant. 
(-) • Not relevant. 
CP6 No cases. (-) • The products comply with the MOPH requirements and have been subjected to previous analysis in the 
MOPH quality control laboratory. Therefore, the company had not encountered such cases.   
CP7 Not relevant. (-) • Not relevant. 
CP8 100%. 
 
(2) • It was mentioned that the PV system functionality complies with the GCC guidelines and the MOPH 
requirements; hence, the company considers the system functional. 
CP9 None. (0) • The company reported that it does not have to start active PV from its side, as it is in the business of 
generic manufacturing only. Bioequivalence studies are enough for its products, and such studies are done 
in the MOPH laboratory. 
• The company follows the pharmacopeia, mainly the USP or BP. 
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Code Response Score * Assessment (Qualitative) 
• In the future, for drugs that are critical, the company may make such efforts if they are part of the MOPH 
requirements. 
Total 
Score 
 (6) Out of 7 [7*2= (14)] is [(100%)] relevant indicators, the obtained score was [(6) = 42.9%] 
CORE OUTCOME/IMPACT INDICATOR 
CO1 No cases. (1) • The company reported that no cases were received. External data from national and international 
regulatory bodies were used. 
• The company complies with GCC guidelines regarding signal generation.  
CO2 Yes.  (2) • The company utilizes both internal and external data from GCC countries and others, including Jordan, 
Lebanon, and Oman. 
• Internal cases were requested from the company: the total number of regulatory actions was approximately 
500, including 1) renewal variation as well as new products; 2) 200 product label changes/variations; 3) no 
actions on safety warnings about medicines or drug withdrawal issues to HCPs; and 4) restrictions on the 
use of paracetamol, for which the company made a flyer to include dose requirements for neonates. This 
issue was reported in Europe, and the company changed the information on its product and communicated 
it to its customers. 
CO3 Not relevant. (-) • Not relevant. 
CO4 Not relevant. (-) • Not relevant. 
CO5 Not relevant. (-) • Not relevant. 
CO6 Not relevant. (-) • Not relevant. 
CO7 Not relevant. (-) • Not relevant. 
CO8 Not relevant. (-) • Not relevant. 
Total 
Score 
 (3) Out of 2 [2*2= (4)] is [(100%)] relevant indicators, the obtained score was [(3) = 75%] 
(*) Score: (2) Yes, fully satisfactory; (1) Yes, partially satisfactory (2); and (0) No includes not satisfactory, missing data, no values, and not applicable. 
(*) Score (-): Not relevant for the evaluation of system performance with WHO indicators. 
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1.5. Public Health Programs Level 
The study assessed the PV system of the Mental Health Strategy (MHS), which 
was represented by one member. The WHO PHP indicators were employed to facilitate 
the discussion on the subject of PV implementation in the MHS, but as the level is not 
that of an actual PHP, the results will be presented qualitatively, and no scores will be 
used to represent the performance (Table 14).  
 
 
Table 14. Pharmacovigilance (PV) implementation within the Mental Health Strategy 
(MHS) 
Indicator Main Concepts Mental Health Strategy Status 
PV activities within the 
program  
The MHS has PV and medication activities within its 
functions: 
• The members of the MHS meet with different 
national stakeholders and request data from them. 
• There is no database for PV or reports.  
• The MHS analyzes data and shares them with 
stakeholders.  
• The MHS processes information from external 
sources.  
• The MHS has audits for monitoring purposes.  
Guidelines or protocols that 
address elements of PV  
A specific section on medication safety, pages 43 and 
48 (document National Mental Health Strategy Impact 
Evaluation-2015). 
Standard ADR reporting form • There is no available ADR reporting form.  
• A standardized national form was deemed useful 
and was recommended. 
• The MHS reported that one of the key challenges 
to PV is that the process of reporting is not 
centralized in the MOPH.  
Availability of records or 
information on medication 
errors, product quality, and 
treatment failures 
Not available.  
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1.6. Higher Academic Institutions Level 
The study assessed the incorporation of PV into the curriculum of various higher 
academic institutions (i.e., CST8), which were represented by one member from each 
institution and two members from QU-College of Pharmacy. The key representative 
members were interviewed during face-to-face meetings except for the key informant 
of the College of Health Sciences at QU, who provided a response via email. The CST8 
description in the WHO PV indicator manual was employed to facilitate the discussion 
on the subject of incorporating PV into the academic programs of various healthcare 
professions. The score for academia will be incorporated into the national level of the 
MOPH. The results will be presented qualitatively, and no scores will be used to 
represent each university (Table 15). 
 
 
Table 15. Pharmacovigilance (PV) incorporation into the curriculum of national higher 
academic institutions 
Candidate Institution PV Incorporation into the Curriculum  
Weill Cornell Medical College √ Regulatory and practice PV. 
College of North Atlantic – 
School of Health Sciences 
√ Regulatory and practice PV.  
University of Calgary  √ PV and medication safety.  
Qatar University 
• College of Medicine  
• College of Pharmacy 
• College of Health 
Sciences 
• √ College of Medicine incorporates it 
across the curriculum. 
• √ College of Pharmacy incorporates it 
across the curriculum based on the WHO 
safety curriculum. It includes the scope of 
regulatory and practice PV.  
• X College of Health Sciences does not 
include it in the curriculum. 
√: PV is integrated into the curriculum. 
X: Pharmacovigilance is not integrated into the curriculum. 
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Key findings from Academic Institutions:  
I. There is a need for a national PV center. 
II. A national independent PV center could be created under an academic 
institution. 
III. Experts from academia could provide valuable input into a national PV center. 
IV. Collaboration with the regulatory body and the PV center will enable effective 
and effective PV practice. For example, the MOPH can delegate the 
responsibility for data analysis, research activities, or information provision to 
experts from academia. 
V. Establishing a PV center under an academic institution could improve the 
reputation and accreditation opportunities of the presenting institution. 
VI. Students could benefit from potential research opportunities in the field of PV. 
VII. The country could utilize graduate students to build the internal capacity for the 
national PV system. 
VIII. Although PV was not included as a separate course in any of the included study 
samples, the basic elements of PV and medication safety were effectively 
implemented in the course work, problem-based learning activities, objective 
structured clinical examination exams, and interprofessional experiences. 
IX. PV is included mainly in undergraduate programs. For instance, QU-College of 
Pharmacy for a minimum of two credit hours, based on estimates. 
X. The students are aware of PV terminology and basic elements, such as ADR 
reports, and practice PV during their rotations in the public sector. 
XI. Undergraduate students are not capable of engaging effectively in advanced PV 
activities such as causality assessment and signal identification. 
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XII. There is little focus on the regulatory aspects of PV, and when included, it will 
cover mainly external regulatory systems, e.g., the QU-College of Pharmacy 
teaches students about the Canadian perspective. 
XIII. The establishment of a PV center in any academic institution will require 
effective planning and allocation of human and financial resources.  
1.7. Comparative Analysis of Qatar Pharmacovigilance Systems Performance 
and the Baseline National Pharmacovigilance Situation  
The following section will provide an assessment of the current baseline PV 
situation employing pictorial illustrations:  
1.7.1. Comparative Analysis and Evaluation of the Baseline Situation (Part 1) 
Figure 15 illustrates the overall or cumulative performance of the subnational 
PV systems in the three PV structure, process, and outcome indicator domains. 
Overall, all subnational PV systems achieved good total PV system 
performance, and the percentages reached the target good performance range (i.e., 50%-
74.9%). However, with the exception of the MOPH, the total PV system performance 
was weak (23.8%). The highest-performing PV system at the subnational level was the 
PHCC PV system, with a total cumulative score of 71.3%. It is important to note that 
the HMC system performed lower on some indicators because HMC (Table 8) did not 
provide the requested missing information. Nevertheless, none of the stakeholders’ PV 
systems fall into the range of excellent performance, (i.e., 75%-100%).  
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Figure 15. Comparative analysis of the total pharmacovigilance (PV) system 
performance of Qatar PV stakeholder systems using the WHO PV indicators (Part 1) 
 
 
1.7.2. Comparative Analysis and Evaluation of the Baseline Situation (Part 2) 
The bar chart (Figure 16) provides an analysis of the baseline PV system 
performance as percentages, including the overall performance of the subnational PV 
systems as well as the performance of the three PV indicator domains, structure, 
process, and outcome indicators at each stakeholder level. 
The structural indicators had the highest scores among the three indicator 
domains, with three of the five PV systems assessed as having excellent performance. 
The performance in the outcome indicators was significantly low, with the MOPH 
achieving poor performance status (0%-24.9%) and HMC, the pharmaceutical industry, 
and the private sector achieving average performance status (25%-49.9%). The process 
indicator performance showed higher status for some stakeholders since their PV 
system activities were successful in meeting the indicator requirements of a functional 
PV system. For instance, performance status exceeding 50% was recorded for HMC, 
PHCC, and the private sector. 
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Figure 16. Comparative analysis and evaluation of the baseline situation of Qatar 
pharmacovigilance (PV) stakeholder systems using the WHO PV indicators (Part 2) 
 
 
1.7.3. Comparative Analysis and Evaluation of the Baseline Situation (Part 3) 
Figure 17 represents the actual performance of the PV subnational systems 
using scores within the main structure, process, and outcome indicator domains as well 
as the overall cumulative scores. 
 The country's PV system performance (i.e., overall national system) was 
calculated by determining the mean value for the actual performance of the structure, 
process, and outcome indicators for each stakeholder; refer to Table R1a and Excel 
spreadsheet R1a in Appendix B for the values and calculations. The calculation of the 
overall national system excluded the community pharmacy sector, as the sector does 
not have many relevant WHO PV indicators; thus, adding it may result in an 
inappropriate representation of the national performance. For the overall performance 
of the country (i.e., overall national system), the scores of the structure, process, and 
outcome indicators were 18.46, 11.88, and 5.1, respectively. 
 As illustrated, there are noticeable differences between subnational systems' 
performance. Generally, the performance on structural indicators was comparable in 
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that all subnational systems achieved some of the PV structures required for a functional 
PV system in the WHO framework. For example, the pharmaceutical industry achieved 
the highest score of 21 for the structural indicators score because it has a dedicated 
department for PV and a dedicated budget for PV, as opposed to other stakeholders 
with internal systems that undertake PV activities but do not have a dedicated 
department or specific parameters for PV. On the other hand, the lowest performance 
of the subnational PV systems was in outcome indicators. Figure 17 shows that the 
performance on outcome indicators was lowest for the MOPH system, with a score of 
2, and highest for the HMC system, with a score of 9. Finally, for the process indicators, 
the scores ranged between 16 for HMC and 5 for the MOPH. 
 
 
 
Figure 17. Comparative analysis and evaluation of the baseline situation of Qatar 
pharmacovigilance (PV) stakeholder systems using the WHO PV indicators (part 3)  
 
 
1.7.4. Comparative Analysis and Evaluation of the Baseline Situation (Part 4) 
Figure 18 is an illustration of the national country situation calculated from the 
actual and desired means for the country/national PV system portrayed in the previous 
  
167 
 
bar chart (Figure 17). 
 Figure 18 highlights a good performance on structural indicators (71.6%). In 
contrast, it clearly shows that at the national level, the system performance had a 
considerable challenge in meeting the WHO requirements for the process (51.2%) and 
outcome (32.3%) indicators. Comparing the actual national situation to the expected 
system performance based on the WHO framework and the target quartile range 
revealed a deficient performance in the process and outcome indicators. This weak 
performance conveys that there are limitations that affect the systems' ability to reach 
the desired performance for basic PV process and system outcomes requirements. 
Specifically, the holistic situation for the national PV system displayed considerable 
limitations in achieving the requirements for the outcome indicators. Finally, the 
national PV system in operation provides 54.7 % of its total expected performance 
status.  
 
 
 
Figure 18. Evaluation of the baseline Qatar pharmacovigilance (PV) system situation 
using the WHO PV indicators (presented as percentages) 
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2. Evaluation of Qatar’s Current National Pharmacovigilance System Based on 
the Minimum Requirements of the WHO  
To address the second objective of this thesis, Table 16 was created to highlight 
the compliance of the current national PV system (represented by the MOPH system) 
with the minimum recognized international requirements determined by the WHO for 
a functional national PV system. The MOPH level is considered the national PV system 
for Qatar, as the MOPH is responsible for the management and regulation of Qatar's 
healthcare system.  
 
 
Table 16. Evaluation of Qatar’s current national pharmacovigilance (PV) system 
based on the minimum requirements of the WHO for a functional national PV system 
Requirement Parameters Compliance 
Status 
Qatar National PV 
System Compliance* 
National PV center • Central workplace. 
• Human resources, 
minimum one full-
time staff. 
• Financial resources, 
basic regular 
funding.  
• Clear mandates. 
• Defined structures. 
• Defined 
responsibilities. 
• International 
collaboration with 
the WHO PIDM. 
Not 
fulfilled. 
No specific PV 
department, but PV 
activities are incorporated 
into the daily activities of 
the MOPH. The MOPH 
hopes that Qatar can 
become a full member 
after it prepares a national 
PV center. 
A national 
spontaneous 
reporting system 
• Reporting system. 
• A national 
individual case 
safety report form, 
i.e., an ADR 
reporting form. 
Not 
fulfilled. 
The MOPH indicated that 
the underreporting issue in 
Qatar is expected to 
continue without the 
existence of national ADR 
reporting forms and a 
national reporting system. 
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Requirement Parameters Compliance 
Status 
Qatar National PV 
System Compliance* 
National database National database. Not 
fulfilled. 
The MOPH reported that 
currently, there is no 
national database for PV 
data management. 
National ADR or 
PV advisory 
committee 
Advisory committee 
able to provide advice 
and technical assistance 
on active and passive 
PV activities. 
Not 
fulfilled. 
There is no specific PV or 
medicine safety advisory 
committee. Therefore, 
according to the MOPH 
informants, in the future, 
having a functional 
committee will serve the 
needs of the country. 
 
Communication 
strategy 
• Strategy for routine 
communication. 
• Strategy for crises 
communication. 
Not 
fulfilled. 
No specific 
communication and 
transparency strategies to 
ensure national 
stakeholder involvement 
in the field of PV. 
However, there is a 
National Health and 
Disaster Preparedness 
Committee that conducts 
regular meetings that 
include national 
stakeholders. 
*Qualitative assessment based on MOPH key informant remarks.  
 
 
3. Highlights of the Strengths, Opportunities, and Weaknesses of the National 
Pharmacovigilance System 
This section presents the results related to objective number 3 for this thesis, 
that is, identifying potential strengths, opportunities, and limitations that can mark the 
development of the current PV system as well as the establishment of a specific PV 
center. The results are based on the evaluation of the PV system at different levels of 
the healthcare system. Procedures to assess the PV system, using the WHO PV 
indicators as well as the views and perceptions of numerous stakeholders on the current 
situation, were employed to identify the challenges and strengths facing PV in Qatar. 
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3.1. Strengths  
This section will be divided into system-based, structural, process, and outcome 
strengths: 
3.1.1. System-Based Strengths 
I. Most stakeholders at the subnational level showed strong interest in PV and 
hoped that the MOPH would inform them about its expectations and collaborate 
with them to discuss opportunities for strengthening PV, as the MOPH was 
considered to be the main stakeholder in protecting health and ensuring drug 
safety. 
II.  The WHO is leveraging support and collaborative opportunities for PV with 
the MOPH.  
III. Leadership and management involvement were reported at the organizational 
level as a factor to improve the safety culture and medication safety. 
IV. The public and private sectors are utilizing safety culture surveys to understand 
healthcare professionals' views on the culture of safety, and the outcome is 
being utilized to improve the system. 
V. Accreditation and performance management have made many improvements in 
the PV systems of public and private sector health institutions. These standards 
have led to improvements and increased the compliance of systems with 
internationally recognized standards, including PV-related concepts. 
VI. Public sector system connections through the Cerner system have made the 
networking simple and the sharing of data a clear task for HMC and PHCC. 
VII. The public sector, namely, HMC and PHCC, has good communication on some 
projects. In addition, these institutions share protocols of primary care. 
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VIII. Some PHCC members are available at the HMC corporate level, e.g., they meet 
monthly on the CP&TC. 
IX. A private hospital reported that HMC provides peer-review support and 
collaborates with it when it needs experts on PV and medication safety who are 
not available at its level.  
3.1.2. Structural Indicator Strengths 
I. Qatar is a member of the GCC countries, and the GCC countries have well-
established guidelines for drug registration, including PV. 
II. MAHs are required to report safety data to comply with the national 
pharmaceutical law and MOPH requirements. 
III. Most stakeholder PV systems reported the existence of a formal system that 
covers PV as part of its duties and/or a policy document that includes 
components of PV, e.g., ADR reporting. 
IV. The pharmaceutical industry reported a budget specifically earmarked for PV-
related activities, and it reported a specific department specifically dedicated to 
PV, with staff members who specialize in the field. 
V. Most stakeholders have guidelines in place to manage drug safety and PV at the 
organizational level. 
VI. Most stakeholders have developed reporting forms that include a specific form 
for ADR reporting or a general form for reporting incidents. 
VII. PV is included in medical, pharmacy, and nursing curricula. 
VIII. On the MOPH website is the GHCC, where members of the public can register 
their complaints, inquiries, and requests by filling out a form. 
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IX. In-service education and training on drug safety and basic PV activities are 
provided by some stakeholders. Some stakeholders, e.g., PHCC, mandate this 
as a key part of performance evaluations. 
X. The MOPH is active in providing training on vaccines at the national level. In 
addition, vaccine vigilance follows a very structured system, and specific forms 
are available for reporting ADRs and other vaccine-related issues. 
XI. HMC established the MSQC, which plays an important role in the HMC PV 
system; it was founded under the Pharmacy Department in HMC. 
XII. The MSQC has adapted well to the challenge of lack of human resources by 
working with part-time members from 12 HMC hospitals; currently, it considers 
its efforts a success. The need for expert staff was added to the corporation 
strategy.  
XIII. HMC is targeting its efforts towards improving healthcare professionals’ 
understanding of internal policies. 
XIV. HMC is making efforts to improve medication safety through its educational 
activities, including seminars and workshops at the national level, e.g., 
community pharmacy involvement. 
XV. Public and private sector design and updates of internal policies follow 
formalized and appropriate systems. 
XVI. The budget was deemed sufficient by many stakeholders for the current 
operation of the system (i.e., the situation does not meet the requirements for 
expansion). 
XVII. The MOPH communicates external drug safety information to the QCHP, 
which creates circulars with instructions and guidelines for clinicians on how to 
act in cases of specific medications.  
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3.1.3. Process and Outcome Indicator Strengths 
I. The MOPH recognizes the need for PV and considers aspects of postmarket 
surveillance and PV to be important parts of the medication management 
process. 
II. HMC reported efforts to conduct medication safety studies as well as active 
surveillance activities. 
III. Most stakeholders reported the presence of PV and medication-related activities 
that include the use of evidence-based approaches and tools at the organizational 
level. 
IV. Most stakeholders reported the use of internal mechanisms to follow up on 
reports and drug safety issues at the organizational level. 
V. For decision making and regulatory actions, the MOPH relies on benchmarks 
from other countries with stringent regulatory authorities, e.g., the FDA and 
EMA. 
VI. The private and public sector reported initiatives to include external drug safety 
warnings or information from their internal decision-making and/or feedback 
processes. 
 3.2. Opportunities 
This section will be divided into system-based, structure, process, and outcome 
opportunities: 
3.2.1. System-Based Opportunities 
I. There is stakeholder awareness and positive perceptions of the need for a 
national PV system to cover the country's needs. 
II. Some stakeholders are willing to coordinate efforts with the MOPH and HMC 
to improve PV and medication safety at the national level. 
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III. MOPH reported a valuable opportunity, as the UMC is encouraging the country 
to become a full member.  
IV. Collaboration between QU and the pharmaceutical industry was reported as a 
potential network for coordinating PV activities. 
3.2.2. Structural Indicator Opportunities 
I. The MOPH has submitted a draft for an updated pharmacy law, or "Pharmacy 
Act". The draft includes many aspects that did not exist in the previous law, and 
it will include PV and medication safety as part of the registration and as part 
of clinical practice in the country. 
II. Qatar is an associate member of the WHO PIDM. 
III. The MOPH reported that public reporting is supported in general and that the 
patient safety reporting system that it is considering implementing includes a 
plan that at some stage, access may be granted so that patients will be able to 
report data themselves, whether for an incident or a complaint. 
IV. The HQPS reported that there is an intended plan for a medication safety 
program. The program is not specific to PV, but the basic elements of the 
program depend on the WHO Global Patient Safety Challenge on Medication 
Safety. The MOPH signed the pledge of the WHO, and it is now in the process 
of taking it further to develop an action plan and engage with national 
stakeholders. 
V. The HQPS reported that there is another future project, the National Patient 
Safety Reporting System, that will include reporting on ADR and medication 
errors.  
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VI. The MOPH reported that documents related to patient safety and spontaneous 
reporting of ADRs were currently in development. In particular, the new action 
plans include several activities to strengthen the system, such as the 
establishment of a data collection system (including data collection tools) to 
collect information from various stakeholders. 
VII. Universities reported that they have experts in the field and can provide input 
into PV either by directly hosting the national PV system or collaborating with 
the MOPH PV system. Additionally, graduate and undergraduate students could 
provide input into the national PV system through research activities.  
3.2.3. Process and Outcome Indicators Opportunities 
I. Most stakeholders are leveraging opportunities to increase their reporting rates 
as well as the system capacity to monitor drug safety. For example, private 
health institutions plan to implement an electronic reporting management 
system such as the Datix system. 
II. The MOPH has a good relationship with the UMC, and it has already been 
successful in becoming an associate member. Hence, the MOPH has been 
granted the privilege of accessing the international system that is designed to 
submit reports. 
III. The potential introduction of clinical coding in the national healthcare system 
could aid in facilitating the process of the WHO PV outcome indicator 
measurement and evaluation. 
IV. HMC is planning to more robustly introduce the concept of economic studies 
into the current system. This could aid in measuring the outcome of the HMC 
PV system activities.  
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3.3. Challenges and Weaknesses  
This section will be divided into system-based, structure, process, and outcome 
challenges:  
3.3.1. System-Based Challenges 
I. According to the stakeholders, the national PV system's current capacity to 
monitor and ensure the safe use of medication is not in a desirable state. 
II. The private sector reported that there is limited capacity, so the system will 
focus its efforts on healthcare treatment needs rather than on prevention. 
III. Throughout the several interviews conducted, the informants reported that there 
is no formal or structured system for the interface of various systems across the 
country, so there is no formal relationship among national PV stakeholders. 
IV. A national communication strategy (including crisis communication) does not 
exist. Additionally, a national emergency plan for higher academic institutions 
does not exist.   
V. There is no formal communication strategy between the departments of the 
MOPH or between the MOPH and other stakeholders in the country. 
VI. According to the MOPH, the governance of the system can impose challenges 
through overregulation, creating many restrictions, delayed communication 
and/or feedback. 
VII. The eHealth strategy project has been delayed for many years because of 
restrictions. 
VIII. There is resistance to sharing data even among governmental hospitals and 
institutions. 
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IX. It was reported that there can be overlap and mixed responsibilities between 
HMC and PHCC, and miscommunication can occur between the tertiary and 
primary care healthcare systems. 
X. PV is a low priority within the healthcare system agenda for some stakeholders 
e.g., some private sector stakeholders. 
3.3.2. Structural Indicator Challenges 
I. There is no document defining a national policy on PV to enable the 
implementation and enforcement of PV activities in the country. 
II. The current law is very old and does not provide comprehensive coverage for 
active and passive PV activities. 
III. The current law does not provide details on PV information sharing or 
transparency issues.  
IV. There is no specific policy or law to cover PV training and the conduct of 
clinical trials, which could constitute a very large risk. 
V. Qatar does not have a national medicine policy that includes medication safety. 
VI. For healthcare professionals, there is no legally binding requirement in the 
current law that mandates reporting; instead, they are advised to report 
medication safety issues. 
VII. There is no national PV center, and there is no functional information and 
technology infrastructure, including the lack of a national database as well as an 
ADR form to collect and analyze data from healthcare professionals and the 
public. 
VIII. A formal system for spontaneous reporting is not available for some 
stakeholders, e.g., community pharmacies. 
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IX. There is a lack of expert staff devoted to drug safety activities. The dearth of 
highly qualified PV professionals can be attributed to the lack of advanced 
training initiatives and limited funding to support in-service training. 
X. The budget constraints within which some of the stakeholders, e.g., those in the 
private sector, operate can affect the acquisition of the structures and 
infrastructure required for PV activities. 
XI. Neither MOPH department concerned with drug safety had the required 
structure to take full responsibility for PV. Neither department has a database 
for the collation and analysis of data. 
XII. The results identified some of the barriers to reporting ADRs in the country, 
including fear of punitive measures, lack of education and training on the 
subject for healthcare professional, barriers in the availability of reporting 
forms, the perception that reporting is not appreciated, low prioritization of PV, 
and a lack of public education on issues of drug safety. 
XIII. A few key informants from the private sector reported that the MOPH website 
does not provide ease of use when extracting information, and it does not 
specify a MOPH expectation for the private sector concerning PV. 
XIV. At present, there is no specific PV or medicine safety advisory committee, drug 
information center, or medical court in the country. 
XV. A challenge was reported in that the drug information services that were 
available in the Qatar National Formulary mobile application (e.g., listing all 
ADR precautions and other safety concerns) have been deorganized, and ADR 
reporting through the application is no longer available. 
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XVI. The MOPH created a reporting form that was previously available online as part 
of the Qatar National Formulary, but because of legislative issues related to 
patient data security, the MOPH did not continue with it. 
XVII. According to the MOPH informants, many healthcare professionals working in 
Qatar do not have PV and ADR reporting as their main job function. 
3.3.3. Process Indicators Challenges 
I. Although HMC and some private hospitals performed satisfactorily in the 
survey, there is still much room for improvement. In particular, the issue of the 
underreporting of ADRs continues to be raised in PV systems. 
II. Currently, there is a lack of national educational efforts that target healthcare 
providers in the private sector, e.g., community pharmacies, on the subject of 
PV. 
III. A lack of coordination and accountability among the disparate stakeholders 
leads to duplicated, fragmented, or overlooked efforts. For example, the MOPH 
reported that there are several isolated and uncoordinated PV activities at the 
national level. 
IV. Underreporting of ADRs has been identified as a key barrier to the effective 
functioning of the PV system at the international (UMC database), national 
(MOPH), and subnational level (e.g., HMC, PHCC).  
V. There is no organized national system to analyze data on drug safety, which 
leads to the inability to utilize and benefit from national reports. 
VI. Public and private health institutions do not constantly track and consolidate 
data on therapeutic ineffectiveness, medicine-related admissions, cost, and 
budget impact data. 
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VII. The ability to collect national data that could be used to inform the decision-
making process as well as the development of national treatment guidelines is 
limited. 
VIII. There are limitations in the process of continuous monitoring of drug quality in 
the country for drugs coming from abroad (i.e., through the airport) or sold 
through social media. 
IX. The country does not have regulations to control the purchase and trade of drugs 
over social media. 
X. The quality of the national ADR reports received by the MOPH was considered 
minimal, which prevents a proper causality assessment. 
XI. Some healthcare professionals in the private and public sectors can have a 
limited ability to fill out complete and high-quality report forms, and their 
ability to detect actual ADR cases can be inadequate. 
XII. One of the major weaknesses in the current PV system is PV communication, 
as it is a low priority among national stakeholders. 
XIII. According to the MOPH policymakers, PV steps and actions are considered 
slow paced. 
XIV. The MOPH reported that patients and the general public make minimal 
contributions to the PV system, and they are not involved in PV decision making 
or the PV policy-setting process. This was linked to limited awareness, time 
constraints, and cultural and linguistic diversity.  
XV. The MOPH reported a problem with how drug safety information is received 
and processed, as the route of communication between MOPH departments is 
tedious, and the process can be slow. 
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XVI. The key informants reported that awareness of active PV is not very uniform or 
consistent among healthcare professionals, and there is a lack of understanding 
of active PV activities and/or studies. 
XVII. It was reported that active PV is not aligned with the scope and nature of the 
work of the private sector. Additionally, it is difficult for private organizations 
to engage in these activities because they do not generate any revenue. 
XVIII. The private and public sectors reported challenges, as the patients do not report 
or provide feedback on their medication use experience. The MOPH reported 
this as well. 
XIX. There is a communication gap between the pharmaceutical industry and the 
private and public sectors. To illustrate, the pharmaceutical industry indicated 
that no safety issue reports on their products had been received. However, the 
public sector and one private hospital reported an issue with the products, which 
had been communicated to the MOPH. 
XX. Academic institutions' inclusion of PV in their curricula can be minimal, and 
only a few credit hours (e.g., 2 credit hours) are provided throughout a whole 
program period. 
3.3.4. Outcome Indicator Challenges 
I. Concerning the evaluation of the benefit-risk ratio, the Pharmacy and Drug 
Control Department reported that at the current level, it does not have enough 
capacity to conduct such an activity. 
II. Regarding signal evaluation, the MOPH commented that there is a lack of 
awareness about how to perform signal evaluation, including the use of relevant 
tools and methods. 
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III. Because the PV system is not in place, the MOPH informants reported that 
MOPH responsiveness to addressing drug safety issues is not appropriate, as the 
actions taken are not documented and not well monitored or evaluated for their 
short-term and long-term impact. 
IV. The MOPH reported that the route from receiving a report to the initiation of 
feedback or taking an action follows an inappropriate review process compared 
to that in other, appropriate PV systems. 
V. Regarding national data, the HQPS reported that service delivery organizations 
do not report hospital admission data. 
VI. Regarding the outcome indicators that deal with financial outcomes and clinical 
outcomes, it was reported that it is difficult to quantify such data, as most sectors 
do not have the human and technical resources required for the collection and 
analysis of data. In addition, the financial resources required for auditing of PV 
outcomes is limited in the private sector. 
VII. The ability of the private and public sectors to identify and evaluate signals is 
limited due to a deficiency in expert human resources and the underreporting 
problem. 
VIII. The private sector informants reported that there could be some delays in 
receiving regulatory actions from the ministry, e.g., delay in receiving MOPH 
circulars. 
IX. MOPH does not conduct financial analysis relevant to PV and medication safety 
activities. 
X. There are no national data on medicine-related admissions and medicine-related 
deaths. 
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CHAPTER V: DISCUSSION AND CONCLUSION 
 
Pharmacovigilance (PV) systems are an important part of healthcare systems. 
Their existence and sustainability are required to safeguard public health and ensure 
medication safety. The challenges and performance inadequacy of these systems are 
well documented in the literature, especially in developing countries. The operational 
capacity and requirements for development of PV systems exert continuous pressure 
on developing countries' healthcare systems. Therefore, it is of paramount importance 
to ensure that such systems are properly evaluated and monitored to ensure that they 
are meeting their objectives. Previously published work has reported many challenges 
regarding PV and medication safety in Qatar. The main challenge is the nonexistence 
of a national PV center to coordinate PV activities across all levels of the national 
healthcare system. To address the reported challenges and to improve PV in Qatar, it is 
essential to understand the baseline situation of the country and identify critical gaps. 
In addition, it is important to consider the views and perceptions of national PV 
stakeholders since the challenges burdening PV systems can be country-specific, and 
solutions may need to be tailored to the country's social, economic, cultural, and 
political contexts. Accordingly, this research aimed to conduct a comprehensive 
analysis of the existing PV and medicine safety systems in Qatar at different levels of 
the healthcare system with reference to the WHO PV framework. Additionally, the 
input of national PV stakeholders was sought to gain a better understanding of the PV 
system status in terms of performance, challenges, opportunities, and potential 
recommendations. To our knowledge, this project was the first MMR designed to 
evaluate the PV system in Qatar.  
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1. The Baseline Pharmacovigilance Situation Based on the WHO Framework 
and Key Informants’ Contributions  
1.1. Overall Qatar Pharmacovigilance System Performance 
1.1.1. WHO Pharmacovigilance indicators 
This study provided a baseline description for the current status of PV following 
a system-based approach of structures, processes, and outcomes. Based on the literature 
covering PV system capacity and evaluation, for any PV system to be functional, it 
must fulfill the system requirements of the structure, process, and outcome elements 
(10, 11, 32). The assessment indicated that there are current disparities in the national 
PV subsystems with respect to the performance of these three major elements (Figure 
16). This is expected to affect the national capacity to monitor and ensure the safe and 
effective use of medication in Qatar. When the data were analyzed in more detail by 
combining the means of PV subsystem performance to achieve a result that represents 
overall performance of the country’s PV system (Figure 18), it was found that there is 
good performance (71.6%) in the structural indicators domain, but the system showed 
less-than-desired performance in both the process (51.2%) and outcome (32.3%) 
domains. This total performance within the average range (54.7%) conveys that there 
are limitations that affect the system’s ability to achieve the desired performance in the 
basic PV requirements determined by the WHO framework. In addition, there is a need 
to target gaps following a phased approach starting from the structural indicator 
requirements, moving to PV processes, and finally reflecting on the potential benefits 
of targeting outcome indicators in the future. The overall performance of the country, 
if PV is addressed properly following a system-based approach, is expected to lead to 
successful implementation of PV within the healthcare system. For instance, Abiri and 
Johnson indicate that due to the satisfactory performance of the national PV center in 
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Sierra Leone, which they evaluated using the IPAT tool, the center has the potential to 
offer leadership for PV implementation (52).  
1.1.2. WHO Minimal Requirements for a Functional System 
According to the WHO, a functional national PV system has the following 
minimal requirements (40): 1) A national PV center with basic financial assistance and 
one dedicated full-time staff, 2) A national spontaneous reporting system and a 
dedicated form for ICSR reporting, 3) A national database, 4) A national PV advisory 
committee, and 5) A communication strategy that includes crisis communication. 
According to these WHO recommendations, Qatar does not have any of the required 
elements for an operational PV system. The assessment indicates that efforts by national 
PV stakeholders need to be consolidated to improve the current PV scenario to comply 
with the defined five areas. Addressing these five areas will ensure the attainment of 
satisfactory PV system capacity to serve the country. For instance, in their study, 
Suwankesawong et al. evaluated the PV systems in ASEAN countries for their ability 
to meet the five requirements. The authors reported that the five areas enabled the 
identification of PV system deficiencies that should be addressed to help the countries 
resolve system capacity and functionality issues. For example, countries with less 
developed PV systems (e.g., Cambodia) reported a challenge in developing a clear 
communication strategy; therefore, the authors recommended improving PV 
communication and ensuring rapid information dissemination (85).  
1.2. Performance of the MOPH Pharmacovigilance System 
This research provided insight into the pattern of PV practices at the MOPH, 
the healthcare regulatory body of Qatar. All interviewed key informants from MOPH 
recognized the need for PV. Additionally, they reported that the country hopes to 
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become a full member of the WHO PIDM in the future. This implies the MOPH 
members' awareness of the importance of PV and postmarketing surveillance to ensure 
effective medication safety monitoring in Qatar. However, the MOPH system has 
achieved average performance status in PV structure indicators (40.3%) and poor 
performance status in the PV process (17.2%) and outcome indicators (9.1%). In 
addition, the total MOPH system performance achieved poor performance status 
(23.8%) (Figure 16). This implies that the MOPH PV system is weak and that the 
system functionality status may impede the MOPH's leadership role in PV 
implementation in Qatar.  
The details of the system analysis indicate that there is a major weakness in the 
performance in structural indicators, as the MOPH does not have the core PV structures, 
including national policies and guidelines relevant to PV, an organized PV center to 
oversee PV activities, national reporting forms, and national computerized systems for 
reporting, in place. This implies the need to prioritize PV within the MOPH agenda and 
the need to commit to implementing the PV structures required for the operation of the 
system as well as to satisfy the outcome indicators criteria determined by the WHO.  
Examining the details of the two departments overseeing the activities related 
to PV, medication safety, and patient safety, the study found variation in the 
implementation of PV procedures. For instance, the Department of Pharmacy and Drug 
Control collects and analyzes data from the international pharmaceutical industry, 
while the HQPS receives national data on medication errors only, and no further data 
analysis is performed, as the department is still in the planning stage of the medication 
safety plan. This implies that the current PV system performance requires major 
improvements from the national stakeholders' side and that the modern scope of a PV 
system is not comprehensively covered under the current MOPH operations. In 
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addition, it sheds light on the fact that PV activities are not coordinated between the 
MOPH departments. This situation may lead to shortfalls in the effective management 
of PV, medication safety, and patient safety due to errors of omission, commission, 
and/or duplication.   
The section below will address the current PV landscape in detail, as the MOPH 
system is considered the current national PV system by national stakeholders, and many 
shortcomings were identified in the system analysis. 
1.2.1. Regulatory Framework 
The assessment found that the MOPH (i.e., CST3) has a regulatory framework 
that includes a defined pharmaceutical law as well as established registries for drug and 
health-related facilities. It also found that stringent regulations to manage the 
pharmaceutical market exist and that issues such as counterfeit medications are not a 
threat to the country, in contrast to the situation in other developing countries (10, 20, 
21, 73).  This is a positive attainment for the national healthcare system, as the literature 
pertinent to national regulatory frameworks indicates that regulatory authorities at the 
national level are expected to establish effective governance structures and systems (10, 
137). The effectiveness of this regulatory framework cannot be addressed by this 
research. However, the details provided indicate that Qatar has a legal basis and 
mandates for MAHs to report ADRs to the MOPH. This means that the MOPH has 
dedicated resources to ensuring that safety data on registered products are collected. 
Based on the literature, this is a standard practice in countries with stringent PV systems 
(138). Further, the law provides no requirement for healthcare professionals to report 
ADR cases. The subject of mandatory reporting has been debated in the literature, and 
there is no substantial evidence for its effect on reporting rates (67). If the MOPH 
considered defining mandates on ADR reporting, it would require the proper 
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consideration of national PV stakeholders’ views and recommendations, especially 
because Qatar does not have a medical court. Without appropriate consideration and 
effective execution, the introduction of this measure could burden the national PV 
system. However, it is worth mentioning that a legal basis for reporting has been 
incorporated into PV systems in some high-income countries (56), such as France, 
where ADR reporting has been mandated since 1984. The reporting of ADRs in France 
was evaluated over a 16-year period, and the reporting rates showed an annual linear 
increase, but the country still considers underreporting of ADRs a challenge (139). In 
addition, Qatar does not have a national medicine policy. This finding indicates the 
need to develop a national medicine policy that is based on the internationally 
recognized standards of the WHO. According to the WHO, a national medicine policy 
is an essential document that should include medication safety, product quality, and PV 
as essential elements. The WHO has also indicated that requirements for the 
institutionalization of a national PV system can be unequivocally included in the 
national medicine policy (140). 
1.2.2. Pharmacovigilance Policy and Guidelines 
In Qatar, a PV policy or guideline (i.e., CST2) does not exist, and the current 
pharmaceutical law does not employ the specific term PV. Key informants from MOPH 
reported that the current law does not comprehensively cover medication safety and PV 
elements. Therefore, Qatar is in need of well-designed and comprehensible PV legal 
provisions to enable the implementation and enforcement of passive and active PV in 
the country. Without defined and enforced PV legal provisions, the standardization of 
PV across the subsystems, the proper coordination of PV subsystems, and the effective 
functionality of the national PV system will remain unattainable. This claim is based 
on major works of the SPS and the SIAPS program. It has been documented that the 
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existence of defined policies on PV reflects a country's commitment to and 
prioritization of medication safety, and such policies are a tool that guides national 
stakeholders to comply with standard PV practices to ensure medication safety and to 
prevent drug-related issues (10, 29, 51). For instance, an evaluation of the Ghana PV 
system indicated that the lack of essential laws and regulations relevant to PV reflected 
many limitations of the system to enforce drug safety monitoring (51). 
The MOPH key informants reported that due to restrictions and overregulation 
by the higher authorities, projects on the healthcare system agenda aimed at 
strengthening medication safety and PV have been disorganized (i.e., Qatar national 
formulary ADR reporting) or delayed (i.e., eHealth strategy) (141). This overregulation 
that prevents the implementation of PV has been reported as a challenge in the literature 
(18).  
1.2.3. MOPH Role in Pharmacovigilance and Pharmacovigilance Center 
Establishment 
The role of regulatory bodies in establishing and ensuring the sustainability of 
PV systems has been clearly delimited by the WHO (67). In developing countries, PV 
systems often do not receive the support required for successful operation or 
institutionalization (20, 21, 72). However, the findings of this study showed that the 
MOPH is in the planning stage to implement initiatives aimed at improving medication 
safety and patient safety. This indicates increased awareness and commitment from the 
MOPH toward PV implementation, as the initiatives extend to PV-related elements. 
Nevertheless, discussion with the MOPH key informants about details on the PV system 
in terms of the structure and infrastructure did not indicate an inclination to establish a 
national PV center (i.e., CST1). Without a visible PV center, opportunities to take 
advantage of the available resources and human resources will remain unfeasible. The 
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literature indicates that a national PV center is the central point for conducting and 
coordinating PV activities following an organized and systematic operational approach. 
If PV systems do not exist or are fragmented, the country can be prevented from making 
the informed decisions required to ensure medication safety and protect public health. 
In addition, in developing countries, the lack of dedicated PV centers has been 
identified as an area requiring targeted national and international efforts (21, 73, 82). 
Finally, the WHO recommends that once a national PV system is sufficiently 
developed, a country can apply to join the WHO PIDM by following the process of 
enrollment (40, 67).  
1.2.4. Pharmacovigilance Advisory Committee 
The Pharmacy and Drug Control Department is currently responsible for 
providing advice on PV and medication safety as part of its roles and responsibilities. 
However, the lack of an organized and dedicated PV or medication safety advisory 
committee (i.e., CST10) can hinder PV development in the country. The assistance such 
a committee can offer, if established, includes but is not limited to safety data collation 
and evaluation, risk evaluation and minimization, PV communication, and provision of 
information (1, 67). This finding is supported by the national PV stakeholders’ remarks. 
Regardless of the sector in which they worked, the national PV stakeholders addressed 
the need for such a committee and the benefits it could provide for the subnational 
systems and the country. Moreover, the WHO has identified the existence of a PV 
advisory committee as one of the five areas required for a functional PV system (40). 
1.2.5. Drug Information Center 
The study found that the provision of PV information is an important area that 
requires attention. Additionally, stakeholders in national PV subsystems identified the 
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need for a dedicated system for the provision of information, such as a drug information 
center. The country would benefit from the establishment of a drug information center 
or a committee within the MOPH to provide this function. The drug information center, 
if established, would assist both the private and public sectors by providing expertise 
in the area of drug information. The drug information center could also be linked to the 
PV center to support the scope of PV services provided in the country (142).  
1.2.6. Pharmacovigilance Stakeholder Coordination  
The study found a wide gap in national PV stakeholders' coordination, which is 
an important element for PV success. In Qatar, there is no formal or structured approach 
for multisectoral involvement in PV or for subnational PV systems to interface. 
Coordination and communication mechanisms need to be developed by the MOPH. 
Based on evidence from the literature, the engagement of national stakeholders through 
collaboration, cooperation, and advocacy patterns can enable PV. Major global PV 
stakeholders such as the WHO and MSH have recognized stakeholder involvement and 
commitment as a major source of PV development, especially in developing countries 
(29). For instance, MSH has emphasized that broken relations between stakeholders 
can often lead to failure in PV implementation and development (69). In addition, 
stakeholder coordination is an important aspect, as even when legislation exists, 
stakeholder participation is affected by other factors (107).   
On the other hand, patterns of interaction between the MOPH, WHO and UMC 
are promising and have had a positive influence on medication safety. To illustrate, the 
MOPH key informants reported that some WHO standards are being considered for 
future projects. In addition, they reported that the WHO is encouraging the country to 
establish a PV system and become a full member of the PIDM. This finding is 
consistent with the literature on the positive influence that external parties can offer to 
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PV (e.g., advocacy support, financial support, technical capacity building, capacity 
building) (102, 143). Additionally, this study found that the reported functionality of 
the national PV system in relation to the pharmaceutical industry and service delivery 
healthcare institutions diverged and did not align with the performance required at the 
national level. According to the MOPH informants, the PV system is considered 
functional by the pharmaceutical industry and international stakeholders. However, 
from the national stakeholder perspective, the current PV system can be considered 
nonfunctional. 
1.2.7. National Reporting Form 
The country has no ICSR or ADR reporting form (i.e., CST6). The study 
indicates that without data collection tools for PV, the ability of Qatar to use 
information to improve medication safety and patient safety as final outcomes is 
undermined, and the quality of patient care is greatly affected (51). This is consistent 
with the findings of Wilbur, who identified the nonexistence of a standardized reporting 
form in Qatar as a potential factor for healthcare professional underreporting (36, 37). 
In addition, the literature on the challenges in PV systems indicates that without data 
collection tools for PV, the potential use of the information remains unfeasible (1, 10, 
20, 71, 72). It is recommended that the national ICSR form be designed to conform 
with global standards to ensure that any data collected comply with the international 
WHO PIDM database (i.e.,VigiBase) and that the country's potential contribution to 
global data will therefore be of value (18, 79). 
1.2.8. The Underreporting Problem 
An evaluation of the MOPH system identified the problem of underreporting by 
national stakeholders. The MOPH reported that during a one-year period, only 10 safety 
  
193 
 
case reports (i.e., CP1) were received from one healthcare institution. The 
underreporting problem is apparent even with the availability of the previous national 
ADR form. The report also indicated that there is resistance to sharing PV data even 
from governmental institutions. This challenge has important implications since the 
national system represented by the MOPH suffers from gaps in other key PV 
requirements for a functional system. Underreporting implies that the country is not 
able to collate data on the safety, quality, and effectiveness of products that are available 
in the market but have not been tested in the population. Consequently, the subsequent 
processes, including data analysis, signal identification, regulatory actions, and 
communication and feedback mechanisms, will remain stagnant. This in turn will affect 
the national system capacity and implementation of PV at the national level. Based on 
the literature, the threshold for the satisfactory performance of the PV system measured 
by reporting rate would require the system to receive 300 reports per million of 
population per year (144). Likewise, under the SPS program, the PV system cannot be 
considered functional with the receipt of a few reports. The SPS program depends on 
the IPAT tool threshold that requires 100 reports per million of population per year an 
acceptable threshold for PV system operational capacity (32, 51). Hence, Qatar does 
not achieve the threshold of an operational PV system. The establishment of a PV center 
will be essential to address the underreporting problem. Zhang et al. reported that 
without a PV center, it is difficult for healthcare professionals and the general public to 
report ADR cases (81).  
1.2.9. The Quality of National Reports 
The quality of the national reports received by the MOPH (i.e., CP5) was 
deemed minimal by both departments concerned with medication safety, as the 
information provided does not permit a proper data analysis (e.g., causality assessment) 
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(i.e., CP4) to be conducted. The quality of the data submitted and the completion of the 
elements required for further data analysis can either undermine or improve PV in the 
country. Therefore, identifying the root cause of the problem at each stakeholder level 
is recommended as the first step. For instance, at the national level, there is no uniform 
ADR form, so the ability to standardize data collection to fulfill all the requirements 
across various stakeholder systems is not feasible. Additionally, at the service delivery 
level, the design of the reporting form and its ability to meet standards of quality as 
well as the awareness of the healthcare workers of the elements that need to be 
satisfactorily completed should be investigated. Identifying the root of the problem at 
the national level as well as at the subsystem level will enable the design and 
implementation of targeted solutions that would address the gaps in PV systems (11, 
79).  
1.2.10. The Pharmacovigilance Culture 
Based on interviews with the MOPH key informants, some reports (e.g., reports 
that include no serious cases or documented cases) may not receive feedback (i.e., CP3). 
This could be disadvantageous for the reporting culture, particularly when the national 
system is experiencing many gaps in PV elements. This finding is supported by the 
study conducted by Wilbur, who found that pharmacists in Qatar reported an issue in 
receiving feedback because the fate of a submitted report can be ambiguous (37). 
Similarly, in interviews with national PV stakeholders, the study found that 
representatives of the public sector felt that efforts to report can be underappreciated. 
Regarding the PV culture, the WHO has indicated that systems with limited capacities 
or systems at an early stage of development should be encouraged to welcome all types 
of reporting (i.e., serious and not serious as well as documented and not documented) 
and provide feedback. This will enable the country to create the “notification culture” 
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required for the initial implementation of PV. The study recommends that for effective 
PV, the culture needs to be improved. This improvement will require time and the 
sharing of responsibility by the reporters and the MOPH system. The culture needs to 
ensure the proper alignment of priorities and stakeholder accountability to avoid the 
conflicts of interest and communication gaps that can impede PV. Building a positive 
culture for PV entails specific national communication strategy, educational 
interventions, efforts to streamline reporting (e.g., the distribution of ADR reports), 
training provisions, a feedback mechanism, the dissemination of information, and 
MOPH assistance in building the resources and capacities of national PV subsystem 
(20, 46, 67, 86). The literature indicates that the culture of PV is founded on a culture 
of safety that requires the input of various PV experts (88). The improvement of the PV 
culture will have positive implications for the gaps found in PV systems, including the 
underreporting of ADRs. Edwards et al. suggest that contemporary PV systems need to 
improve the PV culture (145).  
1.2.11. Data Management  
The study investigated the management of drug safety data within the MOPH 
system. It found defects in the data management process. At the current stage, the 
MOPH does not have a formalized data management system. Additionally, according 
to the HQPS key informants, without PV structures in place, the MOPH PV system will 
remain nonfunctional. Therefore, the implementation of an integrated data management 
system is proposed to maximize data use and evaluation, including causality 
assessment, signal identification, and signal evaluation. In turn, those processes will 
ultimately inform effective information dissemination, decision-making processes, and 
feedback mechanisms to national stakeholders and possibly external parties (e.g., the 
WHO and international pharmaceutical industry) (10, 51, 146). Moreover, in the 
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absence of a structured and standardized data management process, the country may 
suffer from stagnant decision-making processes. This is apparent to some degree, as the 
MOPH stakeholders reported a general reliance on external data to inform national 
regulatory actions and decision-making processes. For the MOPH to improve the 
national PV scenario and realize the process of continuous drug monitoring, the system 
will require the careful implementation of basic PV processes outlined in the WHO PV 
indicator manual. 
 The HQPS department reported that per the health service performance 
agreements, service delivery organizations are required to submit medication error data 
only. This can limit the scope of the collected national PV data. The study found that 
national service delivery organizations do not report ADRs, hospital admission data, 
deaths due to medication errors, and therapeutic ineffectiveness. However, it is 
promising that the HQPS informants remarked that capturing these data might be part 
of the future reporting system. The collation and use of such data is recommended even 
before the future program is implemented. Health facilities can be requested to provide 
the data along with medication error data to avoid lost opportunities to address national 
medication safety issues (29, 51). In the future, the national unified reporting form 
could include such data to facilitate their collection.  
1.2.12. Technical Capacity 
Technical capacity was identified as a barrier within the MOPH system, which 
may undermine the ability to efficiently and effectively implement PV processes. This 
challenge is often reported as a burden in less developed PV systems, especially in 
developing countries or high-income countries with less developed systems. The issue 
of staffing deficiencies (i.e., CST5) in terms of quality and quantity has been reported 
as a major challenge affecting systems functionalities and legislative frameworks in 
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developing countries (20, 21, 29, 31, 73), for instance, among Arab countries, including 
Qatar (25).  Hence, to improve PV, there is a need to build national resource capacities, 
notably with respect to human resources, including the expertise and skills of 
individuals or teams operating within the MOPH system. Moreover, the threshold 
recommended by the IPAT for individuals receiving training in PV is 5% per 
institution, and the inability to meet the threshold is considered a failure to provide the 
training required to ensure system functionality (51). The WHO PV indicator manual 
does not provide a threshold for PV training. However, the literature recommends that 
the threshold of the required capacity to handle individual safety case reports would 
involve the number of reports received per year per designated staff (29). Additionally, 
the WHO requires a minimum of one dedicated full-time member in the PV center for 
the national system to be considered functional (40).   
The MOPH in Qatar is not very active in providing PV training at the national 
level, apart from vaccine training, which is well implemented. Interviews with key 
informants from the MOPH indicated that currently, the MOPH has enough capacity to 
provide training on basic PV activities to address the observed limited awareness. 
Therefore, the study recommends the effective provision of training and education to 
various national stakeholders to improve the operational capacity of the PV system. 
Furthermore, in the future, the successful implementation and operation of a unified PV 
center will require the input of well-informed and knowledgeable stakeholders. In fact, 
the literature indicates that the provision of training and education for healthcare 
professionals and the public is one of the key resources for functional PV systems (46, 
82). 
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1.2.13. Information and Communication Technologies 
The research findings indicate shortcomings in the acquisition of sophisticated 
information (i.e., CST7) and in communication technologies (i.e., CST9). The gaps in 
technological advances are linked to overregulation and ethical concerns regarding the 
confidentiality issues associated with data collation. The study proposes the utilization 
of advanced technologies to allow the country to improve, standardize, and sustain the 
provision of PV services. Ethical and legal issues related to PV data can be resolved if 
they are clearly defined in policy-related documents. Well-designed policies can 
determine the roles and responsibilities of stakeholders and define the parties who have 
access to and manage national PV data (18, 67, 143). MOPH future projects, if 
implemented and sustained appropriately, can improve the national PV system capacity 
and address national stakeholder requests for streamlining PV processes and 
networking. It is also recommended that the use of technology in PV be optimized to 
ensure that the PV systems can cope with the expansion of PV and the challenges 
associated with this expansion (1, 20, 46). In fact, PV system evaluations in many 
African and Asian countries have suggested that regulatory authorities need to invest 
in communication technologies to improve national PV system operational capacity as 
well as to improve the dissemination of essential PV information to national 
stakeholders (29, 31, 51).  
1.2.14. Decision Making and Regulatory Actions 
The MOPH informants reported that their responsiveness to drug safety issues 
(i.e., CO2) is good. The study found that the MOPH relies on benchmark countries with 
stringent regulations; therefore, cases of delay in acting were linked to the unavailability 
of full information for the MOPH to obtain a clear picture. However, the key informants 
reported that the system is challenged by the process of communication within MOPH 
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departments, which is tedious and can be slow. Therefore, it is recommended that 
details on decision making and regulatory actions, including risk management and risk 
communication, with defined timelines be included in the MOPH policies. This will 
permit the MOPH to map the involved teams or individuals and thus reduce the burden 
on other, less relevant MOPH departments. The research findings also indicate that 
following a systematic approach or a standardized process to manage safety alerts from 
external sources would improve PV risk management and communication (10, 51). 
Without informed decisions and regulatory actions based on national data, the 
MOPH system will not be able to monitor medication experiences in the Qatari 
population, which is socially, genetically, and culturally diverse. Data generated from 
diverse populations can provide benefits to global PV as well as national PV (1). In 
fact, under the SIAPS program, countries are expected to identify medication risks 
subsequent to signal generation at the national level. The program also recommends 
periodic reviews of national submitted reports and information collected subsequent to 
national active PV because they are fundamental to the functionality of a 
comprehensive national PV system (29).  
1.2.15. Communication Mechanisms for Pharmacovigilance 
The MOPH informants acknowledged the availability of communication 
mechanisms (i.e., CST9) for PV and medication safety, mainly including the website, 
circulars, and emails, to communicate with national stakeholders and those within the 
MOPH. Further, the MOPH requests that pharmaceutical companies inform national 
stakeholders directly, as national stakeholders do not utilize the MOPH website at the 
anticipated level. The interviews with national stakeholders indicated that circulars 
sometimes reach the facilities at a late stage, and feedback can be received after months. 
This indicates that the communication profile is low and not uniform at the national 
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level. Therefore, it is recommended that a standardized process for PV communication 
be established and that the outcomes of this process be documented, monitored, and 
evaluated. Additionally, a national communication strategy can help the MOPH to 
improve PV in Qatar. In addition, the findings suggest that a newsletter can serve as a 
mechanism of communication with national stakeholders. The newsletter, if well 
designed and sustained, could ultimately lead to developing desirable behaviors and 
serve as a valuable tool of communication with the reporters. 
1.2.16. Risk Minimization and Management 
The study indicates the need for effective PV data utilization to improve safe 
medication use by risk minimization and management activities, as recommended by 
the SPS and SIAPS programs (10, 29, 51). The national system would benefit from 
defining feasible risk mitigation activities at the national level. This definition process 
could have vital implications for the MOPH capacity to improve PV and minimize the 
harm associated with medications because it would influence the conduct of postmarket 
surveillance, risk mitigation, and risk communication activities. Such activities would 
require sustainable funding from the MOPH for successful implementation. The benefit 
of risk mitigation systems has been reported by a study using the IPAT indicator tool 
to evaluate the PV system in Benin. Allabi and Nwokike recommended the 
implementation of risk mitigation systems and protocols to ensure that medication 
safety is emphasized at each stage of the country system (50).  
1.2.17. Evaluation of Benefit-Risk Ratio 
The MOPH informants reported that at the current level, their system does not 
have the capacity to conduct such activities because the process is not simple, requires 
expertise, and possibly requires the input of a specific committee. To strengthen PV, 
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MOPH could advocate for expanding PV provisions and coordinate this initiative with 
other national stakeholders that may have the technical capacity for such an advanced 
process e.g., higher academic institutions.  
1.2.18. Active Pharmacovigilance  
MOPH reported that currently, the system does not have enough capacity to 
conduct active PV activities (i.e., CP9). Also, the MOPH is informed about national PV 
initiatives, including active PV, at a late stage. The study recommends MOPH 
collaboration with other sectors to implement active PV in the country. The reason is 
that active PV provides an innovative approach to collecting and analyzing drug safety 
data and can generate quantitative information in addition to the qualitative information 
obtained by passive surveillanc (29). Moreover, the MOPH informants reported that 
they favor relying on third parties and pharmaceutical companies because active 
surveillance activities are very expensive and require advanced technical knowledge, 
and most of the pharmaceutical companies can perform them successfully. It is 
recommended that subsequent to the establishment of a PV center and the initial 
streamlining of passive surveillance activities, the national PV system can investigate 
the available opportunities to implement active PV and promote the understanding of 
active PV across the subsystems in the country. Under such conditions, efforts should 
be made to identify the measures required to define the elements of active PV in 
national policies, regulations and conceivably laws. The MOPH can also investigate 
how national stakeholders could contribute to active PV through multistakeholder 
collaborative efforts. For instance, medical research centers and universities could 
shape the implementation of active PV in the national PV system (31, 51). Possible 
active PV activities that could benefit the country are the use of registries and intensive 
medicine monitoring (68, 147).  
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1.2.19. Clinical Trials and Pharmacovigilance-Related Research Activities 
Challenges in sharing safety information, the outcomes of clinical trials, and 
other medication safety initiatives (i.e., CP9) were reported by the MOPH informants. 
The study recommends that PV data (e.g., drug safety and effectiveness outcomes) from 
national stakeholder clinical trials and other research activities be shared with the 
MOPH to serve as a potential source to inform decision making and regulatory actions 
at the national level. If such information is not used, the opportunity for Qatar to become 
involved in advanced PV activities will remain unfeasible. In the future, the possibility 
of linking PV data between stakeholders could be investigated (29). Furthermore, the 
study identified a challenge in the current policies and regulations regarding clinical 
trials. The MOPH informants acknowledged that a specific policy or law that covers 
PV training and the conduct of clinical trials is not available, which could be a risk. The 
research division of the MOPH that is responsible for establishing research policies 
covers only certain processes and requirements for research on human subjects (148). 
1.2.20. The General Public 
The study found that the general public makes a minimal to no contribution to 
the national PV system. The reasons for this minimal contribution were the lack of 
awareness of PV, time constraints and cultural and linguistic diversity. Additionally, 
the MOPH key informants reported that the public is not involved in the PV policy 
setting or decision-making process. Further, there is no official reporting form for 
public reporting of medication safety issues (i.e., CST6). However, on the MOPH 
website, the GHCC allows the public to register any complaints, inquiries, and requests. 
In addition, safety warnings are communicated through newspapers and/or media. This 
indicates a good standing in the current stage, but a clear framework that involves the 
public in PV is recommended. This framework must accommodate the population 
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literacy level and cultural diversity.  
Public inclusion should follow a phased approach and will require time and 
dedicated resources. In the initial steps, the general public will be sensitized to PV and 
medication safety (e.g., awareness campaigns); then, efforts should be made to involve 
them in the reporting process (e.g., wide distribution of electronic and/or paper-based 
reporting tools). In addition, it is important to note that the use of media is a potential 
recommendation, but it requires careful consideration and planning. Media can serve 
as an effective tool for communicating with the public or can present risks to the PV 
system, such as the damaged reputation of an institution or a lack of public trust and 
confidence in the healthcare system. Therefore, the use of media should be discussed 
with various stakeholders at the national level, including the media, to ensure that the 
information communicated is balanced and that the media are effective partners in 
improving PV at the national level. Furthermore, long-term efforts to increase public 
participation can include collaboration with schools to educate the students who 
constitute the future generation. This could apply to universities as well. (1, 149).  
Additionally, in the future, representatives of the general public could 
participate in the PV policy setting, PV agenda reforms, and PV decision-making 
process (150). Public involvement in PV has been highlighted in the literature, and 
many countries recognize the public as main stakeholders in PV (151). In addition, 
there is explicit documentation of the benefits of public inclusion in PV. Currently, 
more than 60 countries have developed reporting systems to benefit from public input 
and to ensure the provision of optimal care (152).  
1.2.21. Pharmacovigilance System Outcome Evaluation 
The study found that information on the financial outcome aspects (i.e., CO6, 
CO8) of the MOPH PV system is currently not available. The collection of some PV 
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KPIs was considered feasible by the MOPH informants, but planning would be required 
to develop a methodology of collation and analysis. PV outcome evaluation will be 
feasible and accurate if the MOPH system is reformed and improved, starting with 
structural elements and then moving on to process elements. Based on the WHO 
indicator manual, financial aspects should be emphasized by MOPH in healthcare 
planning and for the evaluation of PV intervention effectiveness. Additionally, if data 
are collected, the national and subnational PV systems with various levels of 
development can identify their ability to fulfill the final desired outcomes relevant for 
the PV system and to monitor progress over time (11, 30, 47). The study indicates that 
this process would also apply to clinical outcomes (i.e., CO3, CO4, CO5, CO7).  
1.2.22. Counterfeit and Substandard Medications 
The study found that counterfeit or substandard medications (i.e., O4) can enter 
Qatar only through drug product promotion and sales through social media (mainly 
Instagram) as well as through the airport. The country has no regulations to control the 
purchase and trade of medications through social media. Therefore, it is recommended 
that this issue be addressed by higher levels within different governmental ministries, 
possibly including the MOPH, the Ministry of Transport and Communication (because 
it is responsible for trade through social media), the Ministry of Commerce and 
Industry, and the Ministry of Municipality and Environment. 
1.2.23. Drug Quality Control laboratory 
The MOPH informant remarks regarding the drug quality control laboratory 
(i.e., ST6) under the Pharmacy and Drug Control Department were positive. This 
indicates that the MOPH is committed to ensuring that the country is able to conduct 
quality testing for medications as well as to detect defects in products registered in 
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Qatar. In the future, it is recommended that the laboratory establish effective 
collaboration with the established PV center and ensure compliance with the WHO 
qualification requirements (10, 11). 
1.3. Performance of the Public Sector Pharmacovigilance System  
The public sector involves the HMC PV system and the PHCC PV system. The 
study focused on the structure, process, and outcome components of these systems. 
Both systems achieved an overall good PV system performance (between 50% and 
77.9%). This indicates that both PV systems have been satisfactorily developed and that 
their functionality status signifies their public sector role as important stakeholders in 
PV implementation at the national level. 
The system analysis found that there is consistency in the performance on 
structural indicators, as both systems had the core PV structures in place, including 
policies and guidelines relevant to PV and related elements (i.e.CST2), a department 
overseeing PV activities (i.e., CST1), reporting forms (i.e., CST6), and computerized 
systems for reporting (i.e., CST7 and ST5). This implies a commitment to 
implementing the PV structures required for the operation of the system. The study 
examined the details of the two systems and found variation in the implementation of 
PV structures. For instance, HMC has reporting forms for patients and for healthcare 
professionals, while PHCC does not have a form for patients to report. Similarly, PHCC 
had two electronic software systems in place, the Datix system and the Cerner system, 
while HMC has only the Cerner system. PHCC can use the Datix system, which allows 
a feedback process, and this feedback is shared across the 25 centers.  
In terms of process indicators, the study found discrepancies in the operations 
of the PV systems. These were is expected because HMC is concerned with the 
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provision of secondary and tertiary healthcare services, while PHCC provides only 
primary care for the Qatari population. In addition, the performance of the HMC system 
might have been higher, but due to missing information for some PV KPIs (i.e., data 
was not provided), the HMC system score was lower than that of the PHCC system.  
For PV outcomes, both systems collected data based on the relevant scope of 
services provided; therefore, we noted that PHCC has only one relevant core outcome 
indicator relevant to signal identification and generation (i.e., CO1). PHCC achieved a 
score of zero, as it does not perform this activity on the submitted reports. The study 
proposes that signal identification be implemented given that a large number of the 
population is covered by the PHCC system.  
The study found that HMC is considering developing its service to include 
active PV activities (i.e., CP9). Further, HMC has conducted projects relevant to the 
outcome indicators, including following up potential signals. In addition, HMC has 
successfully published identified cases and communicated them to the WHO. This 
implies that HMC is striving to achieve the best possible system functionality status as 
well as being committed to contributing to PV implementation as a visible PV 
stakeholder. 
Both public sector systems reported an increased reporting rate (i.e., CP1). 
Furthermore, regarding the quantitative and qualitative information of the generated 
ADR reports, the study found that the HMC system alone reached the desired IPAT 
threshold (100 reports/million of population/year) (32). HMC reported receiving 1599 
ADR reports in 2017, while PHCC reported receiving 50 ADR reports for 2017 that are 
documented in the Datix system. The appropriate threshold for health facilities is based 
on the number of people served per facility (e.g., an institution serving 10,000 patients 
would require a minimum of one report per year for a satisfactory performance). This 
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can have a positive implication for the collation of national drug safety data, especially 
because HMC is responsible for providing care to the majority of the Qatari population. 
 The stakeholders in the HMC PV system, represented by the MSQC, reported 
that there is a need to address the quality of the documented reports (i.e., CP5), as some 
had inadequate information (30% of reports have missing information). Similarly, 
PHCC reported that to date, some of the received reports have had a degree of 
irrelevancy or deficiency. Some healthcare professionals have a lack of knowledge of 
ADRs, and some fail to differentiate between ADRs and side effects. In addition, some 
healthcare professionals report ADRs but do not provide the full information required 
for further analysis. Therefore, the study recommends improving awareness of ADR 
reporting; providing training in methods of collecting the PV data required for 
subsequent analysis, including transcribing data from patients’ health records; and 
improving the accountability of staff to ensure the completeness of the reports (29, 46). 
However, it is important to mention that to address the challenge of the quality of the 
reports, both systems had conducted training and educational initiatives on PV. HMC 
also reported an initiative to improve staff technical capacity by sending some MSQC 
staff to receive training in Uppsala, Sweden. This indicates a commitment to improving 
PV practices, technical capacity, and PV culture in the public sector. Moreover, PHCC 
has included ADR reporting as a staff key performance indicator to improve reporting. 
In line with this, the study recommends the use of key performance indicators, as it can 
be helpful to ensure that staff are aware of the system objectives and to monitor the 
achievement of the system objectives.  
A comparison between the two systems regarding the type or source of the 
submitted reports (i.e., P2) was not feasible, as PHCC was not able to provide details 
on the healthcare professional groups that reported because the Datix system records 
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data anonymously. For HMC, most reports were sent by pharmacy professionals (70-
80%), followed by nurses (10-15%), medical doctors (5%), and dentists (0%). HMC 
reported that despite efforts to increase reporting rates and improve the reporting culture 
among nursing professionals, the underreporting problem persists. The study suggests 
that the challenge could be related to culture. To illustrate, the hierarchical nature of the 
healthcare professions could be a potential cause of the discrepancies observed. This 
claim is supported, as even across the EU PV system, the issue of underreporting has 
been linked to the hierarchical nature of the healthcare system (91). Similarly, in 
developing countries, this hierarchical nature has been linked to the subject of 
underreporting by some professions (71). Consequently, it is recommended that 
reporting be encouraged and that all healthcare professionals feel included by providing 
the necessary assurance that their efforts are appreciated and that they will not be 
threatened, since the safety culture is a shared aspect among healthcare professionals. 
Clarifying the responsibility of each healthcare profession across the PV system would 
also increase the involvement of various healthcare professionals and avoid possible 
duplication of efforts. In addition, major awareness campaigns on the subject of 
reporting to sensitize healthcare professionals and ensure their compliance with best 
practices are recommended. Another potential opportunity is to use the Medical 
Education Department at HMC to build internal capacity by educating medical students 
or other students from various healthcare professional backgrounds on PV activities 
that extend beyond ADR reporting (91). 
For public and/or patients’ contributions, HMC reported that despite the 
availability of forms, the MSQC has not received any reports from patients (i.e., P2). 
This is consistent with the findings at the MOPH level and the PHCC system, as patients 
make a minimal contribution to PV. Public underreporting is a challenge that requires 
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attention. Lack of reporting has been attributed to a lack of awareness and time 
constraints among patients and/or the general public. This finding is consistent with the 
patient underreporting problem even in countries with well-developed PV systems 
(151, 153). However, patient reporting at HMC needs to be targeted and improved to 
ensure that the country benefits from this valuable source of data (154). In general, the 
study recommends that initiatives to increase public awareness focus on both short-
term and long-term (i.e., impact) initiatives. Short-term initiatives can include PV 
communication through social media (given the high availability of mobile technology 
in Qatar), TV, and newspapers (91). Additionally, at the HMC level, a short-term 
initiative is the possibility for patients to report directly without the assistance of a 
pharmacist to avoid any barrier (155); if required, the pharmacist could be involved 
based on whether the patient decides to simplify the process. Long-term efforts include 
collaboration with schools and universities to educate the students who constitute the 
future generation (1, 149).  
Regarding PV data analysis (i.e., core process indicators) and signal 
identification (i.e., CO1), variations were also reported. For instance, HMC follows a 
systematic and evidence-based approach for causality assessment, while PHCC does 
not conduct causality assessment of the received ADR reports. Therefore, it is 
recommended that causality assessment be implemented in the operation of the PHCC 
system, as the opportunity to utilize the data collected on ADRs will be lost without 
proper analysis. In addition, the study found that data on therapeutic effectiveness are 
collated but not analyzed by PHCC. Therefore, it is recommended that all forms of PV 
data be used in the initiatives required to improve patient safety (156).  
In relation to human resources (i.e., CST5), HMC reported that all staff working 
at the MSQC are part-time. This implies that there is a shortage in human resources, as 
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the threshold of the required capacity to handle individual safety case reports would 
involve the number of reports received per year per designated staff (29). For PHCC, 
the study could not identify the exact number of individuals involved in the process. 
The shortcomings in data analysis and subsequent PV activities were attributed to 
technical capacity, the limited number of reports received, the limited number of expert 
human resources, and the fact that PV is still considered to be an emerging concept. 
Therefore, allocating resources to hire experts and building the current staff technical 
capacity by providing training in PV activities, namely, data analysis, data 
management, communication and feedback, and decision-making processes, are 
recommended. Addressing technical capacity can be challenging, as this issue has cost 
implications and requires access to experts who can share their experience and skills. 
Therefore, the study suggests that technical capacity building be discussed with 
universities, which could provide peer experts or theoretical education for healthcare 
professionals. The recommended IPAT threshold for individuals receiving training in 
PV is 5% per institution; inability to meet the threshold is considered a failure in the 
provision of the training required to ensure system functionality (32, 51). 
In terms of financial resources (i.e., CST4), the study found that the resources 
were sufficient. However, as there is no budget allocated for PV, the study suggests the 
allocation of an annual budget for PV and medication safety activities to avoid possible 
fluctuations in PV service provision and PV implementation (11). This is strongly 
recommended for the MSQC, given the limited amount of human capacity to handle 
PV activities, the high number of patients served, and the number of reports generated 
per year.  
The study found good system networking and collaboration between the HMC 
and PHCC systems. The systems are linked through the Cerner system, and both had 
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good communication. The study suggests that leveraging more collaborative efforts on 
PV could further improve the system through the sharing of experiences and system 
structures. On the other hand, coordination and communication with the MOPH were 
reported as an area that requires improvement. Therefore, the study suggests improving 
transparency between the public sector and the MOPH system. The improvement in 
communication between systems is essential for the effective and efficient operation of 
PV at the national and subnational levels. Without effective communication, 
collaboration opportunities can be lost, which can impede PV (1, 157). Finally, the 
development of a clear national communication strategy is recommended to improve 
transparency and avoid conflict of interest between national PV systems (40). 
Only the HMC system reported the consideration of active PV studies (i.e., 
CP9). The HMC plans to expand to include more robust active PV activities are 
promising. Ideally the optimal PV system performance would be achieved. However, 
striving for the optimal state requires time and resources. Therefore, the study 
recommends that before the introduction of advanced services, specific organizational 
challenges be identified and efforts and investment be prioritized to further improve the 
public sector systems. Finally, it is proposed that the public sector invest in the 
harmonization or standardization of active PV practices and base the standards on 
existing international standards or models. 
In conclusion, the study indicates that based on the total system performance, 
both systems can contribute to the country's PV and medication safety. Both systems 
could provide leadership, management, and operational support for the improvement of 
PV in Qatar. For instance, the MSQC could provide support for the future 
implementation of a national PV system.  
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1.4. Performance of the Private Sector Pharmacovigilance System 
The private sector involves private healthcare institutions and private 
community pharmacies. The study focused on the structure, process, and outcome 
components of the PV system.  
1.4.1. Healthcare Institutions  
For healthcare institutions, the system analysis found a degree of consistency in 
the total PV performance in the three indicator categories. Four out of five healthcare 
facilities showed a good PV system performance, indicating that PV implementation 
can be considered appropriately functional. This can be attributed to the fact that the 
sample involved had accreditation requirements to adhere to. Only one healthcare 
facility, Hospital D, achieved an average performance (49.3%), which was near the 
upper limit of average performance (i.e., 25%-49.9%).  
The satisfactory performance in structural indicators can be explained by the 
healthcare institutions’ ability to meet the PV indicator requirements, including the 
availability of a department or network of departments (although not dedicated to PV) 
to oversee PV implementation (i.e., CST1) at the organizational level; the existence of 
main PV structures, including policies and guidelines relevant to PV and related 
elements (i.e., CST2); reporting forms (i.e., CST6); advisory committees to support PV 
implementation (i.e., CST10); databases for documentation of drug-related incidents; 
feedback mechanisms; and communication tools. Nevertheless, when we examined the 
details of the systems, we found discrepancies in the implementation of PV structures. 
For instance, the available policies on medication safety and PV-related elements varied 
in the content covered and the number of policies covering aspects of medication safety. 
Only one institution, Hospital D, reported that it had no specific policies on PV or ADR 
reporting. However, due to changes in management, the hospital was in the process of 
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developing new medication management policies that would cover many aspects of 
medication safety, medication errors, ADRs, and medication quality. This indicates that 
leadership at the organizational level can have a positive influence on PV development 
and implementation. 
Differences in the type of available reporting forms (i.e., CST6) were observed. 
Hospital C had medication error reports, ADR reports, and recall reporting forms, while 
Hospital A had clinical and nonclinical incident reporting forms. Hospital B also had 
an electronic form for healthcare professionals reporting and paper-based forms for 
patient reporting. The design of the reporting form can display the level of commitment 
and the target data that the institution aims to collect. Also, it can show the effect of the 
different accreditation programs (e.g., Canadian vs American accreditation) on the 
implemented PV structures.  
Only Hospital B had a reporting form for patients; other institutions relied on 
their complaint systems to receive any concerns or comments from patients and 
caregivers. This indicates that Hospital B recognizes the public as important PV 
stakeholders and that the higher-level authorities prioritize patient safety. The study 
found that differences in financial resources influenced the implementation of 
sophisticated PV tools and methods among healthcare institutions. For instance, 
Hospital B used the Cerner system in its report management process, while other 
hospitals relied on paper-based reporting that would later be entered into the in-house 
database.  
The content of the reporting form (i.e., CST6) varied, but a common feature was 
that information relevant to counterfeit medications, therapeutic failure, and abuse and 
misuse of medications could be recorded in a free text area by the healthcare 
professionals. It is recommended that a form for medication-related incidents be 
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developed based on standards from the literature to ensure the complete and relevant 
collation of information. This is strongly recommended for institutions that have a 
general incident report form that is not specific to medications. The design of the 
reporting form is essential for effective PV operations. The quality of ADR reporting 
forms and the resulting effect on the quality of the information required for further 
analysis have been described in various countries by Bandekar et al. (79).  
Two institutions reported plans to implement an electronic report management 
system, such as the Datix system, to improve the existing reporting process (i.e., ST5 
and CST7). This study also showed that information on ADRs and other PV-related 
data can be found in electronic health records or paper-based patient files. Such data 
have been used by some institutions to ensure the completion of reporting forms before 
the report assessment process. In line with this, it is recommended that PV data be 
transcribed from patients' records and communicated to the relevant authorities at the 
organizational and national levels (11, 29).  
None of the institutions involved in the present study had a budget dedicated to 
medication safety or PV activities (i.e., CST4). The budgets were deemed sufficient for 
current operations but insufficient for the expansion of services by some key 
informants. Thus, the allocation of a dedicated annual budget for PV and medication 
safety is recommended to ensure that PV-related activities, including education, 
training, reporting tools, systems, and communication facilities, will be sustainable 
(11).  
In addition, the study found that policies relevant to medication safety and PV 
(i.e., CST2) are considered not comprehensive in coverage for the full scope of PV. For 
example, none of the healthcare institutions reported the inclusion of active PV 
initiatives; this omission was associated with the scope of services provided and the 
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belief in the relative safety of products utilized in the private sector. Consequently, it is 
recommended that awareness of the full scope of passive PV and active PV be increased 
to ensure that healthcare institutions are aware of how various sources of PV data could 
be used to improve the safe use of medicines and patient care.   
Some of the key informants reported that the scope of services and the profile 
of products can be considered relatively safe in the private sector compared to the public 
sector. Therefore, the study recommends increasing the awareness of the need for 
passive surveillance or monitoring activities for all drug products, including both high-
risk and low-risk medication. Without continuous monitoring, the occurrence of harm 
cannot be mitigated. The reason is that the occurrence of drug-related problems depends 
on many factors associated with the medical product itself and/or other factors, e.g., 
therapeutic factors and patient-specific factors (1, 11, 68, 158).  
The study found that the term PV may not be specifically employed (e.g., 
policies and training provisions may not employ the term), but the current operation of 
healthcare institutional systems covers some of the elements relevant to PV. 
Consequently, it is recommended that efforts be made to increase the visibility of PV 
and ensure that organizations will link PV directly to medication safety and optimal 
patient care. This could increase awareness at the organizational level of the PV culture 
and its importance. In addition, it will enable healthcare professionals to appreciate the 
potential value of PV in ensuring the safety and effectiveness of medications. In 
addition, it will eventually stimulate the reporting culture and interest in continuous 
vigilance (1, 29).  
The study found that pharmacy and therapeutics committees had an essential 
role in the institutions’ PV systems. The committees were responsible for supporting 
the development of internal PV activities, guiding the implementation of those 
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activities, and developing PV-related strategies at the hospital level. In the literature, 
Nwokike and Joshi identified the need to strengthen pharmacy and therapeutics 
committees in Rwanda to help improve PV in the country (99). Similarly, this study 
recommends building the technical capacity of such committee in aspects relevant to 
data management, operational procedures, and system development. It also 
recommends including PV and safety aspects in the committee terms of reference, key 
performance indicators, and contract agreement. This may help the committee ensure 
that it is meeting the objectives relevant to PV at the organizational level. Those 
recommendations apply to the departments directly involved in PV functions, such as 
pharmacy and therapeutics committees and quality improvement departments.  
For process indicators, the study found discrepancies in the details of PV 
operations across the systems. This can be attributed to discrepancies in the 
organizational structure, the available reporting systems, communication systems, 
organizational culture, resource management process and information and knowledge 
management. The aforementioned factors can influence PV implementation (159). 
However, the level of interest in medication safety, patient safety, and PV was 
determinable. The findings represent the private sector's various efforts to improve 
medication safety and the safety culture at the organizational level.   
The PV system process component performance of Hospital B might have been 
higher, but because information was not provided for some process indicators, the 
system scored lower than it might have. Furthermore, although there was a reported 
increase in the number of reports generated over time across the institutions (i.e., CP1 
and CP2), the study found that underreporting was a common challenge for the private 
sector. For instance, only Hospital D reported receiving an actual ADR report in 2018 
(i.e., CP1), while the others reported receiving reports of other types of cases. The 
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appropriate threshold for health facilities is based on the number of people served per 
facility (e.g., an institution serving 10,000 patients would require a minimum of 1 report 
per year for a satisfactory performance) (32, 51).  Further, the study found that each 
organization used different measures to address the quality of the documented reports 
(i.e., CP5). Measures included the role of the clinical pharmacist in following up and 
completing reports that had inadequate information, direct follow-up with the reporter 
to complete a report, the utilization of patient profiles to fill in missing information, and 
direct follow-up with patients when possible. Similarly, all institutions reported the 
continuous provision of training for healthcare professionals regarding medication 
safety and ADRs reporting. The quality and effectiveness of the provided training are 
not within the scope of this study. However, based on details from the interviews, the 
measures have been successful in improving reporting rates, staff awareness, and the 
positive disclosure culture.   
Many efforts from the private sector aimed at increasing reporting and 
improving the reporting culture among healthcare professionals were described. A 
comparison of the sources of the submitted reports indicates differences in the 
backgrounds of the healthcare professionals generating reports at each institution:  
I. Hospital A: most reports were sent by nursing professionals (80%), followed by 
pharmacists (15%), and medical doctors (5%). 
II. Hospital B did not provide the data required for the indicator code (P2). 
III. Hospital C reported that different types of reports were submitted by different 
healthcare professions. ADR reports were sent only by medical doctors (100%), 
while medication errors were generated by pharmacists (70%) and nurses 
(20%). The hospital reported that doctors are the custodians of patients and are 
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responsible for identifying ADRs cases; ADR reports are submitted and the 
reported details enclosed by the pharmacist in charge.  
IV. Hospital D reported that for different types of reports, the majority are generated 
by medical doctors (70%), followed by nurses (15-20%), dentists (5%) and 
pharmacists (5%). 
The study indicated that the discrepancies observed in reporting could be related to 
the organizational culture. Nevertheless, the safety culture is a shared aspect among 
healthcare professionals; therefore, it is recommended that all types of reporting be 
encouraged and that all healthcare professionals feel included. The perception that PV 
is a shared responsibility between healthcare professionals across the PV system needs 
to be improved. Additionally, the KAP (knowledge, attitude and practice) model or 
Inman’s model of the seven deadly sins of underreporting is proposed to target the 
underreporting professional categories and determine the causes of underreporting 
(160, 161). 
The procedures and methods of PV data analysis (i.e., core process indicators) 
varied between the institutions' PV systems (e.g., causality assessment, i.e., CP4). The 
study found that some hospitals adhere to a formal process of data analysis and use 
evidence-based tools, while others rely on individual or team efforts and experiences 
for an informal method of analysis. Technical capacity issues and the need for experts 
to cover the scope of data analysis were also reported by some key informants. To 
address the challenges in data analysis, systems are advised to conduct continuous 
training and educational initiatives on PV data analysis and management, ensure the 
availability of evidence-based and validated tools, invest in proper documentation 
systems, and ensure access to proper information sources and systems. For instance, 
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Hospital D reported that staff could benefit from access to better information sources 
(i.e., ST4). Accordingly, the study proposed collaboration with and support of the 
private sector from the MOPH, universities, and the Qatar National Library. These 
parties could establish an agreement to use information sources that can be helpful to 
ensure that staff are aware of and can access PV and other medication safety 
information. Additionally, the aforementioned parties can improve staff technical 
capacity by providing some healthcare professionals with training on the subject of 
information management.  
The study found that for PV outcomes, all systems showed low performance. The 
healthcare institutions reported that the collected data were based on the relevant scope 
of services provided. In addition, the study found that the private sector is not well 
equipped for signal identification and generation activities. The majority of institutions 
reported that data on signals were acquired from external sources or the MOPH system. 
The study found that Hospital A was considering developing its system to include 
research activities. It was reported that the hospital was at the foundational stage of 
establishing a research profile and had plans to collaborate with universities in Qatar to 
support research activities. In the future, the private sector can be expected to play a 
role in active PV, clinical research, and clinical trials under the following conditions: 
MOPH support, collaborative opportunities with universities and the public sector, and 
policies and guidelines mandating the collation of real-world data. 
The study found that institutions lack strategies to collate and evaluate the outcomes 
related to PV activities. For instance, it was reported that it is difficult to conduct 
economic studies owing to a lack of human resources, technical capacity, and financial 
resources as well as low interest and/or prioritization. Some institutions reported that in 
the future, a third party (e.g., the MOPH) will need to support and provide advice for 
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such activities if implemented. In addition, almost all institutions reported that such PV 
KPIs are well suited to the scope of the MOPH system. Even though the same 
challenges were reported, Hospital B stated that cost data are available in the system, 
but the number is not recorded as a value. The hospital staff document the cost of cases 
in the system as a bundle. Therefore, cost data can be extracted if desired for specific 
drugs or interventions but not for diseases or conditions. Additionally, the hospital 
conducted a cost-saving study on medications in general but has not specifically studied 
PV or safety alone. The study recommends that cost and clinical outcome data be 
collated and communicated to the MOPH to support further analysis and data utilization 
at the national level; this should be feasible, as not many cases of medicine-related 
illnesses were reported. In addition, the implementation of outcome evaluation at the 
organizational level will require prioritizing the PV KPIs that need to be implemented 
and assessed. The PV outcome evaluation will require real-world data. The collation of 
these data is a time-consuming process that will require different types of resources 
(e.g., money, expertise) (11).  
The study found that for PV KPIs, promising initiatives were mentioned that can 
assist the sectors to collate data that are relevant to the outcome and process indicators. 
It was reported that two drivers will encourage clinical coding across the country in the 
near future. First, a new national health insurance scheme is being introduced that will 
require hospitals to conduct clinical coding for every patient. Second, the Minister of 
Health has committed to an international forum that will promote clinical coding across 
the country.  
Finally, Olsson et al. recommend including the private sector in national PV 
implementation and ensuring the inclusion of quality assurance systems in accreditation 
requirements for the private sector. This will aid in developing PV systems and ensuring 
  
221 
 
the safe use of medication in the private sector (20). 
1.4.2. Community Pharmacies 
For community pharmacies, the analysis indicated that chain pharmacies and 
independent pharmacies showed discrepancies in PV system performance, showing that 
PV implementation at the community pharmacy level was not uniform. The community 
pharmacy PV system is facing many challenges that can lead to weak system 
performance. The PV system weaknesses were attributed to the lack of reporting forms 
at the national level and facility level, lack of a dedicated budget for medication safety 
and PV, lack of national training and educational interventions, and limited awareness 
of PV. However, since the WHO PV indicator checklist was designed for use at the 
national level, the performance of the chain pharmacy group can be considered 
appropriately functional (total performance 57.1%), which can be attributed to the fact 
that the pharmacy group has developed a database for medication safety data, 
encouraged the reporting of recurrent drug-related problem cases, provided training and 
educational interventions on medication safety, communicated with patients about 
medication-related problems, developed a newsletter (not specific to PV) for the 
internal communication and dissemination of information, had a dedicated staff for the 
data management process and educational interventions, collaborated in research 
efforts with QU, had access to the QU e-library, and acknowledged that PV is an 
essential aspect that it plans to implement and improve in the future. On the other hand, 
the independent pharmacy group (total performance 20.2%) reported the need for ADR 
reporting forms, educational interventions, external support for PV activities, and 
information sources as well as improved PV communication and feedback from the 
MOPH.   
The study indicated that PV is weak and not well developed at the community 
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pharmacy level. This level needs to receive more support to address the aforementioned 
challenges. PV implementation in community pharmacies is crucial since the 
community pharmacy can be the first point of contact for patients. Further, the key 
informants reported that the scope of the practice is relatively safe, as the medications 
prescribed are generally safe. However, awareness needs to be improved to sensitize 
pharmacists and pharmacy technicians to the need for continuous monitoring of over-
the-counter medications, prescription medications, and herbal medications. The 
community pharmacies can generate unique national data (e.g., herbal medication ADR 
cases), and communicating these data to the national level can improve medication 
safety and treatment outcomes. Finally, community pharmacies would benefit from 
national policies and guidelines on PV as well as a focal contact point at the national 
level (e.g., the MOPH system or a potential PV center) to facilitate medication safety 
management, improve community pharmacy contributions to PV, improve 
communication with patients on drug safety, and increase involvement in national risk 
mitigation activities (1, 11, 29). 
1.5. Performance of the Pharmaceutical Industry Pharmacovigilance System 
One of the healthcare-related companies (i.e., a pharmaceutical company) 
available in Qatar agreed to participate in this study. The assessment found that the 
overall performance of the industry PV system was 68%, indicating a good system 
performance. This finding implies that the pharmaceutical company had a functional 
PV system. In examining the details of the structure, process, and outcome indicators, 
the study found that the company met the requirements of structural indicators (91.3%, 
within the excellent range) but was unable to provide effective PV operation (45.2%, 
within the good range). PV activities, including data analysis (e.g., causality 
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assessments and signal generation), were deemed not feasible, as the company reported 
that no critical cases in relation to its products had been received. Consequently, the 
performance in the outcome domain was within the average range (58.3%); The 
company reported that internal PV actions exist, and that the company adheres to the 
regulatory requirements of external sources, e.g., the MOPH and international 
regulatory bodies. Moreover, the study found that the PV policies and risk management 
activities of the company were under the GCC guidelines. This had implications for the 
high performance in the structural indicators, as the GCC guidelines design was 
influenced by stringent regulatory authorities, e.g., the EMA (163). In addition, the 
pharmaceutical industry was the only national stakeholder to report the allocation of an 
annual budget dedicated to PV (i.e., CST4) as well as a specific PV department (i.e., 
CST1). Such adherence to stringent standards and the PV KPIs can increase the 
competency of the national pharmaceutical industry. Furthermore, the assessment 
found that the company adhered to the MOPH requirements and that the MOPH 
conducts inspections of the company system. For instance, the company changed its 
ADR reporting form based on the requirements of the MOPH; The quality of the 
reporting form was not assessed, as the ADR reporting form was not shared, and the 
quality of the report design is outside the scope of this study. 
The study indicates that in the absence of national PV guidelines and policies, 
the pharmaceutical industry involvement in national PV and medication safety 
activities, as well as the implementation of risk management activities and plans, will 
remain limited. Without national PV regulations, the potential role of the 
pharmaceutical industry in improving medication safety, quality, and effectiveness, as 
well as patient safety, may be inadequate. The scope of the pharmaceutical industry is 
more profit-driven; therefore, without formal structures and a national PV center in 
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place to ensure its optimal engagement in PV, future issues with national drug products 
and conflict of interest may arise (29). 
1.6. Pharmacovigilance Implementation in Mental Health Strategy 
One of the healthcare-related programs and organizations (i.e., MHS) available 
in Qatar agreed to participate. The system assessment found that the MHS produces the 
“National Mental Health Strategy Impact Evaluation 2015” (162), a document with 
specific sections on medication safety. This indicates that the MHS recognizes the 
importance of medication safety in the operation of the organization. However, the 
MHS reported a lack of the PV tools required for data collection (i.e., ADR reports) 
and data management (i.e., database). Even with the lack of these required tools, the 
MHS reported efforts to analyze data and share them with national stakeholders. Also, 
the MHS processes information from external sources and has audits for monitoring 
purposes. This shows the level of commitment of the MHS to ensuring medication 
safety. Moreover, it has a positive implications for improving the communication 
profile on the subjects of medication safety and PV across the stakeholder system. In 
the future, collaborative and coordinated PV activities to target specific drugs or groups 
could be exploited. 
The MHS reported that at the national level, there is a need for a standardized 
reporting form. This indicates that a common key PV challenge is that the process of 
reporting is not centralized in the MOPH or at the national level. The study proposes 
that a centralized PV system can offer a visible focal point for national stakeholders to 
coordinate PV activities. In addition, the study suggests that the lack of national policies 
and guidelines on PV may limit the MHS capacity and commitment to implement PV 
activities at the organizational level as well as with other stakeholder systems. For 
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instance, the capacity to collect data and use it in risk mitigation activities or signal 
generation was limited. Hence, legal documents defining the roles and responsibilities 
of various stakeholders in PV can be of value to improve patient safety and medication 
safety across the healthcare system. 
1.7. Pharmacovigilance Implementation at the Higher Academic Institutions  
The main purpose was to research the level of PV inclusion in educational 
programs in Qatar within the university curricula of medical doctors, pharmacists, 
nurses, pharmacy technicians, and health scientists (i.e., CST8). The study found that 
basic elements relevant to medication safety and PV, such as spontaneous reporting, 
have been implemented in all programs except that of QU College of Health Sciences, 
as PV is not included in the curriculum. Hence, the study recommends including the 
concepts of PV and ecopharmacovigilance in College of Health Sciences courses. In 
addition, the number of credit hours devoted to PV teaching across different programs 
was 2 credit hours or less over the years of the programs. Not all the key informants 
reported the number of credit hours, as the curriculum may not employ the specific term 
PV, but elements related to PV were included in the courses. The key informants also 
reported that the capacity of students to conduct data evaluation (e.g., causality 
assessment) can be very limited. This indicates that the level of commitment and the 
time committed to PV teaching for undergraduate and postgraduate degree courses 
might be inadequate. Contemplating the importance of PV in the safe use of 
medications and optimal patient care, the study recommends that more time could be 
dedicated to PV in healthcare and health-related science courses. In doing so, 
undergraduates and graduates can become better informed on the potential role of PV, 
including its role in ensuring medication safety and protecting public health, which will 
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help improve PV implementation in the country, e.g., by increasing ADR reporting. 
Recently, the WHO developed a PV core curriculum for universities to follow that 
includes a set of essential PV components and competencies for students. The WHO 
PV curriculum can be integrated or offered as a separate course (163). 
Academic universities can play a substantial role in PV (29). The study indicates 
that many untapped resources exist, including training capacity, research capacity, 
student participation, PV expertise, technical resources, and financial resources. Some 
key informants also reported that the universities could contribute directly through 
hosting a national PV center or closely collaborating with the national PV center when 
established. Potential collaboration at the national level through the provision of 
training or research opportunities was reported. This implies that without a PV system 
and structures in place, the contribution of universities to PV may be limited. In 
addition, effective engagement could aid the country in building internal capacity for 
PV to help secure PV sustainability. Finally, the study suggests that establishing a PV 
center (with membership status in the WHO PIDM) at a university would help the 
country to improve the current PV situation and enhance the reputation of its national 
educational programs at the global level (e.g. accreditation of national educational 
programs). 
The study found that the communication gap in PV can contribute to the limited 
awareness of ongoing PV and medication safety research activities on the premises of 
universities, as there is no structured process in place to communicate this information 
to regulatory bodies or other national stakeholders. Therefore, communication can be 
improved to help PV stakeholders explore the opportunities available for effective 
coordination, resource sharing, information sharing, and the effective division of PV 
responsibility at the national level. In doing so, PV can have a greater impact on public 
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health and reducing drug-related harm as final outcomes (1). 
2. Future Direction Based on the Research Findings 
2.1. Future Work  
The recommendations and future work based on the WHO framework were 
discussed in detail in the results chapter (key informants’ perspective) and discussion 
chapter (researcher’s and key informants’ perspectives). This study highlights the 
challenges, strengths, and opportunities available for PV advancement. It recommends 
addressing the challenges and implementing the recommendations to improve PV in 
Qatar. The study proposes that the WHO PV indicators can be used to generate many 
potential strategies, studies, and activities that can be applied at the national level and 
the stakeholders’ system levels. However, policymakers and administrative authorities 
are advised to prioritize based on the influence of a specific challenge or aspect on the 
PV system to implement corrective actions and/or improvement measures. This would 
involve identifying robust methodologies and consulting experts in the field. 
Furthermore, identifying the challenges to be addressed should follow a system-based 
approach. For instance, technical capacity has been mentioned as a challenge affecting 
various stakeholders' PV systems in terms of the structure, process, and outcome 
domains; therefore, it should be a high priority. The prioritization and the evaluation of 
challenges and their impact on the PV system as well as the healthcare system require 
real-world data that are specific to the organizational level or the country. This process 
must be executed carefully, as the collation of these data is a time-consuming process 
that will require different types of resources (e.g., money, expertise) (11). If not well 
planned and executed, it may lead to failure and the waste of valuable resources.  
Moreover, it is recommended that a study utilizing the WHO methodology be 
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conducted on a larger scale to include the stakeholders that were not covered in the 
present research, for instance, medical centers, MAHs and drug representatives, 
medical device companies, patient organizations, and external actors such as the WHO 
and UMC. This study can be conducted by the MOPH to increase the number of the 
sample representing the country. Email surveys can be sent to national stakeholders, 
one covering the WHO PV indicators and another to identify the barriers and 
opportunities of effective PV in Qatar. This assessment can collect data for the WHO 
PV background information indicators to allow calculation and comparison. In 
addition, a PV system evaluation could be performed every 3 or 5 years to monitor the 
country's PV development (11). 
In addition, the use of the PG framework is proposed for a better understanding 
of the factors enabling PV in the country. This framework allows a qualitative 
assessment of the PV system and PG, including the influence of stakeholders operating 
in the system. The framework suggests that a good PG can enable PV in the country 
(102). The use of the framework is feasible, as the current study obtained ethical 
approval to use the PG framework, but due to the limited number of participants 
agreeing to use it, the PG framework findings were not included. Only the private sector 
stakeholders agreed to utilize the PG framework to give recommendations at the 
country level.  
Below are some examples of areas to be explored in Qatar and possibly in other 
countries, guided by the WHO PV indicator manual and the study findings: 
I. Use the WHO PV indicators to assess the PV system in relation to vaccines, 
herbal products, and medical devices in Qatar. 
II. Conduct a study evaluating the design, understandability, and implementation 
of policies relevant to PV, for instance, the healthcare professionals’ level of 
  
229 
 
comprehension of the available organizational PV policies and the effect on 
their PV practices e.g., ADRs reporting. 
III. Conduct a study evaluating the design of the ADR form and its impact on the 
data quality and reporting rate.  
IV. Assess the public perception of PV and ADR reporting. 
V. Understand the causes of underreporting among healthcare professionals. Use 
the KAP model or Inman’s model of the seven deadly sins of underreporting to 
determine the incidence of ADRs and other drug-related problems in various 
service delivery settings, e.g., emergency settings. 
VI. Conduct economic studies to evaluate the impact of ADRs on the system, e.g., 
the HMC system. 
VII. Study the impact of the planned projects (e.g., the national e-reporting system, 
e-health strategy) (141) in the MOPH environment in relation to professional 
staff views, training preparation, and professional qualification attainment. 
VIII. Research the elements that determine highly qualified PV professionals in 
employment assessments set by organizations (e.g., the elements that determine 
a highly qualified PV professional in employment tests set by the human 
resources departments). 
IX. Address the absence of a professional health court, including the causes and the 
need for such an entity. This can apply to a drug information center as well.  
X. Investigate healthcare students’ perceptions, views, willingness, and readiness 
to be involved in PV activities at the national level. 
XI. Understand the role of health insurance companies in the safe use of medicines, 
PV, prescribing patterns, and polypharmacy. This can help clarify the impact of 
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insurance companies on private sector practices in relation to PV and 
medication safety. 
Further, the value chain analysis, the 5 whys method, and the Fishbone diagrams 
are recommended for a better understanding of the root causes of the reported 
challenges faced at each stakeholder level as well as the national level. This may help 
improve our understanding of the PV system challenges at the strategic level and help 
identify solutions at the operational level. Moreover, it is recommended that national 
PV stakeholders discuss conducting a feasibility study on establishing a national PV 
center, including barriers to its implementation. Initial steps can be taken through the 
use of focus groups method and the 5W2H method (159). 
2.2. Proposal for Pharmacovigilance Center Organizational Structure 
This solution (i.e., a national PV center) is proposed because the Qatari health 
care system is expected to experience rapid growth (54); therefore, the healthcare 
system and pharmaceutical system will require stronger control over the market. The 
proposed PV center (Figure 19) will serve to enable this control by relying on the 
proposed sections that should have a clear and documented division of duties and 
depend on a high level of scalability. Refer to Appendix C for details of the 
organizational structure departments and sections.
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Figure 19. Organized pharmacovigilance center organizational structure 
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3. Strengths and Limitations of the Study 
3.1. Strengths 
I. This is the first study to assess the PV and medication safety system in Qatar 
following a comprehensive system-based approach. The study undertook the 
system evaluation using MMR. 
II. The quantitative part and qualitative part were used for convergence, conformation, 
and triangulation purposes. The two parts provided a complementary picture of the 
PV situation in Qatar. 
III. The quantitative data permitted the characterization and visualization of the 
performance of the national and subnational systems to understand the PV system 
capacities at each level as well as the comparison of national PV subsystem 
capacities.  
IV. The qualitative data provided an in-depth understanding of the views and 
perceptions of national PV stakeholders who operate in the Qatari healthcare 
system. 
V. The study was able to fulfill its intended main aim and objectives. The findings 
highlighted the baseline PV situation and the complexity of the PV landscape across 
the national subsystem as well as the national system level. 
VI. The MMR allowed us to obtain an in-depth understanding of the current PV 
scenario using various internationally recognized tools and research procedures, 
including the WHO PV indicators, the minimum requirements of the WHO for a 
functional PV system, and the input of national PV stakeholders.  
VII. A scoring system was developed to allow the quantitative information to be clearly 
presented. This allowed us to compare the PV system performance status to the 
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WHO PV indicator requirements as well as between national stakeholders' PV 
systems.  
VIII. The qualitative approach allowed us to address the limitations inherent to the WHO 
PV indicators.  
IX. To our knowledge, this is the first MMR in the MENA region to cover the full WHO 
PV indicator manual, including the three indicator domains, structure, processes, 
and outcomes, as well as the main core and complementary indicator categories.  
X. The study involved various levels of the healthcare system, e.g., regulatory bodies, 
the private sector, the public sector, universities, the pharmaceutical industry, and 
healthcare-related organizations. This multistakeholder involvement allowed us to 
understand the PV challenges from different points of view and system 
perspectives. 
XI. A major strength is the analysis of strengths, weaknesses, and opportunities as well 
as the formulation of recommendations based on the key informants’ perspectives 
as well as the researcher's perspective. This approach aided in the generation of 
feasible recommendations and potential solutions to be implemented in Qatar. 
XII. The study is in alignment with current national efforts to improve medication safety 
and patient safety, as outlined in the National Health Strategy (54), the PHCC 
Strategy (164), the establishment of the new MSQC in HMC, and the MOPH 
initiatives to improve the awareness of the safe use of medications and patient care 
in Qatar Patient Safety Week (165).  
XIII. A PV system assessment conceptual framework was developed to guide the study 
and to provide a model for the future implementation of a PV center. It outlines the 
components of the system, factors influencing the system, and the final objectives 
of the PV system. 
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XIV. A PV center organizational structure and project idea report (terms of reference) for 
the center were developed. This could aid policymakers as a model for the 
development of a centralized national PV system in Qatar. 
XV. The study includes the pharmaceutical industry as a main PV stakeholder in the 
assessment and inquired about traditional medicine during the interviews per the 
qualitative part of this MMR. The reason is that the literature on the WHO PV 
indicators has reported that collecting details on the industry and traditional medical 
practices is required for a complete system assessment (18).  
XVI. The study followed a systematic approach and a specific sequence that was used for 
all the subnational systems from the planning stage to the end of the data collection 
process. The reason is that the literature on the WHO PV indicators has noted that 
it may be necessary to position the PV KPIs across the subnational PV systems 
following a harmonized and appropriate process to ensure the ability to conduct a 
comparative analysis and to successfully generate and exchange data (18).  
XVII. In addition, approvals were obtained from all the applicable ethics committees; the 
higher authority at each site was approached, and the QU College of Pharmacy was 
approached to provide a support letter. In doing so, the study gained more official 
ground to conduct interviews with national stakeholders. This is according to the 
WHO remark that the successful implementation of the WHO PV indicators and 
the collection of all required data will depend largely on the respondents providing 
full support during the process of data collection.  
XVIII. The scoring system used allowed us to make an assessment based on the observed 
and reported levels of compliance of the stakeholder PV system with the WHO PV 
framework. This was useful in cases where no proof of evidence on the availability 
of the confirmed subject activity was provided or when certain stakeholders 
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reported that following the WHO PV indicator checklist might reflect an unfair 
assessment score that could affect or provide an incomplete picture of the 
stakeholder system performance regarding compliance with the WHO requirements 
(166). 
XIX. The outcomes of this research include 1) a comprehensive analysis of the Qatar PV 
system; 2) a published systematic scoping review paper titled “A Systematic 
Scoping Review of the State of Pharmacovigilance and Governance in the MENA 
Region: Challenges and Opportunities”; and 3) a potential in-hand paper for 
publication titled “Evaluation of the Pharmacovigilance System in Qatar: A Mixed 
Method Study on Structure, Process and Outcome.” 
3.2. Limitations and Measures to Limit Influences 
3.2.1. Limitations Inherent to the WHO PV Indicators 
For each indicator, a specified limitation is mentioned in the WHO PV manual (11). 
For instance, the structural indicators are limited in their ability to capture full details of the 
actual spectrum of structures within a system since the response is dichotomous, 
qualitatively indicating the existence or absence of a specific measure. This limitation was 
addressed with follow-up questions to understand the situation in a more comprehensive 
manner. 
In this research, a simple scoring scheme was developed to address the PV indicator 
limitations (i.e., no scoring scheme). However, the study did not include official testing of 
the scoring system reliability (i.e., it relied on discussion with an expert only). Notably, the 
WHO foresees the opportunity to develop a scoring scheme for the PV KPIs.  
Outcome indicators usually require official studies with standard protocols or 
depend heavily on data with a level of granularity. This limitation was difficult to address; 
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therefore, we depended on the stakeholders’ ability to provide such data.  
3.2.2. Limitations Inherent to the Study 
3.2.2.1. Response Bias 
In this study, bias could occur when the selected sample reported data to please the 
interviewer. For instance, the sample might have reported compliance with the WHO 
indicators because it was convenient and pleased the interviewer. This is especially an issue 
when the stakeholders perceive that a negative response might have consequences or affect 
the reputation of their system (167). In addition, bias can occur in circumstances where the 
interviews include up to 7 key informants from the same data collection site; some 
individuals might provide answers that are favored by the other key informants even if they 
had a different opinion. Therefore, the participants were assured that their responses would 
be anonymous to reduce the occurrence of this issue, and when the participants requested 
that recording be stopped, this request was fulfilled. 
In this research, response bias was difficult to control. However, some measures 
were applied to minimize this issue. First, for data triangulation, the national stakeholders 
showed the title pages of current policies or documents and the numbers or values available 
in databases or reports noting that PV-related elements are available in addition to 
participating in the semistructured interviews. Second, the nature of this research in 
involving more than one key informant at each data collection level ensured that the 
responses were agreed upon by more than one key informant. Third, the literature was 
searched for proof of evidence, and further investigations were made through second visits 
or sending emails with the transcripts of the interviews and/or the PV indicator checklist 
itself to request further clarifications. Fourth, when there was no proof of evidence, the 
scoring system allowed including the response “yes, partially satisfactory performance”. 
Fifth, the initial key informant or the higher authority at the study site was responsible for 
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the allocation of potential candidates; therefore, the credibility of the sources in 
representing the data site was high. Sixth and finally, the qualitative component helped to 
elaborate the minor details for each study site to show the actual performance of the 
subnational systems for each indicator.  
3.2.2.2. Generalizability 
According to Yin, the case study as a design can have some form of generalizability 
when researchers use case study results to form a broader theory. However, generalizability 
is not the aim of this study. The coverage of this study of many sites aimed to give a 
indications about the current PV situation within Qatar, but the findings cannot be 
generalized. 
For this study, selection bias might have occurred, as the sample might have 
included stakeholders with more robust PV implementation. However, the study used 
multiple case studies following the same methodological steps. In addition, the samples 
were selected based on a prioritized list of the main PV stakeholders. For example, the 
MOPH is the regulatory body; HMC is the main public health services provider; PHCC is 
the main primary care provider; the private hospitals that were included were reputable and 
accredited; the academic institutions involved were all institutions with relevance to 
healthcare and PV; and the pharmaceutical industry was involved. 
For the private sector, the sample can affect the generalizability of findings to the 
Qatar context, as institutions with lower capacities (e.g., medical centers) can have different 
PV system implementation. However, it is important to note that some stakeholders with 
lower PV system implementation were approached, but they declined to participate due to 
their inability to meet the standards required by the WHO framework. This was declared 
by an email from one hospital (indicating that the PV and medication safety department or 
unit was in the process of establishment and the hospital could not participate in the current 
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state), verbal feedback during a face-to-face meeting (indicating that the institution had not 
received ADR reports), and phone conversation with a hospital and private sector 
pharmacies. Other potential stakeholders did not respond to emails even after the initial 
visit of recruitment. 
3.2.2.3. The Validity of the Interview Scripts 
Not all interview scripts were checked to ensure their validity. The study key 
informants were informed that they would be able to validate the findings at their level, so 
the key informants were involved in the process based on their preference. Some, e.g., 
HMC, requested the full interview script; others, e.g., a private health organization, 
requested tabulated results; and others requested a final report and discussion to validate 
the findings. For example, the MOPH requested a one-hour meeting and an 8-page report 
discussing the findings; this meeting involved the primary supervisor and covered the 
MOPH case as well as the country PV scenario. Other stakeholders did not request any 
results, so no measures were taken. 
3.2.2.4. Other Practical Limitations 
I. Discrepancies in awareness of PV science among some stakeholders. This may have 
led to an arbitrary interpretation of the indicator requirements.  
II. Difficulties encountered with high-level participant recruitment. 
III. Difficulties in the process of interview organization (e.g., time consuming, 
organizational reasons or issues). 
IV. Limitations in the interview process (e.g., inadequate interview time allocated, level 
of information provided). 
V. Limitations related to participants (e.g., data provision, recall reliability, 
representation, and follow-up). 
  
239 
 
VI. Lack of reliable data sources and information for some PV KPIs (i.e., estimations 
were provided). 
VII. Missing values and issues in follow-up (several stakeholders did not respond to 
emails requesting missing values for some PV KPIs). 
VIII. Ethical approval delay (it took more than 7 months from the application date to 
obtain the HMC-MRC approval). 
IX. Organizational issues related to participation and resistance to data sharing. 
4. Recommendations  
“What are the most important measures to improve the pharmacovigilance system 
in Qatar based on the WHO PV framework?” This question will be answered in the form 
of recommendations based on the structure, process, and outcome indicators:  
4.1. Structure 
I. The visibility of PV could be increased by establishing an independent national PV 
center to monitor the safety, effectiveness, and quality of medication in the country. 
II. The PV center could be chaired by a PV expert capable of aiding the MOPH to 
produce high-quality, sufficient, and relevant data on medication safety and PV. 
Members of the PV center will need to have multidisciplinary backgrounds in order 
to achieve the desired PV goals. 
III. There is a need to strengthen the PV regulatory framework and mechanisms in the 
country. It is advisable to identify and fill any gaps in the current laws and policies 
and ensure that they comply with the minimum functionality standards of PV 
systems. This should include the development, implementation, and enforcement of 
PV-specific legislation and a national medicine policy.  
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IV. Benchmark countries (e.g., the UK) and international PV regulations can be used 
as models for the development of the regulatory framework and the PV center. For 
instance, if feasible at the MENA region level, the Morocco PV system could be 
used as a benchmark.  
V. Strategies aimed at streaming spontaneous reporting could be developed and 
implemented. They could include but are not limited to establishing a national 
database, developing national reporting forms, ensuring access to forms, providing 
various forms of incentives, protecting the rights of healthcare professionals and 
reporters in general, and safeguarding the ethical aspects. 
VI. A specific committee or a focal contact point at each health institution could be 
implemented. This team or individual should be accountable for PV and drug safety 
at the institutional level e.g., a drug and therapeutics committee. 
VII. Special technical tools, e.g., tools for data mining and signal generation, could be 
introduced for data analysis in future electronic databases.  
VIII. The MOPH could establish a national PV committee as a solution to monitor drug 
safety and coordinate with representatives from various stakeholder systems until a 
specific center is established. This committee should have clear mandates that cover 
all aspects of PV. This committee along with the PV center establishment could 
optimize the interaction between stakeholders. 
IX. A specific communication and transparency strategy could be developed to ensure 
that all parties (e.g., the public, academic institutions) are involved in the field of 
PV. This strategy needs to cover routine and crisis communication.  
X. Resource acquisition (monetary and nonmonetary) for PV needs to be improved to 
ensure sustainable funding for PV. In addition, PV resource allocation needs to be 
strategically executed to ensure equity. Finally, PV resource accumulation must be 
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a priority at the managerial and administrative level across the country to ensure 
effective capacity building.  
XI. Adequate inclusion of PV in educational programs must be a national priority to 
ensure the development of internal capacities. 
XII. PV implementation in specific healthcare programs and organizations is strongly 
recommended. This can ensure the collation of PV data for specific populations, 
e.g., mental health and diabetes patients.  
XIII. The pharmaceutical industry should be vigorously involved in PV to ensure 
effective national drug product monitoring. Also, medical device vigilance is 
required to ensure optimal monitoring of healthcare-related products. 
XIV. Risk mitigation systems need to be developed and/or improved. 
XV. Future strategies should be developed to plan and implement studies and activities 
that cover active PV aspects. 
XVI. The visibility of the general public as key stakeholders in PV should be improved; 
this can include increasing the awareness of the public about PV as well as 
implementing public reporting.  
XVII. Public reporting could be incorporated into the MyHealth patient portal (168).  
XVIII. A drug information center or a drug information service could be established at the 
national level. This could be part of the PV center to reduce the cost and other 
resource implications. It is also recommended for the PV and drug information 
center to collaborate with the Qatar Poison Centre.  
XIX. Strengthen the PV at the healthcare delivery level e.g., strengthen the drug and 
therapeutics committees. 
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4.2. Process 
I. It is crucial to ensure strong links between the MOPH and other stakeholders 
through a mutually beneficial and participatory relationship. 
II. Undergraduate and graduate students at different higher education institutions could 
be utilized to carry out some of the activities or studies for the MOPH system in 
relation to PV and drug safety issues. This would benefit them with hands-on 
experience and learning opportunities. 
III. Continuous education and in-service training should be provided for healthcare 
professionals of different backgrounds. 
IV. It is recommended that the MOPH review the relative contribution of different data 
sources (e.g., spontaneous reporting, medication-related studies, PSUR) to national 
drug safety information.  
V. New methods, e.g., the use of information technology, are needed to address the 
issues of PV in a proactive manner. 
VI. The current decision-making process at each level needs to be reviewed and shared 
in a more transparent manner to improve the process with respect to quality, 
effectiveness, time frame, and economics. 
VII. Consider the feasibility of including higher educational institutions (one institution 
or more) in advanced studies for drug monitoring e.g., intensive drug monitoring. 
VIII. Stakeholders are encouraged to review and improve the current methodologies used 
for risk mitigation activities, PV data analysis and management activities, and 
benefit/risk analysis. 
IX. More awareness of the basic principles of PV systems, quality management 
systems, and risk management systems is necessary. The principles need to be 
understood at the administrative and practical levels.  
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X. Stakeholders need to set “SMART goals” for some PV KPIs in the future; those 
targets can be monitored regularly to continuously improve the capacity of the 
systems. 
XI. The social media promotion and sale of medications need to be monitored by the 
relevant regulatory bodies.  
4.3. Outcome 
I. There is a need to utilize statistical methods and data analysis procedures to analyze 
the current healthcare system with respect to PV and drug safety outcome 
monitoring and/or evaluation. This includes reporting trends and the impact of PV 
activities on the financial outcomes as well as clinical outcomes. 
II. The evaluation of the outcomes of PV warrants further investment (e.g., technical 
capacity, resources allocation, regulatory policies) at the national level since 
emerging safety information is needed.  
III. Utilize PV data on health planning to optimize the utilization of national resources. 
IV. Utilize PV data on auditing of PV targets and measuring the effectiveness of 
interventions to optimize patient care as well as the quality of services, regulatory 
framework, structures, and systems in general. 
V. Systematically review and improve decision making process, regulatory actions and 
PV communication. 
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5. Conclusions 
This mixed-methods research provides an in-depth understanding of the baseline 
pharmacovigilance (PV) situation in the state of Qatar through a comprehensive PV system 
assessment using internationally recognized tools developed by the World Health 
Organization (WHO). According to the WHO minimum requirements for a functional 
system, Qatar has none of the 5 elements required for an operational PV system. 
Consequently, the regulatory body for the PV system (the MOPH) achieved a weak total 
PV system performance status, which can impede the MOPH role in providing leadership 
for PV implementation. The main challenges faced by the MOPH are the lack of an 
organized PV center, lack of PV-specific statutory provisions to implement and enforce PV 
in Qatar, and limitations to communication and coordination with national stakeholders. 
The public sector (i.e., HMC and PHCC) achieved a good total PV system performance, 
signifying its important role in PV implementation. Similarly, most private sector 
healthcare institutions had a good total PV system performance, indicating that PV 
implementation in that sector can be considered appropriate. Gaps for both sectors were 
related to shortfalls in the technical capacity required for PV data analysis, including risk 
management and signal generation, the underreporting problem and lack of awareness of 
PV among the healthcare professionals, and communication gaps with national 
stakeholders. Moreover, the pharmaceutical industry PV system had a good total system 
performance. However, without national PV legislation, the potential role of the 
pharmaceutical industry in improving PV can be inadequate.  
The national PV systems assessed across the different levels of the health care 
system showed discrepancies in PV system performance. National stakeholders' interest in 
PV was in the form of fragmented efforts aimed at improving PV in Qatar. The overall 
performance of the country, if addressed properly following a system-based approach, is 
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expected to result in the successful implementation of PV within the healthcare system. In 
addition, it is recommended that policymakers and administrative authorities prioritize 
challenges or specific aspects based on their influence on their PV system to implement 
corrective actions and/or improvement measures. To improve the national PV scenario and 
achieve the best possible PV system performance, the following steps must be taken. First, 
strengthen the PV regulatory framework, e.g., develop PV specific statutory provision. 
Second, establish an organized national PV center following benchmark countries, e.g., 
Morocco, as a model. Third, implement strategies to streamline spontaneous reporting, e.g., 
develop a national reporting system. Fourth, strategically execute resource acquisition, 
resource allocation, and resource accumulation for PV to ensure sustainability, equity, and 
effective capacity building. Fifth, develop a specific communication strategy to ensure 
strong links between the MOPH and other stakeholders. Sixth, improve the current 
methodologies used for risk mitigation activities, PV data analysis, and data management 
activities. Seventh, ensure the development of internal capacities through the adequate 
inclusion of PV in educational systems. Finally, implement active PV activities through 
multisectoral collaboration, e.g., among academia, research centers, and the MOPH. The 
outcomes of this research can potentially serve to target the challenges and utilize the 
available opportunities to help improve the current PV situation and ensure effective system 
performance and adequacy. Future investigations can focus on aspects relating to the 
governance of the PV system and the feasibility of establishing the proposed PV center 
organizational structure. 
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APPENDIX A: METHODOLOGY CHAPTER RELATED CONTENT  
M1. Qatar University ethical related documents:  
1. QU-IRB research ethics approval (No. QU-IRB 826-E/17). 
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2. QU- College of Pharmacy Support Letter.  
 
 
3. QU- IRB approved consent form. 
Refer to the PHCC consent form.  
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M2. Primary Healthcare Corporation (PHCC) ethical related documents: 
1.  PHCC Ethics Committee research ethics approval (first page only). 
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2. PHCC consent form (first two pages only). 
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3. PHCC participant information sheet (first page only). 
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M3. Hamad Medical Corporation (HMC) ethical related documents: 
1. The Medical Research Center at HMC approval.  
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2. HMC Consent form (first two pages only). 
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M4: Email and hard copy invitation letter. 
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M5. Data Collection instrument 1: The World Health Organization 
pharmacovigilance indicators ready-to-use checklist.
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M6: PV indicators used at each data collection level. 
Table M6: PV indicators used at each data collection level. 
Table: PV indicators used at each data collection level. 
Stakeholder level  Relevant indicators  Not relevant indicators  
Regulatory body system 
level (MOPH) 
 
Core: 
(structure): 1-10 relevant 
(process) 1-9 relevant 
(outcome)1-8 relevant 
 
 
Complementary: 
(structure) 1-11 relevant 
(process) 1-4,7-13 relevant 
(outcome) 1-4,7-8 relevant  
 
Complementary: 
(process) 5-6 not relevant 
(outcome) 5-6,9-12 not 
relevant 
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Public sector level (HMC)  
Core: 
(structure): 1-2, 4-7,9-10 
relevant 
(process): 1-7,9 relevant 
(outcome): 2,3-4,6-8 
relevant 
 
Core: 
(structures): 3,8 not 
relevant 
(process): 8 not relevant 
(outcome): 2,5 not relevant 
 
Complementary: 
(structure): 1-5,7-10 
relevant (process): 2,4-8 
relevant (outcome): 1,9-12 
relevant  
 
Complementary: 
(structures): 6,11 not 
relevant (process): 1,3,9-13 
not relevant 
(outcome): 2-8 not relevant  
Public sector level (PHCC) 
Core: 
(structure): 1-2,4-7,9-10 
relevant 
(process): 1-7,9 relevant                                        
(outcome):1 relevant  
 
Core: 
(Structure): 3,8 not relevant 
(process): 8 not relevant 
(outcome):2-8 not relevant 
 
Complementary: 
(structure):1-5,7-10 
relevant                                         
(process):2,4-8 relevant                                          
(outcome): 1,9-12 relevant 
 
Complementary: 
(structure):6,11 not 
relevant                           
(process):1,3,9-13 not 
relevant                           
(outcome): 2-8 not relevant  
Private sector level (Health 
institutions) 
 
Core  
(structure):1-2,4-7,9-10 
relevant  
(process):1-7,9 relevant 
(outcome):1,3-4,6-8 
relevant  
 
Core  
(structure): 3,8 not relevant                                       
(process): 8 not relevant                                         
(outcome):2,5 not relevant 
 
 
Complementary 
(structure):1-5,7-10 
relevant                                               
(process): 2,4-8 relevant                                                
(outcome):1,5-12 relevant  
 
Complementary 
(structure): 6,11 not 
relevant                                        
(process): 1,3,9-13 not 
relevant                              
(outcome): 2-4 not relevant 
Private sector level 
(pharmacies) 
 
Core  
(structure):1-2,4-7,9-10 
relevant                                           
(process):1-3,5 relevant                                             
(outcome):All not relevant 
 
Core  
(structure): 3,8 not relevant                                           
(process): 4,6-9 not 
relevant                      
(outcome):All not relevant 
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Complementary  
(structure):1-5,9-10 
relevant                                         
(process):5-8 relevant                                          
(outcome):1,7-12 relevant  
 
 
Complementary  
(structure):6-8,11 not 
relevant                                        
(process):1-4,9-13 not 
relevant                                         
(outcome):2-6 not relevant  
Pharmaceutical industry  
Core  
(structure):1-2,4-7.9-10 
relevant 
(process):1-5,8-9 relevant 
(outcome):1-2 relevant   
 
Core  
(structure):3,8 not relevant 
(Process):6-7 not relevant 
(outcome):3-8 not relevant 
 
 
Complementary 
(structure):1,3-6,9-10 
relevant 
(process):2,4,7-8,10-12 
relevant 
(outcome):7-8 relevant  
 
Complementary 
(Structure):2,7-8,11 not 
relevant 
(process):1,3,5-6,9,13 not 
relevant  
(outcome):1-6,9-12 not 
relevant  
Academic institutions  CST8 
 
M7: A List of Stakeholders who were approached but did not agree to participate. 
I. Private hospital: refused to participate by email as they do not have a 
pharmacovigilance or medication safety unit at that time.  
II. Private hospital: refused to participate as they said that they are busy with 
renewing the license.  
III. Private hospital: did not want to participate in a face to face interview they wanted 
by email thus I did not include them. 
IV. Chain pharmacy group: did not agree or disagree to participate. I have sent emails 
and contacted them through phone communication, but they did not arrange a 
final meeting.  
V. Chain pharmacy group: did not agree or disagree to participate I have sent emails 
for 4 people and contacted them through phone, but they did not reply to arrange a 
final meeting.  
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VI. Qatar Diabetes Association: refused to participate through verbal communication 
as they do not have pharmacovigilance related activities e.g. ADRs report 
collection. 
VII. National Cancer Strategy: did not respond to emails.  
VIII. National Diabetes Strategy: did not agree or disagree to participate. I have sent 
emails, but they did not arrange a final meeting. 
IX. Pharmaceutical industry: did not respond to emails or phone calls. 
 
M8. Stakeholder level enrolment and meeting details. 
Table M8. Stakeholder level enrolment and meeting details 
Stakeholder level Ethical 
approval 
First 
approached 
(emails and 
site visit) 
Meeting details  
Ministry of Public Health 
(MOPH):  
• The Department of 
Pharmacy and Drug 
Control 
• The Department of Quality 
and Patient Safety (HQPS)  
QU-IRB November 
2017 
Five meetings  
2/2018 to 6/2018 
Primary Healthcare Corporation 
(PHCC): 
• Medication Management 
Section 
• Risk management section 
• Clinical Information 
Systems team 
• Health Information 
Management team 
PHCC 
Ethics 
committee  
December 
2017 
Two meetings  
• 2/2018 
• 5/2018 
Hamad Medical Corporation 
(HMC):  
• Medication Safety and 
Quality Center (MSQC)  
• HMC Pharmacy 
Department 
HMC-
MRC 
May 2018 Five meetings, from 
6/2018 to 6/2019 
Academia universities: 6 
universities and/or colleges  
QU-IRB November 
2017 
One meeting for 
each university, 
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Stakeholder level Ethical 
approval 
First 
approached 
(emails and 
site visit) 
Meeting details  
from 1/2018 to 
5/2018 
Mental Health Strategy QU-IRB November 
2017 
One meeting, 
5/2018 
Pharmaceutical industry  QU-IRB November 
2017 
Two meetings, 
5/2018 
The private sector, a total of five 
health facilities: 
• Three private hospitals  
• One semi-governmental 
hospital  
• One private healthcare 
group 
QU-IRB 
and 
Hospital 
Ethics 
approval 
when 
applicable 
November 
2017- 
December 
2017 
• Hospital: one 
meeting, 3/2018 
• Hospital: five 
meetings, 
1/2018 
• Hospital: three 
meetings, 
4/2018 
• Hospital: four 
meetings, 
4/2019 
• Hospital: four 
meetings, 
5/2019 
Community pharmacy, a total of 
two: 
• One independent 
pharmacy (24 hours 
service delivery) 
• One chain of pharmacies   
QU-IRB November 
2017 
• Chain pharmacy 
one meeting, 
5/2018 
• Independent 
pharmacy one 
meeting, 4/2018 
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M9. Data collection instrument 2: Semi-structured interview protocol (General).  
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M10. Data collection instrument 3: Semi-structured interview protocol (system-
based approach): 
1. Pharmaceutical Industry interview protocol. 
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2. Academic institutions interview protocol. 
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3. Service delivery organizations (private healthcare institutions and community 
pharmacy). 
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M11. Data collection instrument 4: Researcher created instrument (includes 
observational protocol). 
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M12: Examples of the deductive content analysis process. 
 Table M12: Examples of the deductive content analysis process. 
Table M12: Examples of the deductive content analysis process. 
Category Code  Condensed text Text verbatim 
Structure PV 
centre/department 
 A department 
is concerned 
about PV and 
medication 
safety.  
Yes, there is but it is not a center we have 
both indicators for medications and 
adverse drug reactions under the 
medication safety center... Just a center to 
collect all safety data you can call it semi 
pharmacovigilance. 
Structure  Policy or 
legislation or 
guidelines 
 
Legal 
mandates for 
marking 
authorization 
holders to 
report ADRs.  
Because it is required by law that 
marketing authorization holders the local 
agent should declare to the MOPH 
represented by the Pharmacy And Drug 
Control if there is any quality or safety 
issue they have to report it I think it's even 
mentioned in the law within 10 days or 
within 1 month. 
Process Causality 
assessment 
Causality 
assessment 
following 
evidence-based 
methodology. 
See this is how adverse drug reactions 
have been reported across from all 
Medical Centre as well as Hospital. And 
they reach the clinical pharmacist for 
further analysis. They do the probability 
scaling, Naranjo scaling and based on that 
they prepare a monthly summary. 
Structure Healthcare system 
regulatory 
authority 
 
No structured 
or established 
national 
reporting 
system.  
Within the organization, yes, it is not 
going outside because there is no 
structured way to report to any regulatory 
authority. 
Structure Pharmacovigilance 
education  
 
The college 
program covers 
PV through all 
the years for 
two credit 
hours. 
So, it's a, it's a tough question because 
there's no actual course…our students 
typically take… anywhere between I 
would say 30 and 36 credit units total per 
academic year and maybe perhaps one to 
two of those credit units were associated 
with instruction for PV… but for 
example, professional skills as a two-
credit course, but the whole course is not 
designated for PV. But part of that two 
credits would be, would be dedicated. 
Additional 
system-
based 
approach 
Leadership and 
management 
 
Leadership 
involvement to 
improve the 
PV and 
We are trying to get our leadership 
involved from the beginning stage we are 
trying to do a lot of lectures for them, 
we're trying to explain to them that some 
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Culture  
 
 
reporting 
culture in the 
hospital. 
mistakes happen because the system has 
failed, the system allows that to happen. 
And then sometimes individual 
responsibilities as well. So, we try to 
invite that we are taking some measures, 
we do leadership rounds, but I think it will 
take some time before we can get to the 
just culture. I don't think any organization 
can claim that they have just culture, it's 
very difficult to determine, you know, 
which one is an individual responsibility 
and which one system-related failure. So, 
I think we're getting there. But the 
measures that we're taking right now is to 
get the leadership involved. I think once 
the leadership gives you the assurance that 
we won't penalize you, It makes it easier 
for people to understand, I mean you 
could write as many, as much you like in 
policies, but there should be, you know, a 
follow up through leadership. So that's 
what we're trying to do right now. 
  
317 
 
APPENDIX B: RESULTS CHAPTER RELATED CONTENT  
1) National and Subnational PV System Performance Values and Calculations. 
Table R1a: National and Subnational PV System Performance Values and Calculations. 
National PV system  Actual performance Desired performance 
S: 
structure 
P: 
process 
O: 
outcome 
Overall 
sum 
Overall 
percentage 
S: 
structure 
P: 
process 
O: 
outcome 
Overall 
sum 
MOPH 12.5 5 2 19.5 23.78% 31 29 22 82 
HMC 20.5 16 9 45.5 65% 25 22 23 70 
PHCC 20.5 14 4 38.5 71.30% 25 22 7 54 
PRIVATE 
SECTOR 
(calculated from the 
means S, P, &O of 
the five hospitals) 
17.8 14.9 7 39.7 58.4% 25 22 21 68 
INDUSTRY 21 9.5 3.5 34 68% 23 21 6 50 
MEANS (of 
stakeholder) 
18.46 11.8 5.1 - - 25.8 23.2 15.8 - 
PERCENTAGE 
(calculated based on 
the means of 
stakeholder)  
71.6% 51.2% 32.3% -  100% 100% 100% - 
TOTAL 
PERFORMANCE 
OF QATAR PV 
SYSTEM 
35.44 (54.7%)  64.8 (100%) 
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R1b) Excel spreadsheet database. 
WHO PV indicators Stakeholders Reference recorded values 
Indicator 
Code  
Indicator 
Category 
Code 
Ref  MOPH HMC PHCC H-A  H-B H-C H-D H-E Industry P-A  P- B 
Core 
Indicators 
Structure 
CST1 0 2 1 1 1 1 1 1 2 1 0 
CST2 0 2 2 2 1 1 0 1 2 0 0 
CST3 2 (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) 
CST4 0 0 0 0 0 0 1 0 2 0 0 
CST5 0 1 2 2 1 1 1 2 2 2 1 
CST6 0 2 2 2 2 2 2 1 2 0 0 
CST7 0 2 2 2 2 2 1 1 2 2 0 
CST8 2 (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) 
CST9 2 2 2 2 2 2 2 2 2 2 0 
CST10 1 2 2 2 2 1 2 2 2 2 0 
Total    7 13 13 13 11 10 10 10 16 9 1 
Process  
CP1 0 2 2 1 1 2 2 1 1 0 0 
CP 2 0 2 1 2 1 1 1 2 1 1 0 
CP 3 0 2 2 2 2 2 2 2 1 2 0 
CP 4 0 2 1 2 2 2 0 0 1 (-) (-) 
CP 5 0 1 1 2 2 1 2 1 0 0 0 
CP 6 0 1 1 2 2 2 1 2 (-) (-) (-) 
CP 7 0 1 2 2 1 2 1 2 (-) (-) (-) 
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CP 8 2 (-) (-) (-) (-) (-) (-) (-) 2 (-) (-) 
CP 9 0 1 0 0 0 0 0 0 0 (-) (-) 
Total    2 12 10 13 11 12 9 10 6 3 0 
Outcome 
CO 1 0 2 0 0 1 1 0 0 1 (-) (-) 
CO 2 1 (-) (-) (-) (-) (-) (-) (-) 2 (-) (-) 
CO 3 0 1 (-) 0 1 2 1 0 (-) (-) (-) 
CO 4 0 1 (-) 0 2 1 1 1 (-) (-) (-) 
CO 5 0 (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) 
CO 6 0 0 (-) 0 0 0 0 0 (-) (-) (-) 
CO 7 0 0 (-) 0 1 0 0 0 (-) (-) (-) 
CO 8 0 1 (-) 0 0 0 0 0 (-) (-) (-) 
  Total    1 5   0 5 4 2 1 3 (-) (-) 
Compleme
ntary 
Indicators  
Structure 
ST1 0 1 1 1 1 1 0 1 1 1 0.5 
ST 2 0 1 1 1 1 1 1 1 (-) 1 1 
ST 3 0 1 1 1 1 1 1 1 1 1 1 
ST 4 1 1 1 1 1 1 0 1 1 1 1 
ST 5 0 1 1 1 1 0.5 0 1 1 0.5 0 
ST 6 1 (-) (-) (-) (-) (-) (-) (-) 0.5 (-) (-) 
ST 7 1 1 1 1 1 1 1 1 (-) (-) (-) 
ST 8 1 1 1 1 1 1 1 1 (-) (-) (-) 
ST 9 0.5 0.5 0.5 0.5 1 0.5 0 0.5 0.5 0.5 0 
ST 10 0 0 0 0 0.5 0 0 0.5 0 0 0 
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ST 11 1 (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) 
Total    5.5 7.5 7.5 7.5 8.5 7 4 8 5 5 3.5 
Process  
P 1 0 (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) 
P 2 0 1 0.5 1 0 1 1 1 0.5 (-) (-) 
P 3 0 (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) 
P 4 0 0 0.5 0 0 1 0 1 0.5 (-) (-) 
P 5 (-) 1 1 1 0.5 1 1 1 (-) 1 1 
P 6 (-) 1 1 1 1 1 1 0.5 (-) 1 0 
P 7 0.5 0.5 0.5 0.5 0.5 0.5 0 0.5 0.5 0.5 0 
P 8 0 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0 
P 9 0 (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) 
P 10 1 (-) (-) (-) (-) (-) (-) (-) 0.5 (-) (-) 
P 11 1 (-) (-) (-) (-) (-) (-) (-) 0 (-) (-) 
p12 0.5 (-) (-) (-) (-) (-) (-) (-) 1 (-) (-) 
p13 0 (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) 
Total    3 4 4 4 2.5 5 3.5 4.5 3.5 3 1 
Outcome 
O1 0 1 0 1 0 1 1 1 (-) 0 0 
O2 0 0 (-) (-) (-) (-) (-) (-) (-) (-) (-) 
O 3 0 0 (-) (-) (-) (-) (-) (-) (-) (-) (-) 
O 4 1 (-) (-) (-) (-) (-) (-) (-) (-) (-) (-) 
O 5 (-) 1 (-) 1 0 1 0 1 (-) (-) (-) 
O 6 (-) 0 (-) 0 0 0 0 0 (-) (-) (-) 
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O 7 0 0 (-) 0 0.5 0 0 0 0 0 0 
O 8 0 0 (-) 0 0 0 0 0 0.5 0 0 
O 9 (-) 1 1 0.5 0 1 1 1 (-) 1 1 
O 10 (-) 0 1 0.5 0 1 1 1 (-) 1 1 
O 11 (-) 0 1 0.5 0 1 1 1 (-) 1 0 
O12 (-) 1 1 1 1 1 1 1 (-) 1 1 
Total    1 4 4 4.5 1.5 6 5 6 0.5 4 3 
 
2) National PV System Performance at the MOPH Level. 
Table R2: MOPH PV system performance and capacity results measured by WHO core PV indicators. 
CORE STRUCTURAL INDICATORS 
Code Response Score * Assessment (Qualitative) 
CST1  No specific PV 
department or 
center.  
(0) • No specific PV department. However, PV activities are incorporated within the daily 
activities. They hope to become a full member after they set up a national PV center. 
• The Department of Pharmacy and Drug Control collects data from the MAH and the 
international pharmaceutical industry. However, the department stopped receiving ADRs 
data from healthcare institutions. The department considers the current PV system to be 
functional with the external stakeholders’ side and non-functional from the national 
stakeholders' side. 
• The Department of Healthcare Quality and Patient Safety have future projects that involve 
medication safety (i.e. medication safety plan and national reporting system). Additionally, 
the department receives reports on medication errors as per the health performance 
agreement, but the data captured does not have enough details to conduct in-depth analysis. 
• It was recommended that a specific PV center would be best established as a centralized 
system in the MOPH and collaborative efforts with universities could be pursued for the 
management and operation of the center. 
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CST2 No specific 
national PV 
policy or 
guidelines. 
(0) 
 
• Qatar is a member of the GCC countries. Therefore, they have well-established guidelines 
for drug registration including PV. Additionally, the pharmaceutical law of Qatar covers 
aspects of medication safety, but the specific term of PV is not used.  
• The regulatory framework is defined by the pharmaceutical law. Sections in the law related 
to PV medication safety are covering MAHs. No mandatory reporting for healthcare 
professionals.  
CST3 Yes.  (2) • Yes, the MOPH. The Pharmacy and Drug Control is responsible for pharmaceutical sector 
management and regulations. 
CST4 No specific 
budget 
allocated for 
PV. 
(0) 
 
 
• There is no allocated budget for PV within the MOPH because there is no independent 
body or segregated body responsible for PV.  
• The current budget that is used for covering medication safety activities does not reflect the 
PV functions directly.  
• It was stated that the budget is sufficient for the current operation of the system. However, 
if such a center will be established an additional budget needs to be allocated properly. 
CST5 No. Not- 
applicable.  
(0) 
 
 
• It was reported that a dedicated human resource will be required once a dedicated PV 
center is established as the current manpower will not be enough. 
• The Department of Healthcare Quality and Patient Safety reported that they need human 
resources dedicated to the planned medication safety program. 
• The Department of Pharmacy and Drug Control indicated that there is no dedicated staff 
for PV. But the number of people covering PV and medication safety in the current state is 
sufficient. The MOPH provided training related to vaccine PV only. Otherwise, a limited 
number of MOPH employees make individual efforts to receive training on PV. 
CST6 No national 
standardized 
ADR reporting 
form. 
(0) • Currently, there is no national standardized ADRs reporting from or any form to collect 
national data on medicine-related safety issues.  
• The MOPH plans to create and implement a national patient safety reporting system in the 
near future. 
• There is no reporting form for the general public. However, the public can report their 
complaints through the MOPH website, but it is not specific to medications. 
CST7 No.  
 
(0) 
 
• No PV structures to undertake the basic PV activities. 
• Absence of a national database system for the collection of PV data from all sources. 
• Methods of data collection and transmission were indicated to be nonfunctional for 
national postmarketing surveillance activities but functional for the PV in the registration 
  
323 
 
process and with the pharmaceutical companies. 
• No formal documentation system to collect data from pharmaceutical companies (e.g. no 
records kept for the number of reports). 
• The future project medication safety plan includes requirements for the electronic database 
and at the time of implementation, the MOPH will have to discuss with the company and 
establish all the required details with other stakeholders. 
CST8 Yes. (2) • Yes, refer to the results chapter section 1.6. higher academic institutions level. 
CST9 Yes. (2) • The Department of Pharmacy and Drug Control distributes circulars at the national level 
e.g. safety warnings in the form of memos. Additionally, the MOPH website exists but it is 
not usually used as desired. Thus, the MOPH prefers sending feedback directly to national 
PV stakeholders. 
• The Department of Healthcare Quality and Patient Safety does not have a process in place 
to ensure that the department is following up on medication safety. 
CST10 No. (1) • There is no specific PV or medicine safety advisory committee. Therefore, it was stated 
that in the future, having a functional committee will serve the needs of the country. 
• The Pharmacy and Drug Control Department is currently the body responsible for 
information dissemination and provision of advice on medication safety and PV. 
Total Score  (7) Out of 10 [10*2= (20)] is [(100%)] relevant indicators the obtained score was [(7) =35%] 
CORE PROCESS INDICATORS 
Code Response Score * Assessment (Qualitative) 
CP1 The number of 
records is not 
documented. 
(0) • The Department of Pharmacy and Drug Control reported that currently there is no national 
database for PV data management. Additionally, the number of reports that have been 
received is very limited (i.e., less than 10 ADRs reports were received in 2017 from Qatar 
petroleum). The underreporting issue is expected to continue without the existence of an 
appropriate documentation system and national ADR reporting forms. 
• The Department of Healthcare Quality and Patient Safety stated that since there is no 
structure in place the process indicators are also not in place for the reporting of 
medication safety issues. 
 
CP2 The number of 
records is not 
(0) • No national database or a formal documentation system. 
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documented. 
CP3 The number of 
records is not 
documented. 
(0) • The Department of Pharmacy and Drug Control reported that any issue that is received 
from the external pharmaceutical industry will be communicated to the Qatar Council for 
Health Care Professionals to make it as circulars with instructions and guidelines for 
physicians on how to submit or how to act in cases with that specific medication. 
• The Department of Healthcare Quality and Patient Safety stated that there is no formal 
process in place to ensure that the department is following up on medication safety.  This 
process will be included in the future plan to have a medication safety program. 
CP4 The number of 
records is not 
documented. 
(0) 
 
• The Department of Pharmacy and Drug Control reported that for passive surveillance 
activities the capacity for evidence-based causality assessment, signal investigation and 
other forms of PV data analysis is inadequate. Thus, it is recommended that awareness and 
training are mandatory as such process requires experience and expertise in all elements of 
health care.  
• The Department of Healthcare Quality and Patient Safety stated that the data captured does 
not have sufficient details to conduct in-depth analysis. 
CP5 The number of 
records is not 
documented. 
(0) • The number of records is not documented reports sent from hospitals do not have sufficient 
details and the quality of reports is not satisfactory.  
CP5a: 
None. 
(0) • MOPH has a good relationship with the UMC and they have already been successful to be 
an associate member with UMC. 
• MOPH has been given the privilege to access the international system that is designed to 
submit reports.  
• To improve PV, it was recommended that the country needs to take action to develop the 
national PV system, establish the PV center, hire suitable manpower, and start submitting 
reports. 
CP6 The number of 
records is not 
documented. 
(0) 
 
 
• The number of records is not documented. 
CP7 The number of 
records is not 
documented. 
(0) 
 
 
• The number of records is not documented. 
CP8 100%.  (2) • It is a requirement for registered pharmaceutical companies to have a functional PV 
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system.  
CP9 None.  (0) • For active surveillance activities, MOPH did not report any examples of studies at the 
national level. 
• It was reported that the MOPH does not have enough capacity to conduct such studies. 
• Collaboration with other sectors to conduct such studies was deemed as a potential 
suggestion. The MOPH is aware of the limitations and the risk for such activities. 
• Active surveillance activities are very expensive, require a lot of technical knowledge, and 
most of the pharmaceutical companies do it successfully. Therefore, it was reported that it 
is best to rely on third parties and pharmaceutical companies as they can do it successfully. 
Total score  (2) Out of 9 [9*2= (18)] is [(100%)] relevant indicators the obtained score was [(2)=11.1%] 
CORE OUTCOME/IMPACT INDICATOR 
Code Response Score * Assessment (Qualitative) 
CO1 None. (0) • External data is used only and there are no signals generated at the national level.  
• The Department of Pharmacy and Drug Control commented on signal evaluation that there 
is a lack of awareness about how to do signal evaluation including the use of relevant tools 
and methods. Additionally, it was stated that signal evaluation requires a good effort from 
national stakeholders through improving their reporting rate and quality of submitted 
reports. 
• The Department of Healthcare Quality and Patient Safety reported that signal identification 
and evaluation is not part of their activities. 
CO2 The number of 
records is not 
documented. 
 
 
(1) • Both internal and external data will be considered. However, no documentation system is 
available to record the number. 
• The MOPH has more than 4500 registered pharmaceutical products. Hence, the MOPH 
receives many reports from external sources and issue actions based on them. 
• The registration committee will be responsible for taking regulatory actions. 
• For decision making and regulatory actions, the MOPH mostly relies on benchmarks from 
other countries with stringent regulatory agencies. Because sometimes the national reports 
that they receive does not concise with the global data. Consequently, the MOPH cannot 
immediately take regulatory actions. 
CO3 No data 
provided. 
(0) • The Department of Healthcare Quality and Patient Safety reported that service delivery 
organizations do not report hospital admission data. 
CO4 No data (0) 
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provided. • The Department of Healthcare Quality and Patient Safety reported that service delivery 
organizations do not report death due to medication error data. 
• This data could be part of the morbidity and mortality data. However, it is planned for 
these data to be part of the future reporting system. 
CO5 No data 
provided. 
(0) 
CO6 No data 
provided. 
(0) • According to the health economist in MOPH, the Financial aspects of the PV system (i.e., 
core outcome indicators number 6,7, and 8 as well as Complementary outcome indicators 
number 7 and 8) this information currently is not available in MOPH. However, it is very 
important and worthy to be collected especially indicator number 7 which is considered 
feasible. Nevertheless, this needs good planning for the methodology.  
CO7 No data 
provided. 
(0) 
CO8 No data 
provided. 
(0) 
Total Score  (1) Out of 8 [8*2= (16)] is [(100%)] relevant indicators the obtained score was [(1) =6.3%] 
(*) Score: (2) Yes fully satisfactory; (1) Yes partially satisfactory (2); and (0) No includes not satisfactory, missing data, no values, not 
applicable. 
(*) Score (-): Not relevant for the evaluation of system performance with WHO indicators. 
 
Table R3: MOPH PV system performance and capacity results measured by WHO complementary PV indicators. 
COMPLEMENTARY STRUCTURAL INDICATORS 
Code Score* Answer qualitative  
ST1 (0)  No, as a specific center does not exist. 
ST2 (0) No, not relevant. As the MOPH only regulates medications and not related to the consumption of medicine, this indicator is 
relevant to service delivery organizations. 
ST3 (0) No: there is no PV center.  
ST4 (1) Yes, however, there is no library. The MOPH uses regulatory authorities’ website information e.g. FDA, EMA, WHO 
references.  
ST5 (0) No, this indicator is relevant to service delivery organizations. 
ST6 (1) Yes. Quality Control Lab is a big section (not specific for PV). The lab collaborates with the MOPH Pharmacy and Drug 
Control department because it is a section under it. This lab is linked with the full registration process, and PV is part of it. 
ST7 (1) No, all medications are essential for MOPH. 
ST8 (1) Yes.  
ST9 (0.5) • ST9a: Yes, they have PV related issues covered under vaccine training (not specific to PV). Additionally, they organize 
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pharmacy conferences that have a separate theme for PV and medication safety. 
• ST9b: no, none for the general public. 
 
ST10 (0) No. 
ST11 (1) Yes. The Pharmacy and Drug Control department used to include it on the MOPH website. However, the department realized 
that not all healthcare practitioners are reading the information provided. Therefore, now the Pharmacy and Drug Control assigns 
the companies to distribute it directly to the healthcare organization. 
 
Total 
score  
(5.5) Out of 11 [11*1= (11)] is [(100%)] relevant indicators the obtained score was [(5.5) =50%]. 
COMPLEMENTARY PROCESS INDICATORS 
Code Score* Answer qualitative  
P1 (0) No adequate data. The percentage cannot be calculated as there is no database. Less than 10 reports were sent to the Pharmacy 
and Drug Control department from Qatar petroleum.   
P2 (0) No adequate data. The percentage cannot be calculated because there is no database.  
P3 (0) No adequate data. The percentage cannot be calculated because there is no database.  
P4 (0) No adequate data. The percentage cannot be calculated because there is no database.  
P5 (-) Not relevant.  
P6 (-) Not relevant. 
P7 (0.5) • P7a: yes, one on vaccines (not specific for PV). It was a component that included ADRs of vaccines for health 
professionals.  
• P7b: no, none for the general public.  
P8 (0) No adequate data.  
P9 (0) Only external data.  
P10 (1) 4500 products. P10a: more than 90% of products, as per the agreement. MOPH follow the EMA, USA, Arab guidelines.  
P11 (1) 85% submit PSURs only Arab countries do not submit and this is a challenge for PV. 
P12 (0.5) • P12: no, no adequate data. 
• P12a: yes, 20-25 SPCs due to minor variations.  
P13 (0) None from the national pharmaceutical industry. Although they have a PV system in the industry, they are trying to improve it. 
Total 
score  
(3) Out of 11 [11*1= (11)] is [(100%)] relevant indicators the obtained score was [(3) =27.3%] 
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COMPLEMENTARY OUTCOME/IMPACT INDICATORS 
Code  Score  Answer qualitative 
O1 (0) No report.  
O2 (0) No report.  
O3 (0) No report.  
O4 (1) Less than 1% as there are stringent regulations and medications from reputable sources and mainly brand medications are 
available in Qatar.  
O5 (-) Not relevant.  
O6 (-) Not relevant. 
O7 (0) Beyond the scope of the Pharmacy and Drug Control Department.  
O8 (0) Beyond the scope of the Pharmacy and Drug Control Department.  
O9 (-) Not relevant.  
O10 (-) Not relevant.  
O11 (-) Not relevant.  
O12 (-) Not relevant.  
Total 
score 
(1) Out of 6 [6*1= (6)] is [(100%)] relevant indicators the obtained score was [(1)=16.7%] 
(*) Score: Yes (1), No (0) 
(*) Score (0.5): For Indicators with two Parts (A & B) If (A the answer is No Score to be (0.5) and vice versa for B) 
(*) Score (-): Not relevant for the evaluation of system performance with WHO Indicators. 
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3)  Public Sector: HMC PV System Performance. 
Table R4: HMC PV system performance and capacity results measured by WHO complementary PV indicators. 
COMPLEMENTARY STRUCTURAL INDICATORS 
Code Score* Answer qualitative  
ST1 (1)  Yes, within the MSQC. 
ST2 (1) Yes. 
ST3 (1) Yes, phone, email, and fax. 
ST4 (1) Yes, the e-library has different resources including books and journals. Additionally, MSQC-Drug information. 
ST5 (1) Yes, MSQC has ADR reporting through the Cerner system. 
ST6 (-) Not relevant to HMC. 
ST7 (1) Yes, there is no official essential medication list. However, HMC has an essential list in the drug supply department, and it 
follows the WHO essential medicines list model. 
ST8 (1) Yes. PV data is considered by the CP&TC to develop HMC guidelines. 
ST9 (0.5) • ST9a: Yes, HMC has yearly conferences on medication safety that includes PV. In conferences, HMC provides training in 
workshops and there are lectures open for all the healthcare providers. To date, HMC conducted these two times. 
Additionally, HMC pharmacy conferences have a separate theme for PV. 
• ST9b: No. 
ST10 (0) No, however, it is under future plans. 
ST11 (-) Not relevant to HMC. 
Total 
score  
(7.5) Out of 9 [9*1= (9)] is [(100%)] relevant indicators the obtained score was [(7.5) =83.3%] 
COMPLEMENTARY PROCESS INDICATORS 
Code Score* Answer qualitative  
P1 (-) Not relevant to HMC. 
P2 (1) Yes.  
• P2a: Medical doctors, 5%. 
• P2b: Dentists, 0%. 
• P2c: Pharmacists, 70-80%. 
• P2d: Nurses, 10-15%. 
• P2e: The general public, i.e., HMC patients 0%, 
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• P2f: Manufacturers, no, that process is not relevant to HMC. 
P3 (-) Not relevant to HMC. 
P4 (0) No. HMC does not have this data. 
P5 (1) Yes. An estimate of 70 to 80% are aware of processes of ADR reporting, 100% are aware of the term ADR, and only 40 % of 
them report. 
P6 (1) Yes, patients receive complete education and ADR is a part of the education. Therefore, 90% of them get an education but 
understanding of areas where to report could be an issue that contributes to not receive any reports from the patients. 
P7 (0.5) • P7a: For the year 2018, one conference and one symposium on medication safety. The symposium had different themes 
including PV. Additionally, HMC provided training to community pharmacists on medication safety, which included 
PV and ADR.  
• P7b: None, for the public. 
P8 (0.5) • P8a: Number of healthcare professionals attended the conference on medication safety was 700, the medication 
symposium was 250, and community pharmacy around 70 people. 
• P8b: None, for the public. 
P9 (-) Not relevant to HMC. 
P10 (-) Not relevant to HMC. 
P11 (-) Not relevant to HMC. 
P12 (-) Not relevant to HMC. 
P13 (-) Not relevant to HMC. 
Total 
score  
(4) Out of 6 [6*1= (6)] is [(100%)] relevant indicators the obtained score was [(4) =66.7%] 
COMPLEMENTARY OUTCOME/IMPACT INDICATORS 
Code  Score  Answer qualitative 
O1 (1) Yes, the percentage of preventable ADRs is 5% for all HMC hospitals for the year 2018.  
O2 (0) No, MSQC does not have these data, HMC indicated that this data could be with the Fetomaternal Medicine Unit or the MOPH. 
O3 (0) No, MSQC does not have these data. 
O4 (-) Not relevant to HMC. No cases in HMC.  
O5 (1) Yes, for the past three years 0.16 per one thousand admissions. 
O6 (0) No, HMC does not have these data. HMC indicated that it is non-applicable because it was reported that it is not an indicator for 
HMC, therefore, they do not capture these data.  
O7 (0) There are plans for “Economic Studies”, however, HMC did not conduct such studies. MSQC indicated that there is one ongoing 
  
331 
 
study about clinical interventions of pharmacists and its impact on the cost and length of stay. However, the study is still under 
process results is not calculated yet. 
O8 (0) No, HMC does not have these data. 
O9 (1) Yes, four medicines per prescription for the whole HMC system. 
O10 (0) No. HMC captures these data, however, HMC does not analyze overdosing, HMC analyzes only dosing errors. However, if they 
plan to investigate the medication error data to capture overdosing data HMC may get this information. HMC reported that the 
percentage of dosing errors is 40% as an estimation. 
O11 (0) No, HMC does not have these data. Data is captured. However, there is no formal process to conducted analysis and get the 
percentage. 
O12 (1) Yes, from 90 to 100% of patients receive this information because 90% receive complete education including ADRs. 
Total 
score 
(4) Out of 11 [11*1= (11)] is [(100%)] relevant indicators the obtained score was [(4) =36.4%]. 
(*) Score: Yes (1), No (0). 
(*) Score (0.5): For Indicators with two Parts (A & B) If (A the answer is No Score to be (0.5) and vice versa for B). 
(*) Score (-): Not relevant for the evaluation of system performance with WHO indicators. 
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4) Public Sector Level: PHCC PV System Performance. 
Table R5: PHCC PV system performance and capacity results measured by WHO complementary PV indicators. 
COMPLEMENTARY STRUCTURAL INDICATORS 
Code Score* Answer qualitative  
ST1 (1) Yes. There are systems that can be accessed from different computers (i.e., Multum, Cerner, and Datix systems). 
ST2 (1) Yes.  
ST3 (1) Yes. 
ST4 (1) Yes, e-library that includes journals, UpToDate, and many other sources.  
ST5 (1) Yes, the Datix system. 
ST6 (-) Not relevant.  
ST7 (1) Yes, an essential medicine list. This is a mandatory aspect and it is included in the polices.  
ST8 (1) Yes, PHCC has a guidelines committee (includes more than 14 consultants) that uses internal (national level guidelines) and 
international sources of information (guideline references) to develop the clinical guidelines used in primary care.  
ST9 (0.5) • ST9a: Yes, for example, ADRs reporting.  
• ST9b: For the general public only raising awareness (not specific to PV), e.g., antibiotic awareness week, medication 
reconciliation, and declaring allergy status.  
ST10 (0) No tools are available. It was reported that PHCC needs to specialize in PV in the next steps. 
ST11 (-) Not relevant. 
Total 
score  
(7.5) Out of 9 [9*1= (9)] is [(100%)] relevant indicators the obtained score was [(7.5) =83.3%] 
COMPLEMENTARY PROCESS INDICATORS 
Code Score* Answer qualitative  
P1 (-) Not relevant. 
P2 (0.5) No answer was provided. It was reported that PHCC cannot provide by stakeholders because the reporting in the system is 
anonymous.  
P3 (-) Not relevant. 
P4 (0.5) No answer was provided. PHCC cannot provide by stakeholders because the reporting is anonymous. 
P5 (1) 80% are aware because PHCC conducts Contentious Professional Development programs. This includes ADRs that are 
considered one of the Required Organizational Practice (ROPs) recommended by the accreditation body Joint Commission 
International.  
P6 (1) 10-20% are aware of ADRs and 100% are aware and get counseling on medication use and side effect.  
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P7 (0.5) • P7a: yes, once per year. 
• P7b: no, patient counseling and the patient antibiotic week includes medication safety but not specifically for PV. 
P8 (0.5) • P8a: 80 pharmacists and nurses. 
• P8b: more than one thousand. 
P9 (-) Not relevant. 
P10 (-) Not relevant. 
P11 (-) Not relevant. 
P12 (-) Not relevant. 
P13 (-) Not relevant. 
Total 
score  
(4) Out of 6 [6*1= (6)] is [(100%)] relevant indicators the obtained score was [(4) =66.7%] 
COMPLEMENTARY OUTCOME/IMPACT INDICATORS 
Code  Score  Answer qualitative 
O1 (0) PHCC does not have this assessment.  
O2 (-) Not relevant. 
O3 (-) Not relevant. 
O4 (-) Not relevant. 
O5 (-) Not relevant. 
O6 (-) Not relevant. 
O7 (-) Not relevant. 
O8 (-) Not relevant. 
O9 (1) 4 to 5. 
O10 (1) 5% estimate.  
O11 (1) 30%. The Datix system sends alerts and PHCC staff make the decision to reject or accept based on the category of interaction 
from A to X, e.g., B or C accept and X reject.  
O12 (1) 10-20% are aware of ADRs and 100% are aware and get counseling on medication use and side effects. 
Total 
score 
(4) Out of 5 [5*1= (5)] is [(100%)] relevant indicators the obtained score was [(4) =80%]. 
(*) Score: Yes (1), No (0). 
(*) Score (0.5): For Indicators with two Parts (A & B) If (A the answer is No Score to be (0.5) and vice versa for B). 
(*) Score (-): Not relevant for the evaluation of system performance with WHO indicators. 
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5) Private sector: Healthcare Institutions PV system performance. 
1. Hospital A 
Table R6: Hospital “A” PV system performance and capacity results measured by WHO core PV indicators. 
CORE STRUCTURAL INDICATORS 
Code Response Score * Assessment (Qualitative) 
CST1  Yes.  (1)  • Applicable however no specific PV department, The Safety and Quality Department in 
collaboration with the Pharmacy Department are responsible for medication safety and PV aspects. 
• An incident reporting system that's divided into two functions clinical incident function and the 
non-clinical incident function. 
• The hospital is functional in terms of reporting of individual cases and there is an increase in 
reporting over time. The hospital tried to develop and nurture a positive culture so that people will 
feel more inclined to report incidents without any threat of being blamed or punished or 
disciplined. The hospital has policies that support this philosophy. Nevertheless, it was noted that 
reporting could be improved further. 
CST2 Yes. (2) 
 
• From a hospital perspective, a range of policies and procedures, which are mainly focused on 
medication safety and outlines the requirements for PV. However, those are not specific to PV. 
Those are hospital-based policies that are aligned with national requirements and accreditation 
requirements. 
• In terms of policies on medication safety, it is comprehensive and regularly updated. 
• There is a regular process of identifying any new policies or procedures as a part of the informing 
processes through incident reporting. For example, if there are incidents related to a particular issue 
the hospital would update the policies and procedures and offers education related to those 
medications. 
CST3 Not relevant. (-) • Not relevant. 
CST4 No dedicated 
budget for 
PV. 
(0) 
 
 
• No specific budget allocated for PV. The hospital doesn’t have a specific budget for medication 
safety.  
• A number of medication safety initiatives and practices have been implemented and were 
supported, some of which have had a cost implication, and the budget has been provided.  
• If the requested initiative can justify a safety improvement, or an efficiency improvement resources 
will be provided. 
• It was reported that there are no barriers with respect to the resources required to address 
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medication safety. 
CST5 Yes.  (2) 
 
 
• Yes. Human resources are sufficient, but it's not dedicated.  
• The people who are involved in the review and analysis of incidents related to medication safety 
are full-time staff.  
CST6 Yes. 
 
 
(2) • An incident reporting system that's divided into two functions clinical incident function and the 
non-clinical incident. Therefore, from a clinical perspective, if there were any incidents related to 
medication safety, it would be recorded. For the non-clinical reporting perspective, if there was an 
issue around the storage of medication or supplies or breakage or incidents that don't involve a 
patient. 
• It is a paper-based system. The incidents will be collated on a monthly basis. The Safety and 
Quality Department will look at incidents in the near-miss of all types, but one of the subcategories 
is specifically related to medication safety. It was noted that this will offer an opportunity to 
capture the information and to review incidents to implement improvement. Hence, the hospital 
legitimizes that by giving its own subcategory. 
• Reporting by the public can be through the feedback forms, however, it is a generic form and it 
does not categorize the feedback. The documentation is a free text format and allows the patient to 
raise an issue or provide either negative or positive feedback.  
CST7 Yes. A 
process and 
database exist. 
(2) 
 
 
• Incidents will be documented in a database that collects information based on the type of incident. 
For medication-related, it also categorizes the risk level of the incident and the Safety and Quality 
Department uses the severity assessment code, which applies levels of risk to stratify the 
seriousness of the incident.  
• For lower risk levels the analysis and feedback will be at the department level however for the 
more serious levels, the Safety and Quality Department will take this responsibility. 
• The Safety and Quality Department has a documented process in terms of time frames for analysis 
and providing feedback and/or recommendations.  The hospital has a complete feedback loop in 
terms of communicating the process of investigation, the outcomes, recommendations for 
improvements. 
• The hospital has a very structured electronic medical record and it is easy to interrogate the system 
and gather any missing information. Hence, the information will be captured in two places. 
• The databases are an Excel spreadsheet. It was noted that it is a labor-intensive system database, 
and the hospital is planning to implement an automated system. 
CST8 Not relevant. (-) • Not relevant. 
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CST9 Yes.  (2) • The hospital has a website with a range of resources that support safety and quality for patients. 
This includes policies and procedures related to medication safety. Additionally, the hospital has 
information bulletins that highlight any changes in practice, or any new standard related to 
medication safety. The hospital has a robust IT system which is the basis of communication. 
• An example of hospital communication with the public includes the collaboration with media for 
health promotion as well as social media distribution to provide key information to the community. 
In addition, on the webpage, there is information for patients in terms of how they can contribute to 
the safety of their own care. 
CST1
0 
Yes.  (2) • The Pharmacy and Therapeutics Committee is responsible and accountable for all aspects of 
medication safety and management. It is chaired by a medical consultant and has representation 
from across the hospital including the pharmacy department.  
Total 
Score 
 (13) Out of 8 [8*2= (16)] is [(100%)] relevant indicators the obtained score was [(13) =81.3%] 
CORE PROCESS INDICATORS 
Code Response Score * Assessment (Qualitative) 
CP1 Yes. (1) 
 
• All the reports were preventable. 
• For medication incidents, the total number for 2017 was 72 reports. Medication incidents per 
100,000 occupied beds days (OBDs) was 0.30 for the year 2017. 
• The hospital reinforces the need to report and they are promoting positive culture towards safety as 
it gives an opportunity to focus on the system's aspect rather than the individual aspect. Currently, 
the staff is much more willing to report. Additionally, on a regular basis, the hospital assesses the 
safety culture, and the results demonstrate that people are becoming more confident to report. 
CP1a: 
Not relevant.  
(-) 
CP2 Yes. 
 
(2) 
 
 
• For medication incidents, the total number from 2014 to 2017 was 329 reports. The majority are in 
the low-risk category. Most of these would be near misses rather than actual incidents. 
• From a governance perspective, the database gives a clear picture of areas where there is a need for 
focus in terms of policies, procedures, education, or improved supervision. For example, the 
hospital had several prescription errors and the database showed a very clear pattern related to 
prescription. As a result of that, the hospital implemented an electronic prescription system. Hence, 
the current system formalizes the reporting process, improves communications, and reinforces the 
need to report to the hospital staff. 
CP3 100%.  (2) 
 
 
• The hospital doesn’t keep a record, but an estimate will be close to 100%. After the investigation 
feedback is provided to 100% of the incidents.  
• The feedback loop is considered complete and quite rapid. The hospital policies define the time 
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frames, but some incidents require more investigation. The Safety and Quality Department often 
will do root cause analysis on such cases and this might be delayed if a key person is on leave. 
CP4 100%. (2) 
 
 
• The Safety and Quality Department conducts analysis on all the reports; however, it may be in a 
relatively informal sense. A formal process like a root cause analysis will be done for the high-risk 
category, which is a limited number of cases. But the majority includes near misses those will be 
reviewed in a less structured and less formal way. 
• The hospital has sufficient expertise in terms of root cause analysis. Members individually or 
collectively involved are the Safety and Quality Department director, the Deputy Chief of medical 
staff, and the quality assurance committee. However, it was stated that for data analysis it would be 
good to have a statistician with more developed statistical and analytical skills and to have specific 
software for analysis as well. 
• For the lower-level risk cases, the department head would conduct the review, and they have the 
required skills.  
CP5 100% (2) 
 
 
• All are satisfactory or completed. If they're incomplete, the Safety and Quality Department will 
return the report until it will be satisfactorily completed with all the key information required.  
• The capacity of people across the organization to complete the documentation correctly is quite 
high. In addition, it is included in the orientation for new staff.  
• The hospital does report to the MOPH, only a few key performance indicators will be reported to 
MOPH. One of the indicators relates to medication incidents. The hospital report on a quarterly 
basis, but data will be provided by month. Then the MOPH provides the hospital with the 
benchmark results to do a comparative analysis between hospitals across the country. 
CP5a: 
Not relevant. 
(-) 
 
CP6 No cases. (2) • The hospital doesn’t have any cases reported.  
CP7 No cases.  (2) 
 
• In 2017, no cases were reported. In 2016, two cases were reported, one of these cases were related 
to vaccination. The majority of incidents are reported near misses. 
CP8 Not relevant. (-) • Not relevant. 
CP9 None.  (0) 
 
• The hospital doesn’t get involved in medication research or clinical trials. But it was noted that the 
hospital is at the foundation stage of establishing a research profile and collaborating with some of 
the universities in Qatar to support research activities. The hospital foresees a role for the private 
sector to be involved in research and conducting clinical trials in the future. 
• The hospital has some surveillance activities however not from a research perspective, e.g., 
infection control, hand hygiene, staff surveillance. Additionally, the hospital looks longitudinally at 
the data and the trends. For example, the hospital identified through incidents reported that high 
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concentration electrolytes were being managed at a unit level, and medications were being 
reconstituted by nurse staff rather than the pharmacy staff. Therefore, through risk management 
processes, and by proactively looking from a risk point of view this was made as a centralized 
function under pharmacy by professional pharmacy staff.  
Total 
Score 
 (13) Out of 8 [8*2= (16)] is [(100%)] relevant indicators the obtained score was [(13)=81.3%] 
CORE OUTCOME/IMPACT INDICATOR 
Code Response Score * Assessment (Qualitative) 
CO1 None.  (0) • None.  
CO2 Not relevant. (-) • Not relevant. 
CO3 No. (0) • The hospital doesn’t have this information documented. Over the last year, there was one reported 
case of a deliberate overdose with the misuse and abuse of medications.  
• The hospital reported that from a clinical coding point they do not have comprehensively coded 
data on that information either. The hospital staff does not code every admission, only admissions 
where the insurance company requires clinical coding. Additionally, the hospital classifies 
admissions into specialties rather than into conditions, e.g., medicine or surgery, obstetrics, etc. 
• It was stated that there could be an underestimation of the connections between medication and 
presenting conditions. 
• It was reported that there are two drivers to encourage clinical coding across the country in the near 
future. First, a new national health insurance scheme being introduced later this year, and part of it 
will require hospitals to conduct clinical coding on every patient. Second, the Minister of Health 
has given the commitment to an international forum, and this can promote clinical coding across 
the country.  
CO4 No Cases. (0) • No documentation for this indicator. 
• In the last two years, no cases of death were reported.  
CO5 Not relevant. (-) • Not relevant. 
CO6 No.   (0) • The hospital does not have any specific information on that because the occurrence of medicine-
related illness is very low. Additionally, the hospital does specific clinical costing for outliers only. 
• It was reported that the hospital will definitely consider the cost implications if it was relevant to 
their practice. 
CO7 No. (0) • The hospital does not have this information documented. Additionally, no cases were relevant to 
this indicator in practice. 
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CO8 No.  (0) • The hospital does not have this information documented. Additionally, no cases were relevant to 
this indicator in practice. 
Total 
Score 
 (0) Out of 6 [6*2= (12)] is [(100%)] relevant indicators the obtained score was [(0) =0%] 
(*) Score: (2) Yes fully satisfactory; (1) Yes partially satisfactory (2); and (0) No includes not satisfactory, missing data, no values, not applicable. 
(*) Score (-): Not relevant for the evaluation of system performance with WHO indicators. 
 
Table R7: Hospital “A” PV system performance and capacity results measured by WHO complementary PV indicators. 
COMPLEMENTARY STRUCTURAL INDICATORS 
Code Score* Answer qualitative  
ST1 (1)  Yes, in the pharmacy a few computers are dedicated to the management of all aspects of medication and pharmacy practice. 
And for prescribing or access to pharmacological information, any computer in the organization can be used. 
ST2 (1) Yes, the pharmacy department manages and compute the storage and distribution of medications. Part of pharmacy key 
stakeholders has access to stores databases, and pharmacy reports utilization of medication on a regular basis. 
ST3 (1) Yes, a good system of communication and it's available to all staff, e.g., emails and a website. 
ST4 (1) Yes, access to regulations, policies, and procedures. Additionally, specific medications resources including drug Information 
sheets, the BNF and other formularies. 
ST5 (1) Yes, a database that has been developed in house, it's an internal system. 
ST6 (-) Not relevant. 
ST7 (1) Yes, maintained by the Pharmacy Department. It comprises a couple of critical medications and emergency medications. 
ST8 (1) Yes. About 20 staff are involved in developing guidelines for specific conditions. Those guidelines are based on international 
standards of care and international treatment guidelines. In addition, they've been customized to the local environment to be 
more specific, and those include certain safety precautions. 
ST9 (0.5) 
 
Yes. 
• ST9a: for health professionals, the hospital provides training on medication safety or any specific medication safety 
initiatives. Additionally, the hospital supports national medication initiatives. For example, workshops and activities at the 
MOPH related to antibiotic usage and prescription administration. 
• ST9b: little effort made with the general public, only through media. 
ST10 (0) No. 
ST11 (-) Not relevant.  
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Total 
score  
(7.5) Out of 9 [9*1= (9)] is [(100%)] relevant indicators the obtained score was [(7.5) =83.3%] 
COMPLEMENTARY PROCESS INDICATORS 
Code Score* Answer qualitative  
P1 (-) Not relevant.  
P2 (1) No, no specific record in the database on such categorization. The hospital collects information on reporting including the 
healthcare profession, however, the information is not analyzed. Estimates on the overall clinical incident reporting (i.e., not 
exclusive to medication) are 80% nursing, 15% pharmacist, and 5% medical doctors.  
P3 (-) Not relevant. 
P4 (0) No, no specific record in the database on such categorization. The hospital collects information on reporting including 
profession, but the information is not analyzed. Estimates on the overall clinical incident reporting (i.e. not exclusive to 
medication) are 80% nursing, 15% pharmacist, and 5% medical doctors. 
P5 (1) On ADRs, it is very high 100%. It's part of the orientation for all new staff. Additionally, the old staff are subjected to regular 
education. 
P6 (1) An estimate of 5%. 
The hospital encourages disclosure, and the policy supports this disclosure, but the hospital doesn’t capture or formally collate 
the present picture.  
It was reported that people are fearful of the law and fearful of the implications for them from a licensing perspective because 
although the hospital promotes reporting culture internally and focus more on systems, the government departments have less 
of a focus on safety culture and more on the disciplinary approach.  
P7 (0.5) Yes.  
• P7a: For the healthcare professionals as an estimate about six sessions. The hospital focusses mainly on medication 
safety and doesn't tend to use the term PV. 
• P7b: For the public, the hospital doesn’t conduct any specific sessions or any activities specific to medication safety. 
All the patients are given medication counseling. 
P8 (0.5) Yes.  
• P7a: For the healthcare professionals’ participation would be about 400 approximately it covers a combination of 
pharmacy, medicine and nursing staff. 
• P7b: For the public, none. 
P9 (-) Not relevant. 
P10 (-) Not relevant. 
P11 (-) Not relevant. 
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P12 (-) Not relevant. 
P13 (-) Not relevant. 
Total 
score  
(4) Out of 6 [6*1= (6)] is [(100%)] relevant indicators the obtained score was [(4) =66.7%] 
COMPLEMENTARY OUTCOME/IMPACT INDICATORS 
Code  Score  Answer qualitative 
O1 (1) 100% as most of the cases relate to human error which would be preventable. 
O2 (-) Not relevant. 
O3 (-) Not relevant. 
O4 (-) Not relevant. 
O5 (1) In 2017 one case that was a specific medication error. A vaccination that was given twice to the same child. But based on the 
literature for that medication, there was no harm associated with it. Therefore, it was reported that the number of patients 
affected for the physical effect would be zero, and the number of patients involved is one. 
O6 (0) The hospital doesn’t have that information, not recorded. 
O7 (0) The hospital doesn’t have that information, not recorded or calculated. 
O8 (0) The hospital doesn’t have a specific budget related to medication safety or PV activities.  
O9 (0.5) The pharmacy department captures these data. 
O10 (0.5) The pharmacy department captures these data. 
O11 (0.5) The pharmacy department captures these data. 
O12 (1) The hospital provides medication counseling for all patients, 100% medicine use and 5% ADR. 
Total 
score 
(4.5) Out of 9 [9*1= (9)] is [(100%)] relevant indicators the obtained score was [(4.5) =50%] 
(*) Score: Yes (1), No (0). 
(*) Score (0.5): For Indicators with two Parts (A & B) If (A the answer is No Score to be (0.5) and vice versa for B). 
(*) Score (-): Not relevant for the evaluation of system performance with WHO indicators. 
 
 
 
 
  
342 
 
2. Hospital B 
Table R8: Hospital “B” PV system performance and capacity results measured by WHO core PV indicators. 
CORE STRUCTURAL INDICATORS 
Code Response Score * Assessment (Qualitative) 
CST1  No specific PV 
department. 
(1)  • The Quality Department is responsible for covering medication safety and PV. 
• In addition, the Pharmacy and Therapeutics Committee and the Pharmacy Director all are 
coordinated at the hospital level to cover PV and medication safety. 
• All concerned parties have available communication tools to ensure medication safety at the 
hospital level. Every month all concerned parties have a joint meeting.  
CST2 Yes. (1) 
 
• Range of policies that focus on medication safety, however, policies are not specific to PV. 
• The hospital considers the laws and policies of the country to ensure that there are complying with 
the country laws. 
CST3 Not relevant. (-) • Not relevant.  
CST4 No specific 
budget for PV. 
(0) 
 
• There is no specific budget dedicated to PV. However, generally, the hospital considers the budget 
sufficient to cover medication safety activities. 
CST5 Yes.  (1) 
 
 
• It was reported that the quality department does not need a dedicated full-time staff for PV as the 
practice of PV is coordinated at the hospital level and their expertise is good and sufficient.  
• The Pharmacy and Therapeutics Committee has multidisciplinary staff.  
• The clinical pharmacist is responsible for conducting data analysis including severity assessment 
and causality assessment.  
CST6 Yes. 
 
(2) 
 
 
 
 
 
 
• The hospital has two report forms an electronic form for healthcare professionals and paper-based 
patients forms or cards. 
• The patient cards were developed in a very simple way so that the patient will be encouraged to 
report. Patients can submit the card directly or send a photo to the hospital WhatsApp number.  The 
hospital staff noticed that the patients are responding and up taking this. For example, some people 
sent photos to the hospital using WhatsApp. 
• There are no specific field for medication counterfeit or substandard or therapeutic ineffectiveness, 
suspected misuse, abuse of medication. The hospital wants to streamline reporting thus the form 
will be initially filled by the reporter and the missing information will be generated by the clinical 
pharmacist.   
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CST7 Yes. A process 
and database 
exist. 
(2) 
 
 
• It was reported that the electronic database is the Cerner system. 
• The clinical pharmacist will follow-up with the reporters to complete all key information required 
for analysis. Then he/she will examine the patient case using scientific tools and methods. This 
includes determining the preventability of ADR, the causality assessment using Naranjo nomogram 
for adverse drug reaction assessment, and severity assessment using the Hartwig severity 
assessment scale.   
• After the clinical pharmacist completes the received reports checking process, it will be sent to the 
quality department. The quality department will then do more processing and will issue feedback. 
• Feedback to healthcare professionals is through the “Thank you Doctor letter”. Feedback will be 
provided for everyone who has reported in order to encourage staff and increase the reporting rate. 
Additionally, the hospital endorses the concept of no-blame culture to the staff. 
CST8 Not relevant (-) • Not relevant. 
CST9 Yes.  (2) • The hospital had a previous project to develop a bulletin and it had all PV related information. 
However, unfortunately, there were many challenges with the marketing administration, therefore 
the project was canceled. It was reported that the hospital is very strict with branding and 
visualization. Hence, currently, the staff communicate by email. 
• Additionally, the webpage will be used for communication with staff members, clinicians mainly. 
For example, any subject discussed in the Pharmacy and Therapeutics Committee, e.g., decisions or 
the actions that are undertaken will be included in a specific part of the webpage. 
CST1
0 
Yes.  (2) • The Pharmacy and Therapeutics Committee is governing medication management and use. Hence, 
it is the main committee to discuss and advise on safety issues and medication-related information. 
• It is a multi-disciplinary committee and ad-hoc members can be added when necessary. As per the 
policy, the committee members are ought to have a meeting every quarter. 
Total 
Score 
(11)  Out of 8 [8*2= (16)] is [(100%)] relevant indicators the obtained score was [(11) =68.8%] 
CORE PROCESS INDICATORS 
Code Response Score * Assessment (Qualitative) 
CP1 The value was 
not provided. 
(1) 
 
• Data is available but the value was not provided. The Canadian accreditation body requires hospital 
data to be presented along with a full analysis. This includes but not limited to the rate of 
medication errors, ADRs reporting through the last 3 years, the number of reports from different 
healthcare professional backgrounds, and clinical pharmacist intervention. 
CP1a: 
Not relevant. 
(-) 
CP2 The value was 
not provided. 
(1) 
 
• Data is available; however, the value was not provided. 
• The reporting rate in the hospital increased after some initiatives. The clinical pharmacist was 
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 assigned to be involved in the educational campaign for the staff.  The reporting forms were 
distributed in the hospital to be accessible to everyone. The pharmacists are in close communication 
with healthcare practitioners and can assist them in reporting. Additionally, the staff were 
encouraged to report. 
CP3 100%  (2) 
 
 
• Feedback is documented. Every reporter will receive a Thank you letter. 
• The hospital will give reporters a thank you letter in front of everybody to encourage them and to 
change the perception of people who think that when they report an ADR it means that they have 
made an error.  The hospital wants to exclude this fear and make reporting an open manner.  
CP4 100%  (2) • Every report will be assessed following a structured process. 
CP5 100% (2) 
 
 
• Cerner system will be used to extract missing information from the patient records.  
• The clinical pharmacist will ensure to complete the report information before conducting the 
analysis. 
• In addition, a report will be prepared to be discussed in the Pharmacy and Therapeutics Committee 
meeting. 
CP5a: 
Not relevant. 
(-) 
 
 
• The hospital sends the compiled and approved report to the Healthcare Quality and Patient Safety 
Department in the MOPH because it is requested to send them the medication errors report on 
monthly bases. 
CP6 No cases. (2) • No cases were encountered. The clinical pharmacist will work with the physicians if there are any 
suspected cases or contributing factors including patient adherence.  
CP7 The value was 
not provided. 
(1) 
 
 
 
• Data is available for medication errors from 2016 to 2018; however, the value was not provided. 
• The hospital will put the category of harm based on the National Coordinating Council for 
Medication Error Reporting and Prevention (NCC MERP).  
• Additionally, root cause analysis for medication errors was conducted more than once even though 
it did not cause harm for the patient. 
CP8 Not relevant. (-) • Not relevant. 
CP9 None. (0) • None.  
Total 
Score 
(11)  Out of 8 [8*2= (16)] is [(100%)] relevant indicators the obtained score was [(11) =68.8%] 
CORE OUTCOME/IMPACT INDICATOR 
Code Response Score * Assessment (Qualitative) 
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CO1 Yes.  (1) • It was reported that glucosamine in more than one patient caused swelling in the joint area, and 
there were cases with vancomycin that had the same report. 
CO2 Not relevant. (-) • Internal actions will be documented in the Pharmacy and Therapeutics Committee, and by the end 
of the year, it will be included in the annual report. Appropriateness of internal actions will be 
assessed based on the case this can include tracking changes in reporting rates and communicate 
directly with staff. 
• It was reported that there is no feedback from the MOPH this was recognized as the MOPH are at 
the phase of data collection. It was recommended that MOPH can utilize this data and share it at the 
national level for health institutions to reflect on their current performance compared to others, e.g., 
the issues that are happening in other systems. This can result in the development of awareness 
programs for healthcare professionals, patients, and the public. 
CO3 No cases. (1) • No cases. 
• The hospital does not have this record because their patients are mainly admitted to surgeries. Thus, 
this was noted as not applicable to the hospital context. Based on the data for the year 2017 there 
was zero rate infection. Hence, there were no cases of readmission. 
CO4 No cases. (2) • No cases of death. 
• The hospital does not have documentation, because no cases of death occurred. However, it was 
stated that if death will occur this will be addressed including investigation and conducting root 
cause analysis to prevent the occurrence of future cases. 
CO5 Not relevant.  (-) • Not relevant. 
CO6 Not 
documented.  
(0) • Data is available in the system, but the number is not recorded as a value. The hospital staff 
document the cost of cases in the system as a bundle. Cost data can be extracted if they want to for 
specific drugs or interventions, not disease or conditions. Also, no cases of medicine-related 
illnesses were reported. 
CO7 No cases.  (1) • No cases required an extension of hospital stay.  
CO8 Not 
documented. 
(0) • It was reported that conducting economic studies will be difficult as the staff number is small and 
resources are not enough. If needed in the future the hospital may need a third party to consult in 
such studies. 
Total 
Score 
 (5) Out of 6 [6*2= (12)] is [(100%)] relevant indicators the obtained score was [(5) =41.7%] 
(*) Score: (2) Yes fully satisfactory; (1) Yes partially satisfactory (2); and (0) No includes not satisfactory, missing data, no values, not applicable. 
(*) Score (-): Not relevant for the evaluation of system performance with WHO indicators. 
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Table R9: Hospital “B” PV system performance and capacity results measured by WHO complementary PV indicators. 
COMPLEMENTARY STRUCTURAL INDICATORS 
Code Score* Answer qualitative  
ST1 (1)  Yes, the Cerner system can be used from any computer. 
ST2 (1) Yes, in the Cerner system. 
ST3 (1) Yes, emails and the website. 
ST4 (1) Yes, UpToDate, Lexicomp, and other online sources. Additionally, hard copies are available in the pharmacies, however, 
online sources are mainly used. 
ST5 (1) Yes, the Cerner system. 
ST6 (-) Not relevant. 
ST7 (1) Yes, the Pharmacy and Therapeutics Committee will meet to update the Cerner formulary regularly. 
ST8 (1) Yes.  
ST9 (1) 
 
 
 
Yes. 
• ST9a: lecture series and journal clubs will be held regularly. Additionally, workshops and conferences are ongoing. 
• ST9b: the patient reporting cards, medication reconciliation, and the hospital follow the teach three techniques (i.e. 
informing patients on drug indication, drug use, and drug side effects) with patients. 
ST10 (0.5) 
 
 
Yes. 
• ST10a: for health professionals, competency questions will be available. 
• ST10b: none. It was noted that public involvement will need human and financial resources. The idea is possible and 
there is a consideration from the hospital side, however, it is not easy to ensure its sustainability and it will need a 
special project. 
ST11 (-) Not relevant. 
Total 
score  
(8.5) Out of 9 [9*1= (9)] is [(100%)] relevant indicators the obtained score was [(8.5) =94.4%] 
COMPLEMENTARY PROCESS INDICATORS 
Code Score* Answer qualitative  
P1 (-) Not relevant. 
P2 (0) The data is available; however, values were not provided. 
• P2a:  
• P2b: 
• P2c: 
• P2d: 
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• P2e:  
• P2f:  
P3 (-) Not relevant. 
P4 (0) The data is available; however, values were not provided. 
• P4a: 
• P4a: 
• P4a: 
• P4a: 
P5 (0.5) No percentage provided however the hospital conducts regular training and academic detailing. 
P6 (1) 100%. Patients awareness is high as a result of the following initiatives the patient reporting cards, medication reconciliation, 
and the teach three techniques (i.e., informing patients on drug indication, drug use, and drug side effects). 
P7 (0.5) Ongoing training is available based on needs. The hospital does not keep records (i.e., no documentation). 
• P7a:  
• P7b:  
P8 (0.5) • P8a: The numbers were not provided because there is no documentation system for such initiatives. However, the 
hospital conducts face to face training for new joining members or on the occurrence of trends or cases that require 
training. 
• P8b: The numbers were not provided because there is no documentation system for such initiatives. 
P9 (-) Not relevant. 
P10 (-) Not relevant. 
P11 (-) Not relevant. 
P12 (-) Not relevant. 
P13 (-) Not relevant. 
Total 
score  
(2.5) Out of 6 [6*1= (6)] is [(100%)] relevant indicators the obtained score was [(2.5) =41.7%] 
COMPLEMENTARY OUTCOME/IMPACT INDICATORS 
Code  Score  Answer qualitative 
O1 (0) The data is available; however, no value was provided. 
O2 (-) Not relevant. 
O3 (-) Not relevant. 
O4 (-) Not relevant. 
O5 (0) Not documented in this format, therefore, data was not provided. 
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O6 (0) Not documented. 
O7 (0.5) The hospital did a cost-saving study on medications in general including safety and improving the processes, the hospital 
saved a half-million Qatari Riyal for different things related to medications. However, there is no specific study on PV or 
safety alone. 
O8 (0) No, specific data on PV. 
O9 (0) Data is available; however, no value was provided. 
O10 (0) Data is available; however, no value was provided. 
O11 (0) Data is available; however, no value was provided. 
O12 (1) 100%. 
Total 
score 
(1.5) Out of 9 [9*1= (9)] is [(100%)] relevant indicators the obtained score was [(1.5) =16.7%] 
(*) Score: Yes (1), No (0). 
(*) Score (0.5): For Indicators with two Parts (A & B) If (A the answer is No Score to be (0.5) and vice versa for B). 
(*) Score (-): Not relevant for the evaluation of system performance with WHO indicators. 
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3. Hospital C  
Table R10: Hospital “C” PV system performance and capacity results measured by WHO core PV indicators. 
CORE STRUCTURAL INDICATORS 
Code Response Score * Assessment (Qualitative) 
CST1  No specific 
PV 
department. 
(1)  • Applicable but no specific PV department, there is a Pharmacy and Therapeutics Committee. 
• The Role of this committee is to govern many aspects including ADR. Additionally, the group has 
indicators to follow including ADRs. For example, ADRs reports will be collated from across all 
medical centers and the Hospital.  
• The committee encompasses multidisciplinary members. The committee reaches the clinical 
pharmacist for further analysis and based on that a monthly summary will be prepared and 
disseminated among all healthcare providers on a timely basis.  
CST2 Yes. (1) 
 
• Yes, a range of policies that cover aspects relevant to PV. 
• It was reported that at the national level there is no policy document for PV. 
CST3 Not relevant. (-) • Not relevant. 
CST4 No specific 
budget for PV. 
(0) 
 
 
• It was reported that there is no dedicated budget for PV. The allocation of resources will be based 
on request when the committee requires anything it will be supported, e.g., educational activities, 
purchasing a software, etc. 
CST5 Yes. (1) 
 
• The current human resources are enough to cover PV and medication safety. All members are full 
time, and all are briefed about terms of reference including their roles and responsibilities. 
CST6 Yes. (2) • The group has three paper-based reporting forms this includes ADRs reporting form, medication 
errors reporting form, and a medication recall form. 
• Misuse and abuse are not common. The group does not have any report on patient use for 
medication this is only included during patient examination for clinical information. 
• It was reported that staff are trained on reporting and that the reporting rate has increased by 45-
55%. Healthcare professions showed an increased awareness on the subject of reporting.  
• It was reported that there is no form for the public because this must be under the MOPH. However, 
there is a complaint system and the staff do work to resolve any issue within a maximum of 30 
working days. 
CST7 Yes. A 
process and a 
database exist. 
(2) 
 
 
• It was reported that the doctors are the custodian of patients and are responsible for identifying 
ADR. ADRs reports will be submitted and details reported will be enclosed by the pharmacist in 
charge. Then the severity will be rated, and the Naranjo scale will be used to show the probability. 
Within 48 hours it will go to the quality department. Then the committee will hold a monthly 
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discussion on the subject. 
• The database is in the form of an Excel spreadsheet. In the future, there is a plan to purchase 
software that was implemented in one of the hospitals as a testing phase. 
• The feedback will be provided to healthcare professionals on the group internet website and 
Yammer group website. 
CST8 Not relevant. (-) • Not relevant. 
CST9 Yes.  
 
(2) • The feedback will be provided to healthcare professionals on the group website and Yammer group 
website. 
• The quality department will update the news for the internet website in the form of files that are 
accessible to all medical centers and hospitals. For example, a summary of medication errors will be 
posted in one sheet accessible for all relevant staff. 
CST1
0 
Yes.  (1) • Pharmacy and Therapeutics Committee is responsible for governing aspects related to medication 
safety and taking a joint decision on relevant aspects. The committee provides advice to ensure 
patient safety across the group. 
• The group has quarterly meetings to address the challenges or concerns raised, and they have 
immediate meetings on emergency basis.  
Total 
Score 
 (10) Out of 8 [8*2= (16)] is [(100%)] relevant indicators the obtained score was [(10) =62.5%] 
CORE PROCESS INDICATORS 
Code Response Score * Assessment (Qualitative) 
CP1 One case in 
2017. 
(2) • To improve reporting across the medical centers and hospitals. The group undertook measures to 
improve reporting this includes leadership programs, enforcing the concept of no blame culture, and 
following up on reporting in a timely manner. Additionally, the group provides over time and after 
job time training. 
 CP1a: 
Not relevant. 
(-) 
CP2 Yes.  (1) • The value can be obtained from the database. The numbers will be compiled, 87 cases were reported 
in 2017. 
• It was reported that the rate and quality of reporting have increased and when gaps are identified 
feedback will be provided. In 2016, they only had 5 to six reports submitted while in 2017 there was 
an improvement of more than 300-400% fold. This surge was indicated as a result of all the 
initiatives undertaken to increase the awareness of healthcare professionals. Along with the 
development of a standardized reporting form with mandatory fields of reporting. 
CP3 100%. (2) 
 
• Feedback is provided to all reports. 
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 • The feedback will be provided as verbal feedback on some cases that have room for improvement, 
however, if nothing must be improved the staff will be informed about the incidents and their 
numbers only. 
• The group issue feedback in a consolidated monthly report thus at the monthly rounds feedback will 
be given to all reports. For critical cases, the whole team will be informed directly.  
• The group has a safety meter in all the medical clinics this includes ADR reporting. 
CP4 100%. (2) 
 
 
• They conduct the assessment for all the received reporting forms. 
• The process includes ensuring that minimum documentation required to analyze the data is captured 
during the reporting itself. Then, the clinical pharmacist will do analysis e.g. the probability scaling, 
preventability, and severity. In addition, they will determine if the case is an idiosyncratic reaction 
or an actual ADR. 
• It was reported that assessment is done based on scientific tools and guidelines to ensure that the 
process is meeting most of the requirements of evidence-based assessment. 
• The level of expertise to conduct causality assessment is sufficient as no complicated cases are 
encountered in the scope of the group practice. 
CP5 
 
Yes. (1) 
 
 
• It was reported that within the organization all reports will be satisfactorily completed and sent to 
the quality department for compilation. 
• For ADR reporting to the MOPH, it was reported that there is no structured way to report to any 
regulatory authority, e.g., the pharmacy and drug control department would not request any ADR 
reports.  For medication error data, it will be sent to the MOPH as part of the key performance 
indicators. 
CP5a: 
Not relevant. 
(-) • Not relevant. 
CP6 No cases.  (2) 
 
 
• No cases were received. The group follows the trends for internal purposes only. 
• The report forms include predisposing clinical factors for reporters to complete, e.g., renal 
dysfunction, genetics, age, gender, multiple therapies, and so on. 
• The patients will be counseled on the importance of following the regimen and the provided 
additional instructions.  
CP7 4.19% for 
2017. 
(2) 
 
 
• It was reported that their measures to build a culture that supports reporting have increased the 
number of reports however underreporting can be attributed to resistance to change for some staff 
with more than 15 years of practice. 
CP8 Not relevant. (-) • Not relevant. 
CP9 None. (0) • It was reported that the private sector is not permitted to conduct this type of research in their 
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 centers and only therapeutic follow up is permitted. 
Total 
Score 
 (12) Out of 8 [8*2= (16)] is [(100%)] relevant indicators the obtained score was [(12) =75%] 
CORE OUTCOME/IMPACT INDICATOR 
Code Response Score * Assessment (Qualitative) 
CO1 One case. (1) • It was reported that one case with the injection Voltic, there were many ADRs coming due to the 
single brand, and it was not a piece of information provided from the MOPH, it was an internal call. 
The group had cases reported frequently and they did test doses. Therefore, one signal was given 
internally, and the group withdraws the drug from their system. 
• The staff are aware of the subject matter as there is a policy on signal cases and on drug recalls. 
• The group will use interoffice notes to communicate signals to end-users. There is an action plan to 
communicate signals to external parties if needed. 
• The group will depend on causality analysis to know if this is happening in all centers then this will 
be referred to the committee to make the decision, based on the severity and frequency of reports 
the action will be taken. Actions implemented after a signal notice is the responsibility of the 
committee. There is no delay in such cases that affect patient safety. 
CO2 Not relevant. (-) • The group will act as directed by the MOPH. Additionally, the group relies on external reputable 
sources like the US FDA. 
CO3 One case. (2) • One reported case from 2016 to date; Allopurinol and Stevens-Johnson syndrome. 
• The group does not quantify the burden of medication-related hospitalization because it will be 
referred to the public sector, e.g., financial burden. 
CO4 No cases. 
 
(1) • No cases encountered.  
• It was reported that the inclusion of this indicator in the group system will require staged execution 
and building of the capacity including infrastructure, manpower, and others. Therefore, capturing 
this indicator and ensuring that the process is sustainable will require a period of time. 
CO5 Not relevant. (-) • Not relevant. 
CO6 No.  (0) • Not estimated. 
• The group does not have a health economist. 
• It was reported that for this indicator information is sensitive and hard to extract. This needs to 
happen within the MOPH and there should be a system in place for such studies.  
CO7 No.  (0) • Not available or documented. 
• It was recommended that this information will be beneficial for health planning if it was estimated 
at the national level under the regulatory body. 
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CO8 No.  (0) • Not available or documented. 
Total 
Score 
 (4) Out of 6 [6*2= (12)] is [(100%)] relevant indicators the obtained score was [(4) =33.3%] 
(*) Score: (2) Yes fully satisfactory; (1) Yes partially satisfactory (2); and (0) No includes not satisfactory, missing data, no values, not applicable. 
(*) Score (-): Not relevant for the evaluation of system performance with WHO indicators. 
 
Table R11: Hospital “C” PV system performance and capacity results measured by WHO complementary PV indicators. 
COMPLEMENTARY STRUCTURAL INDICATORS 
Code Score* Answer qualitative  
ST1 (1)  Yes. 
ST2 (1) Yes. The British National Formulary and they compare against the prescription bill. 
ST3 (1) Yes. 
ST4 (1) Yes, the British National Formulary. 
ST5 (0.5) Yes. Excel spreadsheet. 
ST6 (-) Not relevant. 
ST7 (1) Yes, critical medicine list. The group does perform VED analysis (vital, essential, and desirable matrix). 
ST8 (1) Yes, there are certain conditions to be monitored like antibiotic prophylaxis. 
ST9 (0.5) • ST9a: Yes, mandatory once every quarter for all staff related to medication safety, e.g., physicians, pharmacists, 
dietitians, and others. 
• ST9b: For the public, radio talks on medication safety and other aspects. Additionally, antibiotic awareness week the 
group communicated with the public through social media and website platforms. 
ST10 (0) No, no tools used, however, they train them based on their internal data. 
ST11 (-) Not relevant. 
Total 
score  
(7) Out of 9 [9*1= (9)] is [(100%)] relevant indicators the obtained score is [(7) =77.8%] 
COMPLEMENTARY PROCESS INDICATORS 
Code Score* Answer qualitative  
P1 (-) Not relevant. 
P2 (1) Yes.  
• P2a: 100% ADR and 10% medication errors. 
• P2b:   
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• P2c: 70% medication errors, prescription errors mainly. 
• P2d: 20% medication errors. 
• P2e:  
• P2f:  
P3 (-) Not relevant. 
P4 (1) Less Than 1%. 
P5 (1) All relevant groups are knowledgeable. 100%, because it is a part of the group induction models, on quarterly bases the staff is 
training on that. 
P6 (1) Yes, 100% receive counseling by pharmacists.  Drugs that have the potential to cause an ADR are explained very well by the 
pharmacist when they dispense. 
P7 (0.5) Yes. 
• P7a: Compulsory mandatory module is conducted (more than 25 sessions in 2017), and every quarter the group do 
refresher training for pharmacy staff. 
• P7b: Radio talk to the public on medication safety and there is a platform to address their concerns. 
P8 (0.5) • P8a: Yes 70-80% of healthcare professions, 280 individuals. 
• P8b: radio talk for the general public. 
P9 (-) Not relevant. 
P10 (-) Not relevant. 
P11 (-) Not relevant. 
P12 (-) Not relevant. 
P13 (-) Not relevant. 
Total 
score  
(5) Out of 6 [6*1= (6)] is [(100%)] relevant indicators the obtained score was [(5) =83.3%] 
COMPLEMENTARY OUTCOME/IMPACT INDICATORS 
Code  Score  Answer qualitative 
O1 (1) One case. 
O2 (-) Not relevant. No cases were encountered. 
O3 (-) Not relevant. 
O4 (-) Not relevant. 
O5 (1) One case. 
O6 (0) Not able to quantify. 
O7 (0) The group does not have these data. 
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O8 (0) Not able to quantify. 
O9 (1) Yes, Five. 
O10 (1) Yes 10 to 12% 
O11 (1) No, no cases 
O12 (1) Yes, 100%. 
Total 
score 
(6) Out of 9 [9*1= (9)] is [(100%)] relevant indicators the obtained score was [(6) =66.7%] 
(*) Score: Yes (1), No (0). 
(*) Score (0.5): For Indicators with two Parts (A & B) If (A the answer is No Score to be (0.5) and vice versa for B). 
(*) Score (-): Not relevant for the evaluation of system performance with WHO indicators. 
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4. Hospital D 
Table R12: Hospital “D” PV system performance and capacity results measured by WHO core PV indicators. 
CORE STRUCTURAL INDICATORS 
Code  Response Score * Assessment (Qualitative) 
CST1  No specific PV 
department or 
unit. 
(1) • The Quality and Patient Safety Department are responsible for the collation and analysis of 
medicine-related safety issue reports. The department does not have a well-established system or 
protocols for PV and ADRs.  
• At the current state, they are focused on patient safety and enhancing quality. The department 
members are planning to initiate the processes which enhance patient safety. Plans include 
educational programs and the priority is to educate the staff on the importance and process of 
reporting.   
CST2 No specific PV 
policy or 
guidelines. 
(0) 
 
• No, the hospital does not have specific policies on PV or ADR reporting.   
• The hospital is in the process of developing all medication management policies. The new policies 
will cover many aspects of medication safety, medication errors, ADRs, quality of the medication. 
The new policies will have a certain timeline to be revised and updated regularly by the 
management 
CST3 Not relevant. (-) • Not relevant. 
CST4 No specific 
budget 
allocated for 
PV.  
(1) • There is no dedicated financial provision for PV activities. 
• The department has support from the management for their need’s fulfillment by request (case by 
case), e.g., educational aspects. Currently, the budget is sufficient because the system is not very 
well established. 
CST5 Yes. Not 
sufficient.   
(1) • The department has 3 full-time members, one from a pharmacy background and two from a 
nursing background. The department reported that to have a well-established PV system in the 
future the current human resources is not enough. It was reported that there is a need for pharmacy 
background professionals to support educational activities on medication management and safety. 
Additionally, there is a need for staff with experience in vigilance and medication safety, data 
analysis, and risk management.  
• The current members are enthusiastic and are self-directed toward improvement even if there is no 
formal education provided for them at the current position. 
• The department developed a competency chart that mentions all the activities for clinical 
pharmacists, and it includes the process of ADR detection and reporting. 
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CST6 Yes.  
 
(2) • The hospital has two paper-based reporting forms, and they are fully integrated into the system. 
First, the occurrence variance report, it is used for reporting medication errors and other safety 
issues. This report has space (i.e., free text area) to write manually the sub-indicators CST6b to 
CST6c, and CST6d. Second, ADR s reporting form that is available in the previous policy manual. 
The current ADR form does not have all elements required for causality assessment the new one 
that they will implement will be more appropriate. 
• There are no report forms for patients CST6e. However, they are planning to educate the patients 
on how to observe any untoward reaction, how to report it, and how to get back to the hospital. The 
department noted that there is a lack of communication from the patient side as they do not report 
or get back to the facility to address their concerns or complaint. 
CST7 Yes, they have 
a process and 
an excel 
database. 
(1) 
 
• A process for data collection, analysis, and feedback exits but it is not well developed. The 
department collects information from the paper-based reports in an Excel sheet database. 
• The department performs data analysis on the received reports mainly medication error reports and 
follows that with categorization and trend analysis.  Additionally, the outcome of the analysis is 
used to provide recommendations to inform the prescribers. They have already recruited clinical 
pharmacists to have an oversight on all the medication-related activities including reporting. As a 
result of their efforts in the past two years, they noticed that medication errors are not being 
repeated compared to previous years. 
• The pharmacist will categorize the medication errors and make the final report every month. This 
report will be sent to the medical director to forward it to the hospital staff to avoid repeating these 
medication errors in the future. 
• Feedback can include calling the prescribers or they send a report with the reference to ask for their 
explanation in case of medication errors. 
• The hospital has medication error boards, which are submitted to the quality improvement team or 
pharmacist to enter data in the system as key performance indicators. Then they submit this data to 
MOPH. 
• The department reported some barriers to implement Electronic Medical Records (EMR) for the 
inpatient consequently they have manual or paper-based medical records.  
CST8 Not relevant. (-) • Not relevant. 
CST9 Yes, monthly 
newsletter. 
(2) • Yes, the hospital publishes a monthly newsletter that includes PV and medication safety issues e.g. 
safety warnings from FDA website. The impact of information shared on professional behavior is 
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considered profound because the staff became more vigilant and if they have any concerns, they 
will call the pharmacist or other responsible staff. This feedback is offering an educational benefit 
and is reducing medication error cases. The future plan includes developing a specifically 
approved format for the newsletter.  
• They do not have a system for the public. However, the hospital plans to develop patient's 
instruction cards at the time of discharge to include information on medication uses, side effects, 
how to take the medication, etc. 
• The current policy manual doesn't specify the communication flow, timelines, and communication 
and emergencies. They do it at the individual level and there is no proper standardized process to 
follow. 
CST1
0 
Yes, The 
Pharmacy and 
Therapeutics 
Committee. 
(2) • The Pharmacy and Therapeutics Committee can provide relevant advice on medication safety and 
PV and are responsible for the decision-making process. The timelines for meetings are specified 
in the policy (every three months) but the members meet frequently (once per month) and in 
emergencies, they have immediate meetings. 
• They are working on plans to developing drug formulary, changing the policy manual, developing 
guidelines, developing drug protocols for staff, and preparing instruction cards. 
• The committee consists of nine members of different professional backgrounds including medical 
director, chief clinical officer, quality manager, chief nursing officer, infection control nurse, 
clinical pharmacist, supply chain manager, and a manager from the internal medicine.  
• The committee requires a clinical pharmacist and an expert in data management and data analysis 
to fulfill their future plans successfully.  
Total 
Score 
 (10) Out of 8 [8*2= (16)] is [(100%)] relevant indicators the obtained score was [(10) =62.5%] 
CORE PROCESS INDICATORS 
Code Response Score * Assessment (Qualitative) 
CP1 One reported 
ADR case in 
2018. 
(2) • It was reported that a minimum number of people are interested in reporting this causing an under-
reporting problem.  The barriers to reporting were lack of knowledge, fear, and reluctance to 
report. The latter is an issue especially among nurse practitioners, this due to the previous 
management that was in favor of doctors, they were considered the ultimate authority in the care of 
patients. 
• They continuously address the under-reporting issue by educating the staff, increasing awareness 
on the importance of reporting, encouraging staff to report, publishing the newsletter, and the full 
support provided by the new management to endorse teamwork. After introducing the new 
policies, the department has plans to implement regular educational programs for the staff for 
 CP1a: 
Not relevant. 
(-) 
  
359 
 
training and education on various issues.  
CP2 16 total reports 
in 2018. 
(1) • The most frequently reported cases in 2018 were medication errors (n=15) and non-preventable 
ADR case (n=1) reported by a nurse. 
• After the department started analyzing the reports and making final monthly reports to be sent to 
the medical director who will communicate with the prescribers, they observed over time that the 
frequency of reports on medication errors was reduced. 
CP3 100% (2) • Every report will be analyzed, and the department will provide feedback within 3 weeks or less to 
prepare the monthly report. 
CP4 No evidence-
based causality 
assessment.  
(0) • Estimation of 60 to 70% will be assessed but no evidence-based tool will be used reports 
assessment rely on the discussion between department members and based on the evidence 
provided in the literature. The reports will be assessed but it's not a hundred percent, because some 
of the doctors, they're visiting doctors. Thus, it may difficult to communicate with them for the 
cases. 
• The results will be submitted in a report to the pharmacy and therapeutics committee to develop 
strategies.  
• The department noted that there is a need for experts in the future who are able to conduct the data 
analysis utilizing validated tools and statistical methods. 
CP5 100%. (2) • 100% of medication error reports are submitted to the MOPH.  
• The department is required to create an Excel file key performance indicator where all the 
medication error data will be submitted to the MOPH. The ADR case was included in the same 
file. However, the department doesn't receive any feedback from the MOPH and the didn't get any 
communication on how to improve.  
• There is a focus from the MOPH on vaccine safety and reporting. The vaccination department is 
responsible for sending reports and recording their files in a registry. Additionally, they are in 
continuous communication with the MOPH regarding any memo or procedure they need to follow. 
Moreover. the MOPH is coming for frequent inspections to see whether if the hospital complies 
with the rules and regulations for vaccines. In addition, MOPH conducted workshops on vaccines, 
therefore the hospital is following the proper procedures for vaccines. It was reported that this 
focus needs to be on medications as well.  
CP5a: 
Not relevant.  
(-) 
CP6 No reported 
cases. 
(1) • No reported cases from healthcare professionals or patients.  They do not have a specific process to 
distinguish the causes of therapy failure they depend on observation only.  
• Underreporting of therapeutic ineffectiveness was linked to the underreporting issue, lack of 
sufficient human resources (i.e., only one pharmacist to cover many areas), lack of knowledge, and 
patients’ complaints are not documented.  
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CP7 93.75% (1) • Out of 16 reports, 15 were medication error cases.  
• It was reported that medication error reporting varies between various hospital settings. 
Additionally, in outpatient settings, there is no reporting on medication errors.  
CP8 Not relevant.  (-) • Not relevant. 
CP9 None. (0) • No studies. It was reported that healthcare professionals will only be aware of active surveillance 
activities once they receive training, education, have a proper protocol in place, and the initiation 
of such studies. 
Total 
Score 
 (9) Out of 9 [8*2= (16)] is [(100%)] relevant indicators the obtained score was [(9) =56.3%] 
CORE OUTCOME/IMPACT INDICATOR 
Code Response Score * Assessment (Qualitative) 
CO1 None. (0) • No signals identified and no systematic process in place to identify signals.  
• It was conveyed that the possibility of introducing the process in the dynamics of the system in the 
future will require a well-established reporting system, advocating healthcare practitioners on 
reporting, a team of experts in this field, and a protocol to verify whether it was related to the drug. 
CO2 Not relevant. (-) • The hospital depends on the MOPH circulars and guidelines. Additionally, the hospital contacts the 
MOPH to ensure they are following the right procedures and following practice standards.  
• The pharmacy and therapeutics committee is responsible for taking internal actions, guiding the 
implementation of those actions, and develop strategies at the hospital level. The hospital does not 
have strategies to evaluate the outcomes of the internal actions on the long term. 
• At the individual level hospital staff (various departments) will check the FDA website and other 
official websites to follow on aspects that can be addressed at the hospital level. This will be done 
in case if there is a warning or an instruction not provided from the MOPH side. For instance, there 
was no warning for fluoroquinolones from the MOPH, but it was reported on the FDA website.  
• Information from MOPH and other global sources will be communicated in the monthly 
newsletter. 
CO3 One case in 
2018. 
(1) • One admission, the patient was allergic to Cefuroxime this was mentioned in the patient profile, 
but the doctor prescribed without checking and the patient was admitted to the emergency 
department. The burden of medication-related admissions is not documented in a database. 
• The hospital reported a few barriers that can lead to undetected hospital admission due to 
medicine-related problems. The absence of software to report and record errors. The limited 
number of expert manpower able to detect this indicator. Also, reporting by a healthcare 
professional is inadequate. 
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• The hospital aims to establish a well-developed system that includes analysis of the burden of 
medicines-related problems and their impact on hospital admissions to identify the problems and 
address them accordingly.  
CO4 None. (1) • No reported or detected cases of death.  
CO5 Not relevant.  (-) • Not relevant.  
CO6 No data 
documented. 
(0) • There is no documentation system for this data.  
• If such data will be generated the hospital will require expert manpower for this indicator. 
CO7 No data 
documented. 
(0) • There is no documentation system for this data.  
CO8 No data 
documented. 
(0) • There is no documentation system for this data.  
Total 
Score 
 (2) Out of 6 [6*2= (12)] is [(100%)] relevant indicators the obtained score was [(2) =16.7%] 
(*) Score: (2) Yes fully satisfactory; (1) Yes partially satisfactory (2); and (0) No includes not satisfactory, missing data, no values, not applicable. 
(*) Score (-): Not relevant for the evaluation of system performance with WHO indicators. 
 
Table R13: Hospital “D” PV system performance and capacity results measured by WHO complementary PV indicators. 
COMPLEMENTARY STRUCTURAL INDICATORS 
Code Score* Answer qualitative  
ST1 (0)  No. 
ST2 (1) Yes. The internet. 
ST3 (1) Yes, Phone and email. 
ST4 (0) No, there are no sources of information or a dedicated library. The staff has their personal references like the British National 
Formulary (BNF).  
ST5 (0) No. 
ST6 (-) Not relevant. 
ST7 (1) Yes, there is no official essential medication list, but the hospital has a drug formulary.  
ST8 (1) Yes. PV data is continuously considered to develop hospital guidelines. Additionally, they follow the MOPH guidelines for 
some diseases. 
ST9 (0) • ST9a: No, they educate the prescribers at the individual level and they disseminate safety alerts and a newsletter. The 
hospital has plans to conduct educational and training sessions after the implementation of the new policies. 
  
362 
 
• ST9b: No, only patient counseling. The hospital has plans to develop medication instruction cards.  
ST10 (0) No, but the hospital wants to have recommendations to develop tools used in hospitals with well-established systems. 
ST11 (-) Not relevant to HMC. 
Total 
score  
(4) Out of 9 [9*1= (9)] is [(100%)] relevant indicators the obtained score was [(4) =44.4%] 
COMPLEMENTARY PROCESS INDICATORS 
Code Score* Answer qualitative  
P1 (-) Not relevant. 
P2 (1) Yes.  
• P2a: Medical doctors, 0%. 
• P2b: Dentists, 0%. 
• P2c: Pharmacists, estimate 95%.  
• P2d: Nurses, estimate 5%. 
• P2e: The general public, patients 0%, 
• P2f: Manufacturers, no, that process is not relevant. 
P3 (-) Not relevant. 
P4 (0) No. The hospital does not have this data. 
P5 (1) Yes. An estimate of 60% aware of ADR. 
P6 (1) Yes, patients receive education and ADR is a part of the education for some selected drugs. Thus, 30% of them get an 
education on ADR and side effects to avoid the issue of non-adherence from the patients. 
P7 (0) • P7a: For the year 2018, no face to face training. Education is through the publication of a monthly newsletter, monthly 
internal seminars or sessions, and instructions handouts which include PV and medication safety. Training is not 
defined in the policy documents, but it is done by the Quality and Patient Safety Department that takes into 
consideration the needs and the required content for training and education.  
• P7b: None, for the public. 
P8 (0.5) • P8a: number of health professionals involved in educational efforts from 40-60 prescribers, nurses, pharmacists or 
other relevant professionals. 
• P8b: None, for the public. 
P9 (-) Not relevant. 
P10 (-) Not relevant. 
P11 (-) Not relevant. 
P12 (-) Not relevant. 
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P13 (-) Not relevant. 
Total 
score  
(3.5) Out of 6 [6*1= (6)] is [(100%)] relevant indicators the obtained score was [(3.5) =58.3%] 
COMPLEMENTARY OUTCOME/IMPACT INDICATORS 
Code  Score  Answer qualitative 
O1 (1) Yes, the percentage of preventable ADRs is 0% for the one case received in 2018.  
O2 (-) Not relevant. 
O3 (-) No, the hospital does not have this data, and no cases were reported or observed. 
O4 (-) Not relevant. One case of acetaminophen discoloration from the national pharmaceutical industry this was reported to the 
MOPH.  
O5 (0) Data not documented for this indicator.  
O6 (0) No, the hospital does not have this data. The hospital indicated that it is non-applicable as it is not an indicator relevant for the 
private sector therefore, they do not capture this data.  
O7 (0) No, the hospital does not have this data. The hospital indicated that it is non-applicable as it is not an indicator relevant for the 
private sector therefore, they do not capture this data.  
O8 (0) No, the hospital does not have this data. The hospital indicated that it is non-applicable as it is not an indicator relevant for the 
private sector therefore, they do not capture this data.  
O9 (1) Yes, a minimum of five medicines per prescription. Polypharmacy is a reported issue among prescribers.  
O10 (1) 10% as an estimation. 
O11 (1) 5% as an estimation. The hospital does not have this data for the outpatient pharmacy. Data is captured for the inpatient setting 
only. 
O12 (1) Yes, 100% of patients receive information on the use of their medications and 30% of the people receive education including 
ADRs. 
Total 
score 
(5) Out of 9 [9*1= (9)] is [(100%)] relevant indicators the obtained score was [(5)=55.6%] 
(*) Score: Yes (1), No (0). 
(*) Score (0.5): For Indicators with two Parts (A & B) If (A the answer is No Score to be (0.5) and vice versa for B). 
(*) Score (-): Not relevant for the evaluation of system performance with WHO indicators. 
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5. Hospital E 
Table R14: Hospital “E” PV system performance and capacity results measured by WHO core PV indicators. 
CORE STRUCTURAL INDICATORS 
Code Response Score * Assessment (Qualitative) 
CST1  No specific PV 
department.  
(1)  • The Pharmacy department is overseeing aspects related to PV and medication safety. The 
department has the technical knowledge, skills, and appropriate resources. The department 
communicates through email with all healthcare providers on medication-related safety issues. 
• The pharmacy department collaborates with the Quality Improvement Department which offers a 
more generic role in medication safety. The quality improvement coordinator trends data for 
adverse drug events and the pharmacists provide consulting or advisory services. 
• The hospital does not have formalized structures, the PV system is at an early stage of 
development. 
• If needed the Pharmacy and Therapeutics Committee will be included.  
CST2 No specific 
policy on PV.  
(1) 
 
• No specific policy on PV.  The hospital has an internal policy on adverse event reporting, which 
encompasses medication errors, safety. Additionally, other policies relevant to medication safety 
like high alert or high-risk medications and dispensing guidelines. 
• The existing policies are not comprehensive to cover the full scope of PV. Policies are updated 
every two years. 
• The Head of the Pharmacy Department is responsible for developing and enforcing those policies. 
CST3 Not relevant.  (-) • Not relevant.  
CST4 No specific 
budget for PV. 
(0) 
 
• The hospital is in the process of expansion by adding another facility. Hence, looking at newer 
innovations and challenges coming, a specific budget that is assigned for medication safety will be 
required. 
CST5 Yes.  (2) 
 
 
• Yes, human resource for the existing system is enough. The level of expertise of staff conducting 
the analysis is sufficient for the institution. 
• For PV activities including ADRs one or two full-time, pharmacists’ staff are available. The job 
description includes medication safety and ADR reporting, however, the staff are not trained 
specifically on PV. 
• With the upcoming expansion, there is a need for more expressive including a pharmacist who has 
experience in PV to contribute to the development of new policies and providing training and 
education.   
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CST6 No.  
 
 
 
(1) 
 
 
 
 
 
• No, ADR reporting form. The hospital has an adverse event reporting form, not specific for 
medications. Both harder and soft copies are available. 
• The form has specific fields and subcategories e.g. ADR, drug interactions, drug alerts, and safety 
issues. It is like an occurrence variance report form format. For example, if the pharmacist wants to 
report substance abuse or something there is an insert format to mention that on the form. 
• The report form is a standalone or separate system, it's not linked to the EMR. The hospital has an 
in-house developed system.  
• No standard reporting form for the general public. It was reported that A national PV policy can 
include this form. The hospitals cannot initiate such activity alone as the MOPH has defined very 
specific national patient rights and responsibilities. The hospital is by law required to abide by that 
and the hospital responsibilities have been revised to reflect that.   
• The hospital has defined complaint policy. The Public Relations Department is responsible for 
managing patients’ complaints. If a patient has some complaints regarding medication, this will be 
sent to the quality improvement and risk management committee to review the case file. The 
hospital must respond within seven working days of receiving it. Most cases reported are 
dispensing errors and one complaint was an adverse response to a drug.  
CST7 Yes. They have 
a process and 
an excel 
database. 
(1) 
 
 
• There is a process but it’s not very formalized.  The hospital system does have a database, but the 
information is stored in an Excel spreadsheet. 
• Means of providing feedback includes mail communication and verbal discussion. 
• The recording and analysis are done for every report received this will include drug-related 
problems reports and other incidents. The data from all reports are reviewed by the quality 
improvement coordinator to collate and analyze the data.  
• The hospital will investigate to determine the cause of the incidents, whether the drug was 
responsible. Therefore, the hospital tries to do a root cause analysis for all investigations. Then, 
then the information will be combined to see the possibility of initiating system changes. The 
Failure Mode and Effects Analysis (FMEA) will be used to look at the probability, occurrence, and 
severity.  
• It was reported that a comprehensive system for risk management and an incident report will be 
beneficial as the in-house system has its own limitations and is not built by experts. However, the 
budget will not be sufficient, and the management may not accept such change.  
CST8 Not relevant. (-) • Not relevant. 
CST9 Yes.  (2) • The hospital has a newsletter published every quarter and they have their own website. 
• For the newsletter, it can include safety information or warnings. However, it is not very 
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comprehensive feedback but the general perception among healthcare professionals that it adds 
value, but it needs to cover more topics. The quality of reported information will be checked this 
includes a review of the source of information. It should be from a recognized peer-reviewed 
journal and from a regulatory authority a credible source like the US FDA, t EMA, or MOPH. 
• For the website, it is not used for PV or drug safety information communication. It was reported 
that MOPH overregulates such activities so if they will add information on it has to be approved by 
the MOPH. Hence, it was reported that the best resource or tool for having a safety alert is the 
MOPH website. 
• Emergency and disaster preparedness plan is available and part of it includes the pharmacy 
department activities and medicines. Further, the hospital participates at the ministerial level in the 
National Health and Disaster Preparedness Committee meetings. 
CST1
0 
Yes.  (2) • The Pharmacy and Therapeutics Committee serves as an advisory committee on medication safety. 
It encompasses six people from a different professional background. However, depending on the 
topic discussed members can be added. The committee meets every three months. 
• The committee reviews the procurement of new medicine, medication safety issues of current 
medicines, and new systems to improve medication management in the hospital. 
Total 
Score 
 (10) Out of 8 [8*2= (16)] is [(100%)] relevant indicators the obtained score was [(10) =62.5%] 
CORE PROCESS INDICATORS 
Code Response Score * Assessment (qualitative) 
CP1 No cases 
reported in 
2018. 
(1) • Out of the 65 reports received in 2018, none were cases of ADRs. It was reported that it is difficult 
to determine if the cases are ADR because it needs a lot of expertise. 
• The culture of reporting among healthcare practitioners is positive. The number of reports has 
improved over the years with the new policies and strategies implemented. However, 
underreporting remains a challenge. Healthcare professionals understand that reporting is 
important, and it can improve the system, however, some are still afraid to report and this will take 
time to change.  
• The quality of documentation is good for data analysis and it is determined internally by internal 
policies and externally by the MOPH and the accreditation body. 
CP1a: 
Not relevant. 
(-) 
CP2 More than 
1000 reports. 
 
(2) 
 
 
• More than 1000 reports. 
• In 2011, they had 3 reports however now reporting has improved dramatically.  
• The strength of the database is good for the moment; however, it lacks the capacity to expand. 
With the hospital expansion plans, there is a need to procure a more professional and robust report 
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management system. 
• To improve reporting rates and culture the hospital gets the leadership involved and they are 
conducting a lot of lectures. The hospital does leadership rounds, but it will take some time to 
achieve a just culture because it's difficult to determine if the error is an individual responsibility or 
system-related failure. Therefore, leadership involvement will give the assurance that there will be 
no penalization. The hospital did a patient safety culture survey for the staff and based on the 
results the line managers were informed to give the staff assurance that they won't be penalized. 
Additionally, the hospital does reviews of incentive potency.  
CP3 100%. (2) 
 
 
• 100% of the reports receive feedback. 
• The process is very formalized. A copy of the report and the feedback in the form of 
recommendation or course of action will be sent by email. The email will be sent to the head of the 
department to disseminate that information within that department. A file will be used to document 
all the feedback reports provided.  
• The hospital has defined timelines for any investigation or review. Within seven days feedback 
must be received otherwise the reporters can formally make a complaint that they have not 
received any feedback. No delays were encountered because a lot of resources are dedicated to this 
process. However, when the balance of information is not enough this will be acknowledged by 
email, indicating that this process might take some time because all the relevant information 
required for feedback is not collected yet. 
CP4 No cases of 
ADRs.  
(0) 
 
 
• An estimate of 90% of the reports will be assessed; Not all the reports require an assessment. 
• The level of pharmacy staff expertise is enough. When the pharmacy department does not have the 
capacity to review a case, because the internal expertise is not sufficient the hospital will get a peer 
review, either internally from the organization or externally through HMC or some other 
organization whom the hospital has collaborated with. 
CP5 Yes. (1) 
 
 
• Reports are not sent to the MOPH. However, they submit the information that has an impact on the 
MOPH (Pharmacy and Drug Control Department). In addition, every quarter, medication error data 
will be sent to the MOPH as key performance indicators requirements, ADRs data is not requested 
from the MOPH. It was reported that it's an informal system and it's not a very formalized 
structure.  
• The MOPH monitoring on vaccines is very robust, there's a formal system. There are defined 
forms, hotlines to contact with the MOPH, regular inspections, and provision of training.  
• The clinical investigations from MOPH exist however there are no timelines defined and proper 
formal instruction for the investigation is not provided. 
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CP5a: 
Not relevant. 
(-) 
 
• Not relevant. 
CP6 3%. (2) 
 
 
• In 2018, two reported cases with fertility medications. 
• This data is documented, and the investigation is done following a specific format. For example, if 
the staff get a case, they try to categorize the possible reason for failure. First, if the medication 
properly indicated for the patient. Second, whether the patient met the criteria for the medicine 
(e.g., ethnic variation). Third, the storage conditions for the medicine, Fourth, if the route of 
administration was done correctly and so on. Hence, the staff will follow the omission 
methodology or exclusion. 
• The investigation is very intensive, and it requires a lot of expertise and it may require consulting 
expertise from the MOPH or other organizations. 
CP7 76.92% (2) 
 
 
• In 2018, out of all the 65 reports received 50 reports were medication error cases. Most of them 
were near misses, only one or two were not a near miss.  
• The number of cases is limited because their scope of service is defined and mostly includes 
relatively safe drugs (e.g., no chemotherapy drugs). However, it can also be attributed to healthcare 
professionals underreporting and patients not reporting or getting back to healthcare professionals 
to address drug-related problems. 
CP8 Not relevant. (-) • Not relevant. 
CP9 None. (0) 
 
• The awareness is not very uniform or consistent among healthcare professionals on active PV, 
there's always a lack of understanding of these studies. 
• The factors that enable private hospitals to participate in such studies would include. First, that 
such studies are mandated by the MOPH. Because active PV is not in alignment with the scope and 
nature of work and it is very difficult for private organizations to engage in this activity as it 
doesn't generate any revenue. Second, if there's a policy at the national level to cover active PV. 
Third, if there will be some incentives for organizations that are doing active surveillance. 
Incentives would include MOPH support by providing expertise in PV and statistical analysis. 
Total 
Score 
 (10) Out of 8 [8*2= (16)] is [(100%)] relevant indicators the obtained score was [(10) =62.5%] 
CORE OUTCOME/IMPACT INDICATOR 
Code Response Score * Assessment (Qualitative) 
CO1 No. (0) • None. 
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CO2 Not relevant. (-) • For internal actions, it was noted that it regulates the practice and gives the clinicians a broader 
understanding that review and monitoring are undertaken. Additionally, many healthcare 
professionals value the feedback provided. 
• The Pharmacy and Therapeutics Committee is responsible for concluding the appropriateness of 
internal measures. Additionally, the committee reviews any action or warning provided by the 
MOPH. For complaint-based concerns the Quality Improvement, Risk Management Committee, 
and the Medical Administration will be responsible; mainly the Quality Improvement. 
CO3 Not 
documented.  
(0) • Not quantifiable as it does not align with the objectives of private healthcare providers. 
• It was reported that despite the admission diagnosis, the determination is made by the consultant. 
CO4 No cases. (1) • No cases and data are not documented for this indicator. 
CO5 Not relevant.  (-) • Not relevant. 
CO6 Not 
documented.  
(0) • No, it was reported that it is difficult to quantify and that the hospital doesn't have the means and 
the intention to measure this indicator. 
• In terms of costing, it was reported that this will benefit the organization for investing in important 
areas, but the private institutions are not in the business of prevention; They're in the business of 
care. 
• It was reported that the MOPH does have cost analysis and does perform a cost-benefit analysis. 
But it can be not as robust as desired and MOPH may lack experts in the field of economy. For 
instance, MOPH used to release a healthy economy magazine every year, but the hospital did not 
see this for a very long period.  
CO7 Not 
documented. 
(0) • The hospital doesn’t have enough information to quantify that data.  
CO8 Not 
documented. 
(0) • No information as it is does not align with the organization's scope of practice. It was reported that 
if this indicator will be of importance or significance to the current practice the hospital will 
definitely monitor. 
Total 
Score 
 (1) Out of 6 [6*2= (12)] is [(100%)] relevant indicators the obtained score was [(1) =8.3%] 
(*) Score: (2) Yes fully satisfactory; (1) Yes partially satisfactory (2); and (0) No includes not satisfactory, missing data, no values, not applicable. 
(*) Score (-): Not relevant for the evaluation of system performance with WHO indicators. 
 
  
370 
 
Table R15: Hospital “E” PV system performance and capacity results measured by WHO complementary PV indicators. 
COMPLEMENTARY STRUCTURAL INDICATORS 
Code Score* Answer qualitative  
ST1 (1)  Yes, the Pharmacy Department, analyzes the data using computers. 
ST2 (1) Yes. The hospital system uses electronic prescription thus it's easy to monitor. The hospital reports called Consumption 
Reports, to see which doctors are prescribing, the consumption rate for medicine, and others. 
ST3 (1) Yes, Phone, email. 
ST4 (1) Yes, The British Pharmacopoeia and Qatar National Formulary application. 
ST5 (1) Yes, electronic health records. 
ST6 (-) Not relevant. 
ST7 (1) Yes, there is no official essential medication list. However, a hospital formulary of essential drugs that is updated every three 
years or when drugs are added or deleted. 
ST8 (1) Yes. PV data is considered. 
ST9 (0.5) • ST9a: not specifically for PV. But the hospital does train the staff on new drugs including the indications and 
guidelines. Additionally, aspects of medication safety the hospital has an adverse event reporting training at the staff 
orientation and every year.  
• ST9b: No. patient counseling only. Additionally, the hospital made educational efforts in schools to educate them 
about antibiotics to explain that antibiotics should not be taken very regularly, and the person should question the 
need for the antibiotic written by doctors. Furthermore, students were told about antimicrobial resistance and how it 
is building up in the world.  
ST10 (0.5) • ST10a: Yes, the hospital has developed tools for adverse event reporting online. In addition, policies are available 
online through the portal. 
• ST10b: No. 
ST11 (-) Not relevant. 
Total 
score  
(8) 
 
Out of 9 [9*1= (9)] is [(100%)] relevant indicators the obtained score was [(8) =88.9%] 
COMPLEMENTARY PROCESS INDICATORS 
Code Score* Answer qualitative  
P1 (-) Not relevant. 
P2 (1) Yes. The hospital sends a combined report to the MOPH regarding medication-related admissions or errors and patient safety 
issues. It is difficult to quantify in terms of percentage. However, as an estimate:  
• P2a: Medical doctors, 70%. 
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• P2b: Dentists, 5%. 
• P2c: Pharmacists, 5%. 
• P2d: Nurses, 15-20%. 
• P2e: The general public, 2-3% patient-provider occurrences. 
• P2f: Manufacturers. The companies do send a circular if there is an issue, but the hospital did not receive any so far.  
P3 (-) Not relevant. 
P4 (1) Yes. From 60 to 65 total reports: 
• P4a: 30 or 48. 
• P4b: 1 or 2. 
• P4c: 3 or 4. 
• P4d: 15. 
P5 (1) Yes. 100%. 
P6 (0.5) Yes. Difficult to quantify as it is not documented. The patients receive counseling at two areas one at the consultation stage 
where the doctor tells them about the adverse event of the medications, and then with the pharmacists. Consequently, health 
professionals educate patients about medication safety using the terms adverse event or side effects that are not present in the 
leaflet, but ADR as a term maybe not used. 
P7 (0.5) • P7a: Three to four last year. For example, initially during orientation and then every six months as a refresher course; 
This is a requirement.  
• P7b: None. 
P8 (0.5) • P8a: Yeah, 100% received training. The healthcare staff number was around 280 to 290. 
• P8b: None. 
P9 (-) Not relevant. 
P10 (-) Not relevant. 
P11 (-) Not relevant. 
P12 (-) Not relevant. 
P13 (-) Not relevant. 
Total 
score  
(4.5) Out of 6 [6*1= (6)] is [(100%)] relevant indicators the obtained score was [(4.5) =75%] 
COMPLEMENTARY OUTCOME/IMPACT INDICATORS 
Code  Score  Answer qualitative 
O1 (1) No cases. 
O2 (-) Not relevant. 
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O3 (-) Not relevant. 
O4 (-) Not relevant. 
O5 (1) No cases. 
O6 (0) Not documented. 
O7 (0) Not documented. 
O8 (0) Not documented. 
O9 (1) Yes, 5 per prescription. 
O10 (1) 2-3%. 
O11 (1) 4-5%. 
O12 (1) Yes, 100% of patients receive this information. 
Total 
score 
(6) Out of 9 [9*1= (9)] is [(100%)] relevant indicators the obtained score was [(6) =66.7%] 
(*) Score: Yes (1), No (0). 
(*) Score (0.5): For Indicators with two Parts (A & B) If (A the answer is No Score to be (0.5) and vice versa for B). 
(*) Score (-): Not relevant for the evaluation of system performance with WHO indicators. 
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6) Private Sector: Healthcare Institutions PV System Performance Comparison. 
Table R16: Private sector level Healthcare Institutions PV system performance comparison. 
Hospital 
E  
Hospital 
D  
Hospital 
C  
Hospital 
B  
Hospital 
A  
Mean  Desired 
performance   
 
10 10 10 11 13 10.8 16 Core structure 
indicators  
10 9 12 11 13 11 16 Core process 
indicators  
1 2 4 5 0 2.4 12 Core outcome 
indicators  
8 4 7 8.5 7.5 7 9 Complementary 
structure 
indicators  
4.5 3.5 5 2.5 4 3.9 6 Complementary 
process indicators  
6 5 6 1.5 4.5 4.6 9 Complementary 
outcomes 
indicators  
18 14 17 19.5 20.5 - 25 Total structural 
score  
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14.5 12.5 17 13.5 17 - 22 Total process 
score  
7 7 10 6.5 4.5 - 21 Total outcome 
score  
 39.5 33.5 44 39.5 42 - 68 Sum of total 
Structure, 
process, and 
outcome 
58.08824 49.26471 64.70588 58.08824 61.76471 100 Percentage 
 
  
  
375 
 
7) Private Sector: Community Pharmacies PV System Performance. 
Table R17: Community Pharmacy A” PV system performance and capacity results measured by WHO complementary PV indicators. 
COMPLEMENTARY STRUCTURAL INDICATORS 
Code Score* Answer qualitative  
ST1 (1)  Yes, since the is a confidentiality factor reports are being stored in a single computer. 
ST2 (1) Yes. Access to information from MOPH circulars and access to Qatar University library. 
ST3 (1) Yes, emails and phones.  
ST4 (1) Yes, online resources, Qatar University library, BNF hard copy, BNF online, and access to Lexicomp. 
ST5 (0.5) Yes, however, as an Excel spreadsheet.  
ST6 (-) Not relevant. 
ST7 (-) Not relevant. 
ST8 (-) Not relevant. 
ST9 (0.5) 
 
• ST9a: Yes, monthly meetings and once in two months' training.  
• ST9b: None for the public. 
ST10 (0) None. 
ST11 (-) Not relevant. 
Total 
score  
(5) Out of 7 [7*1= (7)] is [(100%)] relevant indicators the obtained score was [(5) =71.4%] 
COMPLEMENTARY PROCESS INDICATORS 
Code Score* Answer qualitative  
P1 (-) Not relevant. 
P2 (-) Not relevant. 
P3 (-) Not relevant. 
P4 (-) Not relevant. 
P5 (1) 100% are aware of ADR reporting but the staff have not been specifically trained for higher levels of practice (i.e., 
advanced). 
P6 (1) Yes, less than 20%. 
It was reported that there there's a need for widespread training among healthcare professionals to counsel the patients on 
ADRs. 
P7 (0.5) • P7a: a total of six in 2017. 
• P7b: none. 
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P8 (0.5) • P8a: 82.  
• P8b: none. 
P9 (-) Not relevant. 
P10 (-) Not relevant. 
P11 (-) Not relevant. 
P12 (-) Not relevant. 
P13 (-) Not relevant. 
Total 
score  
(3) Out of 4 [4*1= (4)] is [(100%)] relevant indicators the obtained score was [(3) =75%] 
COMPLEMENTARY OUTCOME/IMPACT INDICATORS 
Code  Score  Answer qualitative 
O1 (0) One case could have been prevented. A patient having a penicillin allergy and was prescribed cephalosporin, which was still 
a safe choice, but the patient had an allergic reaction. 
O2 (-) Not relevant. 
O3 (-) Not relevant. 
O4 (-) Not relevant. 
O5 (-) Not relevant. 
O6 (-) Not relevant. 
O7 (0) No official documentation. It was reported that cost-saving aspects in relation to the community pharmacy if taken into 
consideration, the investment made on PV will reflect upon the image of a particular chain of pharmacies, which could be a 
cost contributing by attracting others. 
O8 (0) No official documentation. 
O9 (1) Two. 
O10 (1) One. 
O11 (1) Less than one. 
O12 (1) More than 50%. 
There is a need for a structured way to counsel the patients. The pharmacy group can recommend this initiative at the 
ministry level as currently, pharmacists are counseling patients on ADRs out of their own interest or commitment. But if it 
becomes a part of the legal framework or a part of the compulsory professional practice it will make a significant change. 
Total 
score 
(4) Out of 7 [7*1= (7)] is [(100%)] relevant indicators the obtained score was [(4) =57.1%] 
(*) Score: Yes (1), No (0). 
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Table R18: Community Pharmacy B PV system performance and capacity results measured by WHO Complementary PV indicators. 
COMPLEMENTARY STRUCTURAL INDICATORS 
Code Score* Answer qualitative  
ST1 (0.5)  Yes, there is a computer but for general use by pharmacists, the pharmacy has a limited number of websites to have a 
connection and use information. 
ST2 (1) Yes. Medscape, prescriptions, PubMed, and BNF. 
ST3 (1) Yes, emails and phones. 
ST4 (1) Yes, Medscape, PubMed, BNF. 
ST5 (0) None.  
ST6 (-) Not applicable. 
ST7 (-) Not relevant.  
ST8 (-) Not relevant.  
ST9 (0) 
 
 
None.  face to face communication between pharmacists. The pharmacy has a limited number of pharmacists and good 
internal communication. The pharmacist provides information for patients and some attend conferences that can include 
medication safety.  
ST10 (0) None. 
ST11 (-) Not relevant. 
Total 
score  
(3.5) Out of 7 [7*1= (7)] is [(100%)] relevant indicators the obtained score was [(3.5) =50%] 
COMPLEMENTARY PROCESS INDICATORS 
Code Score* Answer qualitative  
P1 (-) Not relevant.  
P2 (-) Not relevant. 
P3 (-) Not relevant. 
P4 (-) Not relevant. 
P5 (1) 3 out of five. 
P6 (0) Based on the individual pharmacist. 
P7 (0) None.  
(*) Score (0.5): For Indicators with two Parts (A & B) If (A the answer is No Score to be (0.5) and vice versa for B). 
(*) Score (-): Not relevant for the evaluation of system performance with WHO indicators. 
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P8 (0) None.  
P9 (-) Not relevant. 
P10 (-) Not relevant. 
P11 (-) Not relevant. 
P12 (-) Not relevant. 
P13 (-) Not relevant. 
Total 
score  
(1) Out of 4 [4*1= (4)] is [(100%)] relevant indicators the obtained score was [(1) =25%] 
COMPLEMENTARY OUTCOME/IMPACT INDICATORS 
Code  Score  Answer qualitative 
O1 (0) Cases of harm reached the patient, cases of side effects occurred 3 to 4 during a one-year period. However, for Atropine spray, 
there are so many people who are suffering and cases occur almost on a daily basis. 
O2 (-) Not relevant. 
O3 (-) Not relevant. 
O4 (-) Not relevant. 
O5 (-) Not relevant. 
O6 (-) Not relevant. 
O7 (0) None. Because the community pharmacy doesn’t have this kind of complicated aspects like hospital pharmacy. 
O8 (0) None.   
O9 (1) 4 
O10 (1) 40%, it occurs frequently, and it is a big problem specifically with antibiotics use patients are given high doses or treatment for 
a longer duration.  
O11 (0) Not quantified. There is a limited number of higher risk mediations that the pharmacy can prescribe e.g., a limited number of 
medications for chronic use. About 2% of prescription comes with an allergy thus the pharmacist discusses with the doctor to 
change it. 
O12 (1) Yes, 10% on ADR and 100% on the use of their prescription medication. Some pharmacists counsel for all types of 
medications e.g. adverse effects of herbal medications. 
Total 
score 
(3) Out of 7 [7*1= (7)] is [(100%)] relevant indicators the obtained score was [(3) =42.9%] 
(*) Score: Yes (1), No (0). 
(*) Score (0.5): For Indicators with two Parts (A & B) If (A the answer is No Score to be (0.5) and vice versa for B). 
(*) Score (-): Not relevant for the evaluation of system performance with WHO indicators. 
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8) The Pharmaceutical Industry Pharmacovigilance System Performance. 
Table R19: Pharmaceutical Industry PV system performance and capacity results measured by WHO complementary PV indicators. 
COMPLEMENTARY STRUCTURAL INDICATORS 
Code Score* Answer qualitative  
ST1 (1)  Yes, a dedicated computer and FTP server. 
ST2 (-) Not relevant.  
ST3 (1) Yes, functional communication (24/7), this includes phone, email, webpage, and server.  
ST4 (1) Yes, internet access, websites of regulatory bodies, books, access to reference materials like GCC PV guidelines. 
ST5 (1) Yes. Excel sheets will be used for documentation through the system. Once completed they approve it in each department 
then it will go to the documentation room. The company has a proper filing system. 
ST6 (0.5) Quality Assurance decisions will be made according to the Quality Control laboratory analysis. The company complies with 
the MOPH requirement, however, this is not in the form of collaboration. 
ST7 (-) Not relevant. 
ST8 (-) Not relevant. 
ST9 (0.5) • ST9a: The company has training procedures internal and external, also they use presentations for educational 
purposes. 
• ST9b: No training courses for the general public but sometimes when they launch their products, they will share 
information with guest e.g. media. 
ST10 (0) Web-based PV training tools are not available. 
ST11 (-) Not relevant.  
Total 
score  
(5) Out of 7 [7*1= (7)] is [(100%)] relevant indicators the obtained score was [(5) =71.4%] 
COMPLEMENTARY PROCESS INDICATORS 
Code Score* Answer qualitative  
P1 (-) Not relevant. 
P2 (0.5) No reports received. 
P3 (-) Not relevant. 
P4 (0.5) No, the company does not have this data. 
P5 (-) Not relevant. 
Yes, 100% of all staff are well knowledgeable about ADRs. 
P6 (-) Not relevant. 
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P7 (0.5) • P7a: Face-to-face training sessions as part of the quality assurance program. Every quarter they conduct the training, 
thus every year they have a training plan for each department. Additionally, training on the job or of the new 
employees is provided. 
• P8b: None. 
P8 (0.5) • P8a: Every department will conduct their training. It is cross-functional hence no specific number, but 100% of staff 
received it. 
• P8b: None. 
P9 (-) Not relevant. 
P10 (0.5) No. Risk management plan not applicable to their products, Total products with PV plan, Total 780 products. 
P11 (0) It was reported that PSUR is not applicable to their products. For PSUR, they have GCC guidelines that they follow.    
P12 (1) No cases for products; no safety issues. 
P13 (-) Not relevant. 
Total 
score  
(3.5) Out of 7 [7*1= (7)] is [(100%)] relevant indicators the obtained score was [(3.5) =50%] 
COMPLEMENTARY OUTCOME/IMPACT INDICATORS 
Code  Score  Answer qualitative 
O1 (-) Not relevant. 
O2 (-) Not relevant. 
O3 (-) Not relevant. 
O4 (-) Not relevant. 
O5 (-) Not relevant. 
O6 (-) Not relevant. 
O7 (0) The company noted that data on cost-saving due to PV activities is not documented.   
O8 (0.5) According to the company representative health budget impact is the responsibility of the financial team. The company did 
not share value.     
O9 (-) Not relevant. 
O10 (-) Not relevant. 
O11 (-) Not relevant. 
O12 (-) Not relevant. 
Total 
score 
(0.5) Out of 2 [2*1= (2)] is [(100%)] relevant indicators the obtained score was [(0.5) =25%] 
(*) Score: Yes (1), No (0). 
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(*) Score (0.5): For Indicators with two Parts (A & B) If (A the answer is No Score to be (0.5) and vice versa for B). 
(*) Score (-): Not relevant for the evaluation of system performance with WHO indicators. 
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APPENDIX C: PROPOSAL FOR ESTABLISHMENT OF NATIONAL 
PHARMACOVIGILANCE CENTER  
National Pharmacovigilance Center Project Idea 
1. Why This Solution Is Proposed in Qatar? 
The Qatari health care system is expected to experience rapid growth. Therefore, the 
healthcare system and the pharmaceutical system will require stronger control over the market. 
The proposed PV center will serve as the organization that will enable this by relying on the 
proposed sections that should have a clear and documented segregation of duties and depend 
on a high level of scalability. 
After the implementation of the anticipated new pharmaceutical law, the section 
concerned with the legal aspects will be crucial to enable facilitating the communication and 
disputes resolution between stakeholders as well as for providing clarification and updates to 
stakeholders on regulations. 
The different sections are proposed, and each should have a specific responsibility as 
the nature of activities required from each requires a different set of competencies and skills. 
2. Overview of National PV Centers 
International standards require that any drug to be released in the market it has to follow 
a specific system that ensures the efficacy and safety of the drug in preclinical testing and 
clinical trial testing. Further, after the realization of the need for continuous monitoring of 
released products the system of post-marketing surveillance was introduced. Postmarketing 
surveillance monitor the safety profile of marketed drugs this can include but not limited to 
detecting ADRs. 
Postmarketing surveillance requires systems and structures in place to undertake the 
required functions. Therefore, PV centers were established in many countries to ensure that a 
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systematic process will be followed to guarantee drug safety in the country. To establish an 
effective PV center some specific criteria can be followed. This process follows an almost 
harmonized process as many global parties (e.g., WHO and SPS program) have shaped the 
criteria required by countries to create the fit for purpose plan to build an effective PV center. 
Countries aiming to succeed in building and sustaining an active PV center will require 
to study the various issues that could be encountered during the process. This can include the 
level of national healthcare system advancement as well as the degree of involvement and 
participation expected from the national PV stakeholders. Therefore, fit for the purpose set up 
at first is the guide to the success of a PV Centre. 
The PV center can be established under the health authority, governmental professional 
body, or other governmental departments. Additionally, some countries establish national PV 
centers under higher academic institutions or hospital organizations. Irrespective of the body 
overseeing PV the establishment of a PV center will require national PV stakeholders to 
maintain effective communication that is required to ensure the enhancement of the PV center 
performance and effectiveness to meet its objectives. In line with this, the establishment of the 
PV center will require a focal point and an appointed professional staff from each national PV 
stakeholder. In addition, to effective communication, effective collaboration and coordination 
between stakeholders as well as good public relations all are essential elements to ensure the 
effectiveness of the PV center.  
3. The Need for PV Center  
The obligation to have a persistent vigilance on medicines throughout the product life cycle 
and at each stakeholder system, including the use of medicine in the post-marketing period. 
This center can provide direct input or better advice for PV related processes including 
reporting, assessment, and management of medications as well as the consumers of 
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medications. 
4. The Objective of The PV Center 
A PV center is an organized entity that utilizes various resources to ensure medication 
safety, protect the public from medication harm, and prevent or minimize the occurrence of 
possible ADRs and other drug-related problems. The PV center can identify, collate, assess 
data on drug safety as well as prevent the occurrence of drug safety issues. Additionally, the 
PV center can communicate the risk associated with drugs to support the implementation of 
necessary actions and decision-making process to minimize the risk at the national level. 
Ultimately the PV center will reduce the morbidity and mortality associated with drug-related 
problems as well as it will protect the public health. 
5. The PV Center Functions 
An organized PV center capacity to operate will require resources, manpower, structures, 
and systematic functions. It is expected from the PV center to deliver the following:  
I. Promote PV in the country by gathering and managing reports on ADRs and other drug-
related problems. 
II. Performs PV activities at the national level and international level. 
III. Identify, evaluate, and communicate signals of drug safety. 
IV. Evaluate the risks associated with drug-related problems and implement actions to manage 
the risks. 
V. Detect quality issues with drugs that could potentially lead to the occurrence of ADRs.  
VI. Detect any issues related to the promotional activities of drugs or irrational prescribing of 
medicine to aid national PV systems to prevent and eradicate such activities. 
VII. Guarantee effective communication with the general public and other PV stakeholders to 
ensure the safe use of medications and protect the health of medication consumers in the 
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country. 
VIII. Integrate the outcomes of research activities in the national policies, standard treatment 
guidelines, and health programs or activities. 
IX. Generate, manage, and maintain medication utilization information.  
6. The PV Center Organizational Structure 
6.1. Administration 
1 Head of the Center. 
2 Assistant to International Relations. 
3 Executive Assistant (Secretary).  
Note: the relationship should be direct and exclusive between the head and the assistant. 
6.2. Sections 
1. Planning and Technical 
• Personnel is responsible for planning (leaders of the creation of regulations, studies, 
and operation procedures). 
• Personnel is responsible for technical services and research and development. 
2. Legal and Permits 
• Monitoring the implementation and compliance with the regulations. 
• Issuing permits to stakeholders (e.g. how to use medications in the organization, what 
studies could be conducted). 
• Responsible for stakeholder coordination (how to arrange with other national 
stakeholders, how to connect the responsibilities of the PV center with other 
administrators from different organizations (i.e., interface of systems). 
• Responsible for official relations with the public, media, and international parties. 
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3. Economic Regulations 
• Analyze the healthcare system and the pharmaceutical market of Qatar and manage the 
budget required for the PV center. 
4. Internet Technology Section 
• Management of Information e-services and communication support to PV stakeholders.   
• Development of information technology infrastructure solutions and unified 
telecommunications facilities including solutions for physical and virtual meetings.  
5. Medicine Management Section 
• Medicines care records and reporting. 
• PV stakeholders report management and recording. 
6. Stakeholder Communication Section 
• Management of MOPH communication. 
• Management of government & semi-government, pharmaceutical industry, private 
sector stakeholders, and all healthcare stakeholders PV relevant communication. 
• Management of pharmacies PV relevant communication. 
• Administration and management of PV relevant Records. 
Notes: 
1. Under each section, there could be a unit responsible for each aspect or else a person who 
has the capacity to serve different aspects at once. 
2. The employees under each section could be part-time only. 
3. The expected minimum number of required manpower for the PV center is 4 (I head + 3 
members). 
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7. Meeting requirements  
• The routine meeting is advised to be held on a quarterly basis.  
• The emergency meeting is advised to be held within 24-48 hours.  
8. PV center funding  
The annual budget required for the operation of the PV center will depend on the 
population size, the rate of reporting, and the method and expense for collecting PV related 
data from various stakeholders. The estimated required budget can be provided by the 
regulatory authority of Qatar.  
9. Capacity Building 
The organized PV center will require effective building up of formal capacities that are 
required for effective, efficient, and sustainable functionality and development. This will 
mainly depend on the function of the legal framework and PV policies.  Those will define the 
system and roles. Building capacities would also entail the proper management and monitoring 
of medications and other health-related products. This will be feasible with the proper 
utilization of workforce and infrastructure. The later will aid the effective utilization of service 
and equipment. All the aforementioned components if managed well and benefited from proper 
coordination will ensure effective capacity building. In so doing, a robust PV system will be 
established without the need to implement inconvenient changes in the resources, social 
structures, technologies, and personalities. 
10. Conclusion   
PV center can be the best-fit idea for many countries to activate the post-marketing 
surveillance of drug products, enable effective PV implementation, and achieve context-
specific regulatory decisions. However, to establish an effective, efficient, and sustainable PV 
system a holistic approach must be followed that includes baseline analysis; effective planning; 
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efficient implementation approaches; and effective national PV stakeholders participation, 
communication, and accountability. 
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